{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [],
   "source": [
    "import threading\n",
    "import time\n",
    "import openai\n",
    "from threading import Lock\n",
    "from langchain_community.embeddings import OpenAIEmbeddings\n",
    "# from langchain_openai import OpenAIEmbeddings\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "import json\n",
    "from langchain_community.vectorstores import Chroma\n",
    "import pandas as pd\n",
    "import sys\n",
    "import ast"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'c:\\\\Users\\\\Pyrack\\\\Desktop\\\\dorisjv\\\\dorisclinicaltrials\\\\Notebooks'"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pwd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv(\"FinalCTTrialsDF_Full_w_ContactInfo_LocList_testing.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_1 = pd.read_csv(\"FinalCTTrialsDF_P1_w_ContactInfo_LocList.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0.3</th>\n",
       "      <th>Unnamed: 0.2</th>\n",
       "      <th>Unnamed: 0.1</th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>LOCATIONS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>NCT03275311</td>\n",
       "      <td>Evolution of the Therapeutic Care in Metastati...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03275311</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Metastatic Breast Cancer</td>\n",
       "      <td>July 2014</td>\n",
       "      <td>December 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients 18 years or olde...</td>\n",
       "      <td>The primary outcome measure is to describe the...</td>\n",
       "      <td>Secondary outcomes focus on the impact of ther...</td>\n",
       "      <td>The study does not specify particular interven...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': \"Institut de Cancérolog...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20</td>\n",
       "      <td>20</td>\n",
       "      <td>20</td>\n",
       "      <td>20</td>\n",
       "      <td>NCT06145399</td>\n",
       "      <td>A Study of 1 8F-FDHT PET/MRIScans in Women Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06145399</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Breast Carcinoma, Metastatic Br...</td>\n",
       "      <td>October 24, 2023</td>\n",
       "      <td>October 24, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals aged ≥ 18 yea...</td>\n",
       "      <td>The primary outcome is to correlate 18F-FDHT u...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>Participants with histologically confirmed AR+...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': 'Memorial Sloan Ketteri...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>21</td>\n",
       "      <td>21</td>\n",
       "      <td>21</td>\n",
       "      <td>21</td>\n",
       "      <td>NCT05496101</td>\n",
       "      <td>CLI and FAR for Intraoperative Margin Assessment</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05496101</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer Female</td>\n",
       "      <td>November 21, 2022</td>\n",
       "      <td>December 31, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes female subjects ≥18 years...</td>\n",
       "      <td>The primary outcome focuses on the margin stat...</td>\n",
       "      <td>Secondary outcomes include the agreement betwe...</td>\n",
       "      <td>The intervention involves the use of the Light...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': \"Guy's and St Thomas NH...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>22</td>\n",
       "      <td>22</td>\n",
       "      <td>22</td>\n",
       "      <td>22</td>\n",
       "      <td>NCT05935384</td>\n",
       "      <td>SIBYL: obServation of Therapy Response With lI...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05935384</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer, Colorectal Cancer,...</td>\n",
       "      <td>October 25, 2023</td>\n",
       "      <td>August 30, 2029</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients treated with fir...</td>\n",
       "      <td>The primary outcome is the sensitivity of circ...</td>\n",
       "      <td>Secondary outcomes include RECIST v1.1 respons...</td>\n",
       "      <td>The intervention involves the Guardant360 diag...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': 'Orchard Healthcare Res...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>23</td>\n",
       "      <td>23</td>\n",
       "      <td>23</td>\n",
       "      <td>23</td>\n",
       "      <td>NCT05281237</td>\n",
       "      <td>Avecure Flexible Microwave Ablation Probe For ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05281237</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Stage I - II Primary Lung Cancer, Stage I Lung...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 30, 2025</td>\n",
       "      <td>22 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals with Stage I ...</td>\n",
       "      <td>The primary outcomes focus on the feasibility ...</td>\n",
       "      <td>Secondary outcomes involve examining histologi...</td>\n",
       "      <td>The intervention involves the use of the AveCu...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>17887</td>\n",
       "      <td>17887</td>\n",
       "      <td>17887</td>\n",
       "      <td>17887</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>17888</td>\n",
       "      <td>17888</td>\n",
       "      <td>17888</td>\n",
       "      <td>17888</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>17896</td>\n",
       "      <td>17896</td>\n",
       "      <td>17896</td>\n",
       "      <td>17896</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>17897</td>\n",
       "      <td>17897</td>\n",
       "      <td>17897</td>\n",
       "      <td>17897</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>17930</td>\n",
       "      <td>17930</td>\n",
       "      <td>17930</td>\n",
       "      <td>17930</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0.3  Unnamed: 0.2  Unnamed: 0.1  Unnamed: 0   NCT_NUMBER  \\\n",
       "0                0             0             0           0  NCT03275311   \n",
       "1               20            20            20          20  NCT06145399   \n",
       "2               21            21            21          21  NCT05496101   \n",
       "3               22            22            22          22  NCT05935384   \n",
       "4               23            23            23          23  NCT05281237   \n",
       "...            ...           ...           ...         ...          ...   \n",
       "1095         17887         17887         17887       17887  NCT05006131   \n",
       "1096         17888         17888         17888       17888  NCT04679064   \n",
       "1097         17896         17896         17896       17896  NCT04491864   \n",
       "1098         17897         17897         17897       17897  NCT05905939   \n",
       "1099         17930         17930         17930       17930  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     Evolution of the Therapeutic Care in Metastati...   \n",
       "1     A Study of 1 8F-FDHT PET/MRIScans in Women Wit...   \n",
       "2      CLI and FAR for Intraoperative Margin Assessment   \n",
       "3     SIBYL: obServation of Therapy Response With lI...   \n",
       "4     Avecure Flexible Microwave Ablation Probe For ...   \n",
       "...                                                 ...   \n",
       "1095  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "1096  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "1097  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "1098  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "1099  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT03275311   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT06145399   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT05496101   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05935384   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT05281237   Recruiting   \n",
       "...                                                ...          ...   \n",
       "1095  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "1096  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "1097  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "1098  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "1099  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS         START_DATE  \\\n",
       "0                              Metastatic Breast Cancer          July 2014   \n",
       "1     Breast Cancer, Breast Carcinoma, Metastatic Br...   October 24, 2023   \n",
       "2                                  Breast Cancer Female  November 21, 2022   \n",
       "3     Non-small Cell Lung Cancer, Colorectal Cancer,...   October 25, 2023   \n",
       "4     Stage I - II Primary Lung Cancer, Stage I Lung...       June 1, 2022   \n",
       "...                                                 ...                ...   \n",
       "1095                           Pancreatic Cancer, Adult      July 10, 2020   \n",
       "1096                                     Ovarian Cancer   December 1, 2020   \n",
       "1097                                      Breast Cancer     March 11, 2019   \n",
       "1098                                      Breast Cancer       May 31, 2023   \n",
       "1099  Anthracycline Related Cardiotoxicity in Breast...       June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0         December 2024          18 Years||Adult|Older Adult   \n",
       "1      October 24, 2026          18 Years||Adult|Older Adult   \n",
       "2     December 31, 2024          18 Years||Adult|Older Adult   \n",
       "3       August 30, 2029          18 Years||Adult|Older Adult   \n",
       "4         June 30, 2025          22 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "1095      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "1096    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "1097     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "1098       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "1099       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligibility includes patients 18 years or olde...   \n",
       "1     Eligibility includes individuals aged ≥ 18 yea...   \n",
       "2     Eligibility includes female subjects ≥18 years...   \n",
       "3     Eligibility includes patients treated with fir...   \n",
       "4     Eligibility includes individuals with Stage I ...   \n",
       "...                                                 ...   \n",
       "1095  Eligibility includes individuals indicated for...   \n",
       "1096  Eligibility includes recurrent ovarian, Fallop...   \n",
       "1097  Eligible participants are genetic females over...   \n",
       "1098  Eligibility includes patients with HER2-positi...   \n",
       "1099  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcome measure is to describe the...   \n",
       "1     The primary outcome is to correlate 18F-FDHT u...   \n",
       "2     The primary outcome focuses on the margin stat...   \n",
       "3     The primary outcome is the sensitivity of circ...   \n",
       "4     The primary outcomes focus on the feasibility ...   \n",
       "...                                                 ...   \n",
       "1095  The primary outcome is the proportion of scree...   \n",
       "1096  The primary outcome measure is overall surviva...   \n",
       "1097  The study aims to assess the accuracy of MRI D...   \n",
       "1098  The primary outcomes aim to describe the clini...   \n",
       "1099  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes focus on the impact of ther...   \n",
       "1                  No secondary outcomes were provided.   \n",
       "2     Secondary outcomes include the agreement betwe...   \n",
       "3     Secondary outcomes include RECIST v1.1 respons...   \n",
       "4     Secondary outcomes involve examining histologi...   \n",
       "...                                                 ...   \n",
       "1095  Secondary outcomes include the proportion of s...   \n",
       "1096  Secondary outcomes include progression-free su...   \n",
       "1097               No secondary outcomes were provided.   \n",
       "1098  Secondary outcomes focus on describing diagnos...   \n",
       "1099  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study does not specify particular interven...   \n",
       "1     Participants with histologically confirmed AR+...   \n",
       "2     The intervention involves the use of the Light...   \n",
       "3     The intervention involves the Guardant360 diag...   \n",
       "4     The intervention involves the use of the AveCu...   \n",
       "...                                                 ...   \n",
       "1095  The intervention involves screening for pancre...   \n",
       "1096  Interventions include a choice of standard che...   \n",
       "1097  The document does not specify interventions, f...   \n",
       "1098  The study does not specify interventions, as i...   \n",
       "1099  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "1095  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1096  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1097  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1098  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1099  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                                              LOCATIONS  \n",
       "0     [{'Location Facility': \"Institut de Cancérolog...  \n",
       "1     [{'Location Facility': 'Memorial Sloan Ketteri...  \n",
       "2     [{'Location Facility': \"Guy's and St Thomas NH...  \n",
       "3     [{'Location Facility': 'Orchard Healthcare Res...  \n",
       "4     [{'Location Facility': 'Beth Israel Deaconess ...  \n",
       "...                                                 ...  \n",
       "1095  [{'Location Facility': 'Beth Israel Deaconess ...  \n",
       "1096  [{'Location Facility': 'Azienda Ospedaliera Sp...  \n",
       "1097  [{'Location Facility': 'Baylor Scott & White R...  \n",
       "1098  [{'Location Facility': 'Research Site', 'Locat...  \n",
       "1099  [{'Location Facility': 'Texas Tech University ...  \n",
       "\n",
       "[1100 rows x 18 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \n",
       "0     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "...                                                 ...  \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "\n",
       "[3836 rows x 15 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "lung_cancer_df = df[df['CONDITIONS'].str.contains('Lung Cancer', case=False)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Unnamed: 0', 'NCT_NUMBER', 'STUDY_TITLE', 'STUDY_URL', 'STUDY_STATUS',\n",
       "       'CONDITIONS', 'LOCATIONS', 'START_DATE', 'COMPLETION_DATE', 'AGE',\n",
       "       'ELIGIBILITY_CRITERIA', 'PRIMARY_OUTCOMES', 'SECONDARY_OUTCOMES',\n",
       "       'INTERVENTIONS', 'POINT_OF_CONTACT'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Unnamed: 0.3', 'Unnamed: 0.2', 'Unnamed: 0.1', 'Unnamed: 0',\n",
       "       'NCT_NUMBER', 'STUDY_TITLE', 'STUDY_URL', 'STUDY_STATUS', 'CONDITIONS',\n",
       "       'START_DATE', 'COMPLETION_DATE', 'AGE', 'ELIGIBILITY_CRITERIA',\n",
       "       'PRIMARY_OUTCOMES', 'SECONDARY_OUTCOMES', 'INTERVENTIONS',\n",
       "       'POINT_OF_CONTACT', 'LOCATIONS'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_1.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>7</td>\n",
       "      <td>NCT05777603</td>\n",
       "      <td>Study of Aerosolized Antibiotics and Pembroliz...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05777603</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Non Small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'National Institutes of...</td>\n",
       "      <td>February 18, 2024</td>\n",
       "      <td>June 1, 2025</td>\n",
       "      <td>18 Years|120 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults (&gt;=18 years) with ...</td>\n",
       "      <td>The primary outcome is to evaluate the safety ...</td>\n",
       "      <td>Secondary outcomes include determining the rec...</td>\n",
       "      <td>The intervention consists of an experimental a...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3809</th>\n",
       "      <td>3809</td>\n",
       "      <td>NCT06091943</td>\n",
       "      <td>Study to Evaluate the Bioavailability of Tisle...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06091943</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Peking Union Medical C...</td>\n",
       "      <td>November 16, 2023</td>\n",
       "      <td>March 31, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals able to conse...</td>\n",
       "      <td>Primary outcomes include pharmacokinetic measu...</td>\n",
       "      <td>Secondary outcomes focus on additional pharmac...</td>\n",
       "      <td>The study involves two experimental arms. Part...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3811</th>\n",
       "      <td>3811</td>\n",
       "      <td>NCT04892472</td>\n",
       "      <td>EF-36/Keynote B36: A Pilot, Randomized, Open-l...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04892472</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Central Alabama Resear...</td>\n",
       "      <td>July 12, 2021</td>\n",
       "      <td>December 2026</td>\n",
       "      <td>22 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals with a confir...</td>\n",
       "      <td>The primary outcome measure is Progression Fre...</td>\n",
       "      <td>Secondary outcomes include Overall Survival (O...</td>\n",
       "      <td>The study involves two experimental arms. Arm ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3812</th>\n",
       "      <td>3812</td>\n",
       "      <td>NCT05236608</td>\n",
       "      <td>A Study to Evaluate the Combination of Nivolum...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05236608</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Metastatic Non Small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'National Cancer Centre...</td>\n",
       "      <td>November 12, 2021</td>\n",
       "      <td>May 2024</td>\n",
       "      <td>21 Years|99 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with confirmed s...</td>\n",
       "      <td>The study aims to assess the safety profile an...</td>\n",
       "      <td>Secondary outcomes include measuring progressi...</td>\n",
       "      <td>Participants will receive nivolumab and ADG106...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3819</th>\n",
       "      <td>3819</td>\n",
       "      <td>NCT06028152</td>\n",
       "      <td>Using an End-of-life Conversation Game to Enga...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06028152</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Lung Cancer, Genito Urinary Cancer</td>\n",
       "      <td>[{'Location Facility': 'Penn State Cancer Inst...</td>\n",
       "      <td>October 31, 2023</td>\n",
       "      <td>November 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility for cancer patients includes being...</td>\n",
       "      <td>The primary outcome is to assess the experienc...</td>\n",
       "      <td>Secondary outcomes include measuring readiness...</td>\n",
       "      <td>Participants in the experimental arm, labeled ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3826</th>\n",
       "      <td>3826</td>\n",
       "      <td>NCT02955290</td>\n",
       "      <td>CIMAvax Vaccine, Nivolumab, and Pembrolizumab ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT02955290</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Head and Neck Squamous Cell Carcinoma...</td>\n",
       "      <td>[{'Location Facility': 'Indiana University Mel...</td>\n",
       "      <td>December 22, 2016</td>\n",
       "      <td>December 9, 2027</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes ECOG performance status &lt;...</td>\n",
       "      <td>Primary outcomes focus on assessing dose limit...</td>\n",
       "      <td>Secondary outcomes include the incidence of ad...</td>\n",
       "      <td>Interventions involve CIMAvax and nivolumab or...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>632 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "4              4  NCT06249854   \n",
       "7              7  NCT05777603   \n",
       "...          ...          ...   \n",
       "3809        3809  NCT06091943   \n",
       "3811        3811  NCT04892472   \n",
       "3812        3812  NCT05236608   \n",
       "3819        3819  NCT06028152   \n",
       "3826        3826  NCT02955290   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "7     Study of Aerosolized Antibiotics and Pembroliz...   \n",
       "...                                                 ...   \n",
       "3809  Study to Evaluate the Bioavailability of Tisle...   \n",
       "3811  EF-36/Keynote B36: A Pilot, Randomized, Open-l...   \n",
       "3812  A Study to Evaluate the Combination of Nivolum...   \n",
       "3819  Using an End-of-life Conversation Game to Enga...   \n",
       "3826  CIMAvax Vaccine, Nivolumab, and Pembrolizumab ...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "7     https://www.clinicaltrials.gov/study/NCT05777603   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3809  https://www.clinicaltrials.gov/study/NCT06091943   Recruiting   \n",
       "3811  https://www.clinicaltrials.gov/study/NCT04892472   Recruiting   \n",
       "3812  https://www.clinicaltrials.gov/study/NCT05236608   Recruiting   \n",
       "3819  https://www.clinicaltrials.gov/study/NCT06028152   Recruiting   \n",
       "3826  https://www.clinicaltrials.gov/study/NCT02955290   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "7                   Advanced Non Small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3809                         Non-small Cell Lung Cancer   \n",
       "3811                         Non-small Cell Lung Cancer   \n",
       "3812              Metastatic Non Small Cell Lung Cancer   \n",
       "3819  Breast Cancer, Lung Cancer, Genito Urinary Cancer   \n",
       "3826  Advanced Head and Neck Squamous Cell Carcinoma...   \n",
       "\n",
       "                                              LOCATIONS         START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...   February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...      June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...       May 27, 2019   \n",
       "4     [{'Location Facility': 'Korea University Ansan...   February 8, 2024   \n",
       "7     [{'Location Facility': 'National Institutes of...  February 18, 2024   \n",
       "...                                                 ...                ...   \n",
       "3809  [{'Location Facility': 'Peking Union Medical C...  November 16, 2023   \n",
       "3811  [{'Location Facility': 'Central Alabama Resear...      July 12, 2021   \n",
       "3812  [{'Location Facility': 'National Cancer Centre...  November 12, 2021   \n",
       "3819  [{'Location Facility': 'Penn State Cancer Inst...   October 31, 2023   \n",
       "3826  [{'Location Facility': 'Indiana University Mel...  December 22, 2016   \n",
       "\n",
       "        COMPLETION_DATE                                   AGE  \\\n",
       "0     November 17, 2024           18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026           18 Years||Adult|Older Adult   \n",
       "2         February 2025           18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025           19 Years||Adult|Older Adult   \n",
       "7          June 1, 2025  18 Years|120 Years|Adult|Older Adult   \n",
       "...                 ...                                   ...   \n",
       "3809     March 31, 2026           18 Years||Adult|Older Adult   \n",
       "3811      December 2026           22 Years||Adult|Older Adult   \n",
       "3812           May 2024   21 Years|99 Years|Adult|Older Adult   \n",
       "3819      November 2024           18 Years||Adult|Older Adult   \n",
       "3826   December 9, 2027           18 Years||Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "7     Eligibility includes adults (>=18 years) with ...   \n",
       "...                                                 ...   \n",
       "3809  Eligibility includes individuals able to conse...   \n",
       "3811  Eligibility includes individuals with a confir...   \n",
       "3812  Eligibility includes patients with confirmed s...   \n",
       "3819  Eligibility for cancer patients includes being...   \n",
       "3826  Eligibility includes ECOG performance status <...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "7     The primary outcome is to evaluate the safety ...   \n",
       "...                                                 ...   \n",
       "3809  Primary outcomes include pharmacokinetic measu...   \n",
       "3811  The primary outcome measure is Progression Fre...   \n",
       "3812  The study aims to assess the safety profile an...   \n",
       "3819  The primary outcome is to assess the experienc...   \n",
       "3826  Primary outcomes focus on assessing dose limit...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "7     Secondary outcomes include determining the rec...   \n",
       "...                                                 ...   \n",
       "3809  Secondary outcomes focus on additional pharmac...   \n",
       "3811  Secondary outcomes include Overall Survival (O...   \n",
       "3812  Secondary outcomes include measuring progressi...   \n",
       "3819  Secondary outcomes include measuring readiness...   \n",
       "3826  Secondary outcomes include the incidence of ad...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "7     The intervention consists of an experimental a...   \n",
       "...                                                 ...   \n",
       "3809  The study involves two experimental arms. Part...   \n",
       "3811  The study involves two experimental arms. Arm ...   \n",
       "3812  Participants will receive nivolumab and ADG106...   \n",
       "3819  Participants in the experimental arm, labeled ...   \n",
       "3826  Interventions involve CIMAvax and nivolumab or...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \n",
       "0     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "7     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "...                                                 ...  \n",
       "3809  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3811  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3812  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3819  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3826  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "\n",
       "[632 rows x 15 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lung_cancer_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "output = {\"stage\" : \"stage\",\n",
    "          \"age\" : \"age\",\n",
    "          \"gender\" : \"gender\" }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"You are helpful assistant to give stage of cancer ,age and gender from given senetence and give output in json format as {output} \"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "ELIGIBILITY_CRITERIA = df[\"ELIGIBILITY_CRITERIA\"][2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Eligibility includes patients with advanced tumors such as non-small cell lung cancer with ALK/ROS1 gene fusion, malignant pleural mesothelioma, esophageal cancer, and ovarian cancer. Specific cohorts for expansion stage include patients with non-small cell lung cancer who have progressed on or are intolerant to second-generation ALK TKI therapy or any ROS1 TKI therapy, and those with ALK/ROS1 fusion gene positive non-small cell lung cancer without prior TKI treatment. Requirements include ECOG Performance Status ≤ 1, life expectancy ≥ 3 months, at least 1 measurable lesion per RECIST 1.1, adequate organ function, controlled brain metastases, and negative pregnancy test for women of childbearing age. Exclusions include concurrent anti-cancer therapy, recent TKI therapy, unresolved toxicities, swallowing difficulties, significant cardiovascular disease, recent surgery, active infections, known allergies to study drug, pregnant or breastfeeding women, and use of certain CYP inhibitors or substrates.'"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"ELIGIBILITY_CRITERIA\"][2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "response = openai.chat.completions.create(\n",
    "            model='gpt-4-0125-preview', \n",
    "            temperature=0,\n",
    "            messages=[\n",
    "                {\"role\":\"system\", \"content\":system_prompt},\n",
    "                {\"role\":\"user\", \"content\":f\"\"\" Extract the stage of cancer, age and gender from given input {ELIGIBILITY_CRITERIA} and give output in {output} format, stricrtly specify gender as male or female \"\"\"},\n",
    "            ],\n",
    "            max_tokens = 1024,\n",
    "            response_format={ \"type\": \"json_object\" }\n",
    "            \n",
    "        )\n",
    "      "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'{\"stage\": \"advanced\", \"age\": \"not specified\", \"gender\": \"not specified\"}'"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response.choices[0].message.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['18 Years||Adult|Older Adult', '19 Years||Adult|Older Adult',\n",
       "       '18 Years|75 Years|Adult|Older Adult',\n",
       "       '18 Years|120 Years|Adult|Older Adult',\n",
       "       '18 Years|80 Years|Adult|Older Adult',\n",
       "       '21 Years||Adult|Older Adult',\n",
       "       '45 Years|65 Years|Adult|Older Adult', '65 Years||Older Adult',\n",
       "       '18 Years|99 Years|Adult|Older Adult',\n",
       "       '20 Years|75 Years|Adult|Older Adult', '||Child|Adult|Older Adult',\n",
       "       '18 Years|90 Years|Adult|Older Adult',\n",
       "       '18 Years|70 Years|Adult|Older Adult', '25 Years|60 Years|Adult',\n",
       "       '1 Month||Child|Adult|Older Adult', '40 Years|60 Years|Adult',\n",
       "       '18 Years|39 Years|Adult', '45 Years|49 Years|Adult',\n",
       "       '19 Years|85 Years|Adult|Older Adult',\n",
       "       '18 Years|65 Years|Adult|Older Adult',\n",
       "       '18 Years|100 Years|Adult|Older Adult',\n",
       "       '12 Years||Child|Adult|Older Adult', '50 Years||Adult|Older Adult',\n",
       "       '18 Years|66 Years|Adult|Older Adult',\n",
       "       '19 Years|70 Years|Adult|Older Adult',\n",
       "       '18 Years|69 Years|Adult|Older Adult', '18 Years|60 Years|Adult',\n",
       "       '18 Years|95 Years|Adult|Older Adult',\n",
       "       '18 Years|85 Years|Adult|Older Adult',\n",
       "       '20 Years||Adult|Older Adult',\n",
       "       '3 Years|85 Years|Child|Adult|Older Adult',\n",
       "       '1 Year|25 Years|Child|Adult',\n",
       "       '21 Years|99 Years|Adult|Older Adult', '30 Years|49 Years|Adult',\n",
       "       '40 Years||Adult|Older Adult', '30 Years||Adult|Older Adult',\n",
       "       '19 Years|90 Years|Adult|Older Adult', '18 Years|45 Years|Adult',\n",
       "       '36 Years|60 Years|Adult', '45 Years||Adult|Older Adult',\n",
       "       '18 Years|72 Years|Adult|Older Adult', '20 Years|45 Years|Adult',\n",
       "       '18 Years|74 Years|Adult|Older Adult',\n",
       "       '18 Years|67 Years|Adult|Older Adult',\n",
       "       '60 Years||Adult|Older Adult',\n",
       "       '25 Years|85 Years|Adult|Older Adult',\n",
       "       '45 Years|80 Years|Adult|Older Adult',\n",
       "       '18 Years|130 Years|Adult|Older Adult',\n",
       "       '20 Years|69 Years|Adult|Older Adult',\n",
       "       '3 Years||Child|Adult|Older Adult',\n",
       "       '22 Years|75 Years|Adult|Older Adult',\n",
       "       '50 Years|80 Years|Adult|Older Adult',\n",
       "       '19 Years|110 Years|Adult|Older Adult',\n",
       "       '18 Years|76 Years|Adult|Older Adult',\n",
       "       '45 Years|79 Years|Adult|Older Adult',\n",
       "       '12 Months|30 Years|Child|Adult',\n",
       "       '|80 Years|Child|Adult|Older Adult',\n",
       "       '18 Years|88 Years|Adult|Older Adult',\n",
       "       '25 Years||Adult|Older Adult', '|35 Years|Child|Adult',\n",
       "       '20 Years|70 Years|Adult|Older Adult',\n",
       "       '19 Years|150 Years|Adult|Older Adult',\n",
       "       '25 Years|75 Years|Adult|Older Adult', '21 Years|64 Years|Adult',\n",
       "       '50 Years|74 Years|Adult|Older Adult',\n",
       "       '19 Years|80 Years|Adult|Older Adult', '18 Years|50 Years|Adult',\n",
       "       '25 Years|99 Years|Adult|Older Adult', '20 Years|60 Years|Adult',\n",
       "       '70 Years||Older Adult', '5 Years|17 Years|Child',\n",
       "       '16 Years||Child|Adult|Older Adult',\n",
       "       '14 Years|42 Years|Child|Adult', '15 Years|39 Years|Child|Adult',\n",
       "       '19 Years|100 Years|Adult|Older Adult', '18 Years|44 Years|Adult',\n",
       "       '30 Years|75 Years|Adult|Older Adult',\n",
       "       '50 Years|90 Years|Adult|Older Adult', '18 Years|35 Years|Adult',\n",
       "       '19 Years|99 Years|Adult|Older Adult',\n",
       "       '35 Years|70 Years|Adult|Older Adult', '20 Years|54 Years|Adult',\n",
       "       '40 Years|80 Years|Adult|Older Adult', '45 Years|60 Years|Adult',\n",
       "       '50 Years|69 Years|Adult|Older Adult',\n",
       "       '21 Years|80 Years|Adult|Older Adult',\n",
       "       '20 Years|80 Years|Adult|Older Adult', '18 Years|40 Years|Adult',\n",
       "       '45 Years|74 Years|Adult|Older Adult',\n",
       "       '50 Years|99 Years|Adult|Older Adult',\n",
       "       '50 Years|70 Years|Adult|Older Adult',\n",
       "       '35 Years||Adult|Older Adult', '19 Years|64 Years|Adult',\n",
       "       '16 Years|70 Years|Child|Adult|Older Adult',\n",
       "       '|30 Years|Child|Adult', '45 Years|85 Years|Adult|Older Adult',\n",
       "       '50 Years|100 Years|Adult|Older Adult',\n",
       "       '25 Years|80 Years|Adult|Older Adult', '25 Years|45 Years|Adult',\n",
       "       '15 Years|75 Years|Child|Adult|Older Adult',\n",
       "       '18 Years|55 Years|Adult', '51 Years|74 Years|Adult|Older Adult',\n",
       "       '20 Years|89 Years|Adult|Older Adult',\n",
       "       '22 Years|65 Years|Adult|Older Adult',\n",
       "       '1 Year|19 Years|Child|Adult',\n",
       "       '40 Years|74 Years|Adult|Older Adult',\n",
       "       '18 Years|94 Years|Adult|Older Adult',\n",
       "       '19 Years|69 Years|Adult|Older Adult',\n",
       "       '60 Years|105 Years|Adult|Older Adult',\n",
       "       '50 Years|65 Years|Adult|Older Adult',\n",
       "       '21 Years|75 Years|Adult|Older Adult',\n",
       "       '18 Months||Child|Adult|Older Adult',\n",
       "       '50 Years|67 Years|Adult|Older Adult', '25 Years|49 Years|Adult',\n",
       "       '9 Years|26 Years|Child|Adult',\n",
       "       '20 Years|65 Years|Adult|Older Adult',\n",
       "       '55 Years|75 Years|Adult|Older Adult',\n",
       "       '30 Years|70 Years|Adult|Older Adult',\n",
       "       '40 Years|75 Years|Adult|Older Adult', '35 Years|55 Years|Adult',\n",
       "       '25 Years|50 Years|Adult', '35 Years|65 Years|Adult|Older Adult',\n",
       "       '20 Years|48 Years|Adult', '50 Years|60 Years|Adult',\n",
       "       '22 Years||Adult|Older Adult', '25 Years|55 Years|Adult',\n",
       "       '51 Years||Adult|Older Adult',\n",
       "       '21 Years|70 Years|Adult|Older Adult',\n",
       "       '30 Years|65 Years|Adult|Older Adult',\n",
       "       '23 Years|69 Years|Adult|Older Adult', '|21 Years|Child|Adult',\n",
       "       '21 Years|79 Years|Adult|Older Adult',\n",
       "       '17 Years|70 Years|Child|Adult|Older Adult',\n",
       "       '50 Years|75 Years|Adult|Older Adult',\n",
       "       '40 Years|70 Years|Adult|Older Adult',\n",
       "       '24 Years||Adult|Older Adult',\n",
       "       '40 Years|85 Years|Adult|Older Adult',\n",
       "       '40 Years|69 Years|Adult|Older Adult',\n",
       "       '45 Years|75 Years|Adult|Older Adult',\n",
       "       '19 Years|65 Years|Adult|Older Adult',\n",
       "       '14 Years|100 Years|Child|Adult|Older Adult',\n",
       "       '30 Years|80 Years|Adult|Older Adult', '45 Years|55 Years|Adult',\n",
       "       '10 Years||Child|Adult|Older Adult',\n",
       "       '|85 Years|Child|Adult|Older Adult',\n",
       "       '18 Years|84 Years|Adult|Older Adult',\n",
       "       '13 Years||Child|Adult|Older Adult',\n",
       "       '21 Years|100 Years|Adult|Older Adult', '18 Years|38 Years|Adult',\n",
       "       '|50 Years|Child|Adult', '40 Years|68 Years|Adult|Older Adult',\n",
       "       '2 Years|50 Years|Child|Adult',\n",
       "       '18 Years|89 Years|Adult|Older Adult',\n",
       "       '18 Years|78 Years|Adult|Older Adult',\n",
       "       '55 Years||Adult|Older Adult', '40 Years|50 Years|Adult',\n",
       "       '|60 Years|Child|Adult', '30 Years|79 Years|Adult|Older Adult',\n",
       "       '65 Years|100 Years|Older Adult',\n",
       "       '55 Years|79 Years|Adult|Older Adult',\n",
       "       '18 Years|79 Years|Adult|Older Adult', '20 Years|50 Years|Adult',\n",
       "       '30 Years|39 Years|Adult', '9 Years|45 Years|Child|Adult',\n",
       "       '20 Years|79 Years|Adult|Older Adult',\n",
       "       '35 Years|80 Years|Adult|Older Adult',\n",
       "       '65 Years|111 Years|Older Adult',\n",
       "       '1 Year|75 Years|Child|Adult|Older Adult',\n",
       "       '41 Years||Adult|Older Adult',\n",
       "       '20 Years|85 Years|Adult|Older Adult',\n",
       "       '0 Years||Child|Adult|Older Adult',\n",
       "       '21 Years|65 Years|Adult|Older Adult', '18 Years|49 Years|Adult',\n",
       "       '25 Years|65 Years|Adult|Older Adult', '18 Years|59 Years|Adult',\n",
       "       '40 Years|65 Years|Adult|Older Adult', '39 Years|49 Years|Adult',\n",
       "       '1 Month|99 Years|Child|Adult|Older Adult',\n",
       "       '45 Years|64 Years|Adult', '7 Years||Child|Adult|Older Adult',\n",
       "       '3 Years|30 Years|Child|Adult'], dtype=object)"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"AGE\"].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "month_df = df[df['AGE'].str.contains('month', case=False)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "79              1 Month||Child|Adult|Older Adult\n",
       "586               12 Months|30 Years|Child|Adult\n",
       "1566          18 Months||Child|Adult|Older Adult\n",
       "2467          18 Months||Child|Adult|Older Adult\n",
       "2507              12 Months|30 Years|Child|Adult\n",
       "3557    1 Month|99 Years|Child|Adult|Older Adult\n",
       "Name: AGE, dtype: object"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "month_df[\"AGE\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_month = month_df.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>79</td>\n",
       "      <td>NCT02595957</td>\n",
       "      <td>Genomic Services Research Program</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT02595957</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Colon Cancer, Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'National Institutes of...</td>\n",
       "      <td>September 16, 2014</td>\n",
       "      <td>December 31, 2028</td>\n",
       "      <td>1 Month||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes English- or Spanish-speak...</td>\n",
       "      <td>The study aims to assess affective responses a...</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>The study involves two groups: 'Cascade Testin...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>586</th>\n",
       "      <td>586</td>\n",
       "      <td>NCT02574728</td>\n",
       "      <td>Sirolimus in Combination With Metronomic Chemo...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT02574728</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>[{'Location Facility': \"Phoenix Children's Hos...</td>\n",
       "      <td>June 2015</td>\n",
       "      <td>January 2024</td>\n",
       "      <td>12 Months|30 Years|Child|Adult</td>\n",
       "      <td>Eligibility includes participants with relapse...</td>\n",
       "      <td>Primary outcomes focus on the change in radiog...</td>\n",
       "      <td>The secondary outcome is the number of adverse...</td>\n",
       "      <td>Participants will receive oral sirolimus, cele...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1566</th>\n",
       "      <td>1566</td>\n",
       "      <td>NCT04740697</td>\n",
       "      <td>Study to Evaluate the Impact of the Use of Alt...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04740697</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Institut Universitaire...</td>\n",
       "      <td>February 12, 2021</td>\n",
       "      <td>February 2024</td>\n",
       "      <td>18 Months||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals aged ≥ 18 yea...</td>\n",
       "      <td>The primary outcome is the rate of patients wh...</td>\n",
       "      <td>Secondary outcomes include the rate of patient...</td>\n",
       "      <td>Intervention involves patients with localized ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2467</th>\n",
       "      <td>2467</td>\n",
       "      <td>NCT05783908</td>\n",
       "      <td>Impact of Non-magnetic Screen Respiratory Self...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05783908</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patient With Radiotherapy (Linac MRI), Mobile ...</td>\n",
       "      <td>[{'Location Facility': 'Centre Georges-Françoi...</td>\n",
       "      <td>October 16, 2023</td>\n",
       "      <td>September 27, 2025</td>\n",
       "      <td>18 Months||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals at least 18 y...</td>\n",
       "      <td>The primary outcome is to evaluate the effect ...</td>\n",
       "      <td>Secondary outcomes include measuring patient r...</td>\n",
       "      <td>The study involves two arms: one receiving rad...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2507</th>\n",
       "      <td>2507</td>\n",
       "      <td>NCT05569512</td>\n",
       "      <td>Uproleselan With Pre-Transplant Conditioning i...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05569512</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Acute Myeloid Leukemia, Pediatric Cancer</td>\n",
       "      <td>[{'Location Facility': 'University of Alabama ...</td>\n",
       "      <td>October 6, 2022</td>\n",
       "      <td>December 1, 2028</td>\n",
       "      <td>12 Months|30 Years|Child|Adult</td>\n",
       "      <td>Eligibility includes individuals aged 12 month...</td>\n",
       "      <td>Primary outcomes focus on determining the reco...</td>\n",
       "      <td>Secondary outcomes include uproleselan pharmac...</td>\n",
       "      <td>Participants will receive intravenous (IV) upr...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3557</th>\n",
       "      <td>3557</td>\n",
       "      <td>NCT03896958</td>\n",
       "      <td>The PIONEER Initiative: Precision Insights On ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03896958</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Cancer, All Types, Cancer of Liver, Cancer of ...</td>\n",
       "      <td>[{'Location Facility': 'Specicare', 'Location ...</td>\n",
       "      <td>March 21, 2019</td>\n",
       "      <td>March 12, 2024</td>\n",
       "      <td>1 Month|99 Years|Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include all patients diagno...</td>\n",
       "      <td>The study focuses on three primary outcomes ov...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>No specific interventions were detailed.</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "79            79  NCT02595957   \n",
       "586          586  NCT02574728   \n",
       "1566        1566  NCT04740697   \n",
       "2467        2467  NCT05783908   \n",
       "2507        2507  NCT05569512   \n",
       "3557        3557  NCT03896958   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "79                    Genomic Services Research Program   \n",
       "586   Sirolimus in Combination With Metronomic Chemo...   \n",
       "1566  Study to Evaluate the Impact of the Use of Alt...   \n",
       "2467  Impact of Non-magnetic Screen Respiratory Self...   \n",
       "2507  Uproleselan With Pre-Transplant Conditioning i...   \n",
       "3557  The PIONEER Initiative: Precision Insights On ...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "79    https://www.clinicaltrials.gov/study/NCT02595957   Recruiting   \n",
       "586   https://www.clinicaltrials.gov/study/NCT02574728   Recruiting   \n",
       "1566  https://www.clinicaltrials.gov/study/NCT04740697   Recruiting   \n",
       "2467  https://www.clinicaltrials.gov/study/NCT05783908   Recruiting   \n",
       "2507  https://www.clinicaltrials.gov/study/NCT05569512   Recruiting   \n",
       "3557  https://www.clinicaltrials.gov/study/NCT03896958   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "79                          Colon Cancer, Breast Cancer   \n",
       "586                                              Cancer   \n",
       "1566                                      Breast Cancer   \n",
       "2467  Patient With Radiotherapy (Linac MRI), Mobile ...   \n",
       "2507           Acute Myeloid Leukemia, Pediatric Cancer   \n",
       "3557  Cancer, All Types, Cancer of Liver, Cancer of ...   \n",
       "\n",
       "                                              LOCATIONS          START_DATE  \\\n",
       "79    [{'Location Facility': 'National Institutes of...  September 16, 2014   \n",
       "586   [{'Location Facility': \"Phoenix Children's Hos...           June 2015   \n",
       "1566  [{'Location Facility': 'Institut Universitaire...   February 12, 2021   \n",
       "2467  [{'Location Facility': 'Centre Georges-Françoi...    October 16, 2023   \n",
       "2507  [{'Location Facility': 'University of Alabama ...     October 6, 2022   \n",
       "3557  [{'Location Facility': 'Specicare', 'Location ...      March 21, 2019   \n",
       "\n",
       "         COMPLETION_DATE                                       AGE  \\\n",
       "79     December 31, 2028          1 Month||Child|Adult|Older Adult   \n",
       "586         January 2024            12 Months|30 Years|Child|Adult   \n",
       "1566       February 2024        18 Months||Child|Adult|Older Adult   \n",
       "2467  September 27, 2025        18 Months||Child|Adult|Older Adult   \n",
       "2507    December 1, 2028            12 Months|30 Years|Child|Adult   \n",
       "3557      March 12, 2024  1 Month|99 Years|Child|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "79    Eligibility includes English- or Spanish-speak...   \n",
       "586   Eligibility includes participants with relapse...   \n",
       "1566  Eligibility includes individuals aged ≥ 18 yea...   \n",
       "2467  Eligibility includes individuals at least 18 y...   \n",
       "2507  Eligibility includes individuals aged 12 month...   \n",
       "3557  Inclusion criteria include all patients diagno...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "79    The study aims to assess affective responses a...   \n",
       "586   Primary outcomes focus on the change in radiog...   \n",
       "1566  The primary outcome is the rate of patients wh...   \n",
       "2467  The primary outcome is to evaluate the effect ...   \n",
       "2507  Primary outcomes focus on determining the reco...   \n",
       "3557  The study focuses on three primary outcomes ov...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "79                                       Not specified.   \n",
       "586   The secondary outcome is the number of adverse...   \n",
       "1566  Secondary outcomes include the rate of patient...   \n",
       "2467  Secondary outcomes include measuring patient r...   \n",
       "2507  Secondary outcomes include uproleselan pharmac...   \n",
       "3557               No secondary outcomes were provided.   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "79    The study involves two groups: 'Cascade Testin...   \n",
       "586   Participants will receive oral sirolimus, cele...   \n",
       "1566  Intervention involves patients with localized ...   \n",
       "2467  The study involves two arms: one receiving rad...   \n",
       "2507  Participants will receive intravenous (IV) upr...   \n",
       "3557           No specific interventions were detailed.   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \n",
       "79    {'Name': None, 'Organization': None, 'Email': ...  \n",
       "586   {'Name': None, 'Organization': None, 'Email': ...  \n",
       "1566  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "2467  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "2507  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3557  {'Name': None, 'Organization': None, 'Email': ...  "
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_month"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "# Function to convert age format\n",
    "def convert_age_format(age_info):\n",
    "    # Split the age info by \"|\" and extract numerical values\n",
    "    ages = re.findall(r'\\d+', age_info)\n",
    "    \n",
    "    # Convert the numerical values to integers\n",
    "    ages = [int(age) for age in ages if age]  # Filter out empty strings\n",
    "    \n",
    "    # Check if there are any age values\n",
    "    if ages:\n",
    "        # If there are age values, join them with \"years |\" separator\n",
    "        formatted_ages = \" | \".join(f\"{age} years\" for age in ages)\n",
    "    else:\n",
    "        # If no age values are found, return the original age_info\n",
    "        formatted_ages = age_info\n",
    "    \n",
    "    return formatted_ages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "# Function to convert age format\n",
    "def convert_age_format_months(age_info):\n",
    "    # Split the age info by \"|\" and extract numerical values\n",
    "    ages = re.findall(r'\\d+', age_info)\n",
    "    \n",
    "    # Convert the numerical values to integers\n",
    "    ages = [int(age) for age in ages if age]  # Filter out empty strings\n",
    "    \n",
    "    # Check if there are any age values\n",
    "    if ages:\n",
    "        # If there are age values, join them with \"years |\" separator\n",
    "        formatted_ages = \" | \".join(f\"{age} months\" for age in ages)\n",
    "    else:\n",
    "        # If no age values are found, return the original age_info\n",
    "        formatted_ages = age_info\n",
    "    \n",
    "    return formatted_ages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"formatted_age\"] = month_df[\"AGE\"].apply(convert_age_format_months)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>formatted_age</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 16 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT formatted_age  \n",
       "0     {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "...                                                 ...           ...  \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...           NaN  \n",
       "\n",
       "[3836 rows x 16 columns]"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"formatted_age\"] = df['AGE'].apply(convert_age_format)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                        18 years\n",
       "1                        18 years\n",
       "2                        18 years\n",
       "3                        18 years\n",
       "4                        19 years\n",
       "                  ...            \n",
       "3831          18 years | 90 years\n",
       "3832                     18 years\n",
       "3833                     30 years\n",
       "3834    ||Child|Adult|Older Adult\n",
       "3835          18 years | 89 years\n",
       "Name: formatted_age, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"formatted_age\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0               18 Years||Adult|Older Adult\n",
       "1               18 Years||Adult|Older Adult\n",
       "2               18 Years||Adult|Older Adult\n",
       "3               18 Years||Adult|Older Adult\n",
       "4               19 Years||Adult|Older Adult\n",
       "                       ...                 \n",
       "3831    18 Years|90 Years|Adult|Older Adult\n",
       "3832            18 Years||Adult|Older Adult\n",
       "3833            30 Years||Adult|Older Adult\n",
       "3834              ||Child|Adult|Older Adult\n",
       "3835    18 Years|89 Years|Adult|Older Adult\n",
       "Name: AGE, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"AGE\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "def has_numerical_age(age_info):\n",
    "    ages = re.findall(r'\\d+', age_info)\n",
    "    return bool(ages) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>formatted_age</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>35</td>\n",
       "      <td>NCT05364138</td>\n",
       "      <td>Evaluating Scaleup of an Adapted Breast Cancer...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05364138</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Benign Breast Disease, Cervix C...</td>\n",
       "      <td>[{'Location Facility': 'Partners in Health (In...</td>\n",
       "      <td>July 31, 2023</td>\n",
       "      <td>March 30, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include all individuals eva...</td>\n",
       "      <td>The primary outcome focuses on the number of p...</td>\n",
       "      <td>Secondary outcomes include analyzing the media...</td>\n",
       "      <td>The document does not specify interventions di...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>115</td>\n",
       "      <td>NCT05834686</td>\n",
       "      <td>HER2 Expression of CTC to Predict Response in ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05834686</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'The Fifth Medical Cent...</td>\n",
       "      <td>January 1, 2023</td>\n",
       "      <td>April 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals with patholog...</td>\n",
       "      <td>The primary outcome measure is Progression Fre...</td>\n",
       "      <td>Secondary outcomes include the Objective Respo...</td>\n",
       "      <td>The intervention involves detecting HER2 expre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>132</td>\n",
       "      <td>NCT05770544</td>\n",
       "      <td>DETERMINE Trial Treatment Arm 03: Entrectinib ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05770544</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Solid Tumor, Haematological Malignancy, Malign...</td>\n",
       "      <td>[{'Location Facility': 'Belfast City Hospital'...</td>\n",
       "      <td>June 2024</td>\n",
       "      <td>October 2029</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults, teenagers, and ch...</td>\n",
       "      <td>The primary outcomes focus on Objective Respon...</td>\n",
       "      <td>Secondary outcomes include Duration of Respons...</td>\n",
       "      <td>The intervention involves administering entrec...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>227</th>\n",
       "      <td>227</td>\n",
       "      <td>NCT05770102</td>\n",
       "      <td>DETERMINE Trial Treatment Arm 02: Atezolizumab...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05770102</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Malignancy, Malignant Neoplasm, Lymphoprolifer...</td>\n",
       "      <td>[{'Location Facility': 'Belfast City Hospital'...</td>\n",
       "      <td>October 25, 2023</td>\n",
       "      <td>October 2029</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Participants must fulfill eligibility criteria...</td>\n",
       "      <td>The primary outcomes include Objective Respons...</td>\n",
       "      <td>Secondary outcomes encompass Duration of Respo...</td>\n",
       "      <td>The intervention involves administering atezol...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>242</th>\n",
       "      <td>242</td>\n",
       "      <td>NCT05949021</td>\n",
       "      <td>OCTANE: Adjuvant Liposomal Doxorubicin and Car...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05949021</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Triple Negative Breast Cancer (TNBC)</td>\n",
       "      <td>[{'Location Facility': 'RWJBarnabas Health - T...</td>\n",
       "      <td>October 7, 2023</td>\n",
       "      <td>September 30, 2027</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes newly diagnosed early-sta...</td>\n",
       "      <td>The primary outcome is the Disease-Free Surviv...</td>\n",
       "      <td>Secondary outcomes focus on the safety and tox...</td>\n",
       "      <td>The intervention involves a combination of lip...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>296</th>\n",
       "      <td>296</td>\n",
       "      <td>NCT05851677</td>\n",
       "      <td>RC48-ADC in Breast Cancer</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05851677</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Renji Hospital, School...</td>\n",
       "      <td>June 1, 2023</td>\n",
       "      <td>August 2027</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Participants must have histologically confirme...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>The secondary outcome focuses on the assessmen...</td>\n",
       "      <td>The intervention involves administering the dr...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>426</th>\n",
       "      <td>426</td>\n",
       "      <td>NCT04660435</td>\n",
       "      <td>To Identify Primary Resistance to CDK4/6 Inhib...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04660435</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Metastatic Breast Cancer, ER Positive Breast C...</td>\n",
       "      <td>[{'Location Facility': 'Hospital Santo Stefano...</td>\n",
       "      <td>September 1, 2020</td>\n",
       "      <td>December 1, 2026</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Women aged 18 or older with ER-positive, HER2-...</td>\n",
       "      <td>The primary outcome measure is progression-fre...</td>\n",
       "      <td>The secondary outcome measure is the clinical ...</td>\n",
       "      <td>The intervention involves a diagnostic test ca...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>436</th>\n",
       "      <td>436</td>\n",
       "      <td>NCT05305092</td>\n",
       "      <td>Assessment of Brain Cognitive Impairment in Br...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05305092</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Chemo-brain, Endocrine Therapy</td>\n",
       "      <td>[{'Location Facility': 'Tangdu Hospital', 'Loc...</td>\n",
       "      <td>May 31, 2022</td>\n",
       "      <td>May 30, 2027</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include premenopausal women...</td>\n",
       "      <td>The study measures changes in the brain's gray...</td>\n",
       "      <td>Secondary outcomes focus on the change in conc...</td>\n",
       "      <td>Participants undergo PET/MRI scans, complete p...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>546</th>\n",
       "      <td>546</td>\n",
       "      <td>NCT04265937</td>\n",
       "      <td>ScreenIng of Genetic Susceptibility Genes for ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04265937</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Genetic Susceptibility</td>\n",
       "      <td>[{'Location Facility': 'Zhen Hu', 'Location Ci...</td>\n",
       "      <td>July 1, 2019</td>\n",
       "      <td>June 30, 2026</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include breast cancer patie...</td>\n",
       "      <td>The primary outcome is to measure the frequenc...</td>\n",
       "      <td>Secondary outcomes, measured over 1 year, incl...</td>\n",
       "      <td>The document does not specify interventions, s...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>724</th>\n",
       "      <td>724</td>\n",
       "      <td>NCT03953157</td>\n",
       "      <td>Dietary and Exercise Interventions in Reducing...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03953157</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anatomic Stage I Breast Cancer AJCC v8, Anatom...</td>\n",
       "      <td>[{'Location Facility': 'UCLA / Jonsson Compreh...</td>\n",
       "      <td>October 7, 2019</td>\n",
       "      <td>June 1, 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes women diagnosed with loca...</td>\n",
       "      <td>Primary outcomes focus on bone mineral density...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The study involves two experimental arms. Arm ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>868</th>\n",
       "      <td>868</td>\n",
       "      <td>NCT05359120</td>\n",
       "      <td>Pyrotinib Combined With Capecitabine in HER-2 ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05359120</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Henan cancer hospital'...</td>\n",
       "      <td>May 30, 2022</td>\n",
       "      <td>May 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes pathologically diagnosed ...</td>\n",
       "      <td>The primary outcome measure is Time to Failure...</td>\n",
       "      <td>Secondary outcomes include Progression-free su...</td>\n",
       "      <td>Interventions involve patients in three cohort...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1088</th>\n",
       "      <td>1088</td>\n",
       "      <td>NCT05614375</td>\n",
       "      <td>Endoscopic Surgery in the Treatment of Soft Ti...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05614375</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Sarcoma,Soft Tissue, Nasal Cavity Cancer, Para...</td>\n",
       "      <td>[{'Location Facility': 'Yu Hongmeng', 'Locatio...</td>\n",
       "      <td>June 12, 2021</td>\n",
       "      <td>June 12, 2026</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include signing the informe...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include local recurrence-fr...</td>\n",
       "      <td>The intervention involves patients with soft t...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1108</th>\n",
       "      <td>1108</td>\n",
       "      <td>NCT00579514</td>\n",
       "      <td>Germline Alterations of Tumor Susceptibility G...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT00579514</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Bladder Cancer, Kidney Cancer, ...</td>\n",
       "      <td>[{'Location Facility': 'Memorial Sloan Ketteri...</td>\n",
       "      <td>March 2000</td>\n",
       "      <td>March 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with a histologi...</td>\n",
       "      <td>The primary outcome is to collect anonymized g...</td>\n",
       "      <td>The secondary outcome involves analyzing DNA s...</td>\n",
       "      <td>The intervention involves the PCR/PCR/LDR Stra...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1160</th>\n",
       "      <td>1160</td>\n",
       "      <td>NCT05463796</td>\n",
       "      <td>InAdvance: Surveillance, Prevention, and Inter...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05463796</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Cancer Risk, Cancer Predisposition Syndrome, H...</td>\n",
       "      <td>[{'Location Facility': 'Dana Farber Cancer Ins...</td>\n",
       "      <td>April 25, 2023</td>\n",
       "      <td>March 25, 2032</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Participants include those with hereditary can...</td>\n",
       "      <td>The primary outcome is to identify exposures, ...</td>\n",
       "      <td>No secondary outcomes are provided.</td>\n",
       "      <td>Participants across different risk groups (her...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1173</th>\n",
       "      <td>1173</td>\n",
       "      <td>NCT04367779</td>\n",
       "      <td>Research of Biomarkers of Response to Proton B...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04367779</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Brain Cancer, Meningioma, Sarcoma</td>\n",
       "      <td>[{'Location Facility': 'Centre Léon Bérard', '...</td>\n",
       "      <td>September 24, 2020</td>\n",
       "      <td>June 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes male or female patients o...</td>\n",
       "      <td>The primary outcome is to identify predictive ...</td>\n",
       "      <td>Secondary outcomes include identifying predict...</td>\n",
       "      <td>The study involves pediatric and adult patient...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1199</th>\n",
       "      <td>1199</td>\n",
       "      <td>NCT06223763</td>\n",
       "      <td>SUROVA - Surgery in Ovarian Cancer, Comparing ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06223763</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Epithelial Ovarian Cancer, Fallopian Tube Neop...</td>\n",
       "      <td>[{'Location Facility': 'Clínica Universidad de...</td>\n",
       "      <td>January 1, 2024</td>\n",
       "      <td>June 1, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients over 18 years ol...</td>\n",
       "      <td>The primary outcome measure is the comparison ...</td>\n",
       "      <td>Secondary outcomes include comparing Progressi...</td>\n",
       "      <td>Interventions involve cytoreductive surgery ai...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1204</th>\n",
       "      <td>1204</td>\n",
       "      <td>NCT03050268</td>\n",
       "      <td>Familial Investigations of Childhood Cancer Pr...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03050268</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Acute Leukemia, Adenomatous Polyposis, Adrenoc...</td>\n",
       "      <td>[{'Location Facility': \"St. Jude Children's Re...</td>\n",
       "      <td>April 6, 2017</td>\n",
       "      <td>March 31, 2037</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>This study targets individuals with a history ...</td>\n",
       "      <td>The primary outcome of the study is the identi...</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1270</th>\n",
       "      <td>1270</td>\n",
       "      <td>NCT04428515</td>\n",
       "      <td>Pilot Study to Evaluate Photoacoustic Imaging ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04428515</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>[{'Location Facility': 'Sunnybrook Health Scie...</td>\n",
       "      <td>April 23, 2019</td>\n",
       "      <td>April 23, 2027</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals with histolog...</td>\n",
       "      <td>The primary outcome focuses on the correlation...</td>\n",
       "      <td>Secondary outcomes aim to correlate changes in...</td>\n",
       "      <td>The intervention involves the use of a Photoac...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1326</th>\n",
       "      <td>1326</td>\n",
       "      <td>NCT00898131</td>\n",
       "      <td>Collecting Tissue Samples for Future Research ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT00898131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Robert H. Lurie Compre...</td>\n",
       "      <td>August 2001</td>\n",
       "      <td>January 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Participants are eligible if they are undergoi...</td>\n",
       "      <td>The primary outcome is to collect human breast...</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1371</th>\n",
       "      <td>1371</td>\n",
       "      <td>NCT00196833</td>\n",
       "      <td>Breast Cancer in Pregnancy Register Study</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT00196833</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'German Breast Group', ...</td>\n",
       "      <td>April 2003</td>\n",
       "      <td>April 2026</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Women with histologically confirmed breast can...</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1380</th>\n",
       "      <td>1380</td>\n",
       "      <td>NCT04947280</td>\n",
       "      <td>Single Arm Phase II Study of Fractionated Ster...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04947280</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Bone Metastases, Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Fudan University Shang...</td>\n",
       "      <td>January 1, 2021</td>\n",
       "      <td>December 31, 2026</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals with invasive...</td>\n",
       "      <td>The primary outcome measure is the local contr...</td>\n",
       "      <td>Secondary outcomes include evaluating pain con...</td>\n",
       "      <td>The intervention involves participants being p...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1538</th>\n",
       "      <td>1538</td>\n",
       "      <td>NCT05010863</td>\n",
       "      <td>Gastric Cancer Marker Detection and Its Kit De...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05010863</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Gastric Cancer</td>\n",
       "      <td>[{'Location Facility': 'No. 109, Xueyuan West ...</td>\n",
       "      <td>January 1, 2021</td>\n",
       "      <td>December 30, 2030</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients aged ≥18 years w...</td>\n",
       "      <td>The primary outcome is to obtain subject serum...</td>\n",
       "      <td>No secondary outcomes are specified.</td>\n",
       "      <td>The intervention involves blood collection fro...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1692</th>\n",
       "      <td>1692</td>\n",
       "      <td>NCT05913440</td>\n",
       "      <td>HER2-low Unresectable and/or Metastatic Breast...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05913440</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 30, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with confirmed d...</td>\n",
       "      <td>The study aims to assess the overall prevalenc...</td>\n",
       "      <td>Secondary objectives include describing diagno...</td>\n",
       "      <td>The document does not specify interventions, s...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1693</th>\n",
       "      <td>1693</td>\n",
       "      <td>NCT04996615</td>\n",
       "      <td>Artificial Intelligence Analysis for Magnetic ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04996615</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Magnetic Resonance Imaging</td>\n",
       "      <td>[{'Location Facility': \"Peking university peop...</td>\n",
       "      <td>September 1, 2021</td>\n",
       "      <td>September 30, 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients undergoing full ...</td>\n",
       "      <td>The primary outcome is to compare the rates of...</td>\n",
       "      <td>Secondary outcomes involve comparing the sensi...</td>\n",
       "      <td>The intervention involves women at high risk o...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1724</th>\n",
       "      <td>1724</td>\n",
       "      <td>NCT04680442</td>\n",
       "      <td>Safety of Continuing HER-2 Directed Therapy in...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04680442</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Heart Failure</td>\n",
       "      <td>[{'Location Facility': 'Hospital de Clínicas d...</td>\n",
       "      <td>July 1, 2021</td>\n",
       "      <td>December 1, 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Participants must have Stage I-III HER-2 posit...</td>\n",
       "      <td>The primary outcomes focus on the efficacy and...</td>\n",
       "      <td>The secondary outcome measures the composite o...</td>\n",
       "      <td>The study involves two groups: a control group...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1725</th>\n",
       "      <td>1725</td>\n",
       "      <td>NCT02695121</td>\n",
       "      <td>Cancer in Patients on Dapagliflozin and Other ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT02695121</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Bladder Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>January 1, 2017</td>\n",
       "      <td>December 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include patients newly pres...</td>\n",
       "      <td>The primary outcomes focus on the incidence of...</td>\n",
       "      <td>The secondary outcome measures the incidence o...</td>\n",
       "      <td>The document does not specify interventions, s...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1731</th>\n",
       "      <td>1731</td>\n",
       "      <td>NCT05428527</td>\n",
       "      <td>Real-world Clinical Benefit Evaluation in Brea...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05428527</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Cancer-related Fatigue</td>\n",
       "      <td>[{'Location Facility': 'E-Da Cancer Hospital',...</td>\n",
       "      <td>September 8, 2021</td>\n",
       "      <td>December 31, 2023</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include breast cancer patie...</td>\n",
       "      <td>The primary outcome measure is the improvement...</td>\n",
       "      <td>Secondary outcomes include the level of fatigu...</td>\n",
       "      <td>The intervention involves breast cancer patien...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1751</th>\n",
       "      <td>1751</td>\n",
       "      <td>NCT05374603</td>\n",
       "      <td>Savolitinib Combine With Durvalumab in EGFR Wi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05374603</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>November 23, 2022</td>\n",
       "      <td>December 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients 18 years or olde...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Objective Response ...</td>\n",
       "      <td>The intervention involves a combination of two...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1784</th>\n",
       "      <td>1784</td>\n",
       "      <td>NCT04567420</td>\n",
       "      <td>DNA-Guided Second Line Adjuvant Therapy For Hi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04567420</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'University of Arizona ...</td>\n",
       "      <td>February 9, 2021</td>\n",
       "      <td>December 15, 2026</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes Stage II or III, HER2 neg...</td>\n",
       "      <td>The primary outcomes focus on two phases: the ...</td>\n",
       "      <td>Secondary outcomes include assessing the feasi...</td>\n",
       "      <td>The study involves two arms: Arm A (experiment...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1793</th>\n",
       "      <td>1793</td>\n",
       "      <td>NCT05665660</td>\n",
       "      <td>Developing and Evaluating Culturally Relevant ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05665660</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Center for Indigenous ...</td>\n",
       "      <td>June 6, 2023</td>\n",
       "      <td>December 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes women referred for screen...</td>\n",
       "      <td>The primary outcome measure is the uptake of m...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The study involves two experimental arms. The ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1834</th>\n",
       "      <td>1834</td>\n",
       "      <td>NCT05060068</td>\n",
       "      <td>Effect of Intravenous S-ketamine on Opioid Con...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05060068</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer Surgery</td>\n",
       "      <td>[{'Location Facility': 'Second Affiliated Hosp...</td>\n",
       "      <td>October 7, 2021</td>\n",
       "      <td>July 7, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes female patients with an A...</td>\n",
       "      <td>The primary outcome measure is the consumption...</td>\n",
       "      <td>Secondary outcomes include postoperative pain ...</td>\n",
       "      <td>The study involves three arms: a placebo group...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1982</th>\n",
       "      <td>1982</td>\n",
       "      <td>NCT05932121</td>\n",
       "      <td>Cross-sectional Case and Control Study on Qual...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05932121</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Papillary Thyroid Carcinoma, Thyroid Cancer</td>\n",
       "      <td>[{'Location Facility': 'Department of General ...</td>\n",
       "      <td>June 25, 2023</td>\n",
       "      <td>July 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include PTC patients who un...</td>\n",
       "      <td>The primary outcome focuses on the cosmetic ou...</td>\n",
       "      <td>Secondary outcomes include the evaluation of t...</td>\n",
       "      <td>The study involves two groups of PTC patients ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2033</th>\n",
       "      <td>2033</td>\n",
       "      <td>NCT05179824</td>\n",
       "      <td>Tempus Priority Study: A Pan-tumor Observation...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05179824</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Prostate Cancer, Bladder Cancer...</td>\n",
       "      <td>[{'Location Facility': 'Providence Medical Fou...</td>\n",
       "      <td>October 19, 2020</td>\n",
       "      <td>October 19, 2030</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals with solid or...</td>\n",
       "      <td>The primary outcome is to create a robust data...</td>\n",
       "      <td>Secondary outcomes include documenting specifi...</td>\n",
       "      <td>The study involves two groups, both under the ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2081</th>\n",
       "      <td>2081</td>\n",
       "      <td>NCT05769517</td>\n",
       "      <td>PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEA...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05769517</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>BRCA Mutation, Ovarian Cancer, Ultrasound Ther...</td>\n",
       "      <td>[{'Location Facility': 'Fondazione Policlinico...</td>\n",
       "      <td>March 20, 2023</td>\n",
       "      <td>May 2, 2026</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Participants must have available gBRCA1/2 test...</td>\n",
       "      <td>The study aims to enhance and prospectively va...</td>\n",
       "      <td>No secondary outcomes are provided.</td>\n",
       "      <td>The intervention involves conducting a multice...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2108</th>\n",
       "      <td>2108</td>\n",
       "      <td>NCT05228106</td>\n",
       "      <td>68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05228106</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Solid Cancers</td>\n",
       "      <td>[{'Location Facility': 'CHUS', 'Location City'...</td>\n",
       "      <td>January 21, 2022</td>\n",
       "      <td>January 31, 2027</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligible participants include those with a cli...</td>\n",
       "      <td>The primary outcome focuses on the incidence o...</td>\n",
       "      <td>Secondary outcomes aim to generate clinical in...</td>\n",
       "      <td>The intervention involves an intravenous injec...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2137</th>\n",
       "      <td>2137</td>\n",
       "      <td>NCT04068168</td>\n",
       "      <td>Open Label, Multicenter, Real World Practice o...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04068168</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>January 30, 2020</td>\n",
       "      <td>August 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include patients eligible f...</td>\n",
       "      <td>The primary outcomes focus on assessing the sa...</td>\n",
       "      <td>Secondary outcomes aim to evaluate the efficac...</td>\n",
       "      <td>The document does not provide specific details...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2418</th>\n",
       "      <td>2418</td>\n",
       "      <td>NCT03452774</td>\n",
       "      <td>SYNERGY-AI: Artificial Intelligence Based Prec...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03452774</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Cancer, Metastatic, Cancer, Cancer of Pancreas...</td>\n",
       "      <td>[{'Location Facility': 'Massive Bio, Inc', 'Lo...</td>\n",
       "      <td>January 1, 2018</td>\n",
       "      <td>June 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with solid and h...</td>\n",
       "      <td>The primary outcome measure is the proportion ...</td>\n",
       "      <td>Secondary outcomes include the impact of CTE o...</td>\n",
       "      <td>The intervention involves Clinical Trial Match...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2464</th>\n",
       "      <td>2464</td>\n",
       "      <td>NCT02302742</td>\n",
       "      <td>Triple Negative Breast Cancer and Germline Her...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT02302742</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Hereditary Breast and Ovarian C...</td>\n",
       "      <td>[{'Location Facility': 'Hays Medical Center Dr...</td>\n",
       "      <td>March 22, 2011</td>\n",
       "      <td>December 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes Triple Negative Breast Ca...</td>\n",
       "      <td>The primary outcomes include the prevalence of...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The study does not involve any interventions a...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2537</th>\n",
       "      <td>2537</td>\n",
       "      <td>NCT05601388</td>\n",
       "      <td>Role of IMP3 Expression in Colorectal Carcinom...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05601388</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Faculty of Medicine', ...</td>\n",
       "      <td>October 1, 2022</td>\n",
       "      <td>June 1, 2023</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include patients with color...</td>\n",
       "      <td>The primary outcome is to evaluate the immunoh...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>No interventions were specified.</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2545</th>\n",
       "      <td>2545</td>\n",
       "      <td>NCT05564377</td>\n",
       "      <td>Targeted Therapy Directed by Genetic Testing i...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05564377</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Malignant Solid Neoplasm, Anatomic St...</td>\n",
       "      <td>[{'Location Facility': 'University of Alabama ...</td>\n",
       "      <td>April 7, 2023</td>\n",
       "      <td>July 1, 2030</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with measurable ...</td>\n",
       "      <td>Primary outcomes focus on the accrual, assignm...</td>\n",
       "      <td>Secondary outcomes include the rate of positiv...</td>\n",
       "      <td>Interventions vary across multiple experimenta...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2609</th>\n",
       "      <td>2609</td>\n",
       "      <td>NCT05834699</td>\n",
       "      <td>HER2 Expression of CTC to Predict Response in ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05834699</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'The Fifth Medical Cent...</td>\n",
       "      <td>January 1, 2023</td>\n",
       "      <td>April 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals with patholog...</td>\n",
       "      <td>The primary outcome measure is Progression Fre...</td>\n",
       "      <td>Secondary outcomes include the Objective Respo...</td>\n",
       "      <td>The intervention involves detecting HER2 expre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2616</th>\n",
       "      <td>2616</td>\n",
       "      <td>NCT05677308</td>\n",
       "      <td>LYNPARZA Breast Cancer in the Adjuvant Setting...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05677308</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>March 7, 2023</td>\n",
       "      <td>December 31, 2026</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients initiating treat...</td>\n",
       "      <td>The primary outcome is to measure the incidenc...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>No specific interventions were detailed.</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2618</th>\n",
       "      <td>2618</td>\n",
       "      <td>NCT04050423</td>\n",
       "      <td>Investigation of Ultrasound Imaging and Spectr...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04050423</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Sunnybrook Health Scie...</td>\n",
       "      <td>September 23, 2014</td>\n",
       "      <td>September 2029</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes both women and men with s...</td>\n",
       "      <td>The primary outcome is to select the best quan...</td>\n",
       "      <td>The secondary outcome focuses on correlating t...</td>\n",
       "      <td>The document does not specify interventions, s...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2644</th>\n",
       "      <td>2644</td>\n",
       "      <td>NCT04428528</td>\n",
       "      <td>Photoacoustic Imaging for Characterizing Breas...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04428528</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Sunnybrook Health Scie...</td>\n",
       "      <td>February 13, 2017</td>\n",
       "      <td>February 13, 2029</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes men and women aged 20-80,...</td>\n",
       "      <td>The primary outcome focuses on correlating tre...</td>\n",
       "      <td>The secondary outcome aims to investigate if b...</td>\n",
       "      <td>The study involves two arms using the Photoaco...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2691</th>\n",
       "      <td>2691</td>\n",
       "      <td>NCT02206984</td>\n",
       "      <td>Endocrine Response in Women With Invasive Lobu...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT02206984</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'UAB Comprehensive Canc...</td>\n",
       "      <td>September 30, 2015</td>\n",
       "      <td>March 2023</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes women with histologically...</td>\n",
       "      <td>The primary outcome measure is the change in K...</td>\n",
       "      <td>Secondary outcomes include measuring estrogen ...</td>\n",
       "      <td>The study involves three active comparator arm...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2794</th>\n",
       "      <td>2794</td>\n",
       "      <td>NCT05483712</td>\n",
       "      <td>Brass Mesh Bolus in Rotational Post-Mastectomy...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05483712</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Nova Scotia Health Aut...</td>\n",
       "      <td>January 18, 2023</td>\n",
       "      <td>November 21, 2023</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Women undergoing rotational chest wall radioth...</td>\n",
       "      <td>The primary outcome measure is the skin dose e...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The intervention involves patients undergoing ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2985</th>\n",
       "      <td>2985</td>\n",
       "      <td>NCT03687151</td>\n",
       "      <td>Population-based Cancer Observatory</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03687151</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>[{'Location Facility': 'Nice University Hospit...</td>\n",
       "      <td>January 1, 2005</td>\n",
       "      <td>December 31, 2050</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria include all subjects diagno...</td>\n",
       "      <td>The primary outcome is the enumeration of each...</td>\n",
       "      <td>No secondary outcomes are specified.</td>\n",
       "      <td>The study involves an observational interventi...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3242</th>\n",
       "      <td>3242</td>\n",
       "      <td>NCT00437879</td>\n",
       "      <td>Ultrasound Imaging, Spectroscopy and Ultrasoun...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT00437879</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer Invasive</td>\n",
       "      <td>[{'Location Facility': 'Sunnybrook Health Scie...</td>\n",
       "      <td>December 17, 2008</td>\n",
       "      <td>June 2029</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals with histolog...</td>\n",
       "      <td>The primary outcome involves correlating chang...</td>\n",
       "      <td>Secondary outcomes focus on examining changes ...</td>\n",
       "      <td>The document does not specify interventions di...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3250</th>\n",
       "      <td>3250</td>\n",
       "      <td>NCT03578380</td>\n",
       "      <td>Supermicrosurgery for Breast Cancer Survivors ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03578380</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Secondary Lymphedema, Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Sykehuset Telemark', '...</td>\n",
       "      <td>January 26, 2016</td>\n",
       "      <td>December 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Participants are eligible if they have unilate...</td>\n",
       "      <td>The primary outcome measure is the volume of t...</td>\n",
       "      <td>The secondary outcome is the health-related qu...</td>\n",
       "      <td>The study involves two arms: the experimental ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3314</th>\n",
       "      <td>3314</td>\n",
       "      <td>NCT05440929</td>\n",
       "      <td>Evaluation of the Acceptability, Appropriatene...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05440929</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Metastatic Breast Cancer, End of Life</td>\n",
       "      <td>[{'Location Facility': 'University of North Ca...</td>\n",
       "      <td>July 15, 2022</td>\n",
       "      <td>July 15, 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Participants must have verbal informed consent...</td>\n",
       "      <td>The primary outcomes focus on identifying key ...</td>\n",
       "      <td>Secondary outcomes aim to identify key barrier...</td>\n",
       "      <td>The intervention involves conducting semi-stru...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3328</th>\n",
       "      <td>3328</td>\n",
       "      <td>NCT03941639</td>\n",
       "      <td>Using Imaging Data and Genomic Data to Predict...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03941639</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'The Chinese University...</td>\n",
       "      <td>September 1, 2019</td>\n",
       "      <td>June 1, 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Individuals are eligible if they have a clinic...</td>\n",
       "      <td>The primary outcome is the area under the rece...</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>Not specified.</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3370</th>\n",
       "      <td>3370</td>\n",
       "      <td>NCT05770037</td>\n",
       "      <td>DETERMINE Trial Treatment Arm 01: Alectinib in...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05770037</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Solid Tumor, Haematological Malignancy, Malign...</td>\n",
       "      <td>[{'Location Facility': 'Belfast City Hospital'...</td>\n",
       "      <td>December 18, 2023</td>\n",
       "      <td>October 2029</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults, teenagers, and ch...</td>\n",
       "      <td>The primary outcomes are Objective Response (O...</td>\n",
       "      <td>Secondary outcomes include Duration of Respons...</td>\n",
       "      <td>The intervention involves administering alecti...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3512</th>\n",
       "      <td>3512</td>\n",
       "      <td>NCT04549571</td>\n",
       "      <td>Improving Patient-Centered Communication in Br...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04549571</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anatomic Stage 0 Breast Cancer AJCC v8, Anatom...</td>\n",
       "      <td>[{'Location Facility': 'Kaiser Permanente-Vall...</td>\n",
       "      <td>January 15, 2021</td>\n",
       "      <td>January 2027</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes women aged 21-84, newly d...</td>\n",
       "      <td>The primary outcome is patient knowledge about...</td>\n",
       "      <td>Secondary outcomes include patient self-effica...</td>\n",
       "      <td>Interventions involve patients using the iCanD...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3531</th>\n",
       "      <td>3531</td>\n",
       "      <td>NCT03995082</td>\n",
       "      <td>Breast Cancer Patient Engagement With Patient ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03995082</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'University of Colorado...</td>\n",
       "      <td>October 30, 2019</td>\n",
       "      <td>June 2025</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>The study targets adult females (18 years or o...</td>\n",
       "      <td>The primary outcome is patient satisfaction wi...</td>\n",
       "      <td>Secondary outcomes include various BREAST Q Pa...</td>\n",
       "      <td>Participants in the experimental group will re...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3537</th>\n",
       "      <td>3537</td>\n",
       "      <td>NCT05044689</td>\n",
       "      <td>Case Control Study to Identify Modifiable Risk...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05044689</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Colorectal Cancer, Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Obafemi Awolowo Univer...</td>\n",
       "      <td>April 12, 2021</td>\n",
       "      <td>April 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>For the case group, patients must have a histo...</td>\n",
       "      <td>The primary outcomes include the development a...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The study involves two main interventions acro...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3665</th>\n",
       "      <td>3665</td>\n",
       "      <td>NCT05601440</td>\n",
       "      <td>Liquid-biopsy Informed Platform Trial to Evalu...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05601440</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'BCCA - Cancer Centre f...</td>\n",
       "      <td>June 13, 2023</td>\n",
       "      <td>June 2028</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults (≥18 years) with h...</td>\n",
       "      <td>The primary outcomes focus on evaluating the i...</td>\n",
       "      <td>Secondary outcomes include assessing the numbe...</td>\n",
       "      <td>The study involves three experimental arms: Su...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3822</th>\n",
       "      <td>3822</td>\n",
       "      <td>NCT05631873</td>\n",
       "      <td>Colonoscopy Screening: Setting Epic Follow-up ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05631873</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Concordance Between Colonoscopy Follow up Inte...</td>\n",
       "      <td>[{'Location Facility': 'Massachusetts General ...</td>\n",
       "      <td>November 18, 2022</td>\n",
       "      <td>June 30, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Inclusion criteria focus on GI specialists at ...</td>\n",
       "      <td>The primary outcomes involve implementing a ne...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The intervention consists of a research assist...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "35            35  NCT05364138   \n",
       "115          115  NCT05834686   \n",
       "132          132  NCT05770544   \n",
       "227          227  NCT05770102   \n",
       "242          242  NCT05949021   \n",
       "296          296  NCT05851677   \n",
       "426          426  NCT04660435   \n",
       "436          436  NCT05305092   \n",
       "546          546  NCT04265937   \n",
       "724          724  NCT03953157   \n",
       "868          868  NCT05359120   \n",
       "1088        1088  NCT05614375   \n",
       "1108        1108  NCT00579514   \n",
       "1160        1160  NCT05463796   \n",
       "1173        1173  NCT04367779   \n",
       "1199        1199  NCT06223763   \n",
       "1204        1204  NCT03050268   \n",
       "1270        1270  NCT04428515   \n",
       "1326        1326  NCT00898131   \n",
       "1371        1371  NCT00196833   \n",
       "1380        1380  NCT04947280   \n",
       "1538        1538  NCT05010863   \n",
       "1692        1692  NCT05913440   \n",
       "1693        1693  NCT04996615   \n",
       "1724        1724  NCT04680442   \n",
       "1725        1725  NCT02695121   \n",
       "1731        1731  NCT05428527   \n",
       "1751        1751  NCT05374603   \n",
       "1784        1784  NCT04567420   \n",
       "1793        1793  NCT05665660   \n",
       "1834        1834  NCT05060068   \n",
       "1982        1982  NCT05932121   \n",
       "2033        2033  NCT05179824   \n",
       "2081        2081  NCT05769517   \n",
       "2108        2108  NCT05228106   \n",
       "2137        2137  NCT04068168   \n",
       "2418        2418  NCT03452774   \n",
       "2464        2464  NCT02302742   \n",
       "2537        2537  NCT05601388   \n",
       "2545        2545  NCT05564377   \n",
       "2609        2609  NCT05834699   \n",
       "2616        2616  NCT05677308   \n",
       "2618        2618  NCT04050423   \n",
       "2644        2644  NCT04428528   \n",
       "2691        2691  NCT02206984   \n",
       "2794        2794  NCT05483712   \n",
       "2985        2985  NCT03687151   \n",
       "3242        3242  NCT00437879   \n",
       "3250        3250  NCT03578380   \n",
       "3314        3314  NCT05440929   \n",
       "3328        3328  NCT03941639   \n",
       "3370        3370  NCT05770037   \n",
       "3512        3512  NCT04549571   \n",
       "3531        3531  NCT03995082   \n",
       "3537        3537  NCT05044689   \n",
       "3665        3665  NCT05601440   \n",
       "3822        3822  NCT05631873   \n",
       "3834        3834  NCT05905939   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "35    Evaluating Scaleup of an Adapted Breast Cancer...   \n",
       "115   HER2 Expression of CTC to Predict Response in ...   \n",
       "132   DETERMINE Trial Treatment Arm 03: Entrectinib ...   \n",
       "227   DETERMINE Trial Treatment Arm 02: Atezolizumab...   \n",
       "242   OCTANE: Adjuvant Liposomal Doxorubicin and Car...   \n",
       "296                           RC48-ADC in Breast Cancer   \n",
       "426   To Identify Primary Resistance to CDK4/6 Inhib...   \n",
       "436   Assessment of Brain Cognitive Impairment in Br...   \n",
       "546   ScreenIng of Genetic Susceptibility Genes for ...   \n",
       "724   Dietary and Exercise Interventions in Reducing...   \n",
       "868   Pyrotinib Combined With Capecitabine in HER-2 ...   \n",
       "1088  Endoscopic Surgery in the Treatment of Soft Ti...   \n",
       "1108  Germline Alterations of Tumor Susceptibility G...   \n",
       "1160  InAdvance: Surveillance, Prevention, and Inter...   \n",
       "1173  Research of Biomarkers of Response to Proton B...   \n",
       "1199  SUROVA - Surgery in Ovarian Cancer, Comparing ...   \n",
       "1204  Familial Investigations of Childhood Cancer Pr...   \n",
       "1270  Pilot Study to Evaluate Photoacoustic Imaging ...   \n",
       "1326  Collecting Tissue Samples for Future Research ...   \n",
       "1371          Breast Cancer in Pregnancy Register Study   \n",
       "1380  Single Arm Phase II Study of Fractionated Ster...   \n",
       "1538  Gastric Cancer Marker Detection and Its Kit De...   \n",
       "1692  HER2-low Unresectable and/or Metastatic Breast...   \n",
       "1693  Artificial Intelligence Analysis for Magnetic ...   \n",
       "1724  Safety of Continuing HER-2 Directed Therapy in...   \n",
       "1725  Cancer in Patients on Dapagliflozin and Other ...   \n",
       "1731  Real-world Clinical Benefit Evaluation in Brea...   \n",
       "1751  Savolitinib Combine With Durvalumab in EGFR Wi...   \n",
       "1784  DNA-Guided Second Line Adjuvant Therapy For Hi...   \n",
       "1793  Developing and Evaluating Culturally Relevant ...   \n",
       "1834  Effect of Intravenous S-ketamine on Opioid Con...   \n",
       "1982  Cross-sectional Case and Control Study on Qual...   \n",
       "2033  Tempus Priority Study: A Pan-tumor Observation...   \n",
       "2081  PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEA...   \n",
       "2108  68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor...   \n",
       "2137  Open Label, Multicenter, Real World Practice o...   \n",
       "2418  SYNERGY-AI: Artificial Intelligence Based Prec...   \n",
       "2464  Triple Negative Breast Cancer and Germline Her...   \n",
       "2537  Role of IMP3 Expression in Colorectal Carcinom...   \n",
       "2545  Targeted Therapy Directed by Genetic Testing i...   \n",
       "2609  HER2 Expression of CTC to Predict Response in ...   \n",
       "2616  LYNPARZA Breast Cancer in the Adjuvant Setting...   \n",
       "2618  Investigation of Ultrasound Imaging and Spectr...   \n",
       "2644  Photoacoustic Imaging for Characterizing Breas...   \n",
       "2691  Endocrine Response in Women With Invasive Lobu...   \n",
       "2794  Brass Mesh Bolus in Rotational Post-Mastectomy...   \n",
       "2985                Population-based Cancer Observatory   \n",
       "3242  Ultrasound Imaging, Spectroscopy and Ultrasoun...   \n",
       "3250  Supermicrosurgery for Breast Cancer Survivors ...   \n",
       "3314  Evaluation of the Acceptability, Appropriatene...   \n",
       "3328  Using Imaging Data and Genomic Data to Predict...   \n",
       "3370  DETERMINE Trial Treatment Arm 01: Alectinib in...   \n",
       "3512  Improving Patient-Centered Communication in Br...   \n",
       "3531  Breast Cancer Patient Engagement With Patient ...   \n",
       "3537  Case Control Study to Identify Modifiable Risk...   \n",
       "3665  Liquid-biopsy Informed Platform Trial to Evalu...   \n",
       "3822  Colonoscopy Screening: Setting Epic Follow-up ...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "35    https://www.clinicaltrials.gov/study/NCT05364138   Recruiting   \n",
       "115   https://www.clinicaltrials.gov/study/NCT05834686   Recruiting   \n",
       "132   https://www.clinicaltrials.gov/study/NCT05770544   Recruiting   \n",
       "227   https://www.clinicaltrials.gov/study/NCT05770102   Recruiting   \n",
       "242   https://www.clinicaltrials.gov/study/NCT05949021   Recruiting   \n",
       "296   https://www.clinicaltrials.gov/study/NCT05851677   Recruiting   \n",
       "426   https://www.clinicaltrials.gov/study/NCT04660435   Recruiting   \n",
       "436   https://www.clinicaltrials.gov/study/NCT05305092   Recruiting   \n",
       "546   https://www.clinicaltrials.gov/study/NCT04265937   Recruiting   \n",
       "724   https://www.clinicaltrials.gov/study/NCT03953157   Recruiting   \n",
       "868   https://www.clinicaltrials.gov/study/NCT05359120   Recruiting   \n",
       "1088  https://www.clinicaltrials.gov/study/NCT05614375   Recruiting   \n",
       "1108  https://www.clinicaltrials.gov/study/NCT00579514   Recruiting   \n",
       "1160  https://www.clinicaltrials.gov/study/NCT05463796   Recruiting   \n",
       "1173  https://www.clinicaltrials.gov/study/NCT04367779   Recruiting   \n",
       "1199  https://www.clinicaltrials.gov/study/NCT06223763   Recruiting   \n",
       "1204  https://www.clinicaltrials.gov/study/NCT03050268   Recruiting   \n",
       "1270  https://www.clinicaltrials.gov/study/NCT04428515   Recruiting   \n",
       "1326  https://www.clinicaltrials.gov/study/NCT00898131   Recruiting   \n",
       "1371  https://www.clinicaltrials.gov/study/NCT00196833   Recruiting   \n",
       "1380  https://www.clinicaltrials.gov/study/NCT04947280   Recruiting   \n",
       "1538  https://www.clinicaltrials.gov/study/NCT05010863   Recruiting   \n",
       "1692  https://www.clinicaltrials.gov/study/NCT05913440   Recruiting   \n",
       "1693  https://www.clinicaltrials.gov/study/NCT04996615   Recruiting   \n",
       "1724  https://www.clinicaltrials.gov/study/NCT04680442   Recruiting   \n",
       "1725  https://www.clinicaltrials.gov/study/NCT02695121   Recruiting   \n",
       "1731  https://www.clinicaltrials.gov/study/NCT05428527   Recruiting   \n",
       "1751  https://www.clinicaltrials.gov/study/NCT05374603   Recruiting   \n",
       "1784  https://www.clinicaltrials.gov/study/NCT04567420   Recruiting   \n",
       "1793  https://www.clinicaltrials.gov/study/NCT05665660   Recruiting   \n",
       "1834  https://www.clinicaltrials.gov/study/NCT05060068   Recruiting   \n",
       "1982  https://www.clinicaltrials.gov/study/NCT05932121   Recruiting   \n",
       "2033  https://www.clinicaltrials.gov/study/NCT05179824   Recruiting   \n",
       "2081  https://www.clinicaltrials.gov/study/NCT05769517   Recruiting   \n",
       "2108  https://www.clinicaltrials.gov/study/NCT05228106   Recruiting   \n",
       "2137  https://www.clinicaltrials.gov/study/NCT04068168   Recruiting   \n",
       "2418  https://www.clinicaltrials.gov/study/NCT03452774   Recruiting   \n",
       "2464  https://www.clinicaltrials.gov/study/NCT02302742   Recruiting   \n",
       "2537  https://www.clinicaltrials.gov/study/NCT05601388   Recruiting   \n",
       "2545  https://www.clinicaltrials.gov/study/NCT05564377   Recruiting   \n",
       "2609  https://www.clinicaltrials.gov/study/NCT05834699   Recruiting   \n",
       "2616  https://www.clinicaltrials.gov/study/NCT05677308   Recruiting   \n",
       "2618  https://www.clinicaltrials.gov/study/NCT04050423   Recruiting   \n",
       "2644  https://www.clinicaltrials.gov/study/NCT04428528   Recruiting   \n",
       "2691  https://www.clinicaltrials.gov/study/NCT02206984   Recruiting   \n",
       "2794  https://www.clinicaltrials.gov/study/NCT05483712   Recruiting   \n",
       "2985  https://www.clinicaltrials.gov/study/NCT03687151   Recruiting   \n",
       "3242  https://www.clinicaltrials.gov/study/NCT00437879   Recruiting   \n",
       "3250  https://www.clinicaltrials.gov/study/NCT03578380   Recruiting   \n",
       "3314  https://www.clinicaltrials.gov/study/NCT05440929   Recruiting   \n",
       "3328  https://www.clinicaltrials.gov/study/NCT03941639   Recruiting   \n",
       "3370  https://www.clinicaltrials.gov/study/NCT05770037   Recruiting   \n",
       "3512  https://www.clinicaltrials.gov/study/NCT04549571   Recruiting   \n",
       "3531  https://www.clinicaltrials.gov/study/NCT03995082   Recruiting   \n",
       "3537  https://www.clinicaltrials.gov/study/NCT05044689   Recruiting   \n",
       "3665  https://www.clinicaltrials.gov/study/NCT05601440   Recruiting   \n",
       "3822  https://www.clinicaltrials.gov/study/NCT05631873   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "35    Breast Cancer, Benign Breast Disease, Cervix C...   \n",
       "115                                       Breast Cancer   \n",
       "132   Solid Tumor, Haematological Malignancy, Malign...   \n",
       "227   Malignancy, Malignant Neoplasm, Lymphoprolifer...   \n",
       "242                Triple Negative Breast Cancer (TNBC)   \n",
       "296                                       Breast Cancer   \n",
       "426   Metastatic Breast Cancer, ER Positive Breast C...   \n",
       "436       Breast Cancer, Chemo-brain, Endocrine Therapy   \n",
       "546               Breast Cancer, Genetic Susceptibility   \n",
       "724   Anatomic Stage I Breast Cancer AJCC v8, Anatom...   \n",
       "868                                       Breast Cancer   \n",
       "1088  Sarcoma,Soft Tissue, Nasal Cavity Cancer, Para...   \n",
       "1108  Breast Cancer, Bladder Cancer, Kidney Cancer, ...   \n",
       "1160  Cancer Risk, Cancer Predisposition Syndrome, H...   \n",
       "1173                  Brain Cancer, Meningioma, Sarcoma   \n",
       "1199  Epithelial Ovarian Cancer, Fallopian Tube Neop...   \n",
       "1204  Acute Leukemia, Adenomatous Polyposis, Adrenoc...   \n",
       "1270                               Head and Neck Cancer   \n",
       "1326                                      Breast Cancer   \n",
       "1371                                      Breast Cancer   \n",
       "1380                     Bone Metastases, Breast Cancer   \n",
       "1538                                     Gastric Cancer   \n",
       "1692                                      Breast Cancer   \n",
       "1693          Breast Cancer, Magnetic Resonance Imaging   \n",
       "1724                       Breast Cancer, Heart Failure   \n",
       "1725                      Breast Cancer, Bladder Cancer   \n",
       "1731                             Cancer-related Fatigue   \n",
       "1751                                        Lung Cancer   \n",
       "1784                                      Breast Cancer   \n",
       "1793                                      Breast Cancer   \n",
       "1834                              Breast Cancer Surgery   \n",
       "1982        Papillary Thyroid Carcinoma, Thyroid Cancer   \n",
       "2033  Breast Cancer, Prostate Cancer, Bladder Cancer...   \n",
       "2081  BRCA Mutation, Ovarian Cancer, Ultrasound Ther...   \n",
       "2108                                      Solid Cancers   \n",
       "2137                                        Lung Cancer   \n",
       "2418  Cancer, Metastatic, Cancer, Cancer of Pancreas...   \n",
       "2464  Breast Cancer, Hereditary Breast and Ovarian C...   \n",
       "2537                                  Colorectal Cancer   \n",
       "2545  Advanced Malignant Solid Neoplasm, Anatomic St...   \n",
       "2609                                      Breast Cancer   \n",
       "2616                                      Breast Cancer   \n",
       "2618                                      Breast Cancer   \n",
       "2644                                      Breast Cancer   \n",
       "2691                                      Breast Cancer   \n",
       "2794                                      Breast Cancer   \n",
       "2985                                             Cancer   \n",
       "3242                             Breast Cancer Invasive   \n",
       "3250                Secondary Lymphedema, Breast Cancer   \n",
       "3314              Metastatic Breast Cancer, End of Life   \n",
       "3328                                      Breast Cancer   \n",
       "3370  Solid Tumor, Haematological Malignancy, Malign...   \n",
       "3512  Anatomic Stage 0 Breast Cancer AJCC v8, Anatom...   \n",
       "3531                                      Breast Cancer   \n",
       "3537                   Colorectal Cancer, Breast Cancer   \n",
       "3665                                      Breast Cancer   \n",
       "3822  Concordance Between Colonoscopy Follow up Inte...   \n",
       "3834                                      Breast Cancer   \n",
       "\n",
       "                                              LOCATIONS          START_DATE  \\\n",
       "35    [{'Location Facility': 'Partners in Health (In...       July 31, 2023   \n",
       "115   [{'Location Facility': 'The Fifth Medical Cent...     January 1, 2023   \n",
       "132   [{'Location Facility': 'Belfast City Hospital'...           June 2024   \n",
       "227   [{'Location Facility': 'Belfast City Hospital'...    October 25, 2023   \n",
       "242   [{'Location Facility': 'RWJBarnabas Health - T...     October 7, 2023   \n",
       "296   [{'Location Facility': 'Renji Hospital, School...        June 1, 2023   \n",
       "426   [{'Location Facility': 'Hospital Santo Stefano...   September 1, 2020   \n",
       "436   [{'Location Facility': 'Tangdu Hospital', 'Loc...        May 31, 2022   \n",
       "546   [{'Location Facility': 'Zhen Hu', 'Location Ci...        July 1, 2019   \n",
       "724   [{'Location Facility': 'UCLA / Jonsson Compreh...     October 7, 2019   \n",
       "868   [{'Location Facility': 'Henan cancer hospital'...        May 30, 2022   \n",
       "1088  [{'Location Facility': 'Yu Hongmeng', 'Locatio...       June 12, 2021   \n",
       "1108  [{'Location Facility': 'Memorial Sloan Ketteri...          March 2000   \n",
       "1160  [{'Location Facility': 'Dana Farber Cancer Ins...      April 25, 2023   \n",
       "1173  [{'Location Facility': 'Centre Léon Bérard', '...  September 24, 2020   \n",
       "1199  [{'Location Facility': 'Clínica Universidad de...     January 1, 2024   \n",
       "1204  [{'Location Facility': \"St. Jude Children's Re...       April 6, 2017   \n",
       "1270  [{'Location Facility': 'Sunnybrook Health Scie...      April 23, 2019   \n",
       "1326  [{'Location Facility': 'Robert H. Lurie Compre...         August 2001   \n",
       "1371  [{'Location Facility': 'German Breast Group', ...          April 2003   \n",
       "1380  [{'Location Facility': 'Fudan University Shang...     January 1, 2021   \n",
       "1538  [{'Location Facility': 'No. 109, Xueyuan West ...     January 1, 2021   \n",
       "1692  [{'Location Facility': 'Research Site', 'Locat...        May 30, 2023   \n",
       "1693  [{'Location Facility': \"Peking university peop...   September 1, 2021   \n",
       "1724  [{'Location Facility': 'Hospital de Clínicas d...        July 1, 2021   \n",
       "1725  [{'Location Facility': 'Research Site', 'Locat...     January 1, 2017   \n",
       "1731  [{'Location Facility': 'E-Da Cancer Hospital',...   September 8, 2021   \n",
       "1751  [{'Location Facility': 'Research Site', 'Locat...   November 23, 2022   \n",
       "1784  [{'Location Facility': 'University of Arizona ...    February 9, 2021   \n",
       "1793  [{'Location Facility': 'Center for Indigenous ...        June 6, 2023   \n",
       "1834  [{'Location Facility': 'Second Affiliated Hosp...     October 7, 2021   \n",
       "1982  [{'Location Facility': 'Department of General ...       June 25, 2023   \n",
       "2033  [{'Location Facility': 'Providence Medical Fou...    October 19, 2020   \n",
       "2081  [{'Location Facility': 'Fondazione Policlinico...      March 20, 2023   \n",
       "2108  [{'Location Facility': 'CHUS', 'Location City'...    January 21, 2022   \n",
       "2137  [{'Location Facility': 'Research Site', 'Locat...    January 30, 2020   \n",
       "2418  [{'Location Facility': 'Massive Bio, Inc', 'Lo...     January 1, 2018   \n",
       "2464  [{'Location Facility': 'Hays Medical Center Dr...      March 22, 2011   \n",
       "2537  [{'Location Facility': 'Faculty of Medicine', ...     October 1, 2022   \n",
       "2545  [{'Location Facility': 'University of Alabama ...       April 7, 2023   \n",
       "2609  [{'Location Facility': 'The Fifth Medical Cent...     January 1, 2023   \n",
       "2616  [{'Location Facility': 'Research Site', 'Locat...       March 7, 2023   \n",
       "2618  [{'Location Facility': 'Sunnybrook Health Scie...  September 23, 2014   \n",
       "2644  [{'Location Facility': 'Sunnybrook Health Scie...   February 13, 2017   \n",
       "2691  [{'Location Facility': 'UAB Comprehensive Canc...  September 30, 2015   \n",
       "2794  [{'Location Facility': 'Nova Scotia Health Aut...    January 18, 2023   \n",
       "2985  [{'Location Facility': 'Nice University Hospit...     January 1, 2005   \n",
       "3242  [{'Location Facility': 'Sunnybrook Health Scie...   December 17, 2008   \n",
       "3250  [{'Location Facility': 'Sykehuset Telemark', '...    January 26, 2016   \n",
       "3314  [{'Location Facility': 'University of North Ca...       July 15, 2022   \n",
       "3328  [{'Location Facility': 'The Chinese University...   September 1, 2019   \n",
       "3370  [{'Location Facility': 'Belfast City Hospital'...   December 18, 2023   \n",
       "3512  [{'Location Facility': 'Kaiser Permanente-Vall...    January 15, 2021   \n",
       "3531  [{'Location Facility': 'University of Colorado...    October 30, 2019   \n",
       "3537  [{'Location Facility': 'Obafemi Awolowo Univer...      April 12, 2021   \n",
       "3665  [{'Location Facility': 'BCCA - Cancer Centre f...       June 13, 2023   \n",
       "3822  [{'Location Facility': 'Massachusetts General ...   November 18, 2022   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...        May 31, 2023   \n",
       "\n",
       "         COMPLETION_DATE                        AGE  \\\n",
       "35        March 30, 2024  ||Child|Adult|Older Adult   \n",
       "115           April 2025  ||Child|Adult|Older Adult   \n",
       "132         October 2029  ||Child|Adult|Older Adult   \n",
       "227         October 2029  ||Child|Adult|Older Adult   \n",
       "242   September 30, 2027  ||Child|Adult|Older Adult   \n",
       "296          August 2027  ||Child|Adult|Older Adult   \n",
       "426     December 1, 2026  ||Child|Adult|Older Adult   \n",
       "436         May 30, 2027  ||Child|Adult|Older Adult   \n",
       "546        June 30, 2026  ||Child|Adult|Older Adult   \n",
       "724         June 1, 2025  ||Child|Adult|Older Adult   \n",
       "868             May 2024  ||Child|Adult|Older Adult   \n",
       "1088       June 12, 2026  ||Child|Adult|Older Adult   \n",
       "1108          March 2024  ||Child|Adult|Older Adult   \n",
       "1160      March 25, 2032  ||Child|Adult|Older Adult   \n",
       "1173           June 2024  ||Child|Adult|Older Adult   \n",
       "1199        June 1, 2024  ||Child|Adult|Older Adult   \n",
       "1204      March 31, 2037  ||Child|Adult|Older Adult   \n",
       "1270      April 23, 2027  ||Child|Adult|Older Adult   \n",
       "1326        January 2025  ||Child|Adult|Older Adult   \n",
       "1371          April 2026  ||Child|Adult|Older Adult   \n",
       "1380   December 31, 2026  ||Child|Adult|Older Adult   \n",
       "1538   December 30, 2030  ||Child|Adult|Older Adult   \n",
       "1692        May 31, 2024  ||Child|Adult|Older Adult   \n",
       "1693  September 30, 2025  ||Child|Adult|Older Adult   \n",
       "1724    December 1, 2025  ||Child|Adult|Older Adult   \n",
       "1725   December 31, 2024  ||Child|Adult|Older Adult   \n",
       "1731   December 31, 2023  ||Child|Adult|Older Adult   \n",
       "1751   December 31, 2024  ||Child|Adult|Older Adult   \n",
       "1784   December 15, 2026  ||Child|Adult|Older Adult   \n",
       "1793       December 2025  ||Child|Adult|Older Adult   \n",
       "1834        July 7, 2024  ||Child|Adult|Older Adult   \n",
       "1982       July 31, 2024  ||Child|Adult|Older Adult   \n",
       "2033    October 19, 2030  ||Child|Adult|Older Adult   \n",
       "2081         May 2, 2026  ||Child|Adult|Older Adult   \n",
       "2108    January 31, 2027  ||Child|Adult|Older Adult   \n",
       "2137     August 31, 2024  ||Child|Adult|Older Adult   \n",
       "2418           June 2025  ||Child|Adult|Older Adult   \n",
       "2464       December 2025  ||Child|Adult|Older Adult   \n",
       "2537        June 1, 2023  ||Child|Adult|Older Adult   \n",
       "2545        July 1, 2030  ||Child|Adult|Older Adult   \n",
       "2609          April 2025  ||Child|Adult|Older Adult   \n",
       "2616   December 31, 2026  ||Child|Adult|Older Adult   \n",
       "2618      September 2029  ||Child|Adult|Older Adult   \n",
       "2644   February 13, 2029  ||Child|Adult|Older Adult   \n",
       "2691          March 2023  ||Child|Adult|Older Adult   \n",
       "2794   November 21, 2023  ||Child|Adult|Older Adult   \n",
       "2985   December 31, 2050  ||Child|Adult|Older Adult   \n",
       "3242           June 2029  ||Child|Adult|Older Adult   \n",
       "3250   December 31, 2024  ||Child|Adult|Older Adult   \n",
       "3314       July 15, 2025  ||Child|Adult|Older Adult   \n",
       "3328        June 1, 2025  ||Child|Adult|Older Adult   \n",
       "3370        October 2029  ||Child|Adult|Older Adult   \n",
       "3512        January 2027  ||Child|Adult|Older Adult   \n",
       "3531           June 2025  ||Child|Adult|Older Adult   \n",
       "3537          April 2024  ||Child|Adult|Older Adult   \n",
       "3665           June 2028  ||Child|Adult|Older Adult   \n",
       "3822       June 30, 2024  ||Child|Adult|Older Adult   \n",
       "3834        May 31, 2024  ||Child|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "35    Inclusion criteria include all individuals eva...   \n",
       "115   Eligibility includes individuals with patholog...   \n",
       "132   Eligibility includes adults, teenagers, and ch...   \n",
       "227   Participants must fulfill eligibility criteria...   \n",
       "242   Eligibility includes newly diagnosed early-sta...   \n",
       "296   Participants must have histologically confirme...   \n",
       "426   Women aged 18 or older with ER-positive, HER2-...   \n",
       "436   Inclusion criteria include premenopausal women...   \n",
       "546   Inclusion criteria include breast cancer patie...   \n",
       "724   Eligibility includes women diagnosed with loca...   \n",
       "868   Eligibility includes pathologically diagnosed ...   \n",
       "1088  Inclusion criteria include signing the informe...   \n",
       "1108  Eligibility includes patients with a histologi...   \n",
       "1160  Participants include those with hereditary can...   \n",
       "1173  Eligibility includes male or female patients o...   \n",
       "1199  Eligibility includes patients over 18 years ol...   \n",
       "1204  This study targets individuals with a history ...   \n",
       "1270  Eligibility includes individuals with histolog...   \n",
       "1326  Participants are eligible if they are undergoi...   \n",
       "1371  Women with histologically confirmed breast can...   \n",
       "1380  Eligibility includes individuals with invasive...   \n",
       "1538  Eligibility includes patients aged ≥18 years w...   \n",
       "1692  Eligibility includes patients with confirmed d...   \n",
       "1693  Eligibility includes patients undergoing full ...   \n",
       "1724  Participants must have Stage I-III HER-2 posit...   \n",
       "1725  Inclusion criteria include patients newly pres...   \n",
       "1731  Inclusion criteria include breast cancer patie...   \n",
       "1751  Eligibility includes patients 18 years or olde...   \n",
       "1784  Eligibility includes Stage II or III, HER2 neg...   \n",
       "1793  Eligibility includes women referred for screen...   \n",
       "1834  Eligibility includes female patients with an A...   \n",
       "1982  Inclusion criteria include PTC patients who un...   \n",
       "2033  Eligibility includes individuals with solid or...   \n",
       "2081  Participants must have available gBRCA1/2 test...   \n",
       "2108  Eligible participants include those with a cli...   \n",
       "2137  Inclusion criteria include patients eligible f...   \n",
       "2418  Eligibility includes patients with solid and h...   \n",
       "2464  Eligibility includes Triple Negative Breast Ca...   \n",
       "2537  Inclusion criteria include patients with color...   \n",
       "2545  Eligibility includes patients with measurable ...   \n",
       "2609  Eligibility includes individuals with patholog...   \n",
       "2616  Eligibility includes patients initiating treat...   \n",
       "2618  Eligibility includes both women and men with s...   \n",
       "2644  Eligibility includes men and women aged 20-80,...   \n",
       "2691  Eligibility includes women with histologically...   \n",
       "2794  Women undergoing rotational chest wall radioth...   \n",
       "2985  Inclusion criteria include all subjects diagno...   \n",
       "3242  Eligibility includes individuals with histolog...   \n",
       "3250  Participants are eligible if they have unilate...   \n",
       "3314  Participants must have verbal informed consent...   \n",
       "3328  Individuals are eligible if they have a clinic...   \n",
       "3370  Eligibility includes adults, teenagers, and ch...   \n",
       "3512  Eligibility includes women aged 21-84, newly d...   \n",
       "3531  The study targets adult females (18 years or o...   \n",
       "3537  For the case group, patients must have a histo...   \n",
       "3665  Eligibility includes adults (≥18 years) with h...   \n",
       "3822  Inclusion criteria focus on GI specialists at ...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "35    The primary outcome focuses on the number of p...   \n",
       "115   The primary outcome measure is Progression Fre...   \n",
       "132   The primary outcomes focus on Objective Respon...   \n",
       "227   The primary outcomes include Objective Respons...   \n",
       "242   The primary outcome is the Disease-Free Surviv...   \n",
       "296   The primary outcome measure is Progression-Fre...   \n",
       "426   The primary outcome measure is progression-fre...   \n",
       "436   The study measures changes in the brain's gray...   \n",
       "546   The primary outcome is to measure the frequenc...   \n",
       "724   Primary outcomes focus on bone mineral density...   \n",
       "868   The primary outcome measure is Time to Failure...   \n",
       "1088  The primary outcome measure is overall surviva...   \n",
       "1108  The primary outcome is to collect anonymized g...   \n",
       "1160  The primary outcome is to identify exposures, ...   \n",
       "1173  The primary outcome is to identify predictive ...   \n",
       "1199  The primary outcome measure is the comparison ...   \n",
       "1204  The primary outcome of the study is the identi...   \n",
       "1270  The primary outcome focuses on the correlation...   \n",
       "1326  The primary outcome is to collect human breast...   \n",
       "1371                                     Not specified.   \n",
       "1380  The primary outcome measure is the local contr...   \n",
       "1538  The primary outcome is to obtain subject serum...   \n",
       "1692  The study aims to assess the overall prevalenc...   \n",
       "1693  The primary outcome is to compare the rates of...   \n",
       "1724  The primary outcomes focus on the efficacy and...   \n",
       "1725  The primary outcomes focus on the incidence of...   \n",
       "1731  The primary outcome measure is the improvement...   \n",
       "1751  The primary outcome measure is Progression-Fre...   \n",
       "1784  The primary outcomes focus on two phases: the ...   \n",
       "1793  The primary outcome measure is the uptake of m...   \n",
       "1834  The primary outcome measure is the consumption...   \n",
       "1982  The primary outcome focuses on the cosmetic ou...   \n",
       "2033  The primary outcome is to create a robust data...   \n",
       "2081  The study aims to enhance and prospectively va...   \n",
       "2108  The primary outcome focuses on the incidence o...   \n",
       "2137  The primary outcomes focus on assessing the sa...   \n",
       "2418  The primary outcome measure is the proportion ...   \n",
       "2464  The primary outcomes include the prevalence of...   \n",
       "2537  The primary outcome is to evaluate the immunoh...   \n",
       "2545  Primary outcomes focus on the accrual, assignm...   \n",
       "2609  The primary outcome measure is Progression Fre...   \n",
       "2616  The primary outcome is to measure the incidenc...   \n",
       "2618  The primary outcome is to select the best quan...   \n",
       "2644  The primary outcome focuses on correlating tre...   \n",
       "2691  The primary outcome measure is the change in K...   \n",
       "2794  The primary outcome measure is the skin dose e...   \n",
       "2985  The primary outcome is the enumeration of each...   \n",
       "3242  The primary outcome involves correlating chang...   \n",
       "3250  The primary outcome measure is the volume of t...   \n",
       "3314  The primary outcomes focus on identifying key ...   \n",
       "3328  The primary outcome is the area under the rece...   \n",
       "3370  The primary outcomes are Objective Response (O...   \n",
       "3512  The primary outcome is patient knowledge about...   \n",
       "3531  The primary outcome is patient satisfaction wi...   \n",
       "3537  The primary outcomes include the development a...   \n",
       "3665  The primary outcomes focus on evaluating the i...   \n",
       "3822  The primary outcomes involve implementing a ne...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "35    Secondary outcomes include analyzing the media...   \n",
       "115   Secondary outcomes include the Objective Respo...   \n",
       "132   Secondary outcomes include Duration of Respons...   \n",
       "227   Secondary outcomes encompass Duration of Respo...   \n",
       "242   Secondary outcomes focus on the safety and tox...   \n",
       "296   The secondary outcome focuses on the assessmen...   \n",
       "426   The secondary outcome measure is the clinical ...   \n",
       "436   Secondary outcomes focus on the change in conc...   \n",
       "546   Secondary outcomes, measured over 1 year, incl...   \n",
       "724                No secondary outcomes were provided.   \n",
       "868   Secondary outcomes include Progression-free su...   \n",
       "1088  Secondary outcomes include local recurrence-fr...   \n",
       "1108  The secondary outcome involves analyzing DNA s...   \n",
       "1160                No secondary outcomes are provided.   \n",
       "1173  Secondary outcomes include identifying predict...   \n",
       "1199  Secondary outcomes include comparing Progressi...   \n",
       "1204                                     Not specified.   \n",
       "1270  Secondary outcomes aim to correlate changes in...   \n",
       "1326                                     Not specified.   \n",
       "1371                                     Not specified.   \n",
       "1380  Secondary outcomes include evaluating pain con...   \n",
       "1538               No secondary outcomes are specified.   \n",
       "1692  Secondary objectives include describing diagno...   \n",
       "1693  Secondary outcomes involve comparing the sensi...   \n",
       "1724  The secondary outcome measures the composite o...   \n",
       "1725  The secondary outcome measures the incidence o...   \n",
       "1731  Secondary outcomes include the level of fatigu...   \n",
       "1751  Secondary outcomes include Objective Response ...   \n",
       "1784  Secondary outcomes include assessing the feasi...   \n",
       "1793               No secondary outcomes were provided.   \n",
       "1834  Secondary outcomes include postoperative pain ...   \n",
       "1982  Secondary outcomes include the evaluation of t...   \n",
       "2033  Secondary outcomes include documenting specifi...   \n",
       "2081                No secondary outcomes are provided.   \n",
       "2108  Secondary outcomes aim to generate clinical in...   \n",
       "2137  Secondary outcomes aim to evaluate the efficac...   \n",
       "2418  Secondary outcomes include the impact of CTE o...   \n",
       "2464               No secondary outcomes were provided.   \n",
       "2537               No secondary outcomes were provided.   \n",
       "2545  Secondary outcomes include the rate of positiv...   \n",
       "2609  Secondary outcomes include the Objective Respo...   \n",
       "2616               No secondary outcomes were provided.   \n",
       "2618  The secondary outcome focuses on correlating t...   \n",
       "2644  The secondary outcome aims to investigate if b...   \n",
       "2691  Secondary outcomes include measuring estrogen ...   \n",
       "2794               No secondary outcomes were provided.   \n",
       "2985               No secondary outcomes are specified.   \n",
       "3242  Secondary outcomes focus on examining changes ...   \n",
       "3250  The secondary outcome is the health-related qu...   \n",
       "3314  Secondary outcomes aim to identify key barrier...   \n",
       "3328                                     Not specified.   \n",
       "3370  Secondary outcomes include Duration of Respons...   \n",
       "3512  Secondary outcomes include patient self-effica...   \n",
       "3531  Secondary outcomes include various BREAST Q Pa...   \n",
       "3537               No secondary outcomes were provided.   \n",
       "3665  Secondary outcomes include assessing the numbe...   \n",
       "3822               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "35    The document does not specify interventions di...   \n",
       "115   The intervention involves detecting HER2 expre...   \n",
       "132   The intervention involves administering entrec...   \n",
       "227   The intervention involves administering atezol...   \n",
       "242   The intervention involves a combination of lip...   \n",
       "296   The intervention involves administering the dr...   \n",
       "426   The intervention involves a diagnostic test ca...   \n",
       "436   Participants undergo PET/MRI scans, complete p...   \n",
       "546   The document does not specify interventions, s...   \n",
       "724   The study involves two experimental arms. Arm ...   \n",
       "868   Interventions involve patients in three cohort...   \n",
       "1088  The intervention involves patients with soft t...   \n",
       "1108  The intervention involves the PCR/PCR/LDR Stra...   \n",
       "1160  Participants across different risk groups (her...   \n",
       "1173  The study involves pediatric and adult patient...   \n",
       "1199  Interventions involve cytoreductive surgery ai...   \n",
       "1204                                     Not specified.   \n",
       "1270  The intervention involves the use of a Photoac...   \n",
       "1326                                     Not specified.   \n",
       "1371                                     Not specified.   \n",
       "1380  The intervention involves participants being p...   \n",
       "1538  The intervention involves blood collection fro...   \n",
       "1692  The document does not specify interventions, s...   \n",
       "1693  The intervention involves women at high risk o...   \n",
       "1724  The study involves two groups: a control group...   \n",
       "1725  The document does not specify interventions, s...   \n",
       "1731  The intervention involves breast cancer patien...   \n",
       "1751  The intervention involves a combination of two...   \n",
       "1784  The study involves two arms: Arm A (experiment...   \n",
       "1793  The study involves two experimental arms. The ...   \n",
       "1834  The study involves three arms: a placebo group...   \n",
       "1982  The study involves two groups of PTC patients ...   \n",
       "2033  The study involves two groups, both under the ...   \n",
       "2081  The intervention involves conducting a multice...   \n",
       "2108  The intervention involves an intravenous injec...   \n",
       "2137  The document does not provide specific details...   \n",
       "2418  The intervention involves Clinical Trial Match...   \n",
       "2464  The study does not involve any interventions a...   \n",
       "2537                   No interventions were specified.   \n",
       "2545  Interventions vary across multiple experimenta...   \n",
       "2609  The intervention involves detecting HER2 expre...   \n",
       "2616           No specific interventions were detailed.   \n",
       "2618  The document does not specify interventions, s...   \n",
       "2644  The study involves two arms using the Photoaco...   \n",
       "2691  The study involves three active comparator arm...   \n",
       "2794  The intervention involves patients undergoing ...   \n",
       "2985  The study involves an observational interventi...   \n",
       "3242  The document does not specify interventions di...   \n",
       "3250  The study involves two arms: the experimental ...   \n",
       "3314  The intervention involves conducting semi-stru...   \n",
       "3328                                     Not specified.   \n",
       "3370  The intervention involves administering alecti...   \n",
       "3512  Interventions involve patients using the iCanD...   \n",
       "3531  Participants in the experimental group will re...   \n",
       "3537  The study involves two main interventions acro...   \n",
       "3665  The study involves three experimental arms: Su...   \n",
       "3822  The intervention consists of a research assist...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "35    {'Name': None, 'Organization': None, 'Email': ...   \n",
       "115   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "132   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "227   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "242   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "296   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "426   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "436   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "546   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "724   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "868   {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1088  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1108  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1160  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1173  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1199  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1204  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1270  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1326  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1371  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1380  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1538  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1692  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1693  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1724  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1725  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1731  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1751  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1784  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1793  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1982  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2033  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2081  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2108  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2137  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2418  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2464  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2537  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2545  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2609  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2616  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2618  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2644  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2691  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2794  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2985  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3242  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3250  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3314  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3328  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3370  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3512  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3531  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3537  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3665  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3822  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                  formatted_age  \n",
       "35    ||Child|Adult|Older Adult  \n",
       "115   ||Child|Adult|Older Adult  \n",
       "132   ||Child|Adult|Older Adult  \n",
       "227   ||Child|Adult|Older Adult  \n",
       "242   ||Child|Adult|Older Adult  \n",
       "296   ||Child|Adult|Older Adult  \n",
       "426   ||Child|Adult|Older Adult  \n",
       "436   ||Child|Adult|Older Adult  \n",
       "546   ||Child|Adult|Older Adult  \n",
       "724   ||Child|Adult|Older Adult  \n",
       "868   ||Child|Adult|Older Adult  \n",
       "1088  ||Child|Adult|Older Adult  \n",
       "1108  ||Child|Adult|Older Adult  \n",
       "1160  ||Child|Adult|Older Adult  \n",
       "1173  ||Child|Adult|Older Adult  \n",
       "1199  ||Child|Adult|Older Adult  \n",
       "1204  ||Child|Adult|Older Adult  \n",
       "1270  ||Child|Adult|Older Adult  \n",
       "1326  ||Child|Adult|Older Adult  \n",
       "1371  ||Child|Adult|Older Adult  \n",
       "1380  ||Child|Adult|Older Adult  \n",
       "1538  ||Child|Adult|Older Adult  \n",
       "1692  ||Child|Adult|Older Adult  \n",
       "1693  ||Child|Adult|Older Adult  \n",
       "1724  ||Child|Adult|Older Adult  \n",
       "1725  ||Child|Adult|Older Adult  \n",
       "1731  ||Child|Adult|Older Adult  \n",
       "1751  ||Child|Adult|Older Adult  \n",
       "1784  ||Child|Adult|Older Adult  \n",
       "1793  ||Child|Adult|Older Adult  \n",
       "1834  ||Child|Adult|Older Adult  \n",
       "1982  ||Child|Adult|Older Adult  \n",
       "2033  ||Child|Adult|Older Adult  \n",
       "2081  ||Child|Adult|Older Adult  \n",
       "2108  ||Child|Adult|Older Adult  \n",
       "2137  ||Child|Adult|Older Adult  \n",
       "2418  ||Child|Adult|Older Adult  \n",
       "2464  ||Child|Adult|Older Adult  \n",
       "2537  ||Child|Adult|Older Adult  \n",
       "2545  ||Child|Adult|Older Adult  \n",
       "2609  ||Child|Adult|Older Adult  \n",
       "2616  ||Child|Adult|Older Adult  \n",
       "2618  ||Child|Adult|Older Adult  \n",
       "2644  ||Child|Adult|Older Adult  \n",
       "2691  ||Child|Adult|Older Adult  \n",
       "2794  ||Child|Adult|Older Adult  \n",
       "2985  ||Child|Adult|Older Adult  \n",
       "3242  ||Child|Adult|Older Adult  \n",
       "3250  ||Child|Adult|Older Adult  \n",
       "3314  ||Child|Adult|Older Adult  \n",
       "3328  ||Child|Adult|Older Adult  \n",
       "3370  ||Child|Adult|Older Adult  \n",
       "3512  ||Child|Adult|Older Adult  \n",
       "3531  ||Child|Adult|Older Adult  \n",
       "3537  ||Child|Adult|Older Adult  \n",
       "3665  ||Child|Adult|Older Adult  \n",
       "3822  ||Child|Adult|Older Adult  \n",
       "3834  ||Child|Adult|Older Adult  "
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['AGE'].apply(has_numerical_age) == False]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>formatted_age</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>19 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18 years | 90 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>30 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18 years | 89 years</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 16 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                  formatted_age  \n",
       "0                      18 years  \n",
       "1                      18 years  \n",
       "2                      18 years  \n",
       "3                      18 years  \n",
       "4                      19 years  \n",
       "...                         ...  \n",
       "3831        18 years | 90 years  \n",
       "3832                   18 years  \n",
       "3833                   30 years  \n",
       "3834  ||Child|Adult|Older Adult  \n",
       "3835        18 years | 89 years  \n",
       "\n",
       "[3836 rows x 16 columns]"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [],
   "source": [
    "def filter_by_age(age_input):\n",
    "        output = {\"age_min\" : \"age\",\"age_max\" : \"age\" }\n",
    "        system_prompt = f\"\"\"You are helpful assistant to max age and min age from given senetence and give output in json format as {output} \"\"\" \n",
    "\n",
    "        response = openai.chat.completions.create(\n",
    "            model='gpt-4-0125-preview', \n",
    "            temperature=0,\n",
    "            messages=[\n",
    "                {\"role\":\"system\", \"content\":system_prompt},\n",
    "                {\"role\":\"user\", \"content\":f\"\"\" Extract the max age and min age from given input 18 Years|75 Years|Adult|Older Adult and give output in {output} format. \"\"\"},\n",
    "                {\"role\":\"assistant\", \"content\":\"\"\"{\"age_min\" : \"18\",\"age_max\" : \"75\" }\"\"\" },\n",
    "          {\"role\":\"user\", \"content\":f\"\"\" Extract the max age and min age from given input 18 Years|Adult|Older Adult and give output in {output} format. \"\"\"},\n",
    "                {\"role\":\"assistant\", \"content\":\"\"\"{\"age_min\" : \"18\",\"age_max\" : \"100\" }\"\"\" },\n",
    "          {\"role\":\"user\", \"content\":f\"\"\" Extract the max age and min age from given input 12 Months|30 Years|Child|Adult and give output in {output} format. \"\"\"},\n",
    "                {\"role\":\"assistant\", \"content\":\"\"\"{\"age_min\" : \"1\",\"age_max\" : \"30\" }\"\"\" },\n",
    "          {\"role\":\"user\", \"content\":f\"\"\" Extract the max age and min age from given input ||Child|Adult|Older Adult and give output in {output} format. \"\"\"},\n",
    "                {\"role\":\"assistant\", \"content\":\"\"\"{\"age_min\" : \"18\",\"age_max\" : \"100\" }\"\"\" },\n",
    "          {\"role\":\"user\", \"content\":f\"\"\" Extract the max age and min age from given input {age_input} and give output in {output} format. \"\"\"},\n",
    "            ],\n",
    "            max_tokens = 1024,\n",
    "            response_format={ \"type\": \"json_object\" }\n",
    "            \n",
    "        )  \n",
    "        res = response.choices[0].message.content\n",
    "        return res"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"formatted_age\"] = df[\"AGE\"].apply(filter_by_age)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>formatted_age</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"19\",\"age_max\" : \"100\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"90\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"30\",\"age_max\" : \"100\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\": \"0\", \"age_max\": \"100\"}</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"89\" }</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 16 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                              formatted_age  \n",
       "0     {\"age_min\" : \"18\",\"age_max\" : \"100\" }  \n",
       "1     {\"age_min\" : \"18\",\"age_max\" : \"100\" }  \n",
       "2     {\"age_min\" : \"18\",\"age_max\" : \"100\" }  \n",
       "3     {\"age_min\" : \"18\",\"age_max\" : \"100\" }  \n",
       "4     {\"age_min\" : \"19\",\"age_max\" : \"100\" }  \n",
       "...                                     ...  \n",
       "3831   {\"age_min\" : \"18\",\"age_max\" : \"90\" }  \n",
       "3832  {\"age_min\" : \"18\",\"age_max\" : \"100\" }  \n",
       "3833  {\"age_min\" : \"30\",\"age_max\" : \"100\" }  \n",
       "3834     {\"age_min\": \"0\", \"age_max\": \"100\"}  \n",
       "3835   {\"age_min\" : \"18\",\"age_max\" : \"89\" }  \n",
       "\n",
       "[3836 rows x 16 columns]"
      ]
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       {\"age_min\" : \"18\",\"age_max\" : \"100\" }\n",
       "1       {\"age_min\" : \"18\",\"age_max\" : \"100\" }\n",
       "2       {\"age_min\" : \"18\",\"age_max\" : \"100\" }\n",
       "3       {\"age_min\" : \"18\",\"age_max\" : \"100\" }\n",
       "4       {\"age_min\" : \"19\",\"age_max\" : \"100\" }\n",
       "                        ...                  \n",
       "3831     {\"age_min\" : \"18\",\"age_max\" : \"90\" }\n",
       "3832    {\"age_min\" : \"18\",\"age_max\" : \"100\" }\n",
       "3833    {\"age_min\" : \"30\",\"age_max\" : \"100\" }\n",
       "3834       {\"age_min\": \"0\", \"age_max\": \"100\"}\n",
       "3835     {\"age_min\" : \"18\",\"age_max\" : \"89\" }\n",
       "Name: formatted_age, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"formatted_age\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [],
   "source": [
    "def parse_dict(text):\n",
    "    try:\n",
    "        return ast.literal_eval(text)\n",
    "    except ValueError:\n",
    "        return {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"age_min\"] = df[\"formatted_age\"].apply(lambda x: parse_dict(x).get(\"age_min\", \"\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       18\n",
       "1       18\n",
       "2       18\n",
       "3       18\n",
       "4       19\n",
       "        ..\n",
       "3831    18\n",
       "3832    18\n",
       "3833    30\n",
       "3834     0\n",
       "3835    18\n",
       "Name: formatted_age, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"formatted_age\"].apply(lambda x: parse_dict(x).get(\"age_min\", \"\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"age_min\"] = df[\"formatted_age\"].apply(lambda x: parse_dict(x).get(\"age_min\", \"\"))\n",
    "df[\"age_max\"] = df[\"formatted_age\"].apply(lambda x: parse_dict(x).get(\"age_max\", \"\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>formatted_age</th>\n",
       "      <th>age_min</th>\n",
       "      <th>age_max</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"19\",\"age_max\" : \"100\" }</td>\n",
       "      <td>19</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"90\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>90</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"30\",\"age_max\" : \"100\" }</td>\n",
       "      <td>30</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\": \"0\", \"age_max\": \"100\"}</td>\n",
       "      <td>0</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"89\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>89</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                              formatted_age age_min age_max  \n",
       "0     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100  \n",
       "1     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100  \n",
       "2     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100  \n",
       "3     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100  \n",
       "4     {\"age_min\" : \"19\",\"age_max\" : \"100\" }      19     100  \n",
       "...                                     ...     ...     ...  \n",
       "3831   {\"age_min\" : \"18\",\"age_max\" : \"90\" }      18      90  \n",
       "3832  {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100  \n",
       "3833  {\"age_min\" : \"30\",\"age_max\" : \"100\" }      30     100  \n",
       "3834     {\"age_min\": \"0\", \"age_max\": \"100\"}       0     100  \n",
       "3835   {\"age_min\" : \"18\",\"age_max\" : \"89\" }      18      89  \n",
       "\n",
       "[3836 rows x 18 columns]"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('finalcttrialage.csv',index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"formatted age\"] = df[\"AGE\"][0:3].apply(filter_by_age)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "77    {\"age_min\" : \"18\",\\n          \"age_max\" : \"100\" }\n",
       "78     {\"age_min\" : \"18\",\\n          \"age_max\" : \"75\" }\n",
       "79     {\"age_min\" : \"0\",\\n          \"age_max\" : \"100\" }\n",
       "Name: AGE, dtype: object"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"AGE\"][77:80].apply(filter_by_age)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>formatted age</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\\n          \"age_max\" : \"NA\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\\n          \"age_max\" : \"NA\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\\n          \"age_max\" : \"NA\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\\n          \"age_max\" : \"NA\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"19\",\\n          \"age_max\" : \"NA\" }</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 16 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                                         formatted age  \n",
       "0     {\"age_min\" : \"18\",\\n          \"age_max\" : \"NA\" }  \n",
       "1     {\"age_min\" : \"18\",\\n          \"age_max\" : \"NA\" }  \n",
       "2     {\"age_min\" : \"18\",\\n          \"age_max\" : \"NA\" }  \n",
       "3     {\"age_min\" : \"18\",\\n          \"age_max\" : \"NA\" }  \n",
       "4     {\"age_min\" : \"19\",\\n          \"age_max\" : \"NA\" }  \n",
       "...                                                ...  \n",
       "3831                                               NaN  \n",
       "3832                                               NaN  \n",
       "3833                                               NaN  \n",
       "3834                                               NaN  \n",
       "3835                                               NaN  \n",
       "\n",
       "[3836 rows x 16 columns]"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('finalcttrialage.csv',index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_2 = pd.read_csv('finalcttrial.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>drugs &amp; biomarker</th>\n",
       "      <th>DRUGS</th>\n",
       "      <th>BIOMARKERS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"JS004\", \"Toripalimab\"],\\n\"BIOMARK...</td>\n",
       "      <td>JS004, Toripalimab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n  \"DRUGS\": [],\\n  \"BIOMARKERS\": [\"CD8\"]\\n}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CD8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"APG-2449\"],\\n\"BIOMARKERS\":[]\\n}</td>\n",
       "      <td>APG-2449</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"Circulating Tumor D...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Circulating Tumor DNA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n  \"DRUGS\": [\"Bojungikki-tang\", \"Pembrolizum...</td>\n",
       "      <td>Bojungikki-tang, Pembrolizumab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Niraparib\", \"TSR-042\", \"Dostarlim...</td>\n",
       "      <td>Niraparib, TSR-042, Dostarlimab, Chemotherapy</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Sulforaphane\", \"Doxorubicin\"],\\n\"...</td>\n",
       "      <td>Sulforaphane, Doxorubicin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                                      drugs & biomarker  \\\n",
       "0     {\\n\"DRUGS\":[\"JS004\", \"Toripalimab\"],\\n\"BIOMARK...   \n",
       "1         {\\n  \"DRUGS\": [],\\n  \"BIOMARKERS\": [\"CD8\"]\\n}   \n",
       "2          {\\n\"DRUGS\":[\"APG-2449\"],\\n\"BIOMARKERS\":[]\\n}   \n",
       "3     {\"DRUGS\":[],\"BIOMARKERS\":[\"Circulating Tumor D...   \n",
       "4     {\\n  \"DRUGS\": [\"Bojungikki-tang\", \"Pembrolizum...   \n",
       "...                                                 ...   \n",
       "3831                       {\"DRUGS\":[],\"BIOMARKERS\":[]}   \n",
       "3832  {\\n\"DRUGS\":[\"Niraparib\", \"TSR-042\", \"Dostarlim...   \n",
       "3833                       {\"DRUGS\":[],\"BIOMARKERS\":[]}   \n",
       "3834                 {\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}   \n",
       "3835  {\\n\"DRUGS\":[\"Sulforaphane\", \"Doxorubicin\"],\\n\"...   \n",
       "\n",
       "                                              DRUGS             BIOMARKERS  \n",
       "0                                JS004, Toripalimab                    NaN  \n",
       "1                                               NaN                    CD8  \n",
       "2                                          APG-2449                    NaN  \n",
       "3                                               NaN  Circulating Tumor DNA  \n",
       "4                    Bojungikki-tang, Pembrolizumab                    NaN  \n",
       "...                                             ...                    ...  \n",
       "3831                                            NaN                    NaN  \n",
       "3832  Niraparib, TSR-042, Dostarlimab, Chemotherapy                    NaN  \n",
       "3833                                            NaN                    NaN  \n",
       "3834                                            NaN                   HER2  \n",
       "3835                      Sulforaphane, Doxorubicin                    NaN  \n",
       "\n",
       "[3836 rows x 18 columns]"
      ]
     },
     "execution_count": 88,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [],
   "source": [
    "l1 = list(df.columns)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [],
   "source": [
    "l2 = list(df_2.columns)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [],
   "source": [
    "common_elements = [element for element in l1 if element in l2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Unnamed: 0',\n",
       " 'NCT_NUMBER',\n",
       " 'STUDY_TITLE',\n",
       " 'STUDY_URL',\n",
       " 'STUDY_STATUS',\n",
       " 'CONDITIONS',\n",
       " 'LOCATIONS',\n",
       " 'START_DATE',\n",
       " 'COMPLETION_DATE',\n",
       " 'AGE',\n",
       " 'ELIGIBILITY_CRITERIA',\n",
       " 'PRIMARY_OUTCOMES',\n",
       " 'SECONDARY_OUTCOMES',\n",
       " 'INTERVENTIONS',\n",
       " 'POINT_OF_CONTACT']"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "common_elements"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [],
   "source": [
    "merged_df = pd.merge(df, df_2, on=common_elements)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>...</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>formatted_age</th>\n",
       "      <th>age_min</th>\n",
       "      <th>age_max</th>\n",
       "      <th>drugs &amp; biomarker</th>\n",
       "      <th>DRUGS</th>\n",
       "      <th>BIOMARKERS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n\"DRUGS\":[\"JS004\", \"Toripalimab\"],\\n\"BIOMARK...</td>\n",
       "      <td>JS004, Toripalimab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n  \"DRUGS\": [],\\n  \"BIOMARKERS\": [\"CD8\"]\\n}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CD8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n\"DRUGS\":[\"APG-2449\"],\\n\"BIOMARKERS\":[]\\n}</td>\n",
       "      <td>APG-2449</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"Circulating Tumor D...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Circulating Tumor DNA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"19\",\"age_max\" : \"100\" }</td>\n",
       "      <td>19</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n  \"DRUGS\": [\"Bojungikki-tang\", \"Pembrolizum...</td>\n",
       "      <td>Bojungikki-tang, Pembrolizumab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"90\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>90</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Niraparib\", \"TSR-042\", \"Dostarlim...</td>\n",
       "      <td>Niraparib, TSR-042, Dostarlimab, Chemotherapy</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"30\",\"age_max\" : \"100\" }</td>\n",
       "      <td>30</td>\n",
       "      <td>100</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\": \"0\", \"age_max\": \"100\"}</td>\n",
       "      <td>0</td>\n",
       "      <td>100</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"89\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>89</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Sulforaphane\", \"Doxorubicin\"],\\n\"...</td>\n",
       "      <td>Sulforaphane, Doxorubicin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  ...  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult  ...   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult  ...   \n",
       "2         February 2025          18 Years||Adult|Older Adult  ...   \n",
       "3             July 2026          18 Years||Adult|Older Adult  ...   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult  ...   \n",
       "...                 ...                                  ...  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult  ...   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult  ...   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult  ...   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult  ...   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult  ...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                              formatted_age age_min age_max  \\\n",
       "0     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "1     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "2     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "3     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "4     {\"age_min\" : \"19\",\"age_max\" : \"100\" }      19     100   \n",
       "...                                     ...     ...     ...   \n",
       "3831   {\"age_min\" : \"18\",\"age_max\" : \"90\" }      18      90   \n",
       "3832  {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "3833  {\"age_min\" : \"30\",\"age_max\" : \"100\" }      30     100   \n",
       "3834     {\"age_min\": \"0\", \"age_max\": \"100\"}       0     100   \n",
       "3835   {\"age_min\" : \"18\",\"age_max\" : \"89\" }      18      89   \n",
       "\n",
       "                                      drugs & biomarker  \\\n",
       "0     {\\n\"DRUGS\":[\"JS004\", \"Toripalimab\"],\\n\"BIOMARK...   \n",
       "1         {\\n  \"DRUGS\": [],\\n  \"BIOMARKERS\": [\"CD8\"]\\n}   \n",
       "2          {\\n\"DRUGS\":[\"APG-2449\"],\\n\"BIOMARKERS\":[]\\n}   \n",
       "3     {\"DRUGS\":[],\"BIOMARKERS\":[\"Circulating Tumor D...   \n",
       "4     {\\n  \"DRUGS\": [\"Bojungikki-tang\", \"Pembrolizum...   \n",
       "...                                                 ...   \n",
       "3831                       {\"DRUGS\":[],\"BIOMARKERS\":[]}   \n",
       "3832  {\\n\"DRUGS\":[\"Niraparib\", \"TSR-042\", \"Dostarlim...   \n",
       "3833                       {\"DRUGS\":[],\"BIOMARKERS\":[]}   \n",
       "3834                 {\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}   \n",
       "3835  {\\n\"DRUGS\":[\"Sulforaphane\", \"Doxorubicin\"],\\n\"...   \n",
       "\n",
       "                                              DRUGS             BIOMARKERS  \n",
       "0                                JS004, Toripalimab                    NaN  \n",
       "1                                               NaN                    CD8  \n",
       "2                                          APG-2449                    NaN  \n",
       "3                                               NaN  Circulating Tumor DNA  \n",
       "4                    Bojungikki-tang, Pembrolizumab                    NaN  \n",
       "...                                             ...                    ...  \n",
       "3831                                            NaN                    NaN  \n",
       "3832  Niraparib, TSR-042, Dostarlimab, Chemotherapy                    NaN  \n",
       "3833                                            NaN                    NaN  \n",
       "3834                                            NaN                   HER2  \n",
       "3835                      Sulforaphane, Doxorubicin                    NaN  \n",
       "\n",
       "[3836 rows x 21 columns]"
      ]
     },
     "execution_count": 100,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "merged_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>formatted_age</th>\n",
       "      <th>age_min</th>\n",
       "      <th>age_max</th>\n",
       "      <th>drugs &amp; biomarker</th>\n",
       "      <th>DRUGS</th>\n",
       "      <th>BIOMARKERS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n\"DRUGS\":[\"JS004\", \"Toripalimab\"],\\n\"BIOMARK...</td>\n",
       "      <td>JS004, Toripalimab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n  \"DRUGS\": [],\\n  \"BIOMARKERS\": [\"CD8\"]\\n}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CD8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n\"DRUGS\":[\"APG-2449\"],\\n\"BIOMARKERS\":[]\\n}</td>\n",
       "      <td>APG-2449</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"Circulating Tumor D...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Circulating Tumor DNA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"19\",\"age_max\" : \"100\" }</td>\n",
       "      <td>19</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n  \"DRUGS\": [\"Bojungikki-tang\", \"Pembrolizum...</td>\n",
       "      <td>Bojungikki-tang, Pembrolizumab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"90\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>90</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"100\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Niraparib\", \"TSR-042\", \"Dostarlim...</td>\n",
       "      <td>Niraparib, TSR-042, Dostarlimab, Chemotherapy</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"30\",\"age_max\" : \"100\" }</td>\n",
       "      <td>30</td>\n",
       "      <td>100</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\": \"0\", \"age_max\": \"100\"}</td>\n",
       "      <td>0</td>\n",
       "      <td>100</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}</td>\n",
       "      <td>NaN</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"age_min\" : \"18\",\"age_max\" : \"89\" }</td>\n",
       "      <td>18</td>\n",
       "      <td>89</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Sulforaphane\", \"Doxorubicin\"],\\n\"...</td>\n",
       "      <td>Sulforaphane, Doxorubicin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 20 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       NCT_NUMBER                                        STUDY_TITLE  \\\n",
       "0     NCT05664971  JS004 Combined With Toripalimab and With Stand...   \n",
       "1     NCT05902520  Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2     NCT03917043    APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     NCT05674422  GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     NCT06249854  Efficacy and Safety of Combination Therapy Wit...   \n",
       "...           ...                                                ...   \n",
       "3831  NCT05006131  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  NCT04679064  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  NCT04491864  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  NCT05905939  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  NCT03934905  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                              formatted_age age_min age_max  \\\n",
       "0     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "1     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "2     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "3     {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "4     {\"age_min\" : \"19\",\"age_max\" : \"100\" }      19     100   \n",
       "...                                     ...     ...     ...   \n",
       "3831   {\"age_min\" : \"18\",\"age_max\" : \"90\" }      18      90   \n",
       "3832  {\"age_min\" : \"18\",\"age_max\" : \"100\" }      18     100   \n",
       "3833  {\"age_min\" : \"30\",\"age_max\" : \"100\" }      30     100   \n",
       "3834     {\"age_min\": \"0\", \"age_max\": \"100\"}       0     100   \n",
       "3835   {\"age_min\" : \"18\",\"age_max\" : \"89\" }      18      89   \n",
       "\n",
       "                                      drugs & biomarker  \\\n",
       "0     {\\n\"DRUGS\":[\"JS004\", \"Toripalimab\"],\\n\"BIOMARK...   \n",
       "1         {\\n  \"DRUGS\": [],\\n  \"BIOMARKERS\": [\"CD8\"]\\n}   \n",
       "2          {\\n\"DRUGS\":[\"APG-2449\"],\\n\"BIOMARKERS\":[]\\n}   \n",
       "3     {\"DRUGS\":[],\"BIOMARKERS\":[\"Circulating Tumor D...   \n",
       "4     {\\n  \"DRUGS\": [\"Bojungikki-tang\", \"Pembrolizum...   \n",
       "...                                                 ...   \n",
       "3831                       {\"DRUGS\":[],\"BIOMARKERS\":[]}   \n",
       "3832  {\\n\"DRUGS\":[\"Niraparib\", \"TSR-042\", \"Dostarlim...   \n",
       "3833                       {\"DRUGS\":[],\"BIOMARKERS\":[]}   \n",
       "3834                 {\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}   \n",
       "3835  {\\n\"DRUGS\":[\"Sulforaphane\", \"Doxorubicin\"],\\n\"...   \n",
       "\n",
       "                                              DRUGS             BIOMARKERS  \n",
       "0                                JS004, Toripalimab                    NaN  \n",
       "1                                               NaN                    CD8  \n",
       "2                                          APG-2449                    NaN  \n",
       "3                                               NaN  Circulating Tumor DNA  \n",
       "4                    Bojungikki-tang, Pembrolizumab                    NaN  \n",
       "...                                             ...                    ...  \n",
       "3831                                            NaN                    NaN  \n",
       "3832  Niraparib, TSR-042, Dostarlimab, Chemotherapy                    NaN  \n",
       "3833                                            NaN                    NaN  \n",
       "3834                                            NaN                   HER2  \n",
       "3835                      Sulforaphane, Doxorubicin                    NaN  \n",
       "\n",
       "[3836 rows x 20 columns]"
      ]
     },
     "execution_count": 102,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "merged_df.drop(columns='Unnamed: 0',inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.set_option('display.max_columns', None)  # Display all columns\n",
    "pd.set_option('display.max_rows', None)     # Display all rows\n",
    "pd.set_option('display.width', None)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.reset_option('display.max_columns')\n",
    "pd.reset_option('display.max_rows')\n",
    "pd.reset_option('display.width')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {},
   "outputs": [],
   "source": [
    "merged_df.to_csv('finalcttrialfilterdf.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {},
   "outputs": [],
   "source": [
    "merged_df.drop(columns=['Unnamed: 0','formatted_age','drugs & biomarker'],inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [],
   "source": [
    "merged_df.to_csv('finalcttrialfilterdf.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>age_min</th>\n",
       "      <th>age_max</th>\n",
       "      <th>DRUGS</th>\n",
       "      <th>BIOMARKERS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>JS004, Toripalimab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CD8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>APG-2449</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Circulating Tumor DNA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>19</td>\n",
       "      <td>100</td>\n",
       "      <td>Bojungikki-tang, Pembrolizumab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18</td>\n",
       "      <td>90</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18</td>\n",
       "      <td>100</td>\n",
       "      <td>Niraparib, TSR-042, Dostarlimab, Chemotherapy</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>30</td>\n",
       "      <td>100</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0</td>\n",
       "      <td>100</td>\n",
       "      <td>NaN</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>18</td>\n",
       "      <td>89</td>\n",
       "      <td>Sulforaphane, Doxorubicin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       NCT_NUMBER                                        STUDY_TITLE  \\\n",
       "0     NCT05664971  JS004 Combined With Toripalimab and With Stand...   \n",
       "1     NCT05902520  Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2     NCT03917043    APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     NCT05674422  GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     NCT06249854  Efficacy and Safety of Combination Therapy Wit...   \n",
       "...           ...                                                ...   \n",
       "3831  NCT05006131  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  NCT04679064  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  NCT04491864  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  NCT05905939  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  NCT03934905  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT age_min age_max  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...      18     100   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...      18     100   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...      18     100   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...      18     100   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...      19     100   \n",
       "...                                                 ...     ...     ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...      18      90   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...      18     100   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...      30     100   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...       0     100   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...      18      89   \n",
       "\n",
       "                                              DRUGS             BIOMARKERS  \n",
       "0                                JS004, Toripalimab                    NaN  \n",
       "1                                               NaN                    CD8  \n",
       "2                                          APG-2449                    NaN  \n",
       "3                                               NaN  Circulating Tumor DNA  \n",
       "4                    Bojungikki-tang, Pembrolizumab                    NaN  \n",
       "...                                             ...                    ...  \n",
       "3831                                            NaN                    NaN  \n",
       "3832  Niraparib, TSR-042, Dostarlimab, Chemotherapy                    NaN  \n",
       "3833                                            NaN                    NaN  \n",
       "3834                                            NaN                   HER2  \n",
       "3835                      Sulforaphane, Doxorubicin                    NaN  \n",
       "\n",
       "[3836 rows x 18 columns]"
      ]
     },
     "execution_count": 112,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "merged_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       JS004 Combined With Toripalimab and With Stand...\n",
       "1       Adoptive Cell Therapy Using Cancer Specific CD...\n",
       "2         APG-2449 in Patients With Advanced Solid Tumors\n",
       "3       GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...\n",
       "4       Efficacy and Safety of Combination Therapy Wit...\n",
       "5       Reducing Metabolic Dysregulation in Obese Lati...\n",
       "6       A Phase II Study of TACE Plus PD-1 Antibody in...\n",
       "7       Study of Aerosolized Antibiotics and Pembroliz...\n",
       "8        Characterizing Breast Cancer With 18F-FES PET/CT\n",
       "9       Hypofractionated Pencil-Beam Scanning Intensit...\n",
       "10      CRT Versus Surgery for Retroperitoneal or Para...\n",
       "11      Patritumab Deruxtecan (U3-1402) in Unresectabl...\n",
       "12      Volumetric Specimen Imager Device for the Intr...\n",
       "13      Microvascular Function in Patients Undergoing ...\n",
       "14      Prospective Assessment of Quality of Life in P...\n",
       "15      TT-10 as a Single Agent in Subjects With Advan...\n",
       "16      Testing A New Anti-cancer Drug Combination, En...\n",
       "17                      Fish Oil and EPO in Breast Cancer\n",
       "18      Dose-Reduced Docetaxel With Cyclophosphamide f...\n",
       "19      Adoptive Cell Transfer of Autologous Tumor Inf...\n",
       "20      A Systemic Approach to Study the Traditional C...\n",
       "21      Observational Study of Bone Complications in P...\n",
       "22      Surface Monitoring Technology to Remove The Ma...\n",
       "23      The Efficiency for Stage II-III HR+/HER2+ Earl...\n",
       "24      Comparison of Adjuvant Monotherapy With Endocr...\n",
       "25      Evaluate Impact of Exercise Program on Fatigue...\n",
       "26      Endocrine Therapy Fulvestrant & Palbociclib or...\n",
       "27      Cryoablation Combined With Tislelizumab Plus L...\n",
       "28      Tamoxifen Prediction Study in Patients With ER...\n",
       "29      Exercise in Older Women With Breast Cancer Dur...\n",
       "30      A Phase 2 Study of Avutometinib (VS-6766) Plus...\n",
       "31                   FAZA PETMRI Gastro-Oesophageal Study\n",
       "32      Mind Over Matter for Black and African America...\n",
       "33      Consolidation Chemotherapy for Locally Advance...\n",
       "34      MT2021-27 FT538 Recurrent Ovarian, Fallopian T...\n",
       "35      Evaluating Scaleup of an Adapted Breast Cancer...\n",
       "36      Combination of AK104 and Neoadjuvant Chemoradi...\n",
       "37      Research of Circulating Tumor Cells Released D...\n",
       "38      A Study on the Prevalence of Clinically Useful...\n",
       "39      A Phase 1-2 of ST316 With Selected Advanced Un...\n",
       "40      Maintenance Pembrolizumab at Usual or Low doSE...\n",
       "41      Immunological Function After Radiation With Ei...\n",
       "42      Assessment of Diagnostic Yield Using a Robotic...\n",
       "43      Short Course Radiation Therapy and Combination...\n",
       "44      Study of Gemcitabine, Cisplatin, AB680 and AB1...\n",
       "45      Umbrella Trial Testing Integrative Subtype-Tar...\n",
       "46      Laparoscopic Versus Open Right Colectomy for R...\n",
       "47      Testing the Addition of the Drug Atezolizumab ...\n",
       "48      Circulating Tumour DNA Based Decision for Adju...\n",
       "49      PD-L1 Targeting Nanobody Probe for PET Imaging...\n",
       "50      Comparison of Ultrasound and Breast MRI for Br...\n",
       "51      Development of a Fluorescent Visualization Sys...\n",
       "52      All-Trans Retinoic Acid (ATRA) and Atezolizuma...\n",
       "53      Efficacy and Safety of Combinition of Camreliz...\n",
       "54      Breast Mesh Used in Two-staged Breast Reconstr...\n",
       "55      OPTIMIzation of Treatment SElection and Follow...\n",
       "56      Observational of Adjuvant Treatment of Breast ...\n",
       "57      The Effect of Acupuncture on Nerve Pain Caused...\n",
       "58      A Study of SI-B003 and BL-B01D1+SI-B003 in Pat...\n",
       "59      Imaging Performance Assessment of 89Zirconium-...\n",
       "60      Breast Cancer Survivors Who Experience Aromata...\n",
       "61      Study to Evaluate the Effect of Metformin in t...\n",
       "62      [68Ga]Ga-ABY-025 PET for Quantification of HER...\n",
       "63      Impact of 18F-FES PET on the Therapeutic Treat...\n",
       "64      Evaluating Length of Treatment With PD-1/PD-L1...\n",
       "65      Multimodality Treatment in Stage III Non-small...\n",
       "66      A Study of AZD1390 and Stereotactic Body Radio...\n",
       "67      UGT1A1-Based Irinotecan Therapy for Locally Ad...\n",
       "68                Bethanechol Prior to Pancreatic Surgery\n",
       "69      Randomised Trial Evaluating the Benefit of a F...\n",
       "70      FH-Risk 2.0: Updating Breast Cancer Risk Estim...\n",
       "71      Onco-Genomas Brasil: Mapping Breast and Prosta...\n",
       "72      [18F]Fluoroestradiol-PET/CT Companion Imaging ...\n",
       "73      Vitamin D in Patients With Stage I-III Colon C...\n",
       "74      Atezolizumab Combined With BDB001 AnD Immunoge...\n",
       "75      Testing Sacituzumab Govitecan Therapy in Patie...\n",
       "76      Letrozole With and Without Simvastatin for the...\n",
       "77      A Study of Effect of Megakaryocytes and Platel...\n",
       "78      Aflibercept or Bevacizumab as Second-line Trea...\n",
       "79                      Genomic Services Research Program\n",
       "80      Albumin-bound Paclitaxel and Carboplatin Versu...\n",
       "81      Omission of ALND in Breast Cancer Patients Wit...\n",
       "82      A Study of TQB2450 in Subjects With Stage III ...\n",
       "83      Study of Intra-Arterial Oxaliplatin Plus Capec...\n",
       "84      Fecal Microbial Transplantation Non-Small Cell...\n",
       "85      Aerobic Training and Diet on the Immune System...\n",
       "86        Intravesical Gemcitabine in Patients With NMIBC\n",
       "87      A Study for the Adjuvant Treatment of Breast C...\n",
       "88      Evaluation of the Introduction of a Colorectal...\n",
       "89                     Butyrophilins Role in Colon Cancer\n",
       "90      Evaluation of a Cancer Lysate Vaccine and Mont...\n",
       "91      Organoid-Guided Adjuvant Chemotherapy for Panc...\n",
       "92      Aumolertinib Combined Intrathecal Chemotherapy...\n",
       "93                  Multidisciplinary Approach to Fatigue\n",
       "94      Testing the Addition of Ipatasertib to the Usu...\n",
       "95      What is the Best Interval to Screen Women 45-4...\n",
       "96      Axillary Management in Breast Cancer Patients ...\n",
       "97      Evexomostat Plus Alpelisib and Fulvestrant in ...\n",
       "98      HER2 Expression Detection and Radionuclide The...\n",
       "99      A Study on Adding Precisely Targeted Radiation...\n",
       "100          Interventions to Decrease Financial Toxicity\n",
       "101               Registry Study in MSI/dMMR Solid Tumors\n",
       "102     Testing the Addition of an Anti-cancer Drug, P...\n",
       "103     Targeted Axillary Dissection (TAD) in Early-st...\n",
       "104     Concurrent FOLFIRINOX Plus High Intensity Focu...\n",
       "105     A Phase 1 First-In-Human Study of the Anti-CD7...\n",
       "106     UCDCC#272: IL-2, Radiotherapy, and Pembrolizum...\n",
       "107     A Study of MRG002 in Treatment of Advanced HER...\n",
       "108     RapidPlan Models Establishment for Node-Positi...\n",
       "109     Oncological Benefits of Pressured Intraperiton...\n",
       "110     Oregovomab in Combination With Bevacizumab Plu...\n",
       "111     Clinical Efficacy and Safety of Paclitaxel Pol...\n",
       "112     Using a PET Imaging Agent, 18F-Clofarabine (CF...\n",
       "113     A Study of Pembrolizumab and Cryoablation in P...\n",
       "114     Hypofractionated Vs Conventional Fractionated ...\n",
       "115     HER2 Expression of CTC to Predict Response in ...\n",
       "116     Study of AC699 in Patients With Estrogen Recep...\n",
       "117     RMT in Combination With Durvalumab + Chemo in ...\n",
       "118     Phase II Trial of Trilaciclib, Pembrolizumab, ...\n",
       "119     Famitinib in Combination With Camrelizumab and...\n",
       "120     Trastuzumab Emtansine (T-DM1) in HER2-positive...\n",
       "121     Exploring the Efficacy and Feasibility of the ...\n",
       "122     Cryoablation Combined With Tirelizumab and Bev...\n",
       "123     Metformin and Nightly Fasting in Women With Ea...\n",
       "124     Validation of Rapid On-site Diagnostics in Ear...\n",
       "125     Phase II/III Study to Assess the Efficacy of N...\n",
       "126     At-Home Research Study for Patients With Autoi...\n",
       "127     Study of SHR6390 in Renal Insufficiency and He...\n",
       "128     A Study to Evaluate the Efficacy and Safety of...\n",
       "129     Registry for Intra-Operative Radiotherapy Duri...\n",
       "130     First-in-human Phase I to Evaluate PEP-010 as ...\n",
       "131     Cancer Peptides Plus GM-CSF and Adjuvant in Br...\n",
       "132     DETERMINE Trial Treatment Arm 03: Entrectinib ...\n",
       "133     Phase I Pilot Study of Biodistribution, Metabo...\n",
       "134     A Study of the Treatment of Recurrent Malignan...\n",
       "135              Diabetes Care for Breast Cancer Patients\n",
       "136     Efficacy and Accuracy of Combined Localization...\n",
       "137       Heart Health After Cancer Treatment (HEART-ACT)\n",
       "138     Study of B013 and Nab-Paclitaxel for Locally A...\n",
       "139     Nivolumab and Ipilimumab in Patients With dMMR...\n",
       "140     Phase 2 Basket Trial of Nab-sirolimus in Patie...\n",
       "141                        Bladder Cancer Screening Trial\n",
       "142     Assessment of Cryotherapy's Analgesic Impact i...\n",
       "143     ARX788 in Breast Cancer With Low Expression of...\n",
       "144     A Prospective Phase II Study for Adjuvant Hypo...\n",
       "145     Prediction of Long-term Arm Morbidity Followin...\n",
       "146     EO4010 in Previously Treated Metastatic Colore...\n",
       "147     THE EFFECT OF CANCER EDUCATION ON WOMEN'S AWAR...\n",
       "148     Adoptive T Cell Therapy Following HER2-Pulsed ...\n",
       "149     CompassHER2-pCR: Decreasing Chemotherapy for B...\n",
       "150     Placebo-controlled, Study of Concurrent Chemor...\n",
       "151     ADI-PEG 20 in Combination With Gemcitabine and...\n",
       "152     Palliative Radiotherapy With Lurbinectedin in ...\n",
       "153     Comparing Sentinel Lymph Node (SLN) Biopsy Wit...\n",
       "154          Assessing the Immunogenicity of pING-hHER3FL\n",
       "155     Impact of Virtual Reality on the Mental Health...\n",
       "156     Construction and Validation of an Assessment M...\n",
       "157     Liquid Biopsy and Pancreas Cancer: Detection o...\n",
       "158     Research of Intensive Treatment in Hormone Rec...\n",
       "159     Sentinel Lymph Node Biopsy Versus no Axillary ...\n",
       "160     Conventional Oxygen Therapy Versus Continuous ...\n",
       "161     Effects of a Manual Therapy Program to Reduce ...\n",
       "162     Diagnostic Significance of FDG PET/CT Dynamic ...\n",
       "163     The Incidence of Gallstones After Gastric Canc...\n",
       "164     Implant-based Breast Reconstruction and Mastec...\n",
       "165     Bevacizumab Plus Modiifed FOLFIRINOX in Ovaria...\n",
       "166     Effect of Prophylactic Medical Compression The...\n",
       "167     Kadcyla And Neratinib for Interception of HER2...\n",
       "168     Web-based Pain Coping Skills Training for Brea...\n",
       "169     Study of Osimertinib With Carotuximab in Advan...\n",
       "170     Effect of the Axillary Lymphatic /Vein Reflux ...\n",
       "171     Effect of Azeliragon Combined With Stereotacti...\n",
       "172     A Study of Amivantamab in People With Esophago...\n",
       "173     Neurotization of the Nipple Areolar Complex to...\n",
       "174     Dignity, Legacy, Advocacy, and Support for Adv...\n",
       "175     Pembrolizumab Monotherapy Following Tri-modali...\n",
       "176     PROOFS-Registry - Premenopausal Women With Bre...\n",
       "177     Transcranial Direct-current Stimulation (tDCS)...\n",
       "178     89Zr-girentuximab for PET Imaging of CAIX Posi...\n",
       "179     DOstarlimab in Patients With Recurrent or dMMR...\n",
       "180     A Study of LY2880070 in Participants With Adva...\n",
       "181     A Clinical Trial Assessing BT-001 Alone and in...\n",
       "182               FUSCC Refractory TNBC Umbrella (FUTURE)\n",
       "183     Evaluation of Possible Safety and Efficacy of ...\n",
       "184     Papaverine in Combination With Chemoradiation ...\n",
       "185     Feasibility, Acceptability, and Effectiveness ...\n",
       "186     Durvalumab With Chemotherapy Followed by Seque...\n",
       "187                       ImmunoBreast - A Phase Ib Study\n",
       "188     ROLL Versus Magnetic Seed for Preoperative Loc...\n",
       "189     Harnessing Analysis RNA Expression and Molecul...\n",
       "190     Stereotactic Body Radiation Therapy for Spinal...\n",
       "191     UZ/KU Leuven Program for Post-mortem Tissue Do...\n",
       "192     Sacituzumab Govitecan +/- Pembrolizumab in Met...\n",
       "193     Breast Elasticity Imaging During Neoadjuvant C...\n",
       "194     A Study to Evaluate Safety, Tolerability, Phar...\n",
       "195     A Study of NUC-3373 in Combination With Other ...\n",
       "196     Real-world Study of UTD1 in Chinese Advanced B...\n",
       "197     Ontario-wide Cancer TArgeted Nucleic Acid Eval...\n",
       "198     PD-1 Inhibitor and Chemotherapy With Concurren...\n",
       "199     Overcoming Therapy Resistance in ER+ Breast Ca...\n",
       "200     Alpelisib And Sacituzumab Govitecan For Treatm...\n",
       "201     Study of HER2 Directed Dendritic Cell (DC1) Va...\n",
       "202     Neoadjuvant ArOMatase Inhibitor Therapy for ER...\n",
       "203     A Trial of SHR-A1811versus Pyrotinib in Combin...\n",
       "204     Safe De-escalation of Chemotherapy for Stage 1...\n",
       "205     Shared Decision Making on Care Pathways and CA...\n",
       "206     Monitoring Minimal Residual Disease in Gastric...\n",
       "207     A Phase 1, Multi-Center, Open-Label, Dose-Esca...\n",
       "208     An Open Label Phase 2 Study to Evaluate the Sa...\n",
       "209     Feasibility of 2 Interventions to Reduce Fatig...\n",
       "210     Reducing the Incidence of Symptomatic Brain Me...\n",
       "211     Fluzoparib Combined With Camrelizumab for Main...\n",
       "212     Afuresertib +Sintilimab+Chemotherapy in Patien...\n",
       "213     CLEAR-B: Cancer Landscape - Early Adjuvant Ret...\n",
       "214     Clinical Study of Personalized mRNA Vaccine En...\n",
       "215     Lower-Dose Chemoradiation in Treating Patients...\n",
       "216     Genetic Predisposition to Breast and Ovarian C...\n",
       "217     Using ctDNA to Detect Minimal Residual Disease...\n",
       "218     A Study of Tucatinib and Trastuzumab in People...\n",
       "219     Chronic Intestinal Pathologies Analytical Coho...\n",
       "220     A Study of NTX-1088, a Monoclonal Antibody Tar...\n",
       "221     Effects of Oral Aloe Vera Juice on Chemotherap...\n",
       "222     Study of the Sexual Health of Patients Treated...\n",
       "223     Regorafenib With Low-dose Chemotherapies and A...\n",
       "224     Establishment of Molecular Classification Mode...\n",
       "225            Microbial Diversity of Pancreatic Diseases\n",
       "226     Albumin-Bound Paclitaxel Combined With Antiang...\n",
       "227     DETERMINE Trial Treatment Arm 02: Atezolizumab...\n",
       "228     Osimertinib Plus Chemotherapy vs Osimertinib i...\n",
       "229     Study to Assess the Safety of Alpelisib Plus F...\n",
       "230     Trial Exploring Combined Neoadjuvant Therapy W...\n",
       "231     BreCLIM-2 - A RCT Investigating Local Treatmen...\n",
       "232     Mechanism Exploration of Anti-HER-2 Small-mole...\n",
       "233     Perioperative Lenvatinib With Pembrolizumab in...\n",
       "234     Preoperative Short-course Radiation Followed b...\n",
       "235     Monitoring Response to Neoadjuvant Chemotherap...\n",
       "236     Electroporation and Immunotherapy in Metastati...\n",
       "237     Savolitinib Plus Docetaxel as 2L in EGFR/ALK/R...\n",
       "238     Early Screening of Pancreatic Lesions : Develo...\n",
       "239     NeoTRACK - Dissection of IO Efficacy in NSCLC ...\n",
       "240     A Study to Evaluate the Efficacy and Safety of...\n",
       "241     Re-challenge Therapy With Chemotherapy & Panit...\n",
       "242     OCTANE: Adjuvant Liposomal Doxorubicin and Car...\n",
       "243     A Study of Pembrolizumab in Combination With C...\n",
       "244     Using ctDNA to Determine Therapies for Lung Ca...\n",
       "245     A Clinical Research About CD70-targeted CAR-T ...\n",
       "246     Pressure-enabled Delivery in Radioembolization...\n",
       "247     Telerehabilitation in Survival Breast Cancer P...\n",
       "248     The Unmet Needs of Cancer Survivors in Ausl IR...\n",
       "249     Combination of Nivolumab Immunotherapy With Ra...\n",
       "250     Anti-CD38 Antibody With KRAS Vaccine and Anti-...\n",
       "251     PANFIRE-3 Trial: Assessing Safety and Efficacy...\n",
       "252     Upfront Maintenance Olaparib in Advanced Ovari...\n",
       "253     A Study of Repotrectinib in Combination With C...\n",
       "254     Durvalumab (MEDI4736) Plus Total Neoadjuvant T...\n",
       "255     The Radiation Oncology-Biology Integration Net...\n",
       "256     Study of Pembrolizumab, Lenvatinib and Chemoth...\n",
       "257     A First-in-human Study Using BDC-1001 as a Sin...\n",
       "258     Liquid Biopsies and IMAging for Improved Cance...\n",
       "259                          Quebec Pancreas Cancer Study\n",
       "260     Correlation Between TILs and Blood Cell Counts...\n",
       "261     Leflunomide or Combination of MEK Inhibitor an...\n",
       "262     A Phase I Trial of CCT303-406 in Patients With...\n",
       "263                     Motiva Flora Tissue Expander PMCF\n",
       "264     Prospective Evaluation Of High-Dose Systemic M...\n",
       "265             Breast Cancer Exercise Intervention Study\n",
       "266     Partial Breast Re-irradiation in Women in Wome...\n",
       "267     Investigation of Profile-related Evidence Dete...\n",
       "268     Every Day Counts: A Lifestyle Program for Wome...\n",
       "269     Oxaliplatin Adjuvant Chemotherapy After Curati...\n",
       "270     A RC198 Study in Subjects With Locally Advance...\n",
       "271     Safety and Efficacy Evaluation of the P2Et Ext...\n",
       "272     Compare Adjuvant Chemotherapy of Docetaxel/Cap...\n",
       "273       Pembrolizumab, Ibrutinib and Rituximab in PCNSL\n",
       "274     Selective Omission of Axillary Surgery in Trip...\n",
       "275     Genomically Guided Radiation Dose Personalizat...\n",
       "276     Fruit and Vegetable Intervention in Lactating ...\n",
       "277      (VELA) Study of BLU-222 in Advanced Solid Tumors\n",
       "278     Study on the Value of Non-invasive Dual-Pet In...\n",
       "279     Evaluation of Innovative Therapeutic Approache...\n",
       "280     PT-112 in Subjects With Thymoma and Thymic Car...\n",
       "281     A Study of BL-M02D1 in Patients With Locally A...\n",
       "282     Investigating the Use of taVNS to Treat Insomn...\n",
       "283     To Evaluate the Safety, Tolerability, Pharmaco...\n",
       "284     Eribulin With or Without Trastuzumab-biosimila...\n",
       "285     Nadunolimab in Combination With Gemcitabine Pl...\n",
       "286     A Clinical Trial of TG6050 in Patients With Me...\n",
       "287     Minimal Invasive Axillary Staging and Treatmen...\n",
       "288     Dose Escalation/Dose Expansion Study of PRGN-3...\n",
       "289     Adjuvant Treatment With Cisplatin-based Chemot...\n",
       "290     Transversus Abdominis Plane Blocks With and Wi...\n",
       "291     SX-682 With Pembrolizumab for the Treatment of...\n",
       "292     Calaspargase Pegol-Mnkl and Cobimetinib for th...\n",
       "293     Fulvestrant and Ipatasertib for Advanced HER-2...\n",
       "294     Ph2 Study of Savolitinib and Durvalumab (MEDI4...\n",
       "295     Testing the Use of BRAF-Targeted Therapy After...\n",
       "296                             RC48-ADC in Breast Cancer\n",
       "297     Study of Quality of Life Post Salpingo-oophore...\n",
       "298     SCOUT® Radar Localization in Nonpalpable Breas...\n",
       "299                SABR-CaRe in Early Stage Breast Cancer\n",
       "300     Palliadelic Treatment to Reduce Psychological ...\n",
       "301     Evaluation of a Novel Axillary Lymph Node Ink ...\n",
       "302     LUMINOS-103: A Basket Trial Evaluating the Saf...\n",
       "303     To Evaluate the Safety, Tolerability, and Phar...\n",
       "304     Study Evaluating the Efficacy and Safety of Mu...\n",
       "305     Quadratic Phenotypic Optimisation Platform (QP...\n",
       "306     ELVN-002 in HER2 Mutant Non-Small Cell Lung Ca...\n",
       "307     Empowering Vulnerable and Resilient Latinas to...\n",
       "308     Phase 1 Trial of LVGN6051 as Single Agent and ...\n",
       "309     Identifying Underserved Individuals inTexas Wi...\n",
       "310     Neratinib and Capmatinib Combination (Phase Ib...\n",
       "311     Iadademstat in Combination With Paclitaxel in ...\n",
       "312     Osimertinib With or Without Bevacizumab as Ini...\n",
       "313     KRAS-Targeted Vaccine With Nivolumab and Ipili...\n",
       "314     Pembrolizumab, Capecitabine, and Radiation The...\n",
       "315     MAGE-C2 TCR T Cell Trial to Treat Melanoma and...\n",
       "316     Acupuncture Versus Sham Acupuncture or Usual C...\n",
       "317     A Study of Oleogel-S10 Gel for the Treatment o...\n",
       "318     Moxifloxacin in Adjuvant Treatment of Patients...\n",
       "319                         Lorlatinib Continuation Study\n",
       "320     Effect of Ultrasound Combined With Microbubble...\n",
       "321     A Window of Opportunity Study for Investigatin...\n",
       "322     The Care Tracker Study: Using Patient-Reported...\n",
       "323     A Study of Radiation Therapy to Treat Solid Tu...\n",
       "324        Testing a New Imaging Agent to Identify Cancer\n",
       "325     Nurse-led Proactive Telephone Follow-up With P...\n",
       "326     Endocrine Therapy With Abemaciclib or Chemothe...\n",
       "327     Clinical Validation of Radiomics Artificial In...\n",
       "328     Organ Preservation First Strategy and Intentio...\n",
       "329     Pyrotinib Plus Vinorelbine in Participants Wit...\n",
       "330     BGT007 Cells for the Treatment of Refractory D...\n",
       "331     Phase II Trial of Consolidative Thoracic Radio...\n",
       "332     A Phase I Study of WM-S1-030 in Patients With ...\n",
       "333     An Investigation of Kidney and Urothelial Tumo...\n",
       "334     Safety and Feasibility of Robotic SP Nipple Sp...\n",
       "335     SX-682 and Nivolumab for the Treatment of RAS-...\n",
       "336     Adaptive Approach to Neoadjuvant Therapy to Ma...\n",
       "337     Posterior-line Treatment With Disitamab Vedoti...\n",
       "338     Investigate the Prognostic and Predictive Valu...\n",
       "339     Aumolertinib With or Without Chemotherapy as 1...\n",
       "340     Pharmacokinetic Boosting of Olaparib to Improv...\n",
       "341     Circulating Tumor DNA Monitoring in Breast Can...\n",
       "342     Genomically Guided Radiation Therapy in the Ma...\n",
       "343     Testing the Role of FDG-PET/CT to Predict Resp...\n",
       "344           Financial Toxicity in Breast Cancer Surgery\n",
       "345            CIPN in Early Stage Breast Cancer Patients\n",
       "346     The Prospective Observational COMPRAYA Cohort ...\n",
       "347     Neoadjuvant Therapy Study Guided by Drug Scree...\n",
       "348     Genetic & Pathological Studies of BRCA1/BRCA2:...\n",
       "349     Pressurized Intraperitoneal Aerosol Chemothera...\n",
       "350     All-extremity Exercise During Breast Cancer Ch...\n",
       "351     Computed Tomography in Diagnosing Patients Wit...\n",
       "352     Combination Chemotherapy, Bevacizumab, and/or ...\n",
       "353     Wide Margin vs. Narrow Margin in Postneoadjuva...\n",
       "354                        Susan G. Komen's ShareForCures\n",
       "355     MIRAI-MRI: Comparing Screening MRI for Patient...\n",
       "356     The Possible Range of No.12a Lymph Node Dissec...\n",
       "357     Radioembolization in Elderly/ Fragile Patients...\n",
       "358     Binary Oncolytic Adenovirus in Combination Wit...\n",
       "359     Chemotherapy-Free pCR-Guided Strategy With Tra...\n",
       "360     Decellularized, Whole Donor Nipple-Areola Comp...\n",
       "361     Investigating National Solutions for Personali...\n",
       "362     A PD-1 Checkpoint Inhibitor (Cemiplimab) for H...\n",
       "363     Pamiparib for Consolidation Treatment of Unpro...\n",
       "364     Personalized Second Chance Breast Conservation...\n",
       "365     Cardiac Rehabilitation for Patients Receiving ...\n",
       "366     Safety and Efficacy Analysis of an Antibody As...\n",
       "367     Diagnostic Significance of Single Center, Open...\n",
       "368     Adjuvant Durvalumab for Early Stage NSCLC Pati...\n",
       "369     Quality of Life After Conservative Oncoplastic...\n",
       "370     Neoadjuvant Endocrine Therapy in ER-positive, ...\n",
       "371     Psycho-social Determinant for Sport Practised ...\n",
       "372                               Control Cohort CTRL COH\n",
       "373          STOP-HER2: Stopping Trastuzumab in HER2+ MBC\n",
       "374     Traditional Chinese Medicine Combined With The...\n",
       "375     Infertility Survey Among Reproductive Age Wome...\n",
       "376     A Study to Evaluate Safety and Efficacy of BEY...\n",
       "377     Study Evaluating Neurotoxicity in Patients Wit...\n",
       "378     A Study to Evaluate the Safety and Tolerabilit...\n",
       "379     A Study of Tucatinib or Placebo With Trastuzum...\n",
       "380     BRE-04: Window of Opportunity Trial of Preoper...\n",
       "381     A Phase I/II Study of VLS-1488 in Subjects Wit...\n",
       "382     Carboplatin Intensified Chemotherapy for TRIpl...\n",
       "383        BCG for Therapeutic Use Phase I Clinical Trial\n",
       "384     Evaluation of Prognostic Monitoring for Triple...\n",
       "385     A Feasibility and Safety Study of Intratumoral...\n",
       "386     Safety Study of Whole Body Hyperthermia for Ad...\n",
       "387     Clinical Study of CEA-targeted CAR-T Therapy f...\n",
       "388     A Study of TQB2102 for Injection in Patients W...\n",
       "389     Gene Signatures to Guide HR+MBC Therapy in a D...\n",
       "390     Newton Study (NEW Dosing mainTenance Therapy O...\n",
       "391     Connecting Black Families in Houston, Texas to...\n",
       "392     Specimen PET-CT Imaging for Intraoperative Mar...\n",
       "393     GammaPod Dose Escalation Radiation for Early S...\n",
       "394     A Trial of AK112 (PD-1/VEGF Bispecific Antibod...\n",
       "395     Supervised Exercise, Sleep in Patients With No...\n",
       "396     Radiotherapy Combined With PD-1 Inhibitors and...\n",
       "397     A Study of RC48-ADC for the Treatment of Local...\n",
       "398     Niraparib and Bevacizumab Maintenance Therapy ...\n",
       "399     Adaptive ChemoTherapy for Ovarian Cancer in Pa...\n",
       "400     A Study of NX-1607 in Adults With Advanced Mal...\n",
       "401     The ABC Study: Assessment of Breast Density Cl...\n",
       "402     VoiceS: Voice Quality After Transoral CO2-Lase...\n",
       "403     Zafirlukast in Treatment of Marker Relapsed Ov...\n",
       "404     Identifying Decision Making Needs for Older Ad...\n",
       "405     The ClearCoast™ Magnetic Resonance Outcome PMS...\n",
       "406     Trial of Maintenance With Niraparib- Uterine S...\n",
       "407     Phase 1, First-in-human, Dose-finding and Expa...\n",
       "408     Adaptive Symptom Self-Management Immunotherapy...\n",
       "409     Dietary Habits, Nutritional Knowledge and Phys...\n",
       "410     IMPACT Trial: Intervention to iMProve AdherenC...\n",
       "411     Sacituzumab Govitecan in Primary HER2-negative...\n",
       "412     SHR-1701 in Combination With Chemotherapy and ...\n",
       "413     COntinue the SaMe Systemic Therapy After Local...\n",
       "414     Feasibility of Non-Operative Management of Rec...\n",
       "415     A NIS of Alpelisib in Combination With Fulvest...\n",
       "416     Ultrasound-guided Erector Spinae Plane Block V...\n",
       "417     Decision Making Tool in Supporting Decision Ma...\n",
       "418     Neoadjuvant Immunoradiotherapy in Head & Neck ...\n",
       "419       Pembrolizumab in Muscle-invasive Bladder Cancer\n",
       "420     Ampligen Compared to No Treatment Following FO...\n",
       "421     Administration of Autologous T-Cells Genetical...\n",
       "422     Targeted Alpha Therapy With 225Actinium-Prosta...\n",
       "423     Lenvatinib+Letrozole Versus Fulvestrant in Met...\n",
       "424     COffee and Metabolites Modulating the Gut Micr...\n",
       "425     PRECAMA: Molecular Subtypes of Premenopausal B...\n",
       "426     To Identify Primary Resistance to CDK4/6 Inhib...\n",
       "427     A Study to Determine if the Drug, Pyrvinium Pa...\n",
       "428     Nivolumab During Active Surveillance After Neo...\n",
       "429     A Clinical Study of CD70-targeted CAR-T in the...\n",
       "430     A Prospective, Phase II Trial Using ctDNA to I...\n",
       "431     Longitudinal Investigation of Cancer-related F...\n",
       "432     Gut Microbe Composition, Exercise, and Breast ...\n",
       "433     Neoadjuvant Radiotherapy and Immediate Implant...\n",
       "434     Personalized Oncogenomics (POG) Program of Bri...\n",
       "435     A Safety and Efficacy Study of Intra-tumoural ...\n",
       "436     Assessment of Brain Cognitive Impairment in Br...\n",
       "437     Neoadjuvant TIL- and Response-Adapted Chemoimm...\n",
       "438     Effect of NUTRICAN to Improve Nutritional Stat...\n",
       "439     The Effects of Treating Insomnia on Behavioral...\n",
       "440     Neoadjuvant IBI308, Bevacizumab, Plus Pemetrex...\n",
       "441     Sentinel lympH Node Biopsy With Indocyanine Gr...\n",
       "442     Study of Chemotherapy With Cisplatin/Carboplat...\n",
       "443     Memory and Attention Adaptation Training-Geria...\n",
       "444     TeleHealth Resistance Exercise Intervention to...\n",
       "445     Trial of Individualized Adaptive RT in HPV-rel...\n",
       "446     A Study of Radiation Toxicity in the Liver Usi...\n",
       "447     A Study of Lorigerlimab With Docetaxel or Doce...\n",
       "448     Paclitaxel Therapeutic Drug Monitoring in Canc...\n",
       "449     Abemaciclib in Combination With Androgen Depri...\n",
       "450     Fudan University Shanghai Cancer Center Breast...\n",
       "451     Vocal-cord vs. Complete Laryngeal Radiotherapy...\n",
       "452     Study on Skin Toxicities Induced by Cancer Tre...\n",
       "453     Study of Combination Therapy of D07001-Softgel...\n",
       "454     Evaluating Omission of Granulocyte Colony-stim...\n",
       "455      Alectinib Pharmacokinetic in Patients With NSCLC\n",
       "456                  Early Detection of Pancreatic Cancer\n",
       "457     The Neuroendocrine Effects of Pioglitazone in ...\n",
       "458     Vocational Rehabilitation for the Return to Wo...\n",
       "459     Study of NGM831 as Monotherapy and in Combinat...\n",
       "460     A Study of ART0380 for the Treatment of Advanc...\n",
       "461     Iribrine Plus Tucidinostat in the Treatment of...\n",
       "462     Effect of Montelukast on Doxorubicin Induced C...\n",
       "463     A Study of TAS2940 in Participants With Locall...\n",
       "464     A Study Evaluating the Safety and Efficacy of ...\n",
       "465     Neoadjuvant Pembrolizumab and Axitinib in Rena...\n",
       "466     Anlotinib Combination With Vinorelbine in the ...\n",
       "467                              D4 Choline Breast PET/CT\n",
       "468     Crizotinib in Treating Patients With Stage IB-...\n",
       "469     Difluoromethylornithine and High Dose Testoste...\n",
       "470     A Clinical Study of CEA-targeted CAR-T in the ...\n",
       "471        REJOIN Trial for Older Breast Cancer Survivors\n",
       "472     Chemotherapy and Pelvic Hypofractionated Radia...\n",
       "473     The Association Between CBT-I Dose, Sleep Dura...\n",
       "474     Gemcitabine Versus Reduced-dose Combination Ch...\n",
       "475                                   Protein Needs Study\n",
       "476     Phase I/IIa Study for AZD5335 as Monotherapy a...\n",
       "477     Mutant KRAS -Targeted Long Peptide Vaccine for...\n",
       "478     Study of 68Ga /131I SGMIB-5F7 PET Imaging Targ...\n",
       "479     A Study to Evaluate the Safety and Efficacy of...\n",
       "480     Axillary Staging in Early Breast Cancer: SNB v...\n",
       "481     Coping After Breast Cancer - a Randomized Clin...\n",
       "482     Neoadjuvant Endocrine Therapy +/- the PI3K Inh...\n",
       "483     Opioid-Sparing Effects of Nurse-Delivered Hypn...\n",
       "484     Circulating DNA to Improve Outcome of Oncology...\n",
       "485     Preoperative ChemoRadiation And FOLFOXIRI for ...\n",
       "486     Single Fraction Preoperative Radiotherapy for ...\n",
       "487     Neoadjuvant Dose-dense Chemotherapy for HR+/HE...\n",
       "488     Evaluation of Talazoparib, a PARP Inhibitor, i...\n",
       "489     ASP-1929 Photoimmunotherapy (PIT) Study in Rec...\n",
       "490     Stereotactic Ablative Radiotherapy for OligoMe...\n",
       "491     Cabozantinib in Patients With RET Fusion-Posit...\n",
       "492     Phase II Study of FTD/TPI (Lonsurf) in Metasta...\n",
       "493     Magrolimab in Children and Adults With Recurre...\n",
       "494     Combined Treatment of Durvalumab, Bevacizumab,...\n",
       "495     ZetaFuse™ Bone Graft in the Repair of Bone Def...\n",
       "496     Ultra-hypofractionated for Whole Breast Irradi...\n",
       "497     Neoadjuvant Chemoimmunotherapy Followed By Rad...\n",
       "498     Standard Treatment +/- SBRT in Solid Tumors Pa...\n",
       "499                      Onvansertib + Paclitaxel In TNBC\n",
       "500     Bevacizumab and Tocotrienol in Recurrent Ovari...\n",
       "501     Necitumumab and Trastuzumab in Combination Wit...\n",
       "502     Abemaciclib in Treating Patients With Surgical...\n",
       "503     Study of Sacituzumab Govitecan-hziy and Pembro...\n",
       "504      A Post Marketing Surveillance on Piqray in Korea\n",
       "505     Phase I Trial of Adagrasib (MRTX849) in Combin...\n",
       "506     A Study to Try to Bring Back Radioiodine Sensi...\n",
       "507     Phase I Study of TSN084 in Patients With Advan...\n",
       "508     Diagnostic Performance of Small RNA Blood Test...\n",
       "509     A Study to Evaluate Serplulimab in Combination...\n",
       "510     Sentinel Node Biopsy Vs Observation After Axil...\n",
       "511     Study of Neoadjuvant Chemotherapy Versus Defin...\n",
       "512     Near-Infrared Fluorescence Guided Robotic Pulm...\n",
       "513     A Study of Camizestrant in ER+/HER2- Early Bre...\n",
       "514     PEmbRolizumab verSus chEmotherapy and pEmbroli...\n",
       "515     Assessment of Tool Placement in Pulmonary Nodu...\n",
       "516     Initial Feasibility Study to Treat Borderline ...\n",
       "517     A Phase 3b, Open-label, Multi-center Study on ...\n",
       "518     Novel SEQUEnced Immunotherapy With Anti-angiog...\n",
       "519     Proteomics and Radiomics Research of Breast Ca...\n",
       "520     Identification of Genetic Determinants for Tre...\n",
       "521     Ribociclib vs. Palbociclib in Patients With Ad...\n",
       "522     Claudin 18.2-Targeted Chimeric Antigen Recepto...\n",
       "523     Gemcitabine, Nab-paclitaxel, Durvalumab, and O...\n",
       "524     Comparison of Diagnostic Sensitivity Between c...\n",
       "525     FMT in Checkpoint Inhibitor-mediated Diarrhea ...\n",
       "526     Long-term Outcomes of Lidocaine Infusions for ...\n",
       "527     TMEM-MRI: A Pilot Feasibility Study of MRI for...\n",
       "528     Cemiplimab, Low-Dose Paclitaxel and Carboplati...\n",
       "529     Phase II Study of the Effects of Laparoscopic ...\n",
       "530     Testing Experimental Anti-cancer Drug SLC-391 ...\n",
       "531     Study of CXCR5 Modified EGFR Targeted CAR-T Ce...\n",
       "532     ARTIDIS Nanomechanical Generated Measurements ...\n",
       "533     A Study Evaluating Near-infrared Zone II Imagi...\n",
       "534     Men Moving Forward: A Lifestyle Program for Af...\n",
       "535     Niraparib and TSR-042 for the Treatment of BRC...\n",
       "536      Integrated Cancer Repository for Cancer Research\n",
       "537     Frontline Immunotherapy Combined With Radiatio...\n",
       "538     Pharmacokinetic Study of Skeletal Muscle Area-...\n",
       "539           Genomic Investigation of Unusual Responders\n",
       "540     Bortezomib Followed by Pembrolizumab and Cispl...\n",
       "541     Prevention of Sequelae Pain After Breast Cance...\n",
       "542     Binimetinib and Hydroxychloroquine in Treating...\n",
       "543     Impact of a Sensory Rehabilitation Program on ...\n",
       "544     Abemaciclib + Letrozole +/- Metformin in Recur...\n",
       "545     Trastuzumab + Alpelisib +/- Fulvestrant vs Tra...\n",
       "546     ScreenIng of Genetic Susceptibility Genes for ...\n",
       "547     Study of Palliative Radiation Combined With Pe...\n",
       "548     Efficacy and Safety Study of REM-001 Photodyna...\n",
       "549     SHR-A1811 Versus Investigator's Chemotherapy i...\n",
       "550      Nipple Aspirate Fluid in Detecting Breast Cancer\n",
       "551     To Evaluate the Efficacy of QLH11811 in Advanc...\n",
       "552               Ribociclib and Bicalutamide in AR+ TNBC\n",
       "553     Trial Of PreoperAtive Radiation (TOPAz): A Ran...\n",
       "554     A Study of RGX-104 in Patients With Advanced L...\n",
       "555     NIRAPK : Study of the Relationship(s) Between ...\n",
       "556     Hyperthermic Intraperitoneal Chemotherapy (HIP...\n",
       "557               Impact of Systematic Shaving on Margins\n",
       "558                    Infusion System for Hepatic Cancer\n",
       "559     First in Human Study of TORL-3-600 in Particip...\n",
       "560     Evaluation of Tamoxifen's Efficacy for ER/PR N...\n",
       "561     Second-line Cabozantinib and Atezolizumab in P...\n",
       "562     Testing the Use of Investigational Drugs Atezo...\n",
       "563     CFI-402257, a Potent and Selective TTK Inhibit...\n",
       "564     Feasibility Study: IGNITE-TX (Identifying Indi...\n",
       "565     ASHBY: Accelerated Super-Hypofractionated Brea...\n",
       "566     GM1 Prophylaxis for WBRT Related Cognitive Dys...\n",
       "567     Effect of Huaier Granule on Adjuvant Treatment...\n",
       "568     Volatile Anaesthesia and Perioperative Outcome...\n",
       "569     Neoadjuvant Adebrelimab Plus Etoposide and Cis...\n",
       "570     Study of [18F]FAPI-74 PET in Patients With Gas...\n",
       "571     The Postoperative Radiotherapy in N1 Breast Ca...\n",
       "572            Phase 1b Combo w/ Ribociclib and Alpelisib\n",
       "573     Sentinel Lymph Node Localisation With an Ultra...\n",
       "574     Eribulin Mesylate Combined With Lobaplatin in ...\n",
       "575     A Study of HS-10365 in Patients With Advanced ...\n",
       "576     Chemo-immunotherapy Plus Thoracic Radiotherapy...\n",
       "577     Select the Appropriate Population for Adding C...\n",
       "578     ACTIVPROSEIN : Professional Activity After Bre...\n",
       "579            TEIPP Immunotherapy in Patients With NSCLC\n",
       "580     A Randomized Phase III Study Comparing Mainten...\n",
       "581     GEN1047 for Solid Tumors - First in Human (FIH...\n",
       "582     A Study of SNS-101 (Anti VISTA) Monotherapy an...\n",
       "583     Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Pat...\n",
       "584     Facilitate and Sustain Return to Work After Br...\n",
       "585     Validation of a Screening Scale for Misuse of ...\n",
       "586     Sirolimus in Combination With Metronomic Chemo...\n",
       "587     Nivolumab, Ipilimumab and Chemoradiation in Pa...\n",
       "588     Safety and Efficacy of SPH4336 in Combination ...\n",
       "589     To Explore the Benefits of the MonaLisa Touch®...\n",
       "590        ORB-011 In Patients With Advanced Solid Tumors\n",
       "591     Prospective Observational Study for Breast Mic...\n",
       "592     Shorter Chemo-Immunotherapy Without Anthracycl...\n",
       "593     Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Pat...\n",
       "594     T-DM1 and Tucatinib Compared With T-DM1 Alone ...\n",
       "595     A Multi-Modality Surveillance Program for Wome...\n",
       "596         Collection of Blood From Patients With Cancer\n",
       "597     A Clinical Study of CD70-targeted CAR-T in the...\n",
       "598     A Study for Subjects With Prostate Cancer Who ...\n",
       "599     A Study of Decreasing Radiation Therapy and Ch...\n",
       "600     First in Human Study of TORL-1-23 in Participa...\n",
       "601       HPI Effect in Robotic Urological Surgery on AKI\n",
       "602     A Phase 1/2a Study of 23ME-00610 in Patients W...\n",
       "603            DCE MRI in Patients With Pancreatic Cancer\n",
       "604     Investigation of Urinary Biomarkers for the De...\n",
       "605     Study of Envafolimab Alone or With Lenvatinib ...\n",
       "606     ESTIMation of the ABiLity of Prophylactic Cent...\n",
       "607     Dose-escalation of Regorafenib in Advanced Hep...\n",
       "608     A Study to Investigate Safety and Tolerability...\n",
       "609      TCb vs EC-T in High Risk ER+/HER2- Breast Cancer\n",
       "610     An Observational Study of Patients Receiving T...\n",
       "611     Capecitabine Plus Concomitant Radiation Therap...\n",
       "612     Adverse Childhood Experiences, Adaptation and ...\n",
       "613     Benefit of a Flash Dose of Corticosteroids in ...\n",
       "614     Compare Continuation of Original Targeted Ther...\n",
       "615             Autoantibodies in Breast Cancer Detection\n",
       "616     A Study of SI-B001+SI-B003± Chemotherapy in th...\n",
       "617     Treatment With Tucatinib in Patients With an I...\n",
       "618     CEA Targeting Chimeric Antigen Receptor T Lymp...\n",
       "619     A Window-of-Opportunity Trial of Giredestrant ...\n",
       "620                          Strength After Breast Cancer\n",
       "621     Stereotactic Radiosurgery vs Whole Brain Radio...\n",
       "622     Precise Treatment for BLIS Subtype of TNBC in ...\n",
       "623     Neoadjuvant Her2-targeted Therapy and Immunoth...\n",
       "624     Phase 1/2a Study of SQ3370 in Patients With Ad...\n",
       "625     Preoperative Lenvatinib Plus Pembrolizumab in ...\n",
       "626     Weekly Single Fraction Hypofractionated Adjuva...\n",
       "627     Testing the Combination of the Anti-Cancer Dru...\n",
       "628         TH1902 in Patients With Advanced Solid Tumors\n",
       "629     Endoscopic Optical Coherence Tomography for Sc...\n",
       "630     Omental Tissue Autograft in Human Recurrent Gl...\n",
       "631     Prehabilitation and Rehabilitation in Breast C...\n",
       "632     Administering Peripheral Blood Lymphocytes Tra...\n",
       "633     Chemotherapy and Surgical Resection in Patient...\n",
       "634     A Systems Approach to Immunotherapy Biomarker ...\n",
       "635     Nivolumab and Ipilimumab With or Without Local...\n",
       "636     A Study of BMS-986340 as Monotherapy and in Co...\n",
       "637     P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Tr...\n",
       "638     A Phase 1/1b Study of ZH9 Treatment in Patient...\n",
       "639     A Study of Amivantamab Monotherapy and in Addi...\n",
       "640     The Effect of Metacognition-based, Manualized ...\n",
       "641     Study to Evaluate Sacituzumab Govitecan in Com...\n",
       "642     Efficacy of Tislelizumab and Spartalizumab Acr...\n",
       "643     Dual SSTR2 and Integrin αvβ3 Targeting PET/CT ...\n",
       "644     Adjuvant Ovarian Suppression Plus Aromatase In...\n",
       "645     Finding an Effective Dose of GM1 to Reduce or ...\n",
       "646     STRONG for Surgery & Strong for Life - Against...\n",
       "647     Study of NGM438 as Monotherapy and in Combinat...\n",
       "648     Tolerance and Benefits of Mandibular Advanced ...\n",
       "649     PANCREATIC DISEASE COHORT A Registry and Biosp...\n",
       "650     Regorafenib Alone or in Combination With High/...\n",
       "651     ATATcH Alternating Treatment Plans for Advance...\n",
       "652     Awareness Based Stress Reduction Program Appli...\n",
       "653     Talking to Employers and Medical Staff About B...\n",
       "654     A Study Called ARAMON to Learn to What Extent ...\n",
       "655     NT-I7 (Efineptakin Alfa) in Combination With P...\n",
       "656     EXCEL: Exercise for Cancer to Enhance Living Well\n",
       "657                  Olaparib In Metastatic Breast Cancer\n",
       "658     Chemotherapy in Patients With Relapsed Small C...\n",
       "659     Y-90 With Durvalumab/Gem/Cis in Intrahepatic C...\n",
       "660     Phase III Study of SY-5007, a RET Inhibitor, i...\n",
       "661     Development of a Clinical and Biological Datab...\n",
       "662     Pembrolizumab in Combination With Olaparib in ...\n",
       "663     Analgesic Efficacy of Maxigesic in Breast Canc...\n",
       "664     BreastVAX: Radiation Boost to Enhance Immune C...\n",
       "665                  Detect V / CHEVENDO (Chemo vs. Endo)\n",
       "666     A Study of MRG002 in the Treatment of Patients...\n",
       "667     Can Staging Magnetic Resonance Imaging (MRI) F...\n",
       "668     Study of Sacituzumab Govitecan Versus Treatmen...\n",
       "669     A Study of NT-112 in HLA-C*08:02-Positive Adul...\n",
       "670     'OLAP' (OLAparib Regulatory Post-marketing Sur...\n",
       "671     Transcriptional Map of Ovarian Cancer at the S...\n",
       "672     ADP-A2M4CD8 Monotherapy and in Combination Wit...\n",
       "673     Single-arm, Multi-center Clinical Study of Pyr...\n",
       "674                     Mastectomy Flap Temperature Study\n",
       "675     Prospective Surveillance for Breast Cancer-Rel...\n",
       "676     Pembrolizumab and Olaparib in Homologous-recom...\n",
       "677     huCART-meso + VCN-01 in Pancreatic and Ovarian...\n",
       "678         Cardiac Effects From Radiation Therapy by MRI\n",
       "679     Primary Surgical Prevention of Breast Cancer-r...\n",
       "680     Neoadjuvant Treatment Pegylated Liposomal Doxo...\n",
       "681     Neoadjuvant Chemotherapy With Gemcitabine Plus...\n",
       "682     Induction Chemotherapy in Locally Advanced Hyp...\n",
       "683     Lymphaticovenous Anastomosis as Treatment for ...\n",
       "684     Comparative Study of the Quality of Life of Pa...\n",
       "685     Evaluation of Radiobiological Effects in Skin ...\n",
       "686     TheraT® Vectors (Vaccines) Combined With Chemo...\n",
       "687     A Study of Tumor Imaging With Multispectral Op...\n",
       "688     A Tear-based, Lab-developed Test for Breast Ca...\n",
       "689                  Assessing the Time Demands of Cancer\n",
       "690     SIRT With Tremelimumab and Durvalumab for Rese...\n",
       "691     Neoadjuvant Concomitant Modulated Electro-hype...\n",
       "692     A Study of NovoTTF-200T(P) in Combination With...\n",
       "693     Toripalimab as Monotherapy in Participants Wit...\n",
       "694     Phase I/II Study of the Combination of Irinote...\n",
       "695     Administering Peripheral Blood Lymphocytes Tra...\n",
       "696     Possible Protective Effect of Rosuvastatin in ...\n",
       "697     The Effects of Light Therapy to Treat Cancer-r...\n",
       "698     CDK4/6 Inhibitors in Patients With Hormone Rec...\n",
       "699     Restor. I-131 Upt. + Selpercatinib in RET F-P ...\n",
       "700     Delayed or Upfront Brain RAdiotherapy in Treat...\n",
       "701     A Trial To Find Out If Vidutolimod Together Wi...\n",
       "702     Testing the Addition of the Anti-cancer Viral ...\n",
       "703     Tislelizumab Combined With Chemotherapy in the...\n",
       "704     A Study of BLYG8824A in Participants With Loca...\n",
       "705     Clinical Study on Adjuvant Therapy of TQB3616 ...\n",
       "706     Transcutaneous Electrical Nerve Stimulation in...\n",
       "707     A Study to Assess the Antitumor Activity, Safe...\n",
       "708     Lymphovenous Bypass Procedure Before Underarm ...\n",
       "709     HIPEC in the Treatment of Stage IIc-IV Epithel...\n",
       "710     Impact of Home-based Aerobic and Strength Exer...\n",
       "711                  F-Tryptophan PET/CT in Human Cancers\n",
       "712     Trastuzumab Deruxtecan (T-DXd) Alone or in Seq...\n",
       "713     Trastuzumab Deruxtecan Alone or in Combination...\n",
       "714     Empowering Latinas to Obtain Guideline Concord...\n",
       "715     The Effect of 360° Virtual Reality Movies on F...\n",
       "716     Program of Physical Activity, Nutrition and Su...\n",
       "717     A Phase 3 Study to Evaluate the Safety and Eff...\n",
       "718     The Effects of Acupuncture and the Therapist´s...\n",
       "719     TAS102 in Combination With NAL-IRI in Advanced...\n",
       "720     MRX-2843 and Osimertinib for the Treatment of ...\n",
       "721     Assessment of the Breast Cosmesis Using Deep N...\n",
       "722     A Study of Xevinapant With Cisplatin and Radia...\n",
       "723     Pyrimethamine as an Inhibitor of NRF2 in HPV-u...\n",
       "724     Dietary and Exercise Interventions in Reducing...\n",
       "725          WIRE - Novel Treatments in Renal Cell Cancer\n",
       "726     Metastases Directed Therapy for Oligometastati...\n",
       "727     Nomogram to Predict Breast Cancer Related Lymp...\n",
       "728     Safety and Efficacy of Anti-CD47, ALX148 in Co...\n",
       "729     Trial Comparing Systemic Therapy Alone and Wit...\n",
       "730     Testing the Combination of New Anti-cancer Dru...\n",
       "731     CD40 Agonist, Flt3 Ligand, and Chemotherapy in...\n",
       "732     Study of Neoadjuvant Olaparib Monotherapy and ...\n",
       "733     Choosing Ovarian Preservation or Removal Befor...\n",
       "734     Neo-adjuvant Pembrolizumab as an Alternative T...\n",
       "735                [18F] F-GLN by PET/CT in Breast Cancer\n",
       "736     Time Restricted Eating During Chemotherapy for...\n",
       "737     Testing the Use of Ado-Trastuzumab Emtansine C...\n",
       "738     Basket Trial Exploring the Efficacy and Safety...\n",
       "739     Efficacy of T-Dxd in the Treatment of HER2-pos...\n",
       "740     RCT of Strategies to Augment Physical Activity...\n",
       "741     Tumoral Circulating Cells and Colorectal Cance...\n",
       "742     Liposomal iRInotecan, Carboplatin or oXaliplat...\n",
       "743     Pilot Study of the eHealth Application \"Cancer...\n",
       "744     Dose Escalation of Lapatinib With Paclitaxel i...\n",
       "745     A Study of Reduced-dose Radiation in People Wi...\n",
       "746     UCSD Image-Guided Cognitive-Sparing Radiosurge...\n",
       "747     Study of an Anti-HER3 Antibody, HMBD-001, With...\n",
       "748     Targeted Resection of Axillary Metastatic Lymp...\n",
       "749     Ice Plant Intensive Cream for the Prevention o...\n",
       "750     Evaluation of Cognitive Management for Chemobr...\n",
       "751     Implementation of a Multimodal Prehabilitation...\n",
       "752     A Multicenter Cancer Biospecimen Collection Study\n",
       "753     Internet-delivered Cognitive-Behavioral Interv...\n",
       "754     Autologous Dendritic Cells and Allogenic Dendr...\n",
       "755     Oral Aromatase Inhibitors Modify the Gut Micro...\n",
       "756     NKG2D CAR-NK Cell Therapy in Patients With Ref...\n",
       "757           Efficacy of Point Of Service Testing in MBC\n",
       "758     A Study of the Gut Microbiome in Hormone Recep...\n",
       "759     Tucatinib in Combination With Oral Etoposide a...\n",
       "760     A Prospective, Open-label, Multicenter, Random...\n",
       "761     Predictive Markers of Immune-related Adverse E...\n",
       "762     Adjustable Compression Wrap Versus Compression...\n",
       "763     In Vitro Organoid Drug Sensitivity-Guided Trea...\n",
       "764     ExclUsive endocRine Therapy Or Radiation thera...\n",
       "765     Efficacy of Supplement Adjuvant Capecitabine i...\n",
       "766             Niraparib in Tumors Metastatic to the CNS\n",
       "767     Fear-focused Self-Compassion Therapy for Young...\n",
       "768     Evaluation of the Benefit of a New Surgical Pr...\n",
       "769               Sexual Health in Breast Cancer Patients\n",
       "770     Modified Immune Cells (Autologous CAR T Cells)...\n",
       "771     A Clinical Trial Targeting CEA Chimeric Antige...\n",
       "772     Personalized Electroacupuncture Treatment for ...\n",
       "773     Metastatic Thyroid Cancer Therapy Optimization...\n",
       "774     Phase 3 Study of Toripalimab Alone or in Combi...\n",
       "775      Psychosexual Educational Partners Program (PEPP)\n",
       "776     Adbelizumab Combined With Chemotherapy for Neo...\n",
       "777     Prevention of Symptomatic Skeletal Events With...\n",
       "778     Abemaciclib in Combination With Endocrine Ther...\n",
       "779     Neoadjuvant Fluzoparib in Germline BRCA-mutate...\n",
       "780     Study of De_Intensified Postoperative Radiatio...\n",
       "781     Adjuvant Furmonertinib in Stage IA With High R...\n",
       "782     Enfortumab Vedotin Plus Pembrolizumab for the ...\n",
       "783              Cancer Survivor Cardiomyopathy Detection\n",
       "784     Avelumab and Radiation in Muscle-Invasive Blad...\n",
       "785                 Adjuvant Melatonin for Uveal Melanoma\n",
       "786     Ivosidenib + mFOLFIRINOX in Patients With Rese...\n",
       "787     Improving Survival for Metastatic Lobular Brea...\n",
       "788     Early-Line Anti-EGFR Therapy to Facilitate Ret...\n",
       "789     Monitoring Symptoms to Help Young Women Take H...\n",
       "790     Plasma Proteomic Biomarkers for Early Diagnosi...\n",
       "791     A Randomized Trial of Chemotherapy in Surgical...\n",
       "792        Rehabilitation for People With Advanced Cancer\n",
       "793     A Fluorescent Tumor Marking Agent, Tozuleristi...\n",
       "794     Complete Cytoreduction Followed by IP and Syst...\n",
       "795     Clinico-biological Database in Patients Treate...\n",
       "796     Avapritinib for the Treatment of CKIT or PDGFR...\n",
       "797     A Phase 2 Study to Evaluate the Triplet Combin...\n",
       "798     LEVANTIS-0087A: GAGomes for Multi-Cancer Early...\n",
       "799     Minimally INvasive Colon Cancer Surgery Throug...\n",
       "800     Radiotherapy Delivery in Deep Inspiration for ...\n",
       "801     A Study of Hansoh (HS)-10502 in Patients With ...\n",
       "802     Breast Cancer Prevention and Screening Membership\n",
       "803     The Modulatory Role of Internet MBCT on Extrac...\n",
       "804     Efficacy and Safety of AI-assisted Radiotherap...\n",
       "805     Evaluation of the Medidux™ Digital Health Appl...\n",
       "806     Real World Study on First Line Crizotinib in R...\n",
       "807     Feasibility Study of Biobehavioral Stress Redu...\n",
       "808     Marathon of Hope Cancer Centres Network Study ...\n",
       "809     Evaluation of See.d as an Automated Blood Samp...\n",
       "810     Talazoparib in Combination With Belinostat for...\n",
       "811     Study of Osimertinib+Bevacizumab+Chemotherapy ...\n",
       "812     Fecal Microbiota Transplantation in Treating I...\n",
       "813     IO102-IO103 in Combination With Pembrolizumab ...\n",
       "814     TGRX-326 Chinese Phase I for Advanced Non-smal...\n",
       "815     Liposomal Irinotecan Based FOLFIRI With Bevaci...\n",
       "816                       Cancer Surveillance and Support\n",
       "817          Hand-Foot Exercises on Peripheral Neuropathy\n",
       "818     A Study Evaluating the Efficacy and Safety of ...\n",
       "819     Study of Antivascular Therapy Combined With Ch...\n",
       "820     PD-L1 PET Imaging During Neoadjuvant (Chemo)Ra...\n",
       "821     Phase II Panitumumab-IRDye800 in Head & Neck C...\n",
       "822     A Study of Patients Receiving High-Dose Rate B...\n",
       "823     Chidamide Plus PD-1 Plus Paclitaxel of Neoadju...\n",
       "824     Use of GnRHa During Chemotherapy for Fertility...\n",
       "825     The Effectiveness of Psychological Interventio...\n",
       "826     TARGETed Therapy Drug MONITOring in DIGestive ...\n",
       "827     Peri-Operative Immune Checkpoint Inhibition an...\n",
       "828     Study of Lenvatinib w/ Pembro in Black Partici...\n",
       "829     Study of Neoadjuvant Chemotherapy Plus Trastuz...\n",
       "830     A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B...\n",
       "831     Losartan in Prevention of Radiation-Induced He...\n",
       "832        GammaPod Registry and Quality of Life Nomogram\n",
       "833     Feasibility of Implementing Acupuncture Into F...\n",
       "834     A Study of Targeted Radiation Therapy in Peopl...\n",
       "835                                   ICG and SLN Mapping\n",
       "836     Web-Based Symptom Monitoring and Self-Manageme...\n",
       "837     Lenvatinib Plus Paclitaxel for Patients With A...\n",
       "838     Phase I/II Evaluation of a Cancer Lysate Vacci...\n",
       "839     Predictive Clinical and Biological Parameters ...\n",
       "840     Comparing the QoR of PECS Block and GA in Brea...\n",
       "841     Impact of Pegfilgrastim on Trastuzumab Anti-tu...\n",
       "842     Sotorasib in Advanced KRASG12C-mutated Non-sma...\n",
       "843     Study With Atezolizumab in Combination With Tr...\n",
       "844     A Multicenter, Randomized, Open, Phase III Tri...\n",
       "845     Hepatic Artery Infusion Pump Chemotherapy With...\n",
       "846     Prospective Observational Study on Outcome of ...\n",
       "847     Study of PIK3CA Mutations and Effectiveness an...\n",
       "848     NaliCap (Irinotecan Liposome (Nal-IRI)/Capecit...\n",
       "849     Actinium 225 Labeled Anti-CEA Antibody (Ac225-...\n",
       "850     Phase I Study of the HS-10352 in Patients With...\n",
       "851     Preoperative Short-Course Radiation Therapy Wi...\n",
       "852     Study Maintenance Regorafenib vs Placebo, no P...\n",
       "853     Perioperative Leucovorin, Oxaliplatin, Docetax...\n",
       "854     Exercise and Cognitive (Brain) Function in Bre...\n",
       "855     A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO...\n",
       "856     The Differential Impact of Proton Beam Irradia...\n",
       "857     External Hypofractionated Radiotherapy With Si...\n",
       "858     A Study for the Neoadjuvant Treatment of Breas...\n",
       "859     Evaluation of Vascular Toxicity of Immune Chec...\n",
       "860     A Phase I/II Study of Regorafenib Plus Aveluma...\n",
       "861     A Study of MRG003 in the Treatment of EGFR-pos...\n",
       "862     Non Inferiority Study of Preoperative Chemothe...\n",
       "863     Pembrolizumab With Chemotherapy for Poorly Che...\n",
       "864     Risk Reducing Salpingectomy With Delayed Oopho...\n",
       "865     Serum Biomarkers to Characterize the Effects o...\n",
       "866     [18F]F-AraG PET Imaging to Visualize Tumor Inf...\n",
       "867     A Trial Evaluating the Efficacy of Metastasect...\n",
       "868     Pyrotinib Combined With Capecitabine in HER-2 ...\n",
       "869     Screening Magnetic Resonance Imaging of the Br...\n",
       "870            Seroma Reduction and Drain Free Mastectomy\n",
       "871     ARGONAUT: Stool and Blood Sample Bank for Canc...\n",
       "872     Intraoperative Electron Beam Radiotherapy Boos...\n",
       "873                       Breast Cancer Registry Platform\n",
       "874     Early Detection of Five Common Cancers Using t...\n",
       "875     Study of Cardiopulmonary Exercise Testing in W...\n",
       "876     Health Coaching-Based Navigation at the Conclu...\n",
       "877     Resistance-type Exercise Training in Postmenop...\n",
       "878     Alectinib Followed by Concomitant Consolidatio...\n",
       "879                Imaging of Solid Tumors Using FAP-2286\n",
       "880     PACED-digitized Support During Adjuvant Endocr...\n",
       "881     Statin Addition to Chemotherapy for Advanced P...\n",
       "882                                ETHAN - ET for Male BC\n",
       "883     Clinical Study of Glycosylated Extracellular V...\n",
       "884     Cabozantinib and Dostarlimab in Recurrent Gyne...\n",
       "885                                Ezra Faster Scan Study\n",
       "886     A Study of TransCon TLR7/8 Agonist With or Wit...\n",
       "887     Dosing Study of Radiation Combined With Tislel...\n",
       "888     Healing of Rectal Anastomosis Sealed With a Co...\n",
       "889     Regional Lymph Node Irradiation for High-risk ...\n",
       "890     Colorectal Cancer Screnning Colonoscopy Under ...\n",
       "891     Personalized Patient Derived Xenograft (pPDX) ...\n",
       "892     Evaluation of Efficacy of Comprehensive Genomi...\n",
       "893     Clinical Study of CEA Targeting Chimeric Antig...\n",
       "894     Study to Determine the Safety and Efficacy of ...\n",
       "895     Neoadjuvant Immunotherapy in Combination With ...\n",
       "896     Datopotamab Deruxtecan (Dato-DXd) and Pembroli...\n",
       "897     The Treatment Situation of Chinese County Popu...\n",
       "898     Study of Pembrolizumab (MK-3475) in Participan...\n",
       "899          PET/MR Radiomics for Breast Cancer Diagnosis\n",
       "900     Study of 2141-V11 in People With Non-muscle In...\n",
       "901     BALSTILIMAB on Viral Clearance in HPV+ Orophar...\n",
       "902     Rigosertib Plus Nivolumab for KRAS+ NSCLC Pati...\n",
       "903     MRD Assay Evaluates Recurrence and Response Vi...\n",
       "904     A Study of Samuraciclib and Elacestrant in Par...\n",
       "905     A Phase IIa Randomized, Double-Blinded Clinica...\n",
       "906                      ATEMPT 2.0: Adjuvant T-DM1 vs TH\n",
       "907     Mapping Sentinel Lymph Node in Initial Stages ...\n",
       "908     Assess Use of 18F-Fluciclovine for Patients Wi...\n",
       "909     MNK Inhibitor AUM001 in Combination With Eithe...\n",
       "910     Pembrolizumab With Carboplatin Compared to Car...\n",
       "911     Efficacy Study of Osimertinib in Treatment-naï...\n",
       "912     Ulixertinib/Palbociclib in Patients With Advan...\n",
       "913     Exercise and Diet Counseling Program in Improv...\n",
       "914     Prospective and Retrospective Breast Cancer Da...\n",
       "915     CORRECT Study of Minimal Residual Disease Dete...\n",
       "916     Chemo4METPANC Combination Chemokine Inhibitor,...\n",
       "917     CT-based Radiomics of ALN pCR (ypN0) in Breast...\n",
       "918     Sensory Restoration After DIEP Flap Neurotization\n",
       "919     Safety, PK and Efficacy of ONC-392 in Monother...\n",
       "920     BRE-08 Phase II Study of CMC Regimen for Early...\n",
       "921     Single Center Registration Study on HER2 Expre...\n",
       "922     The Impact of Thymosin α-1 on the Efficacy of ...\n",
       "923     The Effect of Manual Lymph Drainage in the Tre...\n",
       "924     A Prospective Multi-centered Randomized Contro...\n",
       "925     Lenvatinib With Everolimus Versus Cabozantinib...\n",
       "926     A Phase Ib/II Trial to Evaluate the Safety and...\n",
       "927     Effectiveness of Aquatic Exercise on Fatigue, ...\n",
       "928     A Study of Contrast-Enhanced Mammography (CEM)...\n",
       "929     Application of FIT-DNA Detection in Following ...\n",
       "930     Prognostic Relevance of Coagulation Activation...\n",
       "931     Combining Interventions of Fertility Preservat...\n",
       "932     Study to Assess the Efficacy and Safety of Adj...\n",
       "933     Efficacy of Everolimus Combined With First-lin...\n",
       "934     Carboplatin, Pemetrexed, and Atezolizumab in P...\n",
       "935     Structuring of a Lung Cancer Screening Program...\n",
       "936     Study of Atezolizumab + FLOT vs. FLOT Alone in...\n",
       "937     A Study to Assess Efficacy of RXC004 +/- Nivol...\n",
       "938     A Phase II Study of Neoadjuvant Sacituzumab Go...\n",
       "939     Curcumin and Piperine in Patients on Surveilla...\n",
       "940     Diet Modification in pAtients With Luminal Ear...\n",
       "941     Quaratusugene Ozeplasmid (Reqorsa) and Atezoli...\n",
       "942     Dalpiciclib With Endocrine Therapy for Advance...\n",
       "943     Three Antidiarrheal Strategies in HER2+/HR+ Ea...\n",
       "944     Characterization of Extracellular Vesicles in ...\n",
       "945     A First-in-human, Phase I, Open-label, Multice...\n",
       "946     The DIALOGUE Study: Swiss-Korean Billateral Co...\n",
       "947     Biospecimen Procurement for Center for Immuno-...\n",
       "948         A Study of SGN-PDL1V in Advanced Solid Tumors\n",
       "949     Neoadjuvant Durvalumab/Anlotinib /Chemotherapy...\n",
       "950     Clinical Study on the Effect of Brucea Javanic...\n",
       "951     Palliative RadIotherapy of Multiple Metastatic...\n",
       "952     Phase II/III Study of SPH4336 Combined With Le...\n",
       "953     Use of INnovative and Micro-INvasive TEchnique...\n",
       "954     A Study of the Efficacy and Safety of Camreliz...\n",
       "955     Phase Ib/II Trial of Envafolimab Plus Lenvatin...\n",
       "956     Sulindac and Breast Density in Women at Risk o...\n",
       "957     Evaluation of an Integrated Imaging System For...\n",
       "958     A Study to Assess the Effectiveness of Trastuz...\n",
       "959          Hysterectomy and OPPortunistic SAlpingectomy\n",
       "960     Metacognitive Strategy Training in Cancer-rela...\n",
       "961     T Cell Receptor Immunotherapy for Patients Wit...\n",
       "962     Neoadjuvant Trastuzumab, Pertuzumab and Tucati...\n",
       "963     Neoadjuvant Pembrolizumab in Cutaneous Squamou...\n",
       "964     EXOME Analysis Position in the Strategy of Gen...\n",
       "965     Impact of Topical Tranexamic Acid in Breast Re...\n",
       "966     Effect of Anthracyclines and Cyclophosphamide ...\n",
       "967     Reinducing Radioiodine-sensitivity in Radioiod...\n",
       "968     Comprehensive Analysis of Spatial, Temporal an...\n",
       "969     A Study to Learn About a New Medicine Called A...\n",
       "970              Breast Cancer Survivorship Biorepository\n",
       "971     Neoadjuvant Aumolertinib in Patients With AI-d...\n",
       "972     Association of Radiochemotherapy and Immunothe...\n",
       "973     MK-2870 as Monotherapy and in Combination With...\n",
       "974     ZEN003694 Combined With Talazoparib in Patient...\n",
       "975     Feasibility Evaluation of the Muse Magnetic Re...\n",
       "976     The First Line Treatment of Fruquintinib Combi...\n",
       "977     Study of AIC100 CAR T Cells in Relapsed/Refrac...\n",
       "978     FASN Inhibitor TVB-2640 and Trastuzumab in Com...\n",
       "979     Intelligent Vacuum Assisted Biopsy Immediately...\n",
       "980     A First-In-Human, Phase 1 Study Evaluating Ora...\n",
       "981     Pivotal Study of Proton Radiotherapy Treatment...\n",
       "982     Response Prediction of Hyperthermic Intraperit...\n",
       "983     InheriteD brEast caNcer iTalian regIsTrY A Ret...\n",
       "984     ASTX727 in Recurrent/Progressive Non-enhancing...\n",
       "985     A Phase I-II Study to Test the Safety and Effi...\n",
       "986     Phase 1 Study Evaluating the Safety and PK of ...\n",
       "987     Early Detection of Ovarian Cancer Using Plasma...\n",
       "988     Trifluridine/ Tipiracil Plus Panitumumab Versu...\n",
       "989     Inetetamab Combined With Pyrotinib and Chemoth...\n",
       "990     eHealth Delivery Alternative for Cancer Geneti...\n",
       "991     Trial to Compare MRI-guided Precision Prone Ir...\n",
       "992     Cabozantinib and Atezolizumab for the Treatmen...\n",
       "993     DecipHER Trial - DC1 Tx for Early-Stage TNBC a...\n",
       "994               Telerehabilitation in Oncology Patients\n",
       "995         Telemonitoring Hypertension and Breast Cancer\n",
       "996     Neoadjuvant Camrelizumab Plus Chemotherapy in ...\n",
       "997     A Study of TY-302 in Patients With Advanced So...\n",
       "998     Vapocoolant Analgesia for Breast Lymphoscintig...\n",
       "999     A Study of SHR-A1811 Combined With Capecitabin...\n",
       "1000    The Value of Geriatric Assessments in Older Pa...\n",
       "1001    Feasibility of Exosome Analysis in Cerebrospin...\n",
       "1002    Percutaneous Holmium Injection in Pancreatic C...\n",
       "1003    Nano-SMART: Nanoparticles With MR Guided SBRT ...\n",
       "1004    Exercise as Medicine for People With Cancer Sw...\n",
       "1005    PD-1 Inhibitor Combined With Neoadjuvant Chemo...\n",
       "1006    First-in-human Study of DS-1062a for Advanced ...\n",
       "1007    Intestinal Microbiota Impact for Prognosis and...\n",
       "1008    FS120 Phase 1/1b Study in Patients With Advanc...\n",
       "1009    High Risk ER+HER2- T1-2N0-1 Early Breast Cance...\n",
       "1010    Adj. Marker-adjusted Personalized Therapy Comp...\n",
       "1011    Prostate Cancer Screening With Abbreviated MRI...\n",
       "1012    A Study of HC-7366 to Establish the Maximum To...\n",
       "1013    Ascorbate With Durvalumab in Non-Small Cell Lu...\n",
       "1014    [18F]FAraG PET Imaging for Analysis of Biodist...\n",
       "1015                                   The SONImage Study\n",
       "1016    MITO 35B: Olaparib Beyond Progression Compared...\n",
       "1017    Prospective Cohort for Tumor Bed Boost Radioth...\n",
       "1018    Shandong Cancer Hospital Affiliated to Shandon...\n",
       "1019    To Evaluate OBI-833/OBI-821 in Patients With L...\n",
       "1020    Multicentral Preventive Antibiotics With Cyste...\n",
       "1021    Circulating Tumor DNA Enriched, Genomically Di...\n",
       "1022    Determine Safety & Recommended Phase 2 Dosing ...\n",
       "1023    Attention and Interpretation Modification (AIM...\n",
       "1024    Interest of Bilateral Basic Tongue Mucosectomy...\n",
       "1025    Effects of Chemotherapy on Cognitive Function ...\n",
       "1026    Real Life Study Evaluating the Clinical and Or...\n",
       "1027      Bronchoscopic Microwave Ablation of Lung Tissue\n",
       "1028    A First in Human Dose Escalation of Dendritic ...\n",
       "1029    Study to Evaluate Sutetinib Maleate Capsule in...\n",
       "1030    The Effect of the Mobile Application-based Sup...\n",
       "1031    Imaging of Primary or Recurrent Breast Cancer ...\n",
       "1032    Exercise Therapy to Improve Cardiovascular Hea...\n",
       "1033    Evaluation of the Relationship of TOP2α Expres...\n",
       "1034    CYTO Reductive Surgery in Kidney Cancer Plus I...\n",
       "1035    Randomized Comparison Between Sentinel Lymph N...\n",
       "1036    Investigating the Effectiveness of Stereotacti...\n",
       "1037    mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as A...\n",
       "1038    Oral AMXT 1501 Dicaprate in Combination With I...\n",
       "1039    Systems Biology Guided Therapy for Breast Canc...\n",
       "1040    IN10018 in Combination With Standard Chemother...\n",
       "1041    A Deep Learning Method to Evaluate QT on Riboc...\n",
       "1042    TGRX-326 Chinese Phase III for Advanced Non-sm...\n",
       "1043    Assessment of Complete Pathologic Response Aft...\n",
       "1044    Evaluating Omitting of Internal Mammary Irradi...\n",
       "1045    Improving Response to Immunotherapy in Patient...\n",
       "1046    The Registry of Oncology Outcomes Associated W...\n",
       "1047    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in...\n",
       "1048    Reverse Triple Negative Immune Resistant Breas...\n",
       "1049    Precision Immuno-Oncology for Advanced Non-sma...\n",
       "1050    Safety & PK of MBRC-101 in Advanced Refractory...\n",
       "1051    Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody)...\n",
       "1052    A Study to Evaluate the Safety and Tolerabilit...\n",
       "1053    Cetuximab as Salvage Therapy in Patients With ...\n",
       "1054    Utidelone Versus Docetaxel in HER2-negative Lo...\n",
       "1055    Testing the Safety of the Anti-Cancer Drugs Du...\n",
       "1056    Stereotactic Brain-directed Radiation With or ...\n",
       "1057    Hypofractionated vs. Conventional Regional Nod...\n",
       "1058    Genetic Testing in Young Adults With Cancer Study\n",
       "1059    Chk2 Inhibitor for Recurrent EpitheliAl periTo...\n",
       "1060    Study of CAbozantinib in Combination With Atez...\n",
       "1061    Molecular Testing and Imaging in Improving Res...\n",
       "1062    Atrial Fibrillation and Other Cardiac Arrhythm...\n",
       "1063    Physical Activity and Healthy Eating Among You...\n",
       "1064    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 i...\n",
       "1065    Study of TFX06 in Women With Advanced Breast C...\n",
       "1066    Testing the Addition of Whole Brain Radiothera...\n",
       "1067    Immunotherapy Clearance and Phenotype of Circu...\n",
       "1068    The Impact of Inhalation vs Total Intravenous ...\n",
       "1069    Furmonertinib Monotherapy and Combination Ther...\n",
       "1070    Neoadjuvant Therapy vs Standard Therapy in Loc...\n",
       "1071    A Trial of Eribulin in Combination With HP Neo...\n",
       "1072    Neoadjuvant Tislelizumab With Afatinib for Res...\n",
       "1073    'SOURCE - LUNG' Stereotactic Ablative Radiatio...\n",
       "1074    Pamiparib Combined With Surufatinib for the Ne...\n",
       "1075    A Study of STRO-002, an Anti-Folate Receptor A...\n",
       "1076    Image Mining and ctDNA to Improve Risk Stratif...\n",
       "1077    Avelumab or Hydroxychloroquine With or Without...\n",
       "1078    Characterization of 18F-Fluciclovine PET Amino...\n",
       "1079           A Study of TAVO412 in Patients With Cancer\n",
       "1080    Maintenance Ipilimumab + Nivolumab Post Induct...\n",
       "1081    Clinical Study of Camrelizumab Combined With T...\n",
       "1082    Hypoxia During Gastroenterological Endoscope P...\n",
       "1083    Study of an eHealth Delivery Alternative for C...\n",
       "1084    A Study of Tucatinib Given Before Surgery to P...\n",
       "1085    Ultrasound Imaging and Spectroscopy as Early I...\n",
       "1086    Neoadjuvant FOLFOXIRI Versus CapeOX Chemothera...\n",
       "1087    Comparison Trial of Open-tip Pulsed Needle Bio...\n",
       "1088    Endoscopic Surgery in the Treatment of Soft Ti...\n",
       "1089    Aumolertinib Adjuvant Therapy of Resectable St...\n",
       "1090    Fluorescence Imaging of Carcinoma During Breas...\n",
       "1091                                  Tumor-Derived FGF19\n",
       "1092                   Perioperative Mindfulness Proposal\n",
       "1093    Safety Assessment of Concurrent Radiotherapy a...\n",
       "1094    Selinexor in Maintenance Therapy After Systemi...\n",
       "1095    Phase 2 Study Evaluating the Efficacy of the C...\n",
       "1096    Neoadjuvant Nab-paclitaxel in Triple-negative ...\n",
       "1097    WX-0593 Combined With Concurrent Chemoradiothe...\n",
       "1098    Impact of Remimazolam on Prognosis After Bladd...\n",
       "1099    Prospective Study of oncRNA Stratification of ...\n",
       "1100    The Purpose of This Trial is to Determine if R...\n",
       "1101    A Study of BL-M07D1 in Patients With Locally A...\n",
       "1102    Pre-op Pembro + Radiation Therapy in Breast Ca...\n",
       "1103    Enhancing Therapy Adherence Among Metastatic B...\n",
       "1104    PET-MRI for Axillary Staging in Node Negative ...\n",
       "1105    Conversion Therapy of RAS/BRAF Wild-Type Color...\n",
       "1106    Interactive Survivorship Program for the Impro...\n",
       "1107    A Study of LSTA1 When Added to Standard of Car...\n",
       "1108    Germline Alterations of Tumor Susceptibility G...\n",
       "1109    TGRX-326 Chinese Phase II for Advanced Non-sma...\n",
       "1110    Metronidazole as Preoperative Therapy in CRC /...\n",
       "1111    MRD-guided Deferred Adjuvant Therapy in Resect...\n",
       "1112    Phase III Study to Assess AZD9833+ CDK4/6 Inhi...\n",
       "1113    Preoperative Immunotherapy (Pembrolizumab) for...\n",
       "1114    REDEL Trial: Reduced Elective Nodal Dose for A...\n",
       "1115    Neuromodulation of Cardiovascular Risks Associ...\n",
       "1116    Investigation of the Effect of Training on the...\n",
       "1117    Study of KN026 in Combination With Docetaxel a...\n",
       "1118                     Magseed Pro(R)/ Sentimag(R) Gen3\n",
       "1119    ASP-1929 Photoimmunotherapy (PIT) Study in in ...\n",
       "1120    Local Therapy for ER/PR-positive Oligometastat...\n",
       "1121    Prospective Trial of Digital Breast Tomosynthe...\n",
       "1122                           UNC Pleural Fluid Registry\n",
       "1123    Intervening on Women's Health for Rural Young ...\n",
       "1124    A Study of BPI-1178 in Patients With Advanced ...\n",
       "1125          ExPECT: Extraperitoneal End Colostomy Trial\n",
       "1126    Impact of Video Information Support on Preoper...\n",
       "1127    Confirmation of Accuracy of the Tool-in-lesion...\n",
       "1128    Screening For BCRL In Targeted Therapy For Bre...\n",
       "1129    Combination of Olaparib and Navitoclax in Wome...\n",
       "1130    Repeat Breast Conserving Surgery Followed by D...\n",
       "1131    Olaparib in Patients With Recurrent Ovarian Ca...\n",
       "1132    Interest of the Virtual Reality Headset in the...\n",
       "1133    Circulating Tumour Cells Characterization in B...\n",
       "1134    The Impact of Surgical Technique on Circulatin...\n",
       "1135    Study of HuMab-5B1 (MVT-5873) in Subjects With...\n",
       "1136    A Study of OR2805, a Monoclonal Antibody Targe...\n",
       "1137           Total Neoadjuvant Therapy in Rectal Cancer\n",
       "1138    Ultra-hypofractioNated Adjuvant Radiotherapy ±...\n",
       "1139    A Randomized Study Comparing the Immune Modula...\n",
       "1140      VR-based Intervention for Cognitive Restoration\n",
       "1141    Precision Imaging for Early Detection and Targ...\n",
       "1142    Study of the CDK4/6 Inhibitor Palbociclib (PD-...\n",
       "1143    PRELUDE Study of Lymphatic Surgery to Treat Br...\n",
       "1144    Macrophage Imaging Using Ga-MMR-VHH2 in Lung C...\n",
       "1145    Pilot Study of PACHA Program to Enhance Adhere...\n",
       "1146    Neratinib In Combination With Chemotherapy/Tra...\n",
       "1147    Comparing Single vs Multiple Dose Radiation fo...\n",
       "1148    Exploratory Evaluation of the Functional/Emoti...\n",
       "1149    Neoadjuvant Treatment in Rectal Cancer With Ra...\n",
       "1150    Pressurized Intraperitoneal Aerosolized Nab-Pa...\n",
       "1151    Feasibility Trial of Tele-IPT and Tele-Pharmac...\n",
       "1152    Investigation of the Effect of Education on Sy...\n",
       "1153                VS-6766+Abema+Fulv in Met HR+/HER- BC\n",
       "1154    Platinum and Polyadenosine 5'Diphosphoribose P...\n",
       "1155    Effect of Helmet Type, Home-use Low-level Ligh...\n",
       "1156    Ribociclib And Endocrine Treatment of Physicia...\n",
       "1157    Comparison Between Prepectoral and Subpectoral...\n",
       "1158    MITO 35a: Olaparib Maintenance Therapy in Newl...\n",
       "1159    Adjuvant Chemotherapy for Triple Negative Brea...\n",
       "1160    InAdvance: Surveillance, Prevention, and Inter...\n",
       "1161       Vaginal Cuff Brachytherapy Fractionation Study\n",
       "1162    Impact of Recurrence Score on Adjuvant Treatme...\n",
       "1163    Pembrolizumab vs. Observation in People With T...\n",
       "1164    Evaluation of Medical Treatments in MBC Patien...\n",
       "1165                 MARGetuximab Or Trastuzumab (MARGOT)\n",
       "1166    Motiva Flora® Aesthetic Breast Recon® Clinical...\n",
       "1167    Molecularly Targeted Radionuclide Therapy Via ...\n",
       "1168    Targeted PARP or MEK/ERK Inhibition in Patient...\n",
       "1169    A Study of HB0025 Injection in Patients With A...\n",
       "1170    Camu-Camu Prebiotic and Immune Checkpoint Inhi...\n",
       "1171    LLLT for BCRL: a Randomized, Placebo-controlle...\n",
       "1172    HERPET- A Novel PET Imaging Study of HER2 in B...\n",
       "1173    Research of Biomarkers of Response to Proton B...\n",
       "1174    Nivolumab for the Treatment of Patients With M...\n",
       "1175    To Evaluate the Cardiac Safety of Pegylated Li...\n",
       "1176    Phase I Study to Evaluate Safety and Anti-tumo...\n",
       "1177    Eribulin as a Second-line Treatment in Triple-...\n",
       "1178    A Study to Evaluate the Safety of KAND567, in ...\n",
       "1179    3-D Super Resolution Ultrasound Microvascular ...\n",
       "1180    Prospective Evaluation of AI R&D Tool for Pati...\n",
       "1181    Testing the Addition of an Anti-cancer Drug, I...\n",
       "1182    FREDO-ODX Study: FREnch Data on Outcomes in HR...\n",
       "1183    Genetic Predictors of Response to Acupuncture ...\n",
       "1184    Safety and Efficacy of Cyclophosphamide, Soraf...\n",
       "1185    Multicenter Study to Evaluate a Systematized C...\n",
       "1186    Elacestrant for Treating ER+/HER2- Breast Canc...\n",
       "1187    Prognostic Role of Circulating Tumor DNA in Re...\n",
       "1188    PET/CT Imaging of Small Cell Lung Cancer Using...\n",
       "1189    PATHFINDER 2: A Multi-Cancer Early Detection S...\n",
       "1190    Project CADENCE (CAncer Detected Early caN be ...\n",
       "1191    Evaluation of Sequencing of Anthracyclines and...\n",
       "1192    Magseed Enabled Long-Term Localization of Axil...\n",
       "1193    Diagnostic Accuracy Study for OWL-EVO1 as a Lu...\n",
       "1194    Ultrahypofractionation and Normal Tissue Toxicity\n",
       "1195    Immediate Breast Reconstruction Following Mast...\n",
       "1196                   TRUDI: TDXD+Durva in HER2+/Low IBC\n",
       "1197    A Real-world Study of Durvalumab for Lung Canc...\n",
       "1198    Cadonilimab Plus Anlotinib for R/M/P Cervical ...\n",
       "1199    SUROVA - Surgery in Ovarian Cancer, Comparing ...\n",
       "1200    Efficacy and Safety of BCD-100 (Anti-PD-1) in ...\n",
       "1201    A Study of the Addition of Metronomic Capecita...\n",
       "1202    Combination Therapy of RMC-4630 and LY3214996 ...\n",
       "1203    Intensity Modulated Radiotherapy (IMRT) vs. 3D...\n",
       "1204    Familial Investigations of Childhood Cancer Pr...\n",
       "1205    Head-to-head Comparison of Positron Nuclide Ra...\n",
       "1206           ENCOrafenib With Binimetinib in bRAF NSCLC\n",
       "1207    Phase II Study of PRL3-ZUMAB in Advanced Solid...\n",
       "1208    Short-course Radiotherapy Based TNT Combined W...\n",
       "1209    Tucatinib in Patients With Locally Advanced or...\n",
       "1210    IMM2902, a HER2/SIRPα Bispecific mAb-Trap Anti...\n",
       "1211    Immune Induction Strategies to Improve Respons...\n",
       "1212    Radiotherapy Combined With Tislelizumab and Ir...\n",
       "1213    A Platform Study of Novel Agents in Combinatio...\n",
       "1214    Consolidative Radiotherapy for Metastatic Urot...\n",
       "1215       The Breast Cancer Personalized Nutrition Study\n",
       "1216    Patient Education Videos to Improve Patients' ...\n",
       "1217    A Dose Escalation and Dose Expansion Study of ...\n",
       "1218    PRospective rEgistry OF Advanced Stage cancER ...\n",
       "1219    An Investigational Scan (64Cu-DOTA-Trastuzumab...\n",
       "1220    Phase 1/2 Study of Avutometinib (VS-6766) + So...\n",
       "1221             RP-6306 in Patients With Advanced Cancer\n",
       "1222    Improving Theempowerment in Patients With Seve...\n",
       "1223    Single Pre-Operative Radiation Therapy - With ...\n",
       "1224    Study of Stereotactic Radiotherapy for Breast ...\n",
       "1225    Sentinel Lymph Node Biopsy After Neoadjuvant C...\n",
       "1226    Clinical High and Genomic Low Hormone Receptor...\n",
       "1227    Pembrolizumab and Combination Chemotherapy Bef...\n",
       "1228    Screening Contralateral Breast Cancers in Pati...\n",
       "1229    Long-term Safety and Efficacy of GBG Study Par...\n",
       "1230    Evaluating the Effectiveness of an Individuali...\n",
       "1231    Brigatinib and Bevacizumab for the Treatment o...\n",
       "1232    Comparing the Efficacy of Nab-PHP and TCbHP in...\n",
       "1233    Deciphering Mechanisms Underlying Cancer Immun...\n",
       "1234    Neoadjuvant Endocrine Therapy in Breast Cancer...\n",
       "1235    Study of BDC-3042 as Single Agent and in Combi...\n",
       "1236    Utrecht Cohort for Multiple Breast Cancer Inte...\n",
       "1237    A Feasibility Study of Ketorolac Treatment for...\n",
       "1238    Sweden Cancerome Analysis Network - Breast Rec...\n",
       "1239    Investigation of Differential Biology of Benig...\n",
       "1240    Non-interventional Study to Collect Real-world...\n",
       "1241    cfDNA Assay Prospective Observational Validati...\n",
       "1242    Study to Evaluate the Efficacy and Safety of S...\n",
       "1243    Positron Emission Tomograph(PET) Imaging Explo...\n",
       "1244             ZN-c3 + Gemcitabine in Pancreatic Cancer\n",
       "1245    A Study of a Comprehensive Prevention Program ...\n",
       "1246    ALND vs ART in Positive Sentinel Node After Ne...\n",
       "1247    Circulating Tumor DNA and Immunophenotyping as...\n",
       "1248    Chemo-Immunotherapy Followed by Durvalumab and...\n",
       "1249        Psyco Quality of Life and Procreation BRCA1/2\n",
       "1250    Real World Treatment Experience of Patients Wi...\n",
       "1251             Intrathecal Double Checkpoint Inhibition\n",
       "1252    Wide Field OCT + AI for Positive Margin Rates ...\n",
       "1253    Breast Cancer Pre-habilitation and Prospective...\n",
       "1254          Biological Matrices Versus Synthetic Meshes\n",
       "1255    Nitroglycerin Plus Radiotherapy Versus Convent...\n",
       "1256    Electroacupuncture for the Management of Sympt...\n",
       "1257    A Study of AND019 in Women With ER Positive HE...\n",
       "1258    KK-LC-1 TCR-T Cell Therapy for Gastric, Breast...\n",
       "1259    Oregovomab and PLD in PARP Inhibitor Resistant...\n",
       "1260    Treatment of Insomnia in Patients With Breast ...\n",
       "1261    Zimberelimab and Domvanalimab in Combination W...\n",
       "1262    To Evaluate Efficacy and Safety of TT-00420 (T...\n",
       "1263       Unintentional Weight Loss After Oesophagectomy\n",
       "1264    Immunotherapy-related CRP Kinetics in Early an...\n",
       "1265    First-Line Treatment for Advanced Non-squamous...\n",
       "1266    Efficacy of SRT as Salvage Therapy in Patients...\n",
       "1267              Insulin Sensitivity After Breast Cancer\n",
       "1268    Therapeutic Cancer Vaccine (AST-301, pNGVL3-hI...\n",
       "1269    Trial Evaluating the Efficacy and the Safety o...\n",
       "1270    Pilot Study to Evaluate Photoacoustic Imaging ...\n",
       "1271    Precision Chemotherapy Based on Organoid Drug ...\n",
       "1272    Safety of GQ1001 in Adult Patients With HER2-P...\n",
       "1273          A Dose Finding Study to Treat Bone Tumor(s)\n",
       "1274    Preventing Chemotherapy-Induced Peripheral Neu...\n",
       "1275        Registry Study of Pregnancy and Breast Cancer\n",
       "1276    A Trial to Evaluate Safety, Tolerability, Phar...\n",
       "1277    Bevacizumab Plus mFOLFOXIRI as First-line Trea...\n",
       "1278    Proton Therapy to Reduce Acute Normal Tissue T...\n",
       "1279    Short-term Outcomes of Full Bowel Preparation ...\n",
       "1280    Preliminary Evaluation of Screening for Pancre...\n",
       "1281    The Effects of Two Exercise Interventions on B...\n",
       "1282    A Clinical Trial Investigating the Safety, Tol...\n",
       "1283    The Role of Simvastatin in The Epithelial-Mese...\n",
       "1284    Optimal Duration of Oxaliplatin in Adjuvant XE...\n",
       "1285    Researching the Effect of Aerobic Exercise on ...\n",
       "1286    Cardioprotective Effect of Acute Exercise in B...\n",
       "1287    Alectinib in Neo-adjuvant Treatment of Stage I...\n",
       "1288    Neoadjuvant Inetetamab Combined With Pertuzuma...\n",
       "1289    Study of Sacituzumab Govitecan-hziy and Pembro...\n",
       "1290    PD1 Antibody Toripalimab and Chemoradiotherapy...\n",
       "1291    RAGE Inhibition to Decrease Therapy Cardiotoxi...\n",
       "1292    Prospective Evaluation of Pencil Beam Scanning...\n",
       "1293    Breast Cancer Locator Guided vs. Wire Localize...\n",
       "1294    Preoperative, Proton- Radiotherapy Combined Wi...\n",
       "1295    Clinical Trial to Evaluate the Safety and Effi...\n",
       "1296    A Study to Test Different Doses of BI 1810631 ...\n",
       "1297    Evaluating 6-months of HER2-targeted Therapy i...\n",
       "1298    Dabrafenib + Trametinib + PDR001 In Colorectal...\n",
       "1299    Open-Label, Phase 1 Study to Evaluate Duration...\n",
       "1300    ADOPT-PRESTAGE: Study Evaluating the Impact of...\n",
       "1301    A Study of Mitoxantrone Hydrochloride Liposome...\n",
       "1302    Study of Microwave Spherical Ablation and Trad...\n",
       "1303    DLL3-Directed Chimeric Antigen Receptor T-cell...\n",
       "1304    Radiation Therapy Followed by Intrathecal Tras...\n",
       "1305    Serial Circulating Tumor DNA (ctDNA) Monitorin...\n",
       "1306    TrAstuzumab Cardiomyopathy Therapeutic Interve...\n",
       "1307    A Study of RC48-ADC for the Treatment of HER2-...\n",
       "1308    CIRCULATING TUMOR DNA BASED DECISION FOR ADJUV...\n",
       "1309    Diagnostic Performance of an Automated Breast ...\n",
       "1310    Social Risk Factors and Discrimination in Canc...\n",
       "1311    Evaluation of Prognostic Monitoring for Young ...\n",
       "1312    Developing New Educational Materials About Gen...\n",
       "1313             Exercise Post-Diagnosis of Breast Cancer\n",
       "1314    Lurbinectedin Combined With Durvalumab in Pre-...\n",
       "1315    Testing the Combination of Two Approved Chemot...\n",
       "1316    Serratus Plane Block Versus Serratus Plane Blo...\n",
       "1317    PRecision Oncology Evidence Development in Can...\n",
       "1318    Metronomic Oral Chemotherapy With Cyclophospha...\n",
       "1319    Stereotactic Ablative Radiotherapy for Oligo-P...\n",
       "1320        Mammogram Mail- and Phone-based Interventions\n",
       "1321    A Phase II Trial of Camrelizumab in Combinatio...\n",
       "1322    Olaparib in Combination With Vorinostat in Pat...\n",
       "1323    Oncolytic Adenovirus TILT-123 With Pembrolizum...\n",
       "1324    The Effectiveness and Safety of XELOX and Tisl...\n",
       "1325    Cancer and Mild Cognitive Impairment Dyadic In...\n",
       "1326    Collecting Tissue Samples for Future Research ...\n",
       "1327    PD-1 Antibody Combined With COX Inhibitor in M...\n",
       "1328    Carbon Ion Radiation Therapy in the Treatment ...\n",
       "1329    A Phase II Study for p16+ Oropharyngeal Cancer...\n",
       "1330    A Study of A166 in Patients With Advanced Soli...\n",
       "1331    Preoperative Pembrolizumab and Chemotherapy in...\n",
       "1332    Pioglitazone Therapy Targeting Fatigue in Brea...\n",
       "1333    Impact of Dose to Cardiac Substructures on Sur...\n",
       "1334    Anti-PD-1 mAb Plus Metabolic Modulator in Soli...\n",
       "1335    Medial vs. Entire Supraclavicular Lymph Node R...\n",
       "1336    Endocrine Disruptors and Life STILe in Breast ...\n",
       "1337    EXERT-BCH Exercise Regimen to Improve Muscle M...\n",
       "1338    Hypofractionated Radiotherapy in Breast Cancer...\n",
       "1339    Detection of Brain Metastasis by MRI in Metast...\n",
       "1340    Talazoparib in Advanced Breast Cancer Patients...\n",
       "1341    Study of an Anti-HER3 Antibody, HMBD-001, With...\n",
       "1342    Safety and Preliminary Anti-Tumor Activity of ...\n",
       "1343    Phase 3 Study to Evaluate the Efficacy and Saf...\n",
       "1344    Phase Ib/II Trial of Abemaciclib and Elacestra...\n",
       "1345    Tonation Breathing Technique Method to Ease Ar...\n",
       "1346    A Formative Evaluation For Improving Breast Ca...\n",
       "1347    A Trial of Pamiparib With Tislelizumab in Pati...\n",
       "1348    Adding an Immunotherapy Drug, MEDI4736 (Durval...\n",
       "1349    Study of the CDK4/6 Inhibitor Palbociclib (PD-...\n",
       "1350    Study to Evaluate TNG348 Alone and With a PARP...\n",
       "1351    A Dose Escalation Study of Proton and Carbon I...\n",
       "1352    Adopting the MRD Strategy to Optimize Post-ope...\n",
       "1353    Study of Osimertinib + SRS vs Osimertinib Alon...\n",
       "1354    An Exploratory Study to Evaluate Attention Bia...\n",
       "1355    Real-world Data in Patients With Breast Cancer...\n",
       "1356    SH-1028 Tablets Versus Placebo as Adjuvant The...\n",
       "1357    Personalized Neoantigen Peptide-Based Vaccine ...\n",
       "1358    A Phase 1 Study of CPO301 in Adult Patients Wi...\n",
       "1359    Therapeutic Cancer Vaccine (AST-301, pNGVL3-hI...\n",
       "1360    Validation of Scales in Reconstructive Breast ...\n",
       "1361    Omitting vs. Doing Intraoperative Frozen Secti...\n",
       "1362    IDO and PD-L1 Peptide Based Immune-Modulatory ...\n",
       "1363    Gemcitabine and Ex Vivo Expanded Allogenic Uni...\n",
       "1364    A Phase I/II Study of AST-001 in Subjects With...\n",
       "1365    Response to Immunotherapy in MMR-deficient Loc...\n",
       "1366    Decreasing Polypharmacy in Older Adults With C...\n",
       "1367    BI-1607 in Combination With Trastuzumab in Sub...\n",
       "1368    Study of ASTX727 Plus Talazoparib in Patients ...\n",
       "1369    Perioperative Dexmedetomidine and Long-term Su...\n",
       "1370                    Lymphedema After Urologic Surgery\n",
       "1371            Breast Cancer in Pregnancy Register Study\n",
       "1372    Scalable Communication Modalities for Returnin...\n",
       "1373             MarginProbe 2.0 Data Collection Protocol\n",
       "1374    A Study of Intraperitoneally Administered AVB-...\n",
       "1375    Pragmatic Randomized Trial of Proton vs. Photo...\n",
       "1376    Effect of ALND With Vein Branches Reservation ...\n",
       "1377    CPI-0209 Plus Carboplatin in Patients With Pla...\n",
       "1378    Comparison of Analgesic Efficacy of Ultrasound...\n",
       "1379    Open-Label Proof of Concept Study of VP-315 in...\n",
       "1380    Single Arm Phase II Study of Fractionated Ster...\n",
       "1381    Examination of the Effect of Counselling and F...\n",
       "1382    Pediatric Prospective Personalized Immune and ...\n",
       "1383    Magnesium Sulphate to Bupivicaine in Serratus ...\n",
       "1384    Dose Attenuated Chemotherapy in Compromised Pa...\n",
       "1385    Alpha Radiation Emitters Device for the Treatm...\n",
       "1386    Study of Avutometinib (VS-6766) + Adagrasib in...\n",
       "1387    Early Ageing During Therapy in AYA Cancer Pati...\n",
       "1388    Microbiome and Association With Implant Infect...\n",
       "1389    Prognostic and Predictive Markers of Response ...\n",
       "1390    A Phase 1b Study of Gemcitabine and Nab-paclit...\n",
       "1391    Personalized DC Vaccines in Non Small Cell Lun...\n",
       "1392    Trans-Artery/Intra-Tumor Infusion of Checkpoin...\n",
       "1393    One Week Versus Three Week in Adjuvant Radioth...\n",
       "1394    Phase II Trial of Pembrolizumab in Metastatic ...\n",
       "1395    Improving Quality of Life for Patients With Br...\n",
       "1396    Clinical Database of Safe Personalized Adjuvan...\n",
       "1397    EON: A Single-arm Phase II Study of Etigilimab...\n",
       "1398    Temozolomide and Atezolizumab as Second or Thi...\n",
       "1399    Pyrotinib Combined With Capecitabine and Bevac...\n",
       "1400    MammaPrint, BluePrint, and Full-genome Data Li...\n",
       "1401    Clinical Study of Fruquintinib Combined With R...\n",
       "1402                 Platino-resistance in Ovarian Cancer\n",
       "1403    A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B...\n",
       "1404          COsegregation of VARiants in Panel of Genes\n",
       "1405    ICG (Indocyanine Green) Imaging Fluorescence T...\n",
       "1406    A Study of SHR-A1811 Combined With Pyrotinib M...\n",
       "1407    DianaWeb: Before and After Study Online Based ...\n",
       "1408    Neoadjuvant With Trastuzumab, Pyrotinib Plus P...\n",
       "1409    EXErcise Regimen Designed to Improve Functiona...\n",
       "1410       CAR T Cell Immunotherapy for Pancreatic Cancer\n",
       "1411    ER+/HER2- Locally Advanced or Metastatic Breas...\n",
       "1412      Bio Clinical Collection of Urothelial Carcinoma\n",
       "1413    Inetetamab Combined With Pyrotinib Plus Oral V...\n",
       "1414    Non-randomized, Open-label Study of Intralesio...\n",
       "1415    Opioid Free Versus Opioid Based Anaesthesia fo...\n",
       "1416    The C-MERIT Screening Cohort: Contrast-enhance...\n",
       "1417    Collection of Blood From Patients With Cancer,...\n",
       "1418    Concurrent and Adjuvant PD1 Treatment Combined...\n",
       "1419    Gemcitabine, Nab-Paclitaxel, and Bosentan for ...\n",
       "1420    Dynamic Contrast-enhanced MRI Combined With IV...\n",
       "1421    Breast Cancer 2-PREVENT Translational Center o...\n",
       "1422    Follow-Up Study of Subjects Previously Enrolle...\n",
       "1423    VIC-1911 Combined With Osimertinib for EGFR -M...\n",
       "1424    mFOLFIRINOX With or Without Stereotactic Body ...\n",
       "1425    A Trial of Total Versus Partial Omentectomy fo...\n",
       "1426    Assessment of Early-detection Based on Liquid ...\n",
       "1427    Radiometabolic Therapy With 177Lu PSMA in PSMA...\n",
       "1428    Leflunomide in Previously Treated Metastatic T...\n",
       "1429    Monitoring for Cancer Spread to the Central Ne...\n",
       "1430    Evaluation of the Impact of Taking American Gi...\n",
       "1431    Southeast Netherlands Advanced Metastatic Brea...\n",
       "1432    Sequences Of REGorafenib And Trifluridine/Tipi...\n",
       "1433    Phase I/IIa Study of H002 in NSCLC With Active...\n",
       "1434    Sulfasalazine in Decreasing Opioids Requiremen...\n",
       "1435    Mind Programme for Women With Breast Cancer (N...\n",
       "1436    Study BT5528-100 in Patients With Advanced Sol...\n",
       "1437    A Trial of AMXI-5001 for Treatment in Patients...\n",
       "1438    Tele-nursing Practices Based on Technological ...\n",
       "1439    Inspiratory Muscle Training in Obese Breast Ca...\n",
       "1440    Safety, Tolerability, and Efficacy of mFOLFIRI...\n",
       "1441    Pembrolizumab and Olaparib in Cervical Cancer ...\n",
       "1442    A Study of Lorlatinib in Combination With Ramu...\n",
       "1443    Efficacy and Safety of Hyperbaric Oxygen Thera...\n",
       "1444    Dose Escalation and Expansion Clinical Trial o...\n",
       "1445    Intraperitoneal Chemotherapy Guided by the Det...\n",
       "1446    Personalized Neoantigen Vaccine in Combination...\n",
       "1447    Nivolumab After Cyclophosphamide and Doxorubic...\n",
       "1448    T-regulatory Cell Depletion With E7777 Combine...\n",
       "1449    A Study of ZEN003694 in People With Squamous C...\n",
       "1450    To Identify Potential New Urine Markers for th...\n",
       "1451    In Situ Immunomodulation With CDX-301, Radiati...\n",
       "1452    Study of SMT-NK Inj. Plus Pembrolizumab vs Pem...\n",
       "1453    BGT007H Cells for the Treatment of Refractory ...\n",
       "1454    [177Lu]Lu-NeoB in Combination With Ribociclib ...\n",
       "1455       68Ga-NOTA-PEG2-RM26 PET/CT, First in Man Study\n",
       "1456    Lenvatinib and Pembrolizumab Maintenance Thera...\n",
       "1457    Temozolomide and Irinotecan in Patients With M...\n",
       "1458    Exercise to ReGain Stamina and Energy (The EXE...\n",
       "1459    A Phase I Study of Niraparib Administered Conc...\n",
       "1460    Liver SBRT in Combination With Immune Checkpoi...\n",
       "1461    Study of Induction PD-1 Blockade (Nivolumab) i...\n",
       "1462    Combination Immunotherapy in Rare Cancers Unde...\n",
       "1463    Prevalence and Risk Factors for Pain and Relat...\n",
       "1464    Pyrotinib Plus Capecitabine for Adjuvant Treat...\n",
       "1465    ctDNA Assay in Patients With Resectable Pancre...\n",
       "1466    Evaluation of Treatment PERSOnalization Based ...\n",
       "1467    Muscle Energy Technique and Mulligan's Mobiliz...\n",
       "1468    Identifying Prognostic Variables for Persisten...\n",
       "1469    OSE2101 Alone or in Combination With Pembroliz...\n",
       "1470    Study To Assess Safety And Efficacy Of AsiDNA ...\n",
       "1471    Monitoring Response to Neoadjuvant Chemotherap...\n",
       "1472    Three Fraction Radiation to Induce Immuno-Onco...\n",
       "1473    68Ga-RM26-RGD PET/CT Imaging in the GRPR and α...\n",
       "1474    Nivolumab and Ipilimumab Plus Chemotherapy for...\n",
       "1475     Elevate! : An Elderly Breast Cancer Cohort Study\n",
       "1476               Bleeding in Laparoscopic Liver Surgery\n",
       "1477    GM1 Prophylaxis for Post-chemotherapy Cognitiv...\n",
       "1478    A Single Arm Phase II Study of ADjuvant Endocr...\n",
       "1479    Eurythmy Therapy (ERYT) as a Treatment Option ...\n",
       "1480    A Study of BMS-986406 as Monotherapy and Combi...\n",
       "1481    First-Line Treatment of Advanced Non-Small-Cel...\n",
       "1482    A Phase III Randomised Study to Evaluate Dato-...\n",
       "1483    CVM-1118 in Combination With Nivolumab for Unr...\n",
       "1484    A Study of Multiparametric MRI and pHLIP® ICG ...\n",
       "1485    MOST EMPOWER: Optimizing An Emotion Regulation...\n",
       "1486    Study of Nivolumab-Ipilimumab and cfDNA in Lun...\n",
       "1487    Non-invasive Measurement of PD-L1 Levels With ...\n",
       "1488           Fenofibrate Role in Breast Cancer Patients\n",
       "1489    LIVInG With chrONic Cancer TrEatments (LONGEVI...\n",
       "1490    Chronic Toxicities Related to Treatment in Pat...\n",
       "1491    Writing Interventions in Breast Cancer Patient...\n",
       "1492    Testing the Use of Fulvestrant and Binimetinib...\n",
       "1493    A Study Evaluating the Efficacy and Safety of ...\n",
       "1494    Trial Evaluating the Benefit of a Fitness Trac...\n",
       "1495    Trastuzumab Deruxtecan (T-DXd) for People With...\n",
       "1496    Mucosa Adherent Intestinal Microbiome in Micro...\n",
       "1497    Enhanced Monitoring for Better Recovery and Ca...\n",
       "1498    PET MRI as a Staging Tool for Head and Neck Ca...\n",
       "1499    Tranexamic Acid Usage in Bilateral Mastectomy ...\n",
       "1500    Levels of Circulating Tumor DNA as a Predictiv...\n",
       "1501    Study of Safety and Tolerability of BCA101 Mon...\n",
       "1502    Efficacy of Olaparib in Advanced Cancers Occur...\n",
       "1503    A First in Human Study of AdAPT-001 in Subject...\n",
       "1504    Photobiomodulation Therapy for the Management ...\n",
       "1505    High Dose-Rate Brachytherapy for the Treatment...\n",
       "1506    Adebrelimab Combined With Dalpiciclib and Stan...\n",
       "1507    Promoting Genetic Counseling Among African Ame...\n",
       "1508    A Single Arm, Prospective, Open Label, Multi C...\n",
       "1509    PSMA in Gastrointestinal Tumors (GIPSMA, Focus...\n",
       "1510    Tislelizumab in Combination With Pre-operative...\n",
       "1511    Neoadjuvant Ontruzant (SB3) in Patients With H...\n",
       "1512    A Novel 68Ga Labeled FAP Ligand PET/CT in Pati...\n",
       "1513    Pembrolizumab Plus Bevacizumab for Treatment o...\n",
       "1514    Sonoporation and Chemotherapy for the Treatmen...\n",
       "1515        Efficacy of MR-HIFU Ablation of Breast Cancer\n",
       "1516    Super Hypofractionated Irradiation For Whole B...\n",
       "1517    The Diagnostic Value of Nitrogen Element (N) i...\n",
       "1518    Efficacy and Safety of Adjuvant Docetaxel and ...\n",
       "1519    Evaluating and Monitoring Immune and Clinical ...\n",
       "1520    Study of Intravenous and Intraperitoneal Pacli...\n",
       "1521    ACE1702 in Subjects With Advanced or Metastati...\n",
       "1522    Evaluating Safety and Efficacy of Prostate-spa...\n",
       "1523    A Phase 1/2 Study to Evaluate the Safety, Tole...\n",
       "1524    Simultaneous Integrated Boost for Mediastinal ...\n",
       "1525    Adaptive Radiation Planning for the Reduction ...\n",
       "1526    Circulating Tumour DNA (ctDNA) as a Prognostic...\n",
       "1527    Palbociclib for HR Positive / HER2-negative Is...\n",
       "1528                       Opening the Conversation Study\n",
       "1529    Roll-over Study to Allow Continued Access to R...\n",
       "1530    Added Value of Preoperative Contrast Enhanced ...\n",
       "1531    Effects of PARP Inhibitor on Tumor Microenviro...\n",
       "1532    Study of Olaparib in Metastatic Renal Cell Car...\n",
       "1533    Study of the CDK4/6 Inhibitor Abemaciclib in S...\n",
       "1534    Niraparib in Combination With Dostarlimab in P...\n",
       "1535    Assessing Functional Status Needs Via PRO Meas...\n",
       "1536    Post-operative Adjuvant Treatment for HPV-posi...\n",
       "1537    Professional Life After Breast Cancer: Feasibi...\n",
       "1538    Gastric Cancer Marker Detection and Its Kit De...\n",
       "1539    GCC19CART for Patients With Metastatic Colorec...\n",
       "1540    Phase II Study of Regorafenib and Toripalimab ...\n",
       "1541    NYC Cancer Outreach Network in Neighborhoods f...\n",
       "1542    Olaparib With Cediranib or AZD6738 for the Tre...\n",
       "1543    The Establishment of a Survival Prediction Mod...\n",
       "1544    Sorafenib Induced Autophagy Using Hydroxychlor...\n",
       "1545    Imaging Versus Cardiac Biomarker Monitored HER...\n",
       "1546    Pembrolizumab With Standard Cytotoxic Chemothe...\n",
       "1547    Total Neoadjuvant Therapy With Short-course Ra...\n",
       "1548    Asian Multicenter Prospective Study of ctDNA S...\n",
       "1549    Regorafenib Combined With Irinotecan Drug-Elut...\n",
       "1550     Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC\n",
       "1551    Real-Time Assessment Of Breast Cancer Lumpecto...\n",
       "1552    Capecitabine and Cyclophosphamide (XC) as Main...\n",
       "1553    Testing the Addition of Immunotherapy With Hu5...\n",
       "1554    Belzutifan/MK-6482 for the Treatment of Advanc...\n",
       "1555    A Phase Ib Study of HS-10352 Plus Fulvestrant ...\n",
       "1556    Radiotherapy for Extracranial Oligometastatic ...\n",
       "1557        Hepatitis C Screening Paired With Mammography\n",
       "1558    Characterization and Kinetic of Chemotherapy-i...\n",
       "1559    Atezolizumab Plus Etoposide and Platinum in Sm...\n",
       "1560    Addition of Radiotherapy to Standard Medical T...\n",
       "1561    Maintenance Optimization of the Fully Implante...\n",
       "1562    Study to Assess the Efficacy and Safety of Alp...\n",
       "1563    A Prospective Study to Evaluate Continuous Pos...\n",
       "1564    The Association Between Radiation Dermatitis a...\n",
       "1565    Pyrotinib Maleate, Trastuzumab, SHR6390 and Le...\n",
       "1566    Study to Evaluate the Impact of the Use of Alt...\n",
       "1567    Sentinel Lymph Node in Early-Stage Endometrium...\n",
       "1568    Cadonilimab Combined With Fruquintinib and SBR...\n",
       "1569    Pembrolizumab in Preventing Lung Cancer in Pat...\n",
       "1570    Assessment of Breast Cancer Patients Satisfact...\n",
       "1571    Surveillance MRI Registry for Patients Who Had...\n",
       "1572    SNF Platform Study of HR+/ HER2-advanced Breas...\n",
       "1573                     Study of 18F-FFNP Breast PET/MRI\n",
       "1574    Phase 1 Trial of SYNC-T - Immunotherapy for Ad...\n",
       "1575    CAVE-2 GOIM Study: a Clinical Study of the Com...\n",
       "1576     Folic Acid Interferes With Radiation Esophagitis\n",
       "1577    HAI-Floxuridine, or Liver-Tx, Combined With 2n...\n",
       "1578    Short-term Pre-OPerative Durvalumab (MEDI 4736...\n",
       "1579    YES Study - Newly Diagnosed/Metastatic Interve...\n",
       "1580    Clinical Efficacy and Safety of NKT Cell Infus...\n",
       "1581    A Study of Avutometinib (VS-6766) and Defactin...\n",
       "1582                 Personalized Breast Cancer Screening\n",
       "1583    Examining the Cosmetic Results, Quality of Lif...\n",
       "1584    MOnaliZumab in Combination With durvAlumab (ME...\n",
       "1585    Phase I Nab-Paclitaxel Plus Gemcitabine With P...\n",
       "1586    Serum and Tissue Metabolite-based Prediction o...\n",
       "1587    Radiation Therapy With or Without Cisplatin in...\n",
       "1588    Gradient-Echo Spectroscopic Imaging Study of S...\n",
       "1589    Effects of Expectations and Body Image in Brea...\n",
       "1590    Neoadjuvant Treatment of Locally-advanced Brea...\n",
       "1591    Advanced Lung Tumor Treated by Osimertinib Plu...\n",
       "1592    Trial of Ulixertinib in Combination With Hydro...\n",
       "1593    Neo-DAB: Darolutamide and Abemaciclib in Prost...\n",
       "1594    Pancreatic Adenocarcinoma Signature Stratifica...\n",
       "1595                 Reducing Sleep disTurbance in Cancer\n",
       "1596    Evidence Development in Cancer Treatment - Rea...\n",
       "1597    Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitor...\n",
       "1598    Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) A...\n",
       "1599    Feasibility of Online MR-guided Radiotherapy o...\n",
       "1600    Study of Autologous Tumor Infiltrating Lymphoc...\n",
       "1601    PLZ4-Coated Paclitaxel-Loaded Micelles for the...\n",
       "1602    Evaluation of Prognostic Monitoring for Breast...\n",
       "1603    AFT: Introduction of a Full Breast Reconstruct...\n",
       "1604      UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC\n",
       "1605        68Ga PET/CT Imaging in Breast Cancer Patients\n",
       "1606                 Proton Therapy for Esophageal Cancer\n",
       "1607    Using Genetic Profile to Determine the Treatme...\n",
       "1608    Testing the Addition of Anti-Cancer Drug, ZEN0...\n",
       "1609    Efficacy and Safety of Prophylactic Cranial Ir...\n",
       "1610    A Study to Investigate the Safety, Tolerabilit...\n",
       "1611    SMART-ER: Symptom Monitoring With Patient-repo...\n",
       "1612    Safety and Efficacy of Epcoritamab With Gemcit...\n",
       "1613    Atezolizumab + Cabozantinib in Patients w/ Met...\n",
       "1614    Evaluation of the Use of the FUR to Quantify T...\n",
       "1615    Microbiota Transplant to Cancer Patients Who H...\n",
       "1616    Definitive Radiation for High-Risk Spine Metas...\n",
       "1617    Tucatinib Together With Pembrolizumab and Tras...\n",
       "1618    A Vaccine (MV-s-NAP) for the Treatment of Pati...\n",
       "1619    An Open Label, Randomized Study of Neoadjuvant...\n",
       "1620    Quality of Life and Economic Repercussions of ...\n",
       "1621    Neoadjuvant Immunotherapy for Resectable Gastr...\n",
       "1622    A Study of Bi-Ligand-Drug Conjugate CBP-1019 i...\n",
       "1623    Adjuvant Regional Nodal Radiation Therapy for ...\n",
       "1624    Self-administered Acupressure to Improve Cance...\n",
       "1625    Lorlatinib as the First-line Treatment in Chin...\n",
       "1626    Intervention to Improve the Delivery of Follow...\n",
       "1627    Chemoradiation Followed by Durvalumab in Poor ...\n",
       "1628          HRQOL in Locally Advanced Thyroid Carcinoma\n",
       "1629    Assessment of the Quality and Sexual Health Ne...\n",
       "1630    Pembrolizumab in Muscle Invasive/Metastatic Bl...\n",
       "1631    Retrospective and Prospective Evaluation of Sc...\n",
       "1632    Neoadjuvant Tremelimumab and Durvalumab With G...\n",
       "1633    Fluzoparib in Combination With or Without Camr...\n",
       "1634    Antler Plate on Preventing Mammary High-risk L...\n",
       "1635    Safety, Pharmacokinetics and Efficacy of CT-70...\n",
       "1636    Study of TAS-102 Plus Radiation Therapy for th...\n",
       "1637    Study of Sacituzumab Govitecan (SG) in Japanes...\n",
       "1638    Testing the Addition of Radiation Therapy to t...\n",
       "1639    Time-Restricted Eating and Cancer: Clinical Ou...\n",
       "1640    Chidamide/Everolimus for PIK3CA Wild-type/Muta...\n",
       "1641    The Dosing Regimen of Pyrotinib in HER2-positi...\n",
       "1642    Sintilimab in Combination With S-1/Oxaliplatin...\n",
       "1643    Mirvetuximab Soravtansine With Bevacizumab Ver...\n",
       "1644    A Phase I Clinical Trial of FWD1802 in Patient...\n",
       "1645    Neoadjuvant Furmonertinib and Cisplatin/Pemetr...\n",
       "1646    Niraparib, Temozolomide and Atezolizumab in Tr...\n",
       "1647    Interventional Study on DEterminants and Facto...\n",
       "1648    A Clinico-biological Database in Cachexia in P...\n",
       "1649        Inherited Cancer Early Diagnosis (ICED) Study\n",
       "1650    Safety Study of 3D Printing Personalized Biode...\n",
       "1651    Genetically Engineered Natural Killer (NK) Cel...\n",
       "1652    A Phase II Multicenter Study of Chemotherapy V...\n",
       "1653    Interpretations and Predictions of Patient Rep...\n",
       "1654    Mesalamine for Colorectal Cancer Prevention Pr...\n",
       "1655                        Sacituzumab Govitecan In TNBC\n",
       "1656    Multicentric Randomised Trial for Resectable G...\n",
       "1657    Study of AB598 Monotherapy and Combination The...\n",
       "1658    Evaluation of Hypnosis in Virtual Reality on t...\n",
       "1659    Topical Calcipotriene Treatment for Breast Can...\n",
       "1660    A QoL Intervention for Young African American ...\n",
       "1661    High Dose Vitamin C Combined With Metformin in...\n",
       "1662    Alpha Radiation Emitters Device for the Treatm...\n",
       "1663    Neoadjuvant Cetuximab + Chemotherapy Combined ...\n",
       "1664    A Study of Sacituzumab Govitecan (IMMU-132) in...\n",
       "1665    A Study to Investigate the Safety and Efficacy...\n",
       "1666    PSMA-PET: Deep Radiomic Biomarkers of Progress...\n",
       "1667    A Study of Tobemstomig Plus Platinum-Based Che...\n",
       "1668                 99mTc-ABH2 SPECT/CT in Breast Cancer\n",
       "1669    Adjuvant Metronomic Capecitabine Plus Endocrin...\n",
       "1670    Radical Local vs. Palliative Therapy for Breas...\n",
       "1671    A Study of Tobemstomig + Nab-Paclitaxel Compar...\n",
       "1672    4D CT Scan Versus 3D CT Scan Concerning Cardia...\n",
       "1673    Safety & Efficacy of Consolidative Hypofractio...\n",
       "1674    Crizotinb or Standard Chemotherapy in Met Exon...\n",
       "1675    S1501 Carvedilol in Preventing Cardiac Toxicit...\n",
       "1676    A Phase 1-2 Study of ST101 in Patients With Ad...\n",
       "1677    Accelerated Partial Irradiation of the Breast:...\n",
       "1678    First in Human Phase1/2a Clinical Trial of Ant...\n",
       "1679    Evaluation for the Effectiveness and Safety of...\n",
       "1680    Seviteronel in Combination With Chemotherapy i...\n",
       "1681    Gut Microbiome Components Predict Response to ...\n",
       "1682    A Study of Changes in Ki67 Expression in Peopl...\n",
       "1683    Mutant KRAS G12V-specific TCR Transduced T Cel...\n",
       "1684    IORT Following Breast Conserving Surgery for E...\n",
       "1685                   D9319C00001- 1L OC Mono Global RCT\n",
       "1686    Interest of PET/CT at 18F-FDG in the Post-ther...\n",
       "1687    Reconstructions With Back Donor Site Flaps and...\n",
       "1688    A Pilot Study of Monitoring Insulin Levels and...\n",
       "1689    Survey Among Healthcare Professionals Treating...\n",
       "1690    Study of a New Technique for Imaging Pancreati...\n",
       "1691    Effectiveness of Cryotherapy Combined With Com...\n",
       "1692    HER2-low Unresectable and/or Metastatic Breast...\n",
       "1693    Artificial Intelligence Analysis for Magnetic ...\n",
       "1694    Lay Coach-Led Early Palliative Care for Unders...\n",
       "1695    Pilot Study of the Predictive Value of TREM1 E...\n",
       "1696    Clinical Trial Assessing the Safety of Neoadju...\n",
       "1697    Impact of Neoadjuvant Immunotherapy in Early S...\n",
       "1698    Evaluation of a Once Per Day Regimen of Accele...\n",
       "1699    Evaluation of ExacTrac® Imaging Device for Rep...\n",
       "1700    A Digital Therapeutic Solution for Cancer Pati...\n",
       "1701    Impact of Circadian Rhythm on the Spread of Ci...\n",
       "1702    Niraparib and Neratinib in Advanced Solid Tumo...\n",
       "1703    Effect of an Amino Acids and Flavonoids Contai...\n",
       "1704      Spa Therapy for Upper or Lower Limb Lymphoedema\n",
       "1705    Combining Afatinib and Concurrent Chemotherapy...\n",
       "1706    Safety, Tolerability, Pharmacokinetics, Radiat...\n",
       "1707    APL-101 Study of Subjects With NSCLC With c-Me...\n",
       "1708    Big Data for Quality of Life in Head and Neck ...\n",
       "1709    mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody ...\n",
       "1710    Study for Participants Continuing From Pfizer-...\n",
       "1711    EO2 Oxygen Delivery To Study Success Rate of S...\n",
       "1712    Study of Core Needle Biopsy and Cryoablation o...\n",
       "1713    The Evaluation of PC14586 in Patients With Adv...\n",
       "1714    Assessing ImmunoResponse Post Eribulin: Eribul...\n",
       "1715    Trial of Nab-Sirolimus in Combination With Let...\n",
       "1716      Intraoperative Radiation Therapy (IORT) in DCIS\n",
       "1717    MRD Guiding Treatment After Almonertinib Induc...\n",
       "1718    Single Fraction Accelerated Partial Breast Irr...\n",
       "1719    A Study of HER2+ Breast Cancer Patients With A...\n",
       "1720    Sintilimab and Bevacizumab Biosimilar Combined...\n",
       "1721    A Study to Evaluate the Safety, Pharmacokineti...\n",
       "1722    Omission of Breast Surgery for Breast Cancer P...\n",
       "1723    Treatment of Cabotamig (ARB202) in Advanced Ga...\n",
       "1724    Safety of Continuing HER-2 Directed Therapy in...\n",
       "1725    Cancer in Patients on Dapagliflozin and Other ...\n",
       "1726    Effect of Losartan on the Incidence and Severi...\n",
       "1727    Combination of Lymphatico-venular Anastomosis ...\n",
       "1728    Predictive Value of Progastrin Titer at Diagno...\n",
       "1729    Testing the Addition of Radium Therapy (Radium...\n",
       "1730    High-flow Nasal Cannula Oxygenation Decrease H...\n",
       "1731    Real-world Clinical Benefit Evaluation in Brea...\n",
       "1732    LOAd703 Oncolytic Virus Therapy for Pancreatic...\n",
       "1733    Evaluation of the Efficacy and Safety of Nal-I...\n",
       "1734    Assessing the Response Rate of Neo-adjuvant Ta...\n",
       "1735    Niraparib for the Neoadjuvant Treatment of Unr...\n",
       "1736    Clinical Study of Dexmedetomidine Administered...\n",
       "1737    A Comparison of 2 Standard Doses of Bevacizuma...\n",
       "1738    The Efficacy of Hyperthermic Intraperitoneal C...\n",
       "1739    Converting HR+ Breast Cancer Into an Individua...\n",
       "1740    HER2-CAR T Cells in Treating Patients With Rec...\n",
       "1741    CAR-macrophages for the Treatment of HER2 Over...\n",
       "1742    Tinzaparin And Biomarkers After Neoadjuvant Tr...\n",
       "1743    Induction Chemotherapy and Toripalimab for Lar...\n",
       "1744    Training of Arms to Reduce Pain With Periphera...\n",
       "1745    First-line Nab-paclitaxel Plus Cisplatin Plus ...\n",
       "1746    Efficacy of Gembrax Followed by Folfirinox Ver...\n",
       "1747    Surgical or Medical Treatment of Breast Cancer...\n",
       "1748    Safety and Efficacy of Zimberelimab (AB122) in...\n",
       "1749    Administering Peripheral Blood Lymphocytes Tra...\n",
       "1750    Study of Toripalimab for Limited-Stage Small C...\n",
       "1751    Savolitinib Combine With Durvalumab in EGFR Wi...\n",
       "1752    Immunotherapy, Hormone Therapy, and AKT Inhibi...\n",
       "1753                           African Cancer Genome: GMD\n",
       "1754    BRAVE Strategy - Breast Cancer Risk Assessment...\n",
       "1755    Oregovomab Plus Chemotherapy in Neo-adjuvant S...\n",
       "1756    EC-THP Versus TCbHP in HER2-positive Lymph Nod...\n",
       "1757    WaKING: Wnt and checKpoint INhibition in Gastr...\n",
       "1758                 Remote Breast Cancer Screening Study\n",
       "1759    Liquid Biopsy Evaluation and Repository Develo...\n",
       "1760                 Dose-painting Radiation for LA-NSCLC\n",
       "1761    Comparison of Clinical Efficacy Between Letroz...\n",
       "1762    A Study of Chidamide Plus Endocrine in Mainten...\n",
       "1763    Study Comparing the Combination Domvanalimab a...\n",
       "1764    Fruquintinib With mFOLFOX6/FOLFIRI as First-Li...\n",
       "1765    Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes ...\n",
       "1766    The Role of Stereo-tActic BoDy RadIotherApy iN...\n",
       "1767    AMP945 in Combination With Nab-paclitaxel and ...\n",
       "1768    GRACE-trial: a Randomized Active-controlled Tr...\n",
       "1769    A Study of HMBD-002, a Monoclonal Antibody Tar...\n",
       "1770    SMART TNT for the Conservative Management of L...\n",
       "1771    A Clinical Study on Hormone Receptor Positive ...\n",
       "1772    Hypofractionated Vs Conventional Fractionated ...\n",
       "1773    Atezolizumab Immunotherapy, in Immunotherapy N...\n",
       "1774    First-in-Human Study of Mutant-selective PI3Kα...\n",
       "1775    NUC-3373 in Combination With Other Agents in P...\n",
       "1776    Preoperative Fractionated Radiation Therapy Ve...\n",
       "1777    Autologous Patch Healing vs. Secondary Intenti...\n",
       "1778    ONS in Gastrointestinal Cancer Patients Underg...\n",
       "1779    Preoperative Window Opportunity Study With Gir...\n",
       "1780    Clinical Study of CLDN18.2-targeting CAR T Cel...\n",
       "1781    MRI Screening for Brain Metastases Among Patie...\n",
       "1782    Deep sequencIng in Cutaneous Squamous CEll caR...\n",
       "1783    Immunogenicity and Safety of Quadrivalent HPV ...\n",
       "1784    DNA-Guided Second Line Adjuvant Therapy For Hi...\n",
       "1785    Study Comparing EC-T Verses PCb in the Adjuvan...\n",
       "1786    The Theranostic Value of STARD3 in Colorectal ...\n",
       "1787    Correlation of Molecular Markers With Response...\n",
       "1788                      Global Cardio Oncology Registry\n",
       "1789    EA2176: Phase 3 Clinical Trial of Carboplatin ...\n",
       "1790    A Phase Ib Safety lead-in, Followed by Phase I...\n",
       "1791          Cisplatin+Pembrolizumab+RT in Vulvar Cancer\n",
       "1792    A Study of SKB264 for the Treatment of Partici...\n",
       "1793    Developing and Evaluating Culturally Relevant ...\n",
       "1794                Psychological Effects of Implant Loss\n",
       "1795    ABemacicliB or Abemaciclib and HydroxYchloroqu...\n",
       "1796    Digital Phenotyping in Women Over 70 Years of ...\n",
       "1797    A Study to Assess the Efficacy and Safety of I...\n",
       "1798    Role of Gut Microbiome and Fecal Transplant on...\n",
       "1799    Safety and Efficacy of Personalized Neoantigen...\n",
       "1800    A Study of DS-1103a Combination Therapy in Par...\n",
       "1801                                FAZA PET/MRI Pancreas\n",
       "1802    Omission of Surgery in Clinically Low-risk HER...\n",
       "1803    A Study of YL202 in Patients With Locally Adva...\n",
       "1804    A Study Evaluating the Efficacy and Safety of ...\n",
       "1805    Experimental PET Imaging Scans Before Cancer S...\n",
       "1806     Patient Recall of Cancer Screening and Diagnosis\n",
       "1807    Combination Radiotherapy and Radiopharmaceutic...\n",
       "1808    Highly Selective CDK7 Inhibitor Q901 in Select...\n",
       "1809    Optical Surface Monitoring Technology-Guided L...\n",
       "1810    Individualized Dose Escalation of 5-FU for Gas...\n",
       "1811    M7824 and Topotecan or Temozolomide in Relapse...\n",
       "1812    Molecularly Targeted Umbrella Study in Luminal...\n",
       "1813    mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemoth...\n",
       "1814     Home And Locally Observed - Tracking (HALO-Trak)\n",
       "1815    ORE - 30 Seconds (Oncologists Recommend Exerci...\n",
       "1816    A Phase II Clinical Trial to Evaluate Safety a...\n",
       "1817    Efficacy and Accuracy of Combined Localization...\n",
       "1818    Artificial Intelligence Assists Surgeons' Deci...\n",
       "1819    Using Deep Learning Methods to Analyze Automat...\n",
       "1820    A Study of Several Radiation Doses for Patient...\n",
       "1821    Microwave Ablation or Wedge Resection for the ...\n",
       "1822    The Microbiome of Pancreatic Cancer: \"PANDEMIC...\n",
       "1823    TAD in Primary Breast Cancer With Initially ≥ ...\n",
       "1824    A Study of CPI-0209 in Patients With Advanced ...\n",
       "1825    Individualized Response Assessment to Heated I...\n",
       "1826    Fluzoparib and Camrelizumab in Treating Patien...\n",
       "1827    Clinical Outcome of Extracorporeal Shock Wave ...\n",
       "1828    A Study of FX-909 in Patients With Advanced So...\n",
       "1829    Study of Aerobic Training for People Receiving...\n",
       "1830    Neoadjuvant Effect of Albumin Binding Paclitax...\n",
       "1831    An Open-Label Study of INV-1120 as a Single Ag...\n",
       "1832         AXillary Surgery After NeoAdjuvant Treatment\n",
       "1833      Anamorelin Study for Advanced Pancreatic Cancer\n",
       "1834    Effect of Intravenous S-ketamine on Opioid Con...\n",
       "1835    Detection of Tumor DNA in the Blood of Patient...\n",
       "1836    A Study of TAK-186 (Also Known as MVC-101) in ...\n",
       "1837    The Effect of Premedication on Postoperative P...\n",
       "1838    Clinical Utility of FES F18 PET/CT in Metastat...\n",
       "1839    Safety and Efficacy of AsiDNATM, a DNA Repair ...\n",
       "1840    Phase II Study of Concurrent Radiotherapy With...\n",
       "1841    Quality of Life and Cosmetic Outcomes of Breas...\n",
       "1842    Tislelizumab in Combination With Investigation...\n",
       "1843    Phase I Trial of Atezolizumab and Interleukin-...\n",
       "1844    A Randomised Phase II Trial of Osimertinib Wit...\n",
       "1845    Examining and Comparing the Temporal Changes a...\n",
       "1846      Institut Paoli Calmettes Breast Cancer Database\n",
       "1847    A Study Comparing Immunopheresis® Alone or In ...\n",
       "1848    Afatinib in Advanced Refractory Urothelial Cancer\n",
       "1849    Lung Cancer Prevention Screening Programme in ...\n",
       "1850    Targeted Axillary Dissection After Neo-adjuvan...\n",
       "1851       PRE-I-SPY Phase I/Ib Oncology Platform Program\n",
       "1852    A Study of AB801 Monotherapy and Combination T...\n",
       "1853    A Study of BL-M02D1 in Patients With Locally A...\n",
       "1854    Improving Access to Breast Cancer Screening an...\n",
       "1855    Gemcitabine Plus Cisplatin Versus Gemcitabine ...\n",
       "1856    Genetically-informed Therapy for ER+ Breast Ca...\n",
       "1857    Phase II Lenvatinib and Pembrolizumab in Endoc...\n",
       "1858    First in Human Study of NVG-111 in Relapsed/Re...\n",
       "1859    Systemic Immune Checkpoint Blockade and Intrap...\n",
       "1860    Sequential Hypofractionated Radiotherapy Follo...\n",
       "1861    Niraparib Plus Anlotinib for Recurrent Ovarian...\n",
       "1862    Circulating Tumor DNA (ctDNA) for Early Treatm...\n",
       "1863    Imaging Markers of Subclinical Cardiotoxicity ...\n",
       "1864    Study of NGM707 as Monotherapy and in Combinat...\n",
       "1865    Phase II Study of Atezolizumab + Bevacizumab i...\n",
       "1866    The Effects of an Nutritional Intervention on ...\n",
       "1867    Gemcitabine and Cisplatin With or Without CPI-...\n",
       "1868    KN 046 Plus Regorafenib in MSS Metastatic Colo...\n",
       "1869    Research on the Heterogeneity of Taiwanese Bre...\n",
       "1870    Impact of Sleep Disturbance on Cognition and Q...\n",
       "1871    First in Human Study to Evaluate AZD8205 in Pa...\n",
       "1872    Pilot Study to Evaluate the Prevention and Saf...\n",
       "1873    PRophylactic Cerebral Irradiation or Active MA...\n",
       "1874    Neoadjuvant Dalpiciclib Plus Aromatase Inhibit...\n",
       "1875    Phase 1 Study of CK-301 (Cosibelimab) as a Sin...\n",
       "1876    Home Based Exercise for Patients With Breast o...\n",
       "1877    Dacomitinib in Lung Cancer With Uncommon EGFR ...\n",
       "1878    APG-1387 Plus Chemotherapy in Advanced Pancrea...\n",
       "1879    SHARON: A Clinical Trial for Metastatic Cancer...\n",
       "1880    Evaluation of a Promising New Combination of P...\n",
       "1881    Intratreatment FDG-PET During Radiation Therap...\n",
       "1882    Anterior Thoracic Perforating Artery (PATA); S...\n",
       "1883    Effect of Breast Implants om Mammography Scree...\n",
       "1884    First-in-human, Study of MATTISSE® Tissue Engi...\n",
       "1885    Neoadjuvant Endocrine Therapy Versus Chemother...\n",
       "1886        Understanding CARdiac Events in Breast Cancer\n",
       "1887    DNX-2440 for Resectable Colorectal Liver Metas...\n",
       "1888    Early Detection of Treatment Failure in Metast...\n",
       "1889          Adaptive RadioTherapy for OroPharynx Cancer\n",
       "1890    Dose Escalation Study of a PD1-LAG3 Bispecific...\n",
       "1891    A Study of Immunotherapy Combined With Neoadju...\n",
       "1892    Effect and Long-Term Outcomes of Indocyanine G...\n",
       "1893    Effect of Genetic and Epigenetic Factors on th...\n",
       "1894    Adapted Physical Activity in Patients With Res...\n",
       "1895    Testing of Bevacizumab, Erlotinib, and Atezoli...\n",
       "1896    TVB 2640 for Resectable Colon Cancer Other Res...\n",
       "1897    Immunotherapy Using Tumor Infiltrating Lymphoc...\n",
       "1898    Cisplatin Combined With Oral TS-1 in Patients ...\n",
       "1899    Prospective Evaluation of Targeted Axillary Di...\n",
       "1900    Tribally Engaged Approaches to Lung Screening ...\n",
       "1901    A Study to Evaluate the Safety and Efficacy of...\n",
       "1902    Strategy Therapy on Cancer Therapy-Related Car...\n",
       "1903    NBTXR3 and Radiation Therapy for the Treatment...\n",
       "1904    Testing Radiation and HER2-targeted Therapy Ve...\n",
       "1905    Programmed Death-Ligand1 Expression in Her-2 P...\n",
       "1906    Pre Pectoral Implant for Immediate Breast Reco...\n",
       "1907    The Characteristics, Treatment Patterns and Pr...\n",
       "1908    TACTIVE-U: A Study to Learn About the Study Me...\n",
       "1909    The Efficacy of Using Pentoxifylline in Patien...\n",
       "1910    Safely Stopping Pre-medications in Patients Wi...\n",
       "1911    Controlled Low Calorie Diet in Reducing Side E...\n",
       "1912    Fc-Engineered Anti-CTLA-4 Monoclonal Antibody ...\n",
       "1913    Patient-centered Breast Cancer Teleprehabilita...\n",
       "1914    Stereotactic Radiotherapy Combined With Adebre...\n",
       "1915    Study to Assess Safety and PET Imaging Charact...\n",
       "1916    Phase II Study of AK104 (Cadonilimab) for Recu...\n",
       "1917    A Comprehensive Oncology Rehabilitation and Ex...\n",
       "1918    Enhancing Cancer Prevention and Control Pathwa...\n",
       "1919    An Impact Assessment of a Culturally Tailored ...\n",
       "1920    Plasma Biomarker for Aflibercept in Advanced C...\n",
       "1921      Comparison of the Breast Tumor Microenvironment\n",
       "1922    AVI Didactic Experience for Latinx Patient Tre...\n",
       "1923    Phase II IMNN-001 (Also Known as GEN-1) on SLL...\n",
       "1924    A First-in-human Dose Escalation and Expansion...\n",
       "1925    Efficacy of Modified Fruquintinib in Colorecta...\n",
       "1926    A Study of Mental Health Care in People With C...\n",
       "1927    Neoadjuvant Therapy of Pembrolizumab + Ramucir...\n",
       "1928    Efficacy and Safety of Metronomic Oral Vinorel...\n",
       "1929    Performance Assessment of the Fluorescence Tec...\n",
       "1930    Simultaneous Portal and Hepatic Vein Versus Po...\n",
       "1931    Pyrotinib Rechallenge in Her2-positive Metasta...\n",
       "1932    Pyrotinib in Combination With Neoadjuvant Chem...\n",
       "1933    Prehabilitation to Revolutionize Oncology: Tel...\n",
       "1934    TUBectomy With Delayed Oophorectomy in High Ri...\n",
       "1935    Evaluating the Use of Patient Navigation to Pr...\n",
       "1936                        NKG2D CAR-NK & Ovarian Cancer\n",
       "1937    A Study of Bevacizumab, Infusional Fluorouraci...\n",
       "1938    AN0025 and Chemoradiotherapy Combination in Es...\n",
       "1939    A Study of JAB-3312 in Adult Patients With Adv...\n",
       "1940    Early Detection of Gastric Cancer Using Plasma...\n",
       "1941    IMM2902 in Patients With Advanced Solid Tumors...\n",
       "1942        PD1 and PARP for Maintenance Therapy in NSLLC\n",
       "1943    A Phase 1 Study of HRS8807 Monotherapy and in ...\n",
       "1944    Decision Support Training for Advanced Cancer ...\n",
       "1945    Intraperitoneal Aerosolized Nanoliposomal Irin...\n",
       "1946    Oral Vinorelbine and Capecitabine in Advanced ...\n",
       "1947    Huaier Granule in Treating Women With Triple N...\n",
       "1948    Sj-subway, a Predictor for the Recurrence of H...\n",
       "1949    KARMA Kontrast Evaluating Contrast Enhanced Ma...\n",
       "1950        Nonlinear Elasticity Mapping of Breast Masses\n",
       "1951    Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 fo...\n",
       "1952    eHealth Insomnia Intervention for Adult Surviv...\n",
       "1953    ALA-induced Fluorescence Imaging of Breast Can...\n",
       "1954    Chemotherapy and Tislelizumab With Split-cours...\n",
       "1955    Study on Early Auxiliary Diagnosis and Postope...\n",
       "1956    Lu177-EB-PSMA617 Radionuclide Treatment in Pat...\n",
       "1957    Computed Tomography-Guided Stereotactic Adapti...\n",
       "1958    Nivolumab and Ipilimumab and Radiation Therapy...\n",
       "1959    Trans-RosaLEE Study: a Biomarker-directed, Tra...\n",
       "1960    Combination of Atezolizumab With Dendritic Cel...\n",
       "1961          Virtual Rehabilitation for Cancer Survivors\n",
       "1962    Remediation for Mild Cognitive Deficits After ...\n",
       "1963    Lung Nodule Detection Using Ultra-long FOV PET/CT\n",
       "1964    Guided Treatment Based on Mini-PDX in Metastat...\n",
       "1965    Organoid-Guided Chemotherapy for Advanced Panc...\n",
       "1966    Regional Radiotherapy in Biomarker Low-Risk No...\n",
       "1967    Short-term Outcomes of Full Bowel Preparation ...\n",
       "1968    A Study of BL-B01D1 Combined With Osimertinib ...\n",
       "1969         Olaparib in PALB2 Advanced Pancreatic Cancer\n",
       "1970    Study of the Combination of DKN-01 and Nivolum...\n",
       "1971    A Study Comparing the Efficacy of TCbHP and EC...\n",
       "1972    Anlotinib Plus PD-1 Antibody in Standard Chemo...\n",
       "1973    Efficacy and Safety of Dose-dense Chemotherapy...\n",
       "1974                   Daratumumab in STK11 Mutated NSCLC\n",
       "1975    Exploring Cancer-Associated Thromboembolism Pr...\n",
       "1976    Radiotherapy With Tislelizumab in Patients Wit...\n",
       "1977    Immunoassay and Regulation of Traditional Chin...\n",
       "1978    Lorlatinib After Failure of First-line TKI in ...\n",
       "1979    Adebrelimab Plus Cetuximab and Chemotherapy fo...\n",
       "1980    Diagnosis of Nodules ≤2 cm Based on US and CEU...\n",
       "1981    Peri-operative Sintilimab in Combination With ...\n",
       "1982    Cross-sectional Case and Control Study on Qual...\n",
       "1983    Phase IB & II Study of Ribociclib With Trastuz...\n",
       "1984    Diagnostic Performance of Fluorescein as an In...\n",
       "1985    A Study of MQ710 With and Without Pembrolizuma...\n",
       "1986    Deferoxamine Plus Chemotherapy for Metastatic ...\n",
       "1987      Cone Beam Breast CT for Breast Cancer Screening\n",
       "1988    A Study of GB491 in Combination With Letrozole...\n",
       "1989    IMPROVE Intervention Trial Implementing Non-in...\n",
       "1990    A Study of NT-175 in Adult Subjects With Unres...\n",
       "1991    Epacadostat (INCB024360) Added to Preoperative...\n",
       "1992    Dendrobium Huoshanense Suppository in Rectal C...\n",
       "1993    FFNP-PET/MR Imaging of Progesterone Receptor E...\n",
       "1994    HLX301 (TIGIT×PDL1 Bispecific) in Patients Wit...\n",
       "1995    Myofascial Pain Syndrome in Patients With Brea...\n",
       "1996    REBECCA-2 Study: Research on Breast Cancer Ind...\n",
       "1997    Supportive Effects of Craniosacral Therapy for...\n",
       "1998    CRP-guided Transanal Drainage Removal After Re...\n",
       "1999    Retrospective Data Collection on the Use of Mo...\n",
       "2000    Circulating Tumor DNA After Neoadjuvant Chemot...\n",
       "2001    Study of TROP2 CAR Engineered IL15-transduced ...\n",
       "2002    East Asian Breast Cancer Genome Atlas and Recu...\n",
       "2003    Comparing Continuation or De-escalation of Bon...\n",
       "2004    Effects of Yoga on the Quality of Life of Brea...\n",
       "2005    Cyclophosphamide and Dexamethasone for the Tre...\n",
       "2006    A Pivotal Study of Safety and Effectiveness of...\n",
       "2007    The Influence of Treatment Position (Prone vs....\n",
       "2008    Refusal of Breast Surgery in Patients With Bre...\n",
       "2009    Phase Ib Trial of the KRAS G12C Inhibitor Adag...\n",
       "2010    Efficacy of a Combined ACT+ App Intervention t...\n",
       "2011    Add-Aspirin: A Trial Assessing the Effects of ...\n",
       "2012    OH2 Oncolytic Viral Therapy in Non-Muscle-Inva...\n",
       "2013    Pre-pectoral Versus Sub-pectoral Implant Place...\n",
       "2014               DESTINY Breast Respond HER2-low Europe\n",
       "2015    Sequential TAS-OX Alternating With TAS-IRI Plu...\n",
       "2016    Neoadjuvant Chemoradiotherapy Plus Sintilimab ...\n",
       "2017    Implementing Precision Medicine in cOmmunity H...\n",
       "2018    Phase 1b/2 Study of TTI-101 in Combination for...\n",
       "2019    Trastuzumab-deruxtecan in Patients With Triple...\n",
       "2020    IMC001 for Clinical Research on Advanced Diges...\n",
       "2021    Study of ART0380 in Patients With Biologically...\n",
       "2022    Survival Benefits of Statins in Breast Cancer ...\n",
       "2023    A Study of Blood Pressure Control During Cance...\n",
       "2024    BP1001-A in Patients With Advanced or Recurren...\n",
       "2025    Memory Perception Assessment in Central/Non-ce...\n",
       "2026    Single-arm, Single-center, Exploratory Phase I...\n",
       "2027    Oncolytic Adenovirus Combined With PD-1 Inhibi...\n",
       "2028    Breast Margin Study: Routine Cavity Shave Marg...\n",
       "2029    Comparative Effectiveness of Palbociclib Plus ...\n",
       "2030    Canakinumab for the Prevention of Lung Cancer,...\n",
       "2031    The Role of Vitamin D in Predicting Response t...\n",
       "2032    Efficacy and Safety of the Combination of Tras...\n",
       "2033    Tempus Priority Study: A Pan-tumor Observation...\n",
       "2034          Magnetic Resonance Imaging of Breast Cancer\n",
       "2035    Adherence Intervention in Patients With Metast...\n",
       "2036     Culturally Aware AET Non-Initiation Intervention\n",
       "2037    Axillary Surgery De-escalation After Neoadjuva...\n",
       "2038    Study of LVGN6051 (CD137 Agonist Antibody) in ...\n",
       "2039    Study Comparing 4 Cycles With 6 Cycles of TC (...\n",
       "2040    Safety and Efficacy of CEA-targeted CAR-T for ...\n",
       "2041    Prospective, Observational Study on the Caroti...\n",
       "2042    Adjuvant Therapy With an Alpha-lactalbumin Vac...\n",
       "2043    ADSTILADRIN Early Utilization and Outcomes in ...\n",
       "2044    IN10018+ Standard Chemotherapy (+KN046) in Sub...\n",
       "2045    Intraoperative Endoscopic Ultrasound for Pancr...\n",
       "2046    Real World Patient-Reported Outcomes in Chines...\n",
       "2047    mHealth Behavioral Cancer Pain Intervention fo...\n",
       "2048    Pembrolizumab Combined With Double Platinum Ba...\n",
       "2049    A Study of BL-B01D1 in Patients With Unresecta...\n",
       "2050    Combination of Paclitaxel-bevacizumab ± Atezol...\n",
       "2051    Impact of Web Application Support Versus Stand...\n",
       "2052    Sentinel Lymph Node Biopsy With or Without Par...\n",
       "2053    Exercise to Prevent AnthraCycline-based Cardio...\n",
       "2054    Stereotactic Ablative Radiotherapy for Oligo-P...\n",
       "2055    Chemotherapy and Immunotherapy as Treatment fo...\n",
       "2056    Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC\n",
       "2057    Phase 2 DoceRamPem for Patients With Metastati...\n",
       "2058    Phase I/II Study of SY-5007, a RET Inhibitor, ...\n",
       "2059    Safety and Immunogenicity of COVID-19 Vaccinat...\n",
       "2060    First Phase Clinical Trial of Single Agent MBF...\n",
       "2061    PreOperative Endocrine Therapy for Individuali...\n",
       "2062    Utilizing Continuous Glucose Monitoring to Cha...\n",
       "2063    Telaglenastat Hydrochloride and Osimertinib in...\n",
       "2064    A Study of Pyrotinib Plus Capecitabine Combine...\n",
       "2065    PROVIDENCE - Prospective Non-interventional St...\n",
       "2066    Capivasertib + CDK4/6i + Fulvestrant for Advan...\n",
       "2067    Comparison of AT & PR Training to Improve Func...\n",
       "2068    Higher Dose Preoperative taMOxifen in Premenop...\n",
       "2069    Safety, PK and Efficacy of AI-061 in Advanced ...\n",
       "2070    Mind-body Online Therapy in Gynecological Onco...\n",
       "2071    Effect of Aerobic Exercises on Trace Elements ...\n",
       "2072    Trial of Pre-operative Neratinib and Endocrine...\n",
       "2073    Testing the Combination of APG-1252 (Pelcitocl...\n",
       "2074    Breast Reconstruction and Neoadjuvant Radiothe...\n",
       "2075    EO2040 in Combination With Nivolumab, for Trea...\n",
       "2076    Feasibility of Carbon-Dye Marking of Axillary ...\n",
       "2077    FOLFOXIRI With or Without Intensification for ...\n",
       "2078    JAB-2485 Activity in Adult Patients With Advan...\n",
       "2079    Olinvacimab With Pembrolizumab in Patients Wit...\n",
       "2080    Minimal Residual Disease-guided Adjuvant Thera...\n",
       "2081    PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEA...\n",
       "2082    Physical Exercise During Preoperative Chemothe...\n",
       "2083    Long-Term Follow-up Study of Early Stage Breas...\n",
       "2084    ASPIRED-XT: ASPirin Intervention for the REDuc...\n",
       "2085    Assessment of Health Related Quality of Life i...\n",
       "2086    Oxford Pre-cancerous Lymphoproliferative Disor...\n",
       "2087                Mass Balance Study of [14C]Chiauranib\n",
       "2088    PSMA-PET Imaging Before and After ADT in Advan...\n",
       "2089    WoO: Window of Opportunity Trial of Olaparib a...\n",
       "2090    Adjuvant Chemoradiation and Biomarkers of Resp...\n",
       "2091    Alpha Radiation Emitters Device (DaRT) for the...\n",
       "2092    Cardiac Rehabilitation for Breast Cancer Survi...\n",
       "2093    Study of Anlotinib Combined With Docetaxel in ...\n",
       "2094    EMPOWER 3: Improving Palliative Care Health Li...\n",
       "2095    Impact of Endocrine Therapy, Menstrual Cycle, ...\n",
       "2096    Utidelone Plus Bevacizumab for Advanced Breast...\n",
       "2097    Study of Amplitude-Modulated Radiofrequency El...\n",
       "2098    Developing a New MRI Technique to Understand C...\n",
       "2099    Evaluation of an Automated System to Culture M...\n",
       "2100    68Ga-HER2 Affibody PET/CT Imaging for HER2-Pos...\n",
       "2101    Preoperative Magnetic Resonance Imaging to Obt...\n",
       "2102    A Clinical Study on Oncolytic Virus Injection ...\n",
       "2103    First in Human Study of TORL-2-307-MAB in Part...\n",
       "2104           Pancreatic Cancer Evolution Upon Treatment\n",
       "2105    Mass Response of Tumor Cells as a Biomarker fo...\n",
       "2106    Niraparib + Dostarlimab In BRCA Mutated Breast...\n",
       "2107    Datopotamab (DS-1062a) in Advanced and/or Unre...\n",
       "2108    68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor...\n",
       "2109    A Clinical Trial of KVA12123 Treatment Alone a...\n",
       "2110    Phase 1 Study of UCMYM802 Injection in Mesothe...\n",
       "2111    Comparing Combinations of Targeted Drugs for A...\n",
       "2112    Prehabilitation During the Neoadjuvant Window ...\n",
       "2113    Phase 3 Study Randomized Evaluating the Effica...\n",
       "2114    LS301-IT in Partial Mastectomy and Sentinel Ly...\n",
       "2115    A Study Evaluating the Efficacy and Safety of ...\n",
       "2116    Predicting Olaparib Sensitivity in Patients Wi...\n",
       "2117            Chemotherapy Induced Cognitive Impairment\n",
       "2118    Adjuvant Study of Pyrotinib in HER-2 Positive ...\n",
       "2119    Minnelide and Osimertinib for the Treatment of...\n",
       "2120    Pooled Mutant KRAS-Targeted Long Peptide Vacci...\n",
       "2121    Fecal Microbiota Transplantation With Immune C...\n",
       "2122    A Study of JK08, an IL-15 Antibody Fusion Prot...\n",
       "2123    Olaparib and Durvalumab (MEDI4736) in Patients...\n",
       "2124    Trastuzumab Deruxtecan Versus Standard Neoadju...\n",
       "2125    Induction Chemotherapy and Toripalimab Followe...\n",
       "2126    Predicting Effective Adaptation to Breast Canc...\n",
       "2127    Crizotinib in c-MET Mutation Metastatic/Recurr...\n",
       "2128    Glycan Mediated Immune Regulation With a Bi-Si...\n",
       "2129    A Study of Metastatic Gastrointestinal Cancers...\n",
       "2130    A Study Evaluating the Safety, Activity, and P...\n",
       "2131    The Effect of Simulation-Based Breast Health E...\n",
       "2132    HIPEC After Initial CRS in Patients Who Have R...\n",
       "2133    Realistic Evaluation of a Job Retention Progra...\n",
       "2134    Pyrotinib as Neoadjuvant Agent for Non-objecti...\n",
       "2135    Repeated Superselective Intraarterial Cerebral...\n",
       "2136    Nilotinib in Preventing Paclitaxel-Induced Per...\n",
       "2137    Open Label, Multicenter, Real World Practice o...\n",
       "2138    COOL-IT-PRO: Cryoablation of Breast Cancer in ...\n",
       "2139    Phase II Study of Dato-DXd in Triple-negative ...\n",
       "2140    Bupropion in Reducing Cancer Related Fatigue i...\n",
       "2141        FES BPET-DBT in Newly Diagnosed Breast Cancer\n",
       "2142      A Phase 1/2 Study of [225Ac]-FPI-1434 Injection\n",
       "2143    Robot-assisted vs. Open Nipple-sparing Mastect...\n",
       "2144    Care Coordination Educational Intervention Stu...\n",
       "2145    Evaluation of Different Smoking Cessation Prot...\n",
       "2146    Study of Chemotherapy, With or Without Binimet...\n",
       "2147    A Clinical Trial of TQB3909 Tablets in Patient...\n",
       "2148    Effects of Modified Precision Functional Sphin...\n",
       "2149    Phase III Trial Evaluating Radium Bromatum Hom...\n",
       "2150    First-in-Human Study of RLY-5836 in Advanced B...\n",
       "2151    Multi-Reader, Multi-Case, Cross-Over, Retrospe...\n",
       "2152    BIOREN (Predictive BIOmarkers in Metastatic RE...\n",
       "2153    Phase II RCT of an Internet-adaptation of Mana...\n",
       "2154    Adenosine Signaling Modulation and Immune Chec...\n",
       "2155    Proof-of-concept Study of Blood Markers of Tum...\n",
       "2156    Phase II Investigation of Pembrolizumab in Com...\n",
       "2157    Study of XL092 in Combination With Immuno-Onco...\n",
       "2158    Use of Quantitative Ultrasound to Guide Adapti...\n",
       "2159    Safety, Tolerability and Pharmacokinetics of O...\n",
       "2160    Comparing Hypo-fractionated Intensity- Modulat...\n",
       "2161    Pyrotinib After Trastuzumab-based Adjuvant The...\n",
       "2162    Bazedoxifene as a Concomitant Treatment of Pat...\n",
       "2163    Valproic Acid in Combination With Bevacizumab ...\n",
       "2164    Comparison of Low-dose Spiral Breast CT With M...\n",
       "2165       ctDNA Methylation for Detecting Ovarian Cancer\n",
       "2166    Pembrolizumab With Ataluren in Patients With M...\n",
       "2167    PROACT: Can we Prevent Chemotherapy-related He...\n",
       "2168            Erector Spinae Block for Thoracic Surgery\n",
       "2169    Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pa...\n",
       "2170    Eliminating Surgery or Radiotherapy After Syst...\n",
       "2171    Studying the Effect of Denosumab on Preventing...\n",
       "2172    Postoperative Chronic Operation-related Sympto...\n",
       "2173    CAB-ROR2-ADC Safety and Efficacy Study in Pati...\n",
       "2174    FIGO 2018 Stage IB2 Cervical Cancer Treated Wi...\n",
       "2175                           Pancreatic Cancer Genetics\n",
       "2176    Study on the Peristaltic Direction of GI Anast...\n",
       "2177    A Study of T3011 Administered Via Intratumoral...\n",
       "2178    Study of Neoadjuvant Endocrine Therapy in HR P...\n",
       "2179    PSMA-PET/CT to Assess the Expression of Specif...\n",
       "2180    Total Neoadjuvant Therapy With mFOLFOX and Sho...\n",
       "2181    Study of Chemotherapy Combination With Autolog...\n",
       "2182    Evaluating the Safety and Efficacy of a Novel ...\n",
       "2183    HER2-directed Biosimilar in Breast Cancer: Rea...\n",
       "2184    Efficacy and Safety Study of rhTSH for Adjuvan...\n",
       "2185    Deescalation of Endocrine Therapy Duration in ...\n",
       "2186    Dynamic Observational Study With PET of 68Ga-H...\n",
       "2187    First in Human Phase 1 Study of AG01 Anti-Prog...\n",
       "2188    Testing the Addition of the Anti-cancer Drug, ...\n",
       "2189     Prospective Breast Cancer Biospecimen Collection\n",
       "2190    Assessment of Sensory Gating, Attention, and E...\n",
       "2191    Oral Immunonutrition With Synbiotics, Omega 3 ...\n",
       "2192    Molecular Imaging of HER2 Expression in Breast...\n",
       "2193    Digital Phenotyping in Young Breast Cancer Pat...\n",
       "2194    Neoadjuvant Study With Pyrotinib and Trastuzum...\n",
       "2195    Efficacity of Deep Inspiration Breath Hold and...\n",
       "2196      Synapse 3D With Intravascular Indocyanine Green\n",
       "2197    Altered Tumor Oxygenation by Metformin, a Pote...\n",
       "2198    Stereotactic Boost and Short-course Radiation ...\n",
       "2199    Single Cell Immune and Non-immune Correlates o...\n",
       "2200    Alpha Radiation Emitters Device (DaRT) for the...\n",
       "2201    A Study to Prevent Rash in People Starting Alp...\n",
       "2202    Pre Operative Trastuzumab in Operable Breast C...\n",
       "2203    Effects of Carvedilol on Cardiotoxicity in Can...\n",
       "2204    Safety & Efficacy of Durvalumab+Neoadjuvant Ch...\n",
       "2205    Lymphoscintigraphy Directed Elective Neck Radi...\n",
       "2206    Fulvestrant or Capecitabine Combined With Pyro...\n",
       "2207            Axillary Reverse Mapping in Breast Cancer\n",
       "2208    Exome Analysis (Complexe vs Simple) to Help th...\n",
       "2209    A Study of XmAb20717 (Vudalimab)in Patients Wi...\n",
       "2210    Huaier Granule on Reducing the Level of Tumor ...\n",
       "2211    Characterizing Fatigue Experienced by Cancer P...\n",
       "2212      Quality of Life Improvement During Chemotherapy\n",
       "2213    Brain [18F]-FES PET/CT in Patients With Estrog...\n",
       "2214    The Combination of Immunotherapy and Neoadjuva...\n",
       "2215    Combined Immunotherapies in Metastatic ER+ Bre...\n",
       "2216    Home-Based Physical Activity Intervention for ...\n",
       "2217    Dalpiciclib Plus AI (Neoadjuvant Endocrine The...\n",
       "2218    KORTUC Phase II - Intra-tumoural Radiation Sen...\n",
       "2219    PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO ...\n",
       "2220    Longitudinal Sexual and Reproductive Health St...\n",
       "2221    A Pilot Study To Evaluate the Effectiveness of...\n",
       "2222     Mindfulness and Self-compassion Focussed Walking\n",
       "2223    Pembrolizumab and Lenvatinib in Clear Cell Ova...\n",
       "2224    Utility and Usability of ActivSight™ Laser Spe...\n",
       "2225    Stereotactic Body Radiotherapy and Focal Adhes...\n",
       "2226    Study of IDE196 in Patients With Solid Tumors ...\n",
       "2227    The Swedish Study of Liver Transplantation for...\n",
       "2228    Unified Barlow Protocol (UP) in Cancer Survivo...\n",
       "2229    Tumor Treating Fields Therapy in Combination W...\n",
       "2230          Mass Spectral Fingerprinting in Lung Cancer\n",
       "2231    Testing the Addition of Ipatasertib to Usual C...\n",
       "2232    Chemotherapy-induced Cognitive and Brain Chang...\n",
       "2233    Particle-based Partial Tumor Irradiation of Un...\n",
       "2234    Real World Treatment Experience of Patients Wi...\n",
       "2235    Promoting Physical Activity in Breast Cancer S...\n",
       "2236    Safety and Efficacy of Omission of Sentinel No...\n",
       "2237    Standard Dose Versus High Dose of Radiotherapy...\n",
       "2238    D2 vs D3 Lymph Node Dissection for Left Colon ...\n",
       "2239    A Phase II Study Evaluating the Efficacy and S...\n",
       "2240    Durvalumab (MEDI4736) and Tremelimumab and Rad...\n",
       "2241    SABER Study for Selected Early Stage Breast Ca...\n",
       "2242    PIK3CA/PTEN-altered Advanced Breast Cancer Tre...\n",
       "2243    A Clinical Research About CD70-positive Advanc...\n",
       "2244    Discontinuation of CDK4/6 Inhibitors in Patien...\n",
       "2245    Anti-tumor Effect of Ixabepilone in Metastatic...\n",
       "2246    Comparing Decision on Aesthetics After Breast ...\n",
       "2247    CA-4948 in Combination With FOLFOX/PD-1 Inhibi...\n",
       "2248    Discontinuation of Maintenance HER-2 Directed ...\n",
       "2249    Nivolumab With Ipilimumab Combined With TGFβ-1...\n",
       "2250    Bupivacaine vs Placebo for Unilateral Mastecto...\n",
       "2251    Daily Adaptive Radiation Therapy an Individual...\n",
       "2252    Study Evaluating the Efficacy of Maintenance O...\n",
       "2253    Cryoablation Combined With Sintilimab Plus Reg...\n",
       "2254    Exercise as a Preventive Agent to Combat Immob...\n",
       "2255    Adjuvant Befotertinib in Stage IB-IIIB Non-sma...\n",
       "2256    NordicTrip, a Translational Study of Preoperat...\n",
       "2257    DS8201a and Pembrolizumab in Participants With...\n",
       "2258    Safety of Withdrawal of Pharmacological Treatm...\n",
       "2259    Study of the Therapeutic Effect of Atorvastati...\n",
       "2260    Study of Pembrolizumab and Single Agent Chemot...\n",
       "2261    Prediction of Treatment Efficacy of the Combin...\n",
       "2262    Triage of Advanced Cervical Cancer Through Imm...\n",
       "2263    Peer Support For Young Adult Women With High B...\n",
       "2264    Study to Evaluate Efficacy and Safety of Selec...\n",
       "2265    Standard Verbal Counseling With or Without a P...\n",
       "2266    Neoadjuvant Cemiplimab for the Treatment of Re...\n",
       "2267    IPH5201 and Durvalumab in Patients With Resect...\n",
       "2268    A Study to Evaluate the Safety, Pharmacokineti...\n",
       "2269    Randomized Feasibility Trial for Mesh in Pre-P...\n",
       "2270    Perioperative Tislelizumab Combined With Nab-P...\n",
       "2271            Adaptations to Breast Cancer and Exercise\n",
       "2272    First-line Treatment With Camrelizumab + Apati...\n",
       "2273    Chemoradiation vs Immunotherapy and Radiation ...\n",
       "2274    Circulating Biomarker Signatures for the Detec...\n",
       "2275    GDC-0084 in Combination With Trastuzumab for P...\n",
       "2276    Comparative Effectiveness of PAL Based-therapy...\n",
       "2277    Neoadjuvant Therapy Study Guided by Drug Scree...\n",
       "2278    Influence of Intermittent Fasting on Locally A...\n",
       "2279    Omission of SLNB in Triple-negative and HER2-p...\n",
       "2280    Retarded Surgery Following Neoadjuvant Chemoth...\n",
       "2281    Identifying Prognostic Variables for Persisten...\n",
       "2282    Vitamin D and Calcium Supplementation in Breas...\n",
       "2283    A Study to Evaluate the Safety and Pharmacokin...\n",
       "2284    Trial of Nivolumab With FOLFOX After Chemoradi...\n",
       "2285       Radiofrequency Ablation (RFA) in Breast Tumors\n",
       "2286    Capmatinib Plus Trametinib for the Treatment o...\n",
       "2287    Study to Test the Safety and Tolerability of P...\n",
       "2288    Redefining FOLFIORINOX in Older Pancreatic Can...\n",
       "2289    Radiotherapy + Chemoimmunotherapy Followed by ...\n",
       "2290    A Phase III Trial of Neoadjuvant Sintilimab an...\n",
       "2291    Multidisciplinary Approach to Breast Cancer Th...\n",
       "2292    A Research Study to Collect Patient Reported O...\n",
       "2293    Radiotherapy in Preoperative Setting With Cybe...\n",
       "2294    A Study of Radiation Therapy and Cemiplimab fo...\n",
       "2295    Tocotrienol and Bevacizumab in Metastatic Colo...\n",
       "2296    Safety Study of BMX-001 (Radio-protector) in P...\n",
       "2297    Use of Sentinel Lymph Node Biopsy in Patients ...\n",
       "2298    12-week Exercise Intervention Program Versus O...\n",
       "2299    Quick Start Durvalumab Following Chemoradiatio...\n",
       "2300    The DBCG Proton Trial: Photon Versus Proton Ra...\n",
       "2301    Marker Technique Comparison in Targeted Axilla...\n",
       "2302    Interventional Program Educates, Identifies + ...\n",
       "2303    Neoadjuvant Chemotherapy Combined With PD-1 + ...\n",
       "2304    A Study of 68Ga-ABY-025 PET for Non-invasive Q...\n",
       "2305    A Study of QBECO Versus Placebo in the Treatme...\n",
       "2306          Precision-Based Genomics in Prostate Cancer\n",
       "2307    Hyperthermia Treatment Added to Chemotherapy S...\n",
       "2308    Home_Based Digital Mindful Dance Program for B...\n",
       "2309    Protocol for Women at Increased Risk of Develo...\n",
       "2310         Psychosocial eHealth in Advanced Lung Cancer\n",
       "2311    A Study of Ensartinib as Neoadjuvant Therapy f...\n",
       "2312    TACTIVE-U: A Study to Learn About the Study Me...\n",
       "2313    Coping Together: Couple-based Interventions fo...\n",
       "2314    TAS-116 Plus Palbociclib in Breast and Rb-null...\n",
       "2315    MACSSI (MAstectomie Cellules Souches Surveilla...\n",
       "2316    Clinical Study on the Safety and Efficacy of Q...\n",
       "2317    Focused Ultrasound and Gemcitabine in Breast C...\n",
       "2318    Metastasis-directed Therapy for Oligometastase...\n",
       "2319     HMBD-001 in Advanced HER3 Positive Solid Tumours\n",
       "2320    Postmastecomy Internal Mammary Nodal Irradiati...\n",
       "2321    Fulvestrant, Ipatasertib and CDK4/6 Inhibition...\n",
       "2322    Effectiveness of Ultrasound Guided PECS Block ...\n",
       "2323    A Prospective Evaluation of the Peri-operative...\n",
       "2324    Acupuncture Treatment of Vasomotor Symptoms in...\n",
       "2325    Nicotinamide Riboside and Prevention of Cancer...\n",
       "2326    Somatostatin Receptor Imaging in NPC, EBV Rela...\n",
       "2327    LONsurf and G-CSF Use: Being On A Right Dose-i...\n",
       "2328    CAR T Cells in Mesothelin-Expressing Breast Ca...\n",
       "2329    Preventing High Blood Sugar in People Being Tr...\n",
       "2330    Utidelone in Combination With AC Versus Doceta...\n",
       "2331    A Study of Single Fraction Stereotactic Body R...\n",
       "2332             Women at Risk of Breast Cancer and OLFM4\n",
       "2333    Lenvatinib in Locally Advanced Invasive Thyroi...\n",
       "2334    A Study of Short-Course Radiation Therapy With...\n",
       "2335    Stereotactic Body Radiation and Tumor Treating...\n",
       "2336    Rhomboid Intercostal Plane Block on Chronic Pa...\n",
       "2337    Clinical Study of CEA-targeted CAR-T Therapy f...\n",
       "2338    Trastuzumab Combined With Pyrrolidine and Chem...\n",
       "2339    External Vacuum Expansion: Evaluation in Breas...\n",
       "2340    Study to Assess the Impact of Personalized Coa...\n",
       "2341    Breast Cancer With Intraoperative Radiotherapy...\n",
       "2342    Pilot Study of Internet-Delivered Psychologica...\n",
       "2343    A Study of Docetaxel for Injection (Albumin-bo...\n",
       "2344     Predicting Chronic Pain Following Breast Surgery\n",
       "2345    2D Speckle-tracking Echocardiography in Chemot...\n",
       "2346    Choices About Genetic Testing And Learning You...\n",
       "2347    Managing Breast Cancer Treatment: Dyad's Persp...\n",
       "2348         Nasal Mask Kit in Gastrointestinal Endoscopy\n",
       "2349    Pembrolizumab as Neoadjuvant Therapy for Resec...\n",
       "2350    A Phase 1 Study of NM6603 in Advanced Solid Tu...\n",
       "2351    PF-07104091 as a Single Agent and in Combinati...\n",
       "2352    B7-H3-Specific Chimeric Antigen Receptor Autol...\n",
       "2353    Pembrolizumab and Lenvatinib for the Treatment...\n",
       "2354    A Clinical Imaging Study of the Changes in [18...\n",
       "2355    Longitudinal ctDNA Surveillance for Older Wome...\n",
       "2356    Establishment of an ex Vivo Tumor Collection o...\n",
       "2357            Exercise Timing in Breast Cancer Patients\n",
       "2358    Avelumab With Binimetinib, Sacituzumab Govitec...\n",
       "2359    Doxorubicin Hydrochloride and Cyclophosphamide...\n",
       "2360    Influence of Adiposity on IGF-1 and Fitness Re...\n",
       "2361           Real-Life Pilot Feasibility Study (LC_RLP)\n",
       "2362    Interest of the Immunoscore® as a Post-operati...\n",
       "2363    Stress Management and Biological Age in Breast...\n",
       "2364    The Psychology Intervention on Disease Accepta...\n",
       "2365    A Multilevel Intervention to Improve Timely Ca...\n",
       "2366    An Intervention for Female Breast CANcer: Acce...\n",
       "2367    Selective TrkA Inhibitor VMD-928 to Treat TrkA...\n",
       "2368    Deep Learning Algorithms for Prediction of Lym...\n",
       "2369    Bintrafusp Alfa (M7824) in Subjects With Thymo...\n",
       "2370    Abatacept in Immune Checkpoint Inhibitor Myoca...\n",
       "2371    Biodistribution and Kinetics of 18F-AraG in No...\n",
       "2372    Quantifying Systemic Immunosuppression to Pers...\n",
       "2373               Pre-operative Therapy in Breast Cancer\n",
       "2374    A Study of Lazertinib as Consolidation Therapy...\n",
       "2375    Markers to Evaluate the Efficacy of PH-based R...\n",
       "2376    Sodium (23Na) MRI for Tumour Characterisation ...\n",
       "2377        Molecular Signature From Tumor to Lymph Nodes\n",
       "2378    Dose Escalation and Expansion Study of FLX475 ...\n",
       "2379    The Effectiveness of Lymphatic Bypass Supermic...\n",
       "2380    Study of Combined Decompressive Spine Radiosur...\n",
       "2381                                 Neoadjuvant Database\n",
       "2382    Chemotherapy or Chemotherapy Plus PD-1 Antibod...\n",
       "2383    Comparison of Breast Cancer Screening With CES...\n",
       "2384    A Study of Atezolizumab Versus Placebo as Adju...\n",
       "2385    Prophylactic Irradiation to the Contralateral ...\n",
       "2386    Window of Opportunity Study of IPI-549 in Pati...\n",
       "2387    Evaluation of Prognostic Factors: From Breast ...\n",
       "2388    Patient Report Outcome-Reconstruction and Onco...\n",
       "2389    Comparison of Chemotherapy Before and After Su...\n",
       "2390    Clinical Study of Pabolizumab for Neoadjuvant ...\n",
       "2391    The Efficacy and Safety of Sintilimab Plus Anl...\n",
       "2392    Factors Affecting Rehabilitation Time for Post...\n",
       "2393    A Study of Radiation Therapy With Pembrolizuma...\n",
       "2394    Testing the Addition of an Individualized Vacc...\n",
       "2395    Neoadjuvant Pyrotinib Versus Placebo Combined ...\n",
       "2396    Multi-agent Low Dose Chemotherapy GAX-CI Follo...\n",
       "2397    Patients Derived Organoids as a Promising Tool...\n",
       "2398    Ultra-hypofractionated Radiotherapy in Breast ...\n",
       "2399    mULM to Support Breast Cancer Diagnosis and Th...\n",
       "2400    Effects of Cryotherapy on Taxane-Induced Neuro...\n",
       "2401    EUS-guided PORtal Vein Sampling for Circulatin...\n",
       "2402    Panitumumab-IRDye800 in Detecting Cancer in Pa...\n",
       "2403    Image-based AI Predictive Biomarkers for Preci...\n",
       "2404    Adebelizumab Combined With Chemotherapy and Ra...\n",
       "2405    AP-L1898 Capsule in Patients With Non-small Ce...\n",
       "2406    Safety and Efficacy of Repeat Administration o...\n",
       "2407    Testing the Addition of an Anti-Cancer Drug, T...\n",
       "2408    Non-Invasive Artificial Intelligence-Based Pla...\n",
       "2409    First-in-Human Study of ICT01 in Patients With...\n",
       "2410    A Phase I/II Study of Sacituzumab Govitecan Pl...\n",
       "2411    A Study to Learn About the Study Medicine (Cal...\n",
       "2412    Breast Cancer Proteomics and Molecular Heterog...\n",
       "2413    Pembrolizumab in Combination With Plinabulin a...\n",
       "2414    A Study to Develop Molecular Integrated Predic...\n",
       "2415                      PD-L1 Expression in Lung Cancer\n",
       "2416    Two Therapeutic Strategies in First-line in Pa...\n",
       "2417    Assessment of Hypoxia Before Radioembolization...\n",
       "2418    SYNERGY-AI: Artificial Intelligence Based Prec...\n",
       "2419    Collecting and Storing Tissue Samples From Wom...\n",
       "2420    Testing Less Intensive Radiation With Chemothe...\n",
       "2421    Feasibility Study of Multi-Platform Profiling ...\n",
       "2422    Neoadjuvant Dupilumab and Cemiplimab in Patien...\n",
       "2423    Study of Camrelizumab Plus Apatinib and Chemot...\n",
       "2424    Continued Access Study for Participants Derivi...\n",
       "2425    Radiation-induced Cardiac Toxicity After Non-s...\n",
       "2426    A Safety, Tolerability and Efficacy Study of N...\n",
       "2427    Hypnosis for Pain in Black Women With Advanced...\n",
       "2428    A Study of Metronomic CP and JX-594 in Patient...\n",
       "2429    Improving Response to Chemotherapy by Adding P...\n",
       "2430                    Cardiometabolic Screening Program\n",
       "2431    Finding the Cause for Post-Transplant Diabetes...\n",
       "2432    Olaparib With or Without Durvalumab for DDR Ge...\n",
       "2433    Safety and Effectiveness Evaluations of the CO...\n",
       "2434    A Phase II Study of the Safety, Tolerability a...\n",
       "2435    Prospective Study for the Prognostic and Predi...\n",
       "2436    Perioperative Versus Postoperative CapOX Chemo...\n",
       "2437    INCMGA00012 and Pelareorep for the Treatment o...\n",
       "2438    ACTengine® IMA203/IMA203CD8 as Monotherapy or ...\n",
       "2439    Estrogen Receptor (ER) PET/CT Imaging in Breas...\n",
       "2440    Vitamin D and Pre Cachexia and Cancer Cachexia...\n",
       "2441               Smart Bra for Diagnosing Breast Cancer\n",
       "2442    Artificial Intelligence-based Early Screening ...\n",
       "2443    A Pilot Tele-rehabilitation Trial for Breast C...\n",
       "2444    Correlation of FAZA PET Hypoxia Imaging To 3D ...\n",
       "2445    A Phase I Clinical Study of Recombinant Humani...\n",
       "2446    Pembrolizumab With Chemotherapy in Front Line ...\n",
       "2447    Phase I Study of the BBP-398 in Patients With ...\n",
       "2448    Remaxol® in Patients With Drug-induced Liver I...\n",
       "2449    Transvaginal Ultrasonography as a Screening Me...\n",
       "2450    IMGN853 With Carboplatin in Second-line Treatm...\n",
       "2451    Echo-endoscopy Biopsy Impact on the Circulatin...\n",
       "2452    Open-Label Study to Evaluate the Safety, Toler...\n",
       "2453    Study of ADXS-504 Immunotherapy for Recurrent ...\n",
       "2454    RecurIndex Guided Avoidance of Regional Nodal ...\n",
       "2455    A Novel Therapy for Breast Cancer Survivors Wi...\n",
       "2456    4FMFES-PET Imaging of ER+ Advanced Breast Cancers\n",
       "2457    CA-4948 Added to Standard Chemotherapy to Trea...\n",
       "2458            [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer\n",
       "2459    Nivolumab, Ipilimumab and OTSGC-A24 Therapeuti...\n",
       "2460    A Phase Ⅱ Study of Anlotinib Combined With Tis...\n",
       "2461    Clinical Impact and Utility of Digital Health ...\n",
       "2462     A Study of TAS3351 in NSCLC Patients With EGFRmt\n",
       "2463    GCC 1366: Anti-Proliferative Response to NeoAd...\n",
       "2464    Triple Negative Breast Cancer and Germline Her...\n",
       "2465    Tiragolumab With Atezolizumab Plus Bevacizumab...\n",
       "2466    Biomarkers of Angiogenesis for Response to The...\n",
       "2467    Impact of Non-magnetic Screen Respiratory Self...\n",
       "2468         AZD6738 & Gemcitabine as Combination Therapy\n",
       "2469    Phase I/II Trial in ES-SCLC to Enhance Respons...\n",
       "2470    Breast Cancer Risk From Sonographic Glandular ...\n",
       "2471    PD-1 Inhibitor and Anlotinib Combined With Mul...\n",
       "2472    Hypofractionated Irradiation At Regional Nodal...\n",
       "2473    Pain Treatment in a Breast Cancer Population. ...\n",
       "2474    Same Day Discharge for Video-Assisted Thoracos...\n",
       "2475    Personalized Escalation of Consolidation Treat...\n",
       "2476          RC48-ADC in HER2-low Advanced Breast Cancer\n",
       "2477    Phase I/II Study of Immunotherapy Combination ...\n",
       "2478    Pilot Study of Performance Status 2 vs. Perfor...\n",
       "2479    Enfortumab Vedotin for the Treatment of Patien...\n",
       "2480    A Study Evaluating the Safety, Pharmacokinetic...\n",
       "2481    Combining Radiation Therapy With Immunotherapy...\n",
       "2482    Remote Assessment of Cognition, Insulin Resist...\n",
       "2483    Assessing an Oral EGFR Inhibitor, DZD9008 in P...\n",
       "2484    A Study of MRG002 in Patients With HER2-Positi...\n",
       "2485    Personalized Neo-Antigen Peptide Vaccine for t...\n",
       "2486    Apatinib With CDK4/6 Inhibitor and Endocrine T...\n",
       "2487    Pro-Vegetarian Diets, Microbial/Metabolite Pro...\n",
       "2488    Ribociclib Real-world Treatment Patterns and C...\n",
       "2489    Increasing Access to Fertility Preservation fo...\n",
       "2490    A Study to Evaluate Neoadjuvant Sonidegib Foll...\n",
       "2491    Efficacy of Talazoparib in Asian Metastatic Br...\n",
       "2492                  Young Breast Cancer Survivors Study\n",
       "2493    Vaginal Dehydroepiandrosterone (DHEA) in Postm...\n",
       "2494    A Study for Optimization of 6% Hydroxyethyl St...\n",
       "2495    Treating Early-stage Non-Small Cell Lung Cance...\n",
       "2496    A Study of Tucatinib vs. Placebo in Combinatio...\n",
       "2497    Relative Bioavailability/Bioequivalence of Dif...\n",
       "2498                 PEER Trial: Part 2 Rice Technologies\n",
       "2499    A Study of DSP107 Alone and in Combination Wit...\n",
       "2500    Study of TNG260 and an Anti-PD Antibody in STK...\n",
       "2501    PAveMenT: Palbociclib and Avelumab in Metastat...\n",
       "2502    Fruquintinib Plus Camrelizumab and Capecitabin...\n",
       "2503    Radiation Dose Intensification With Accelerate...\n",
       "2504    Rintatolimod, Celecoxib and Interferon Alpha 2...\n",
       "2505    A Multicenter Prospective Phase II Study of Mo...\n",
       "2506    Neoadjuvant Chemoradiotherapy With Sequential ...\n",
       "2507    Uproleselan With Pre-Transplant Conditioning i...\n",
       "2508    Study to Compare the Safety of Immediate One-s...\n",
       "2509    Neoadjuvant Study of Targeting ROS1 in Combina...\n",
       "2510    Nutritional Psychological Intervention and Vom...\n",
       "2511    Diagnostic Efficacies of Sonazoid-CEUS and EOB...\n",
       "2512    A Safety, Pharmacokinetic and Efficacy Study o...\n",
       "2513    CEM to Reduce Biopsy Rates for Less Than Highl...\n",
       "2514    Solid Tumor Analysis for HLA Loss of Heterozyg...\n",
       "2515    Gut and Intratumoral Microbiome Effect on the ...\n",
       "2516    Next-Generation Sequencing-based Germline and ...\n",
       "2517    IMA402 T Cell-Engaging Receptor Molecule (TCER...\n",
       "2518    MONOCENTRIC PERSPECTIVE STUDY: USE OF LIQUID B...\n",
       "2519         CPAP for Esophageal Cancer With Radiotherapy\n",
       "2520    ICG Fluorescence Guided Lymph Node Mapping for...\n",
       "2521    A Phase IB/II Study of Alectinib Combined With...\n",
       "2522    A Phase Ib/II Study of SHR-A1811 Injection in ...\n",
       "2523    Specimen and Data Study for Ovarian Cancer Ear...\n",
       "2524    Improving Cognitive Function Through High-inte...\n",
       "2525    Study of HLX22 in Combanition With Trastuzumab...\n",
       "2526    CATCH: Implementation of Genomics-guided Preci...\n",
       "2527    Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] ...\n",
       "2528             GEN2 Directed Cancer Immunotherapy Trial\n",
       "2529    Neoadjuvant TCHP Versus THP in Patients With H...\n",
       "2530    BCG in Combination With Durvalumab in Adult BC...\n",
       "2531    Phase 1b Study of EZH1/2 Inhibitor Valemetosta...\n",
       "2532       Pneumonitis After Radiotherapy for Lung Cancer\n",
       "2533    Nivolumab and Ipilimumab With and Without Camu...\n",
       "2534    Pilot Study of a MIND Diet Intervention in Wom...\n",
       "2535                 Intravesical BCG vs GEMDOCE in NMIBC\n",
       "2536    A Single-Arm, Open, Exploratory Clinical Study...\n",
       "2537    Role of IMP3 Expression in Colorectal Carcinom...\n",
       "2538    Effect of Lidocaine Transdermal Patch as Add-O...\n",
       "2539             Pancreas Registry and High Risk Registry\n",
       "2540    Post-resection/Ablation Chemotherapy in Patien...\n",
       "2541                      CTNNA1 Familial Expansion Study\n",
       "2542    A Physical Activity Program to Improve Quality...\n",
       "2543    Inetetamab in Combination With Pyrotinib in HE...\n",
       "2544    Durvalumab(MEDI4736) After chemoRadioTherapy(D...\n",
       "2545    Targeted Therapy Directed by Genetic Testing i...\n",
       "2546    Correlation of Clinical Response to Pathologic...\n",
       "2547    Lactobacillus Vaginalis Capsules for Treatment...\n",
       "2548    Interest of PET-MRI in the Evaluation of the R...\n",
       "2549    Local Consolidative Therapy and Durvalumab for...\n",
       "2550    Alpelisib (BYL719) in Combination With Continu...\n",
       "2551    Binimetinib in Patients With BRAF Fusion-posit...\n",
       "2552    Design and Evaluation of the Effects of a Phys...\n",
       "2553                          Taking AIM at Breast Cancer\n",
       "2554    Sequential Chemo-immunotherapy Plus Thoracic R...\n",
       "2555    To Evaluate Efficacy and Safety of Serplulimab...\n",
       "2556    LASER and Radiofrequency for Treatment of Vagi...\n",
       "2557    Adjuvant Therapy of Ensartinib in Stage IB-III...\n",
       "2558    Alternative Dosing Of Niraparib To Decrease Do...\n",
       "2559    A Multicenter, Open and Observational Real Wor...\n",
       "2560     Vaccination With Flt3L, Radiation, and Poly-ICLC\n",
       "2561    Phase II Protocol of Proton Therapy for Partia...\n",
       "2562    Cyclophosphamide and Sirolimus for the Treatme...\n",
       "2563    CDK 4/6 Inhibitor, Ribociclib, With Adjuvant E...\n",
       "2564    Tucidinostat Combined With Metronomic Capecita...\n",
       "2565    Adherence to Lung Cancer Screening by Low-dose...\n",
       "2566    A Phase II Study of Neoadjuvant Sotorasib in C...\n",
       "2567    A Study to Determine Whether Chemotherapy and ...\n",
       "2568    TACTIVE-U: A Study to Learn About the Study Me...\n",
       "2569    First-in-human Trial of PhOx430, a First-in-cl...\n",
       "2570        A Digital Solution for Breast Cancer Patients\n",
       "2571    The Gut Microbiome and Immune Checkpoint Inhib...\n",
       "2572    Tailored Axillary Surgery With or Without Axil...\n",
       "2573    Tablet-based Mobile Health Ultrasound for Poin...\n",
       "2574    Standard Surveillance vs. Intensive Surveillan...\n",
       "2575    Inetetamab Plus Cyclophosphamide Metronomic Ch...\n",
       "2576    Intraoperative Radiation Therapy in Treating P...\n",
       "2577    Effectiveness of AI Genetic Counseling Program...\n",
       "2578    A Study of Tooth Erosion in People With Esopha...\n",
       "2579    Trial of BDC-1001 +/- Pertuzumab in Subjects W...\n",
       "2580    Organoid Model Predictive of Response to Immun...\n",
       "2581    Trial to Evaluate Safety and Tolerability of G...\n",
       "2582    Neoadjuvant/Adjuvant Pembrolizumab Plus Chemot...\n",
       "2583    Effect of Surefire Infusion Device on Tumor Re...\n",
       "2584    Efficacy and Safety of Dronabinol in the Impro...\n",
       "2585    Tg01 Vaccine / Qs-21 Stimulon™ With Or Without...\n",
       "2586    Reducing Fear of Cancer Recurrence in Danish C...\n",
       "2587    Neo-adjuvant Pembrolizumab and Radiotherapy in...\n",
       "2588    Evaluation of PET Probe [68Ga]CBP8 in the Dete...\n",
       "2589    Efficacy of Lifestyle Intervention in BRCA1/2 ...\n",
       "2590    Breaking Through the Brain Fog: An Online Rese...\n",
       "2591        Improving Care After Inherited Cancer Testing\n",
       "2592    A Study Evaluating the Integrative Medicine at...\n",
       "2593    Open-Label Umbrella Study To Evaluate Safety A...\n",
       "2594    Neoadjuvant Chemotherapy With or Without Huaie...\n",
       "2595    High Dose Omeprazole in Patients With Pancreat...\n",
       "2596    Envafolimab as Neoadjuvant Immuntherapy in Res...\n",
       "2597    Study of Zotiraciclib for Recurrent High-Grade...\n",
       "2598    A Study of StrataXRT in the Prevention of Radi...\n",
       "2599    A Study of YL202 in Selected Patients With Adv...\n",
       "2600    Adjuvant Chemotherapy and Anti-PD-1 Antibody i...\n",
       "2601    A Study of Fluzoparib±Apatinib Versus Chemothe...\n",
       "2602    Telephone-Based Intervention in Increasing Adh...\n",
       "2603    Ascending Doses of Ceralasertib in Combination...\n",
       "2604    Induction Chemotherapy Combined With Immunothe...\n",
       "2605    Radiation, Immunotherapy and PARP Inhibitor in...\n",
       "2606    The PhOCus Trial: Implementation of Pharmacoge...\n",
       "2607    SKB264 +/- KL-A167 in Recurrent or Metastatic ...\n",
       "2608    TRADE: Dose Escalation Tolerability of Abemaci...\n",
       "2609    HER2 Expression of CTC to Predict Response in ...\n",
       "2610    Medical Imaging and Thermal Treatment for Brea...\n",
       "2611       Folfox+Irinotecan+Chemort In Esophageal Cancer\n",
       "2612    Circulating Tumor DNA to Monitor Response to N...\n",
       "2613    CCL21-Gene Modified Dendritic Cell Vaccine and...\n",
       "2614      Improving Comprehensive Care of Cancer Patients\n",
       "2615    Biomarkers for Early Detection of Ovarian Canc...\n",
       "2616    LYNPARZA Breast Cancer in the Adjuvant Setting...\n",
       "2617                     The Genomic Medicine at VA Study\n",
       "2618    Investigation of Ultrasound Imaging and Spectr...\n",
       "2619    ONC-392 and Pembrolizumab in Platinum Resistan...\n",
       "2620    Health-Related Quality of Life Coupled With Th...\n",
       "2621    The Thoracic Peri-Operative Integrative Surgic...\n",
       "2622    Genomics Guided Targeted Post-neoadjuvant Ther...\n",
       "2623    Study of Pembrolizumab (MK-3475) and Pembroliz...\n",
       "2624    IKS014 in Advanced Solid Tumors That Express HER2\n",
       "2625    AGuIX Gadolinium-based Nanoparticles in Combin...\n",
       "2626    Prognostic Evaluation of Changing Endocrine Th...\n",
       "2627    Acceptability and Feasibility of Combination T...\n",
       "2628    Durvalumab and Ablative Radiation in Small Cel...\n",
       "2629    CisPlatin plUs Gemcitabine and Nabpaclitaxel (...\n",
       "2630    Safety and Efficacy of Allogeneic HPV-specific...\n",
       "2631    Postoperative Opt-In Narcotics Treatment in Br...\n",
       "2632    Pecha Kucha Method Effects on Posttraumatic Gr...\n",
       "2633    Nivolumab for the Reversal of Squamous Dysplas...\n",
       "2634    CAB-AXL-ADC Safety and Efficacy Study in Adult...\n",
       "2635    Pyrotinib in Women With High-risk in Early Sta...\n",
       "2636    Immune Treatment of Brain Metastasis of Lung C...\n",
       "2637    Tucidinostat and Nab-paclitaxel in Advanced HR...\n",
       "2638    A Predictive Score for Arterial Thrombosis Ass...\n",
       "2639    COmbination of Radiotherapy With Anti-PD-1 Ant...\n",
       "2640    Targeting Triple Negative BREAst Cancer Metabo...\n",
       "2641    Praegnant Breast Cancer: Early/Advanced/Metast...\n",
       "2642    Palbociclib, Trastuzumab,Pyrotinib and Fulvest...\n",
       "2643    A Study Evaluating the Efficacy and Safety of ...\n",
       "2644    Photoacoustic Imaging for Characterizing Breas...\n",
       "2645    Acupuncture for Oxaliplatin-induced Peripheral...\n",
       "2646    Treatment of Frailty With Fisetin (TROFFi) in ...\n",
       "2647    A Study of ARV-471 (PF-07850327) Plus Palbocic...\n",
       "2648    Letrozole as Maintenance Therapy for Post-surg...\n",
       "2649    Proton Versus Photon Therapy in Anal Squamous ...\n",
       "2650    Early Detection of Breast Cancer in Women With...\n",
       "2651    Cemiplimab in High Risk or Locally Advanced Ho...\n",
       "2652    ZEN003694 Combined With Niraparib in Patients ...\n",
       "2653    Contrast-Free Magnetic Resonance Imaging for B...\n",
       "2654    A Study of agenT-797 in Combination With Boten...\n",
       "2655    Osimertinib for Advanced EGFR-positive NSCLC P...\n",
       "2656    Effects of MK-3475 (Pembrolizumab) on the Brea...\n",
       "2657    Determinants of Resistance to Endocrine Therap...\n",
       "2658    NEOadjuvant Chemotherapy Only Compared With St...\n",
       "2659    Radiation Therapy to Relieve Symptoms in Patie...\n",
       "2660    The Effect of Laughter and Mindfulness Therapy...\n",
       "2661    An Investigational Scan (64Cu-Labeled M5A Anti...\n",
       "2662                    Lurbinectedin in FET-Fused Tumors\n",
       "2663    The Role of Lipofilling After Oncoplastic Brea...\n",
       "2664    Study of SBRT/Olaparib Followed by Pembrolizum...\n",
       "2665              Lymphadenectomy in Early Ovarian Cancer\n",
       "2666    Johns Hopkins Breast Cancer Program Longitudin...\n",
       "2667    \"QUAD SHOT\" Radiotherapy With Pembrolizumab in...\n",
       "2668    99mTc-MIRC213 SPECT/CT for the Detection of HE...\n",
       "2669    Improving Communication and Adherence in Black...\n",
       "2670    Fluorescent Probe VGT-309 to ID Cancerous Colo...\n",
       "2671    Interest of Virtual Reality on Anxiety Before ...\n",
       "2672    Sacituzumab Govitecan Before Radical Cystectom...\n",
       "2673    A Clinical Trial to Compare Efficacy and Toler...\n",
       "2674    Assessment of Swallowing Function and Quality ...\n",
       "2675    Intraoperative Use of ClearEdge Device in Brea...\n",
       "2676    Resistance vs. Aerobic Training on Breast Canc...\n",
       "2677    MRI-guided Lateral Lymph Node Dissection in Re...\n",
       "2678    Study of MT-6402 in Subjects With Advanced Sol...\n",
       "2679                         Plan of the Day Radiotherapy\n",
       "2680    Dalpiciclib in Combination With Exemestane and...\n",
       "2681    ENdoluminal LIGHT ActivatED Treatment of Upper...\n",
       "2682    Measuring the Effects of Talazoparib in Patien...\n",
       "2683    Genetic Characteristics of Metastatic Breast C...\n",
       "2684    Comparing Level 1 Compression Sleeves With Rou...\n",
       "2685    A Phase Ⅲ Study of the Efficacy and Safety of ...\n",
       "2686    Faith in Action! A Church-Based Navigation Mod...\n",
       "2687    Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Ta...\n",
       "2688    The Efficacy of Neoadjuvant Chemoradiotherapy ...\n",
       "2689    Identification of New Prognostic Markers for B...\n",
       "2690    Predicting Tumor Metastasis by Employing a Tar...\n",
       "2691    Endocrine Response in Women With Invasive Lobu...\n",
       "2692    Stereotactic Radiation & Abemaciclib in the Ma...\n",
       "2693    Clinical Trial of All-trans-retinoic Acid, Bev...\n",
       "2694    Multidisciplinary Care Pathway With Electronic...\n",
       "2695    Exercises Using Virtual Reality on Cancer Pati...\n",
       "2696    Searching for Masses and Calcifications at the...\n",
       "2697    Phase 1 Trial of SYNC-T - Immunotherapy for Pa...\n",
       "2698    Mecapegfilgrastim for the Prevention of Dalpic...\n",
       "2699    Study of αPD1-MSLN-CAR T Cells to Evaluate the...\n",
       "2700    Radiation Therapy Boost Before Surgery for the...\n",
       "2701    IACS-6274 With or Without Bevacizumab and Pacl...\n",
       "2702    Neoadjuvant Atezolizumab-Based Combination The...\n",
       "2703    Talazoparib Monotherapy in PALB2 Mutation Asso...\n",
       "2704    FS-1502 Versus T-DM1 for HER2-Positive Unresec...\n",
       "2705    Assessing the Effect of DZD9008 on the Pharmac...\n",
       "2706    A Study to Evaluate the Safety and Efficacy of...\n",
       "2707    Diversity and Inclusion in Research Underpinni...\n",
       "2708    A Phase 1/2 Trial of ARV-471 Alone and in Comb...\n",
       "2709    ZN-c3 in Adult Participants With Metastatic Co...\n",
       "2710    A Study of Navicixizumab Monotherapy or in Com...\n",
       "2711    Feasibility of Gallium-68-tilmanocept PET/CT f...\n",
       "2712    Study to Evaluate the Interest of Qutenza in P...\n",
       "2713              Screening Contrast-enhanced Mammography\n",
       "2714    Efficacy and Safety of rhTPO's Prophylactic Tr...\n",
       "2715    NIF-Guided RAMIE Using ICG Versus OTE Feasibil...\n",
       "2716    A Phase I/II Study of Combination Immunotherap...\n",
       "2717    Timing of Start of systemIc Treatment for Asym...\n",
       "2718    Generation of Heart Muscle Cells From Blood or...\n",
       "2719                              COLLISION RELAPSE Trial\n",
       "2720    Validation of a Model for Predicting Anastomot...\n",
       "2721    Novel Lung Imaging in Adults Undergoing Radiat...\n",
       "2722    Comparing Sequential Neoadjuvant Treatment Inc...\n",
       "2723    An Adjuvant Endocrine-based Therapy Study of C...\n",
       "2724    Postoperative Chemotherapy With/Without Radiot...\n",
       "2725    Genetic Analysis-Guided Irinotecan Hydrochlori...\n",
       "2726    Modern Immunotherapy in BCG-Unresponsive, BCG-...\n",
       "2727    National Cancer Institute \"Cancer Moonshot Bio...\n",
       "2728    Combining Anti-PD-L1 Immune Checkpoint Inhibit...\n",
       "2729    Safety of OGT-assisted Overlap Esophagojejunos...\n",
       "2730    Chemoradiotherapy Combined With or Without PD-...\n",
       "2731    Monitoring of Immunological Mechanisms and Bio...\n",
       "2732    HYPofractionated Adjuvant RadioTherapy in 1 Ve...\n",
       "2733    Adjuvant Trastuzumab Deruxtecan (Enhertu) & Ni...\n",
       "2734    A Study of NI-1801 in Patients With Mesothelin...\n",
       "2735    Clinical Information and Biospecimen Collectio...\n",
       "2736    Evolution of the Therapeutic Care in Metastati...\n",
       "2737    A Study of 1 8F-FDHT PET/MRIScans in Women Wit...\n",
       "2738     CLI and FAR for Intraoperative Margin Assessment\n",
       "2739    SIBYL: obServation of Therapy Response With lI...\n",
       "2740    Avecure Flexible Microwave Ablation Probe For ...\n",
       "2741    Inhibition of CArbonic Anhydrase in Combinatio...\n",
       "2742    Development of Patient Derived Xenografts (PDX...\n",
       "2743    ProActIF-01 Trial: Randomized Study of Evaluat...\n",
       "2744    Autologous CD8+ and CD4+ Transgenic T Cells Ex...\n",
       "2745    ORACLE: Observation of ResiduAl Cancer With Li...\n",
       "2746             Couples' QOL in Metastatic Breast Cancer\n",
       "2747    Assessing a Regorafenib-irinotecan Combination...\n",
       "2748    Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Me...\n",
       "2749    Care of the Prostate Cancer Patient and Prospe...\n",
       "2750     Window of Opportunity Study in Colorectal Cancer\n",
       "2751    Concomitant Immune Check Point Inhibitor With ...\n",
       "2752    Carbon-Fibre Accessory (CARA) for Supine Breas...\n",
       "2753    Pharmacokinetics and Safety of Epidiferphane a...\n",
       "2754    Watch and Wait in PD-1 Monoclonal Antibody Tre...\n",
       "2755    Sacituzumab Govitecan +/- Pembrolizumab In HR+...\n",
       "2756    Serum Estradiol (E2) Levels in Breast Cancer P...\n",
       "2757                          Database of Data Collection\n",
       "2758    Phase II Study Comparing Conversion Rate to Su...\n",
       "2759    Safety and Efficacy of RD133 in Subjects With ...\n",
       "2760    Stereotactic Body Radiotherapy in Patients Wit...\n",
       "2761    Testing the Addition of a Type of Drug Called ...\n",
       "2762                 A Beta-only IL-2 ImmunoTherapY Study\n",
       "2763    Study of CYH33 in Combination With Olaparib an...\n",
       "2764    GPC3 Targeted CAR-T Cell Therapy in Advanced G...\n",
       "2765    Transoral Surgical Resection Followed by De-es...\n",
       "2766    Identification and Evaluation of Patients at R...\n",
       "2767     Pembrolizumab + Idelalisib for Lung Cancer Study\n",
       "2768    Tumoral Bone Strength Assessment by Numerical ...\n",
       "2769    Trilaciclib vs Placebo in Patients With Extens...\n",
       "2770    Radiotherapy Combined With Immunochemotherapy ...\n",
       "2771    Immune Response Evaluation in Oligorecurrent a...\n",
       "2772    PaTcH Study: A Phase 2 Study of Trametinib and...\n",
       "2773    Positron Emission Tomography (PET) Imaging Wit...\n",
       "2774    Negative ER Expression Assessed by 18F-FES PET...\n",
       "2775    HER3-DXd in Breast Cancer and NSCLC Brain Meta...\n",
       "2776    Randomized Trial Comparing Standard of Care Ve...\n",
       "2777    Clinical Trial of a Novel Small Molecule EBNA1...\n",
       "2778    The Choice of Treatment Methods and Efficacy o...\n",
       "2779    Study of Combined VisioCyt Test and FGFR3 Muta...\n",
       "2780    DISCO: A Patient Intervention to Reduce the Fi...\n",
       "2781    Safety and Efficacy of CEA-Targeted CAR-T Ther...\n",
       "2782    Clinical Trial of Lurbinectedin as Single-agen...\n",
       "2783    A Study to Evaluate ELU001 in Patients With So...\n",
       "2784    Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas\n",
       "2785    BI-1910 as a Single Agent and in Combination W...\n",
       "2786          Omission of SLNB in cN0 Early Breast Cancer\n",
       "2787    Evaluation of the Implementation of Personalis...\n",
       "2788    Single-dose Preoperative Partial Breast Irradi...\n",
       "2789    Alpha-TEA and Trastuzumab for the Treatment of...\n",
       "2790    A Study of Dato-DXd Versus Investigator's Choi...\n",
       "2791    Bipolar RFA of Painful Extra-spinal Bone Metas...\n",
       "2792    Quantifying Radiation-Induced Skin Reactions: ...\n",
       "2793    ADP-A2M4CD8 as Monotherapy or in Combination W...\n",
       "2794    Brass Mesh Bolus in Rotational Post-Mastectomy...\n",
       "2795                  Metastatic Breast Cancer in Austria\n",
       "2796    Treatment of Triple-negative Breast Cancer Wit...\n",
       "2797    Trial of Ado-Trastuzumab Emtansine for Patient...\n",
       "2798    A Study to Evaluate the Safety and Dosimetry o...\n",
       "2799    CMP-001 and Pre-operative Stereotactic Body Ra...\n",
       "2800    Trastuzumab Deruxtecan in First-line HER2-posi...\n",
       "2801    Pyrotinib Combined With Trastuzumab,Dalpicicli...\n",
       "2802    Platinum Rechallenge in Patients With Platinum...\n",
       "2803    NAPOLI-2: Fluorouracil, Leucovorin, and Nanoli...\n",
       "2804    Neoadjuvant FOLFOX Chemotherapy for Patients W...\n",
       "2805    The PREDICT Study: Prospective Early Detection...\n",
       "2806    Evaluating the Clinical Value of Traditional C...\n",
       "2807    A Study of OR502, a Monoclonal Antibody Target...\n",
       "2808    Pembrolizumab and Lenvatinib in Advanced Cervi...\n",
       "2809    IMM2520, a PD-L1 and CD47 Bispecific Antibody ...\n",
       "2810    Radiation and Durvalumab Immunotherapy As Neoa...\n",
       "2811    A Study of PARG Inhibitor IDE161 in Participan...\n",
       "2812    A Study of RGX-202-01 (Ompenaclid) as Combinat...\n",
       "2813    Trastuzumab Deruxtecan (T-DXd) in Patients Who...\n",
       "2814    The Safety and Efficacy of Specific TIL-TCM Ce...\n",
       "2815    Dose-escalated Adaptive Radiotherapy of Thorac...\n",
       "2816             18F-FDG PET/CT Imaging for Breast Cancer\n",
       "2817    Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/...\n",
       "2818    PD-L2 Targeting Nanobody Radiotracer for PET I...\n",
       "2819    Ketoconazole Before Surgery in Treating Patien...\n",
       "2820    A Prospective, Phase II Trial Using ctDNA to I...\n",
       "2821    A Study of Lenvatinib, Pembrolizumab, and Fulv...\n",
       "2822    First in Human Study of IMGN151 in Recurrent E...\n",
       "2823    This is a Multicenter, Randomized, Double-blin...\n",
       "2824    A Study of Fedratinib With IDH Inhibition in A...\n",
       "2825    Development and Validation of a Novel Function...\n",
       "2826    A Window of Opportunity Study of Pre-operative...\n",
       "2827    Risk of Infertility Related to Adjuvant Chemot...\n",
       "2828          Mind Programme for Women With Breast Cancer\n",
       "2829    Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological...\n",
       "2830    Trastuzumab Deruxtecan (T-DXd): Tailoring Trea...\n",
       "2831    MammaPrint Value for Pre-menopausal Breast Can...\n",
       "2832    A Trial of Early Detection of Molecular Relaps...\n",
       "2833    The Effect of Acupuncture on Cancer-Related Co...\n",
       "2834    A Study of Enzalutamide, Enzalutamide in Combi...\n",
       "2835    Pilot Study to Evaluate if Contrast Enhanced U...\n",
       "2836    Functional Evaluation After Breast Reconstruct...\n",
       "2837    Efficacy and Safety of SPH4336 in Combination ...\n",
       "2838    Modulation of the Gut Microbiome With Pembroli...\n",
       "2839    Immunomonitoring of Breast Cancer Patients Dur...\n",
       "2840    CTCs in Breast Cancer After Neoadjuvant Treatm...\n",
       "2841    Testing the Addition of M3814 (Peposertib) to ...\n",
       "2842    Liver Transplantation for Non-resectable Perih...\n",
       "2843    Dendritic Cell Vaccines Against Her2/Her3 and ...\n",
       "2844    Study of Larotinib in Unresectable Advanced or...\n",
       "2845    Study Of Real-World Evidence In Patients Treat...\n",
       "2846    Local Treatment in ER-positive/HER2-negative O...\n",
       "2847                      Hypnosis: a Path to Appeasement\n",
       "2848    Split Course Adaptive Radiation Therapy With P...\n",
       "2849    A Phase 1/2a Study of IMM-1-104 in Participant...\n",
       "2850    Interest of Circulating Tumor DNA in Digestive...\n",
       "2851    Determination of Microbiological Factors Assoc...\n",
       "2852    Breathe Easier II: A Dyad-based Multiple Behav...\n",
       "2853    Role of the Immune Environment in Response to ...\n",
       "2854    A Study to Evaluate the Efficacy and Safety of...\n",
       "2855    Preoperative Radiotherapy And ASTX660 in Rectu...\n",
       "2856    A Biomarker Screening Protocol for Participant...\n",
       "2857    Dalpiciclib Combination With Fulvestrant and C...\n",
       "2858    Trial Evaluating the Tailored Versus the Syste...\n",
       "2859                          Dual-Tracer Theranostic PET\n",
       "2860              Refining Local-Regional Therapy for IBC\n",
       "2861    Fibroblast Activation Protein Inhibitor PET/CT...\n",
       "2862    Phase 1 Trial of LVGN7409 (CD40 Agonist Antibo...\n",
       "2863    Intraoperative Electron Radiotherapy in Rectal...\n",
       "2864    A Study to Reduce Persistent Post-mastectomy P...\n",
       "2865    MRI-based Approaches for Multi-parametric Mode...\n",
       "2866    First Line Weekly Chemo/Immunotherapy for Meta...\n",
       "2867    An Early Stage Study to Evaluate Oba01 for Inj...\n",
       "2868    Abemaciclib in Combination With Bicalutamide f...\n",
       "2869    A Study of Vericiguat in People With Breast Ca...\n",
       "2870                 Image Guided VATS vs. VATS Resection\n",
       "2871    Immunotherapy Combination: Irradiated PD-L1 CA...\n",
       "2872    Preoperative Radiotherapy and Systemic Therapy...\n",
       "2873    A Study of Icotinib With Chemotherapy as Neoad...\n",
       "2874    Tislelizumab Consolidation Therapy After Radio...\n",
       "2875    Osimertinib Alone or With Chemotherapy for EGF...\n",
       "2876    A Randomized Pilot Study of Evolocumab Plus Ni...\n",
       "2877    Proteomic Guided First-line Precision Treatmen...\n",
       "2878    Prospective Evaluation of High Resolution Dual...\n",
       "2879    A French Observational Study of Indocyanine Gr...\n",
       "2880    Nivolumab Plus Ramucirumab in Patients With Re...\n",
       "2881    A Study of Cemiplimab With Chemotherapy and Im...\n",
       "2882    Clinical Trial of Alpelisb and Tucatinib in Pa...\n",
       "2883    Prognostic Indicators for Radiation-induced Br...\n",
       "2884    Use of the CA 125 Algorithm for the Early Dete...\n",
       "2885    RAD 1802: Pilot Trial of Five Fraction Stereot...\n",
       "2886    A Trial Exploring the Opportune Administration...\n",
       "2887    Optimization of Preoperative Treatment in Loca...\n",
       "2888    A Phase I/II Study With BM7PE Immunotoxin in C...\n",
       "2889    The Efficacy and Safety of Pyrotinib, Trastuzu...\n",
       "2890    Precise Therapy for Refractory HER2 Positive A...\n",
       "2891    A Study Evaluating Different Immunotherapies (...\n",
       "2892    Study of Oral MRT-2359 in Selected Cancer Pati...\n",
       "2893    Phase 1/2 Study to Evaluate EP0062 in Patients...\n",
       "2894    Immunotherapy With IFx-Hu2.0 Vaccine for Advan...\n",
       "2895    Vagus Nerve Preservation and Chronic Cough in ...\n",
       "2896    A First-In-Human Trial of pTTL in Advanced Col...\n",
       "2897    A Study of hSTC810 in Combination With Paclita...\n",
       "2898    Effect of Whey Protein Supplementation on Post...\n",
       "2899    Predictive Clinical and Biological Parameters ...\n",
       "2900    mHealth for Breast Cancer Survivors With Insomnia\n",
       "2901    99mTc-MY6349 SPECT/CT Imaging in Trop2-positiv...\n",
       "2902    TAD After Chemotherapy in Locally Advanced Bre...\n",
       "2903    Artificial Intelligence Supporting CAncer Pati...\n",
       "2904    Impact of Cognitive Behavioural Therapy for In...\n",
       "2905    A Single-arm Clinical Trial of IMGN853 in Chin...\n",
       "2906    64Cu-GRIP B in Patients With Advanced Malignan...\n",
       "2907          A Study of SGN-B6A in Advanced Solid Tumors\n",
       "2908    Testing the Addition of an Anti-Cancer Drug, Z...\n",
       "2909    Study Evaluating the Safety and the Efficacy o...\n",
       "2910    Study of Preservation of Ovarian Reserve Durin...\n",
       "2911    A Study to Evaluate the Efficacy and Safety of...\n",
       "2912    The Use of Shengmai San to Prevent Anthracycli...\n",
       "2913    Phase 1a and Phase 2 Study for Safety, Prelimi...\n",
       "2914    EUropean Real-world Experience Of Previously T...\n",
       "2915    Neoadjuvant Immunotherapy and Chemotherapy for...\n",
       "2916    Tumor Treating Fields for the Treatment of Lep...\n",
       "2917    NUV-868 as Monotherapy and in Combination With...\n",
       "2918    A Study of BMS-986012 in Combination With Carb...\n",
       "2919    Isa-Rd for Frail and/or Much Older Patients Wi...\n",
       "2920    COLLISION XL: Unresectable Colorectal Liver Me...\n",
       "2921    Study of JS004 Combined With Toripalimab for A...\n",
       "2922    An Online Psychosocial Intervention for Fear o...\n",
       "2923    Dexmedetomidine-esketamine Combined Nasal Admi...\n",
       "2924    NeoOPTIMIZE: Early Switching of mFOLFIRINOX or...\n",
       "2925    Clinical Study of HRS-8080 in Combination With...\n",
       "2926    A Prospective, Multi-Centre Trial of TKI Redif...\n",
       "2927    Efficacy and Safety of Fluzoparib Combined Wit...\n",
       "2928    Toripalimab With Paclitaxel and Cisplatin as N...\n",
       "2929    Phase II Trial of Anti-HER2 Treatment in HER2-...\n",
       "2930    Study of AZD9833 Alone or in Combination in Wo...\n",
       "2931    Pembrolizumab and Carboplatin in Treating Pati...\n",
       "2932    Clinical Study of CD70-targeted CAR-T Therapy ...\n",
       "2933    NOSTRA-Feasibility Study: A Study Looking at U...\n",
       "2934    TILs for Treatment of Metastatic or Recurrent ...\n",
       "2935    Subcutaneous Atezolizumab for the Treatment of...\n",
       "2936    A Study to Evaluate Efficacy and Safety of Gir...\n",
       "2937    Biomarkers and Clinical Features of Metastatic...\n",
       "2938    Induction of Cisplatin/Nab-paclitaxel/Pembroli...\n",
       "2939    A Study of Avutometinib and Defactinib in Peop...\n",
       "2940            Application of Radiomics in Breast Cancer\n",
       "2941    Implantation of iodine125-Seeds Combined With ...\n",
       "2942    Monitoring of Chronic Conditions in Breast Cancer\n",
       "2943    A Phase 1/2 Study of BA3071 as Monotherapy and...\n",
       "2944    Micrima MARIA Data Collection for Machine Lear...\n",
       "2945    Two Chemotherapy Regimens Plus or Minus Bevaci...\n",
       "2946    Protection of Cardiovascular Function With Cro...\n",
       "2947    A Study of XMT-1660 in Participants With Solid...\n",
       "2948    Lu-PSMA for Oligometastatic Prostate Cancer Tr...\n",
       "2949    Functional Precision Oncology to Predict, Prev...\n",
       "2950    Statins for Reduction of Cardiac Toxicity in P...\n",
       "2951    New Model for Integrating Person-based Care (P...\n",
       "2952    Evaluating Modifiable Biomarkers for the Predi...\n",
       "2953    CEND-1 in Combination With Neoadjuvant FOLFIRI...\n",
       "2954    Monitoring HER2+ Breast Cancer Neoadjuvant Tre...\n",
       "2955    Project 1: Self-Triage by 2D Full-field Digita...\n",
       "2956      Breast Cancer Survivor Educational Intervention\n",
       "2957    A Trial of YL-13027 in Combination With Gemcit...\n",
       "2958    A Prospective Observational Study to Describe ...\n",
       "2959    The Immune Effects of Fermented Wheat Germ Nut...\n",
       "2960    Estradiol in Treating Patients With ER Beta Po...\n",
       "2961    Older Breast Cancer Patients: Risk for Cogniti...\n",
       "2962    Chemotherapy and Irreversible Electroporation ...\n",
       "2963    Investigating the Effects of Atezolizumab in P...\n",
       "2964    Durvalumab With Trastuzumab and Pertuzumab in ...\n",
       "2965           Sentinel Node Biopsy in Endometrial Cancer\n",
       "2966    Myofascial Massage for Pain and Immobility Fol...\n",
       "2967    Pancreatic Cancer Adaptive Neoadjuvant Chemoth...\n",
       "2968    Efficacy and Safety of Pembrolizumab (MK-3475)...\n",
       "2969    Evaluation of the Impact of a Multidimensional...\n",
       "2970    RC48 Combined With Tislelizumab for Second-lin...\n",
       "2971    A Clinical Research About CD70-targeted CAR-T ...\n",
       "2972           Robot-assisted Approach to Cervical Cancer\n",
       "2973    Organ Preservation in Locally Advanced Rectal ...\n",
       "2974    Identifying and Caring for Individuals With In...\n",
       "2975    Exercise and Tumor Blood Flow in Breast Cancer...\n",
       "2976    Phase I Trial: T4 Immunotherapy of Head and Ne...\n",
       "2977    A Study of Toripalimab Injection (JS001) + Cet...\n",
       "2978    Clinical Study of VG161 in Combination With Ni...\n",
       "2979    Continuous or Intermittent Extension of Adjuva...\n",
       "2980    Taletrectinib Phase 2 Global Study in ROS1 Pos...\n",
       "2981    A Study of Targeted Agents for Patients With R...\n",
       "2982    Intratumoral TriMix Injections in Early Breast...\n",
       "2983    Density Lowering Effect of \"OFS Add on to TMX\"...\n",
       "2984    A Study of TAK-500 With or Without Pembrolizum...\n",
       "2985                  Population-based Cancer Observatory\n",
       "2986    Evaluation of the Effectiveness and Implementa...\n",
       "2987    Determinants of Acquired Endocrine Resistance ...\n",
       "2988        Impact of a Patient Decision Aid Intervention\n",
       "2989    Temozolomide + Nivolumab in MGMT Methylated Oe...\n",
       "2990    Multi-Omics Study of the Effect and Mechanisms...\n",
       "2991    Neo-DIANA: Neoadjuvant Treatment for EGFR Muta...\n",
       "2992    Study of Prediction of Ovarian Reserve in Yong...\n",
       "2993    Pembrolizumab and ADG106 in Advanced Solid Can...\n",
       "2994    Anlotinib Combined With Chemotherapy and Neoad...\n",
       "2995    Effect of Low Intensity Vibration (LIV) on Aro...\n",
       "2996    A Study to Investigate LYL797 in Adults With S...\n",
       "2997    Phase Ib / Regorafenib With Conventional Chemo...\n",
       "2998              Cardio-Oncology Rehabilitation Exercise\n",
       "2999    The Trial Comparing Dose-dense AC-T With TP as...\n",
       "3000    Venous Thromboembolism Prophylaxis After Gynec...\n",
       "3001    Real-time Intraoperative Breast Cancer Visuali...\n",
       "3002    First-in-Human Study of RGT-419B Alone and Wit...\n",
       "3003    NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment ...\n",
       "3004    Study Assessing QBS72S For Treating Brain Meta...\n",
       "3005    A Non-interventional Prospective Study of Earl...\n",
       "3006    A Study to Assess an ATX Inhibitor (IOA-289) i...\n",
       "3007    Sentinel Lymph Node Biopsy With Hybrid Techniq...\n",
       "3008    Quality of Life in Patients With Standard Exte...\n",
       "3009    A Study of Docetaxel for Injection (Albumin-bo...\n",
       "3010    Evaluation of Co-formulated Pembrolizumab/Quav...\n",
       "3011                        Lymphedema Surveillance Study\n",
       "3012    Multi-omics Sequencing in Neoadjuvant Immunoth...\n",
       "3013    Sintilimab Plus Hypofractionated Radiotherapy ...\n",
       "3014    Optimizing Psychological Treatment for Pain Af...\n",
       "3015    The Impact of Radiotherapy on Oligometastatic ...\n",
       "3016    EGFR/B7H3 CAR-T on Lung Cancer and Triple Nega...\n",
       "3017    A Dose Finding Phase 1 of Sarilumab Plus Capec...\n",
       "3018    A Study of Dato-DXd With or Without Durvalumab...\n",
       "3019          TIP in Patients Affected by Metastatic TNBC\n",
       "3020    An Exploratory Study of Atezolizumab and Bevac...\n",
       "3021    Response and Toxicity Prediction by Microbiome...\n",
       "3022           Phase 1 Study of AWT020 in Advanced Cancer\n",
       "3023    Fiber-rich Foods to Treat Obesity and Prevent ...\n",
       "3024    Per-Operative Radiotherapy by Papillon +TM in ...\n",
       "3025    A Study of Tucidinostat Combined With Tisleliz...\n",
       "3026    Efficacy and Safety of PVT-1 Treatment in Pati...\n",
       "3027    Clinico-biological Data Collection Study of Me...\n",
       "3028    An Open-label, Phase I/II Study of PLENA Regim...\n",
       "3029    Oxaloacetate for the Improvement of Cognitive ...\n",
       "3030    Feasibility and Safety of Hybrid Transvaginal ...\n",
       "3031    AC vs TC in Patients With HR-positive, HER2-ne...\n",
       "3032    COGNITION: Genomics-Guided Precision Oncology ...\n",
       "3033    Improving Cancer-related Fatigue, Sexual Dysfu...\n",
       "3034    The Breast Cancer Survivors and Partners Onlin...\n",
       "3035    Impact of Vitamin D Supplementation on the Rat...\n",
       "3036    A Phase 2 Open Label Study of BA3021 in Patien...\n",
       "3037    A Study of Giredestrant in Participants With G...\n",
       "3038    Ribociclib&Belinostat In Patients w Metastatic...\n",
       "3039    Ramucirumab Plus FOLFIRI Versus Ramucirumab Pl...\n",
       "3040    Niraparib With beVAcizumab After Complete cyto...\n",
       "3041    Cetuximab in Third Line for Mutant APC, TP53 a...\n",
       "3042    Clinical Pilot Study for Personalized Risk-bas...\n",
       "3043    Imaging and Blood-Based Biomarkers for the Eva...\n",
       "3044    Neoadjuvant Chemoradiation Therapy Combined Wi...\n",
       "3045    Biomarkers of Efficacy and Tolerability of Sac...\n",
       "3046    ProAgio in Previously Treated Advanced Pancrea...\n",
       "3047    Evaluation of Prognostic Monitoring for Women ...\n",
       "3048    Study of Safety and Efficacy of Brigatinib Plu...\n",
       "3049    Persistent Organic Pollutants and Breast Cance...\n",
       "3050    Evaluation of Changes in the Immunological Mic...\n",
       "3051    Toripalimab With or Without Celecoxib as Neoad...\n",
       "3052        Study to Evaluate CCS1477 in Advanced Tumours\n",
       "3053    Cadonilimab for PD-1/PD-L1 Blockade-refractory...\n",
       "3054    Implementation of the Families Accelerating Ca...\n",
       "3055    Testing the Timing of Pembrolizumab Alone or W...\n",
       "3056    A Phase II, Two-Arm Study of Everolimus and Le...\n",
       "3057    Topical or Oral Minoxidil for the Treatment of...\n",
       "3058    Real Time Molecular Analysis of Breast Cancer ...\n",
       "3059    Niraparib vs Niraparib Plus Bevacizumab in Pat...\n",
       "3060    Early Detection of Endometrial Cancer Using Pl...\n",
       "3061    Efficacy of Tamoxifen Versus Toremifene in CYP...\n",
       "3062    Immunological Variables Associated to ICI Toxi...\n",
       "3063    Comprehensive Analysis of Predictors of the Tr...\n",
       "3064    Hybrid-APC Margin Ablation to Prevent Post EMR...\n",
       "3065    Preliminary Evaluation of [68Ga]CBP8 in Health...\n",
       "3066    OH2 Oncolytic Viral Therapy Via Transcatheter ...\n",
       "3067    Evaluation of Tumour Growth and Oncological Tr...\n",
       "3068    The Effectiveness of Hemopatch® in the Reducti...\n",
       "3069    Radiotherapy for Locally Advanced Pancreatic C...\n",
       "3070                     Switch Maintenance in Pancreatic\n",
       "3071    Prediction of Surgical Resectability After FOL...\n",
       "3072    Prospective Randomized Study of Accelerated Ra...\n",
       "3073    Treatment Monitoring of Patients Receiving CDK...\n",
       "3074    Escitalopram to Placebo in Patients With Local...\n",
       "3075    ACT-MBC: A Study of Circulating Tumor Cells (C...\n",
       "3076    Phase Ib Trial of the KRASG12C Inhibitor Adagr...\n",
       "3077    Biennial CEM in Women With a Personal History ...\n",
       "3078    Experiment on the Use of Innovative Computer V...\n",
       "3079    Mid-point Transverse Process to Pleura Block f...\n",
       "3080    Phase I-II, FIH, TROP2 ADC, Advanced Unresecta...\n",
       "3081    Delayed Sentinel Lymph Node Biopsy in Ductal C...\n",
       "3082    Novel Imaging Technique to Assess Gynecologic ...\n",
       "3083    Modi-1 in Breast, Head and Neck, Ovarian, or R...\n",
       "3084    Stereotactic Adaptive Radiation Therapy of Bor...\n",
       "3085    A Study of Nanrilkefusp Alfa (SOT101) in Combi...\n",
       "3086    CompARE: Escalating Treatment of Intermediate ...\n",
       "3087    Interest of Broadband Spectroscopy Analysis by...\n",
       "3088           Confocal Laser Endomicroscopy VERification\n",
       "3089    Study of ORM-5029 in Subjects With HER2-Expres...\n",
       "3090    Gemcitabine and Celecoxib Combination Therapy ...\n",
       "3091    Retrospective Study of 2nd-line Therapies Afte...\n",
       "3092       CTS2190 Phase I /II Clinical Study in Patients\n",
       "3093       Rapid Autopsy and Procurement of Cancer Tissue\n",
       "3094    Induction Chemotherapy and Toripalimab Followe...\n",
       "3095    A Study of On-treatment ctDNA Changes in Chemo...\n",
       "3096    Cardiac Rehabilitation to Improve Breast Cance...\n",
       "3097    Safety Study of MELK Inhibitor to Treat Patien...\n",
       "3098    A Study to Evaluate the Safety and Effectivene...\n",
       "3099    UCLA Breast Cancer Survivor Health Promotion R...\n",
       "3100    A Clinical Investigation to Confirm the Abilit...\n",
       "3101              ctDNA Monitoring in Early Breast Cancer\n",
       "3102    An Observational Pilot Study to Test a Smartwa...\n",
       "3103    Northern Alberta Linac-MR Image-Guided Radioth...\n",
       "3104    Study of Carboplatin and Mirvetuximab Soravtan...\n",
       "3105    Prospective Research for Elderly (≥65 Years Ol...\n",
       "3106    Endometrial Cancer Patientes MMR Deficient Com...\n",
       "3107    Identification and Preservation of Arm Lymphatics\n",
       "3108    Intrathecal Chemotherapy Through Ommaya Reserv...\n",
       "3109       Mindfulness in Endometrial and Cervical Cancer\n",
       "3110              Talazoparib and Thoracic RT for ES-SCLC\n",
       "3111    Xenografts Development From Surgical Tumor Sam...\n",
       "3112    A Study of XZP-3287 in Combination With Fulves...\n",
       "3113    Chemotherapy and Maximal Tumor Debulking of Mu...\n",
       "3114    Clinical Study of the Efficacy and Safety of B...\n",
       "3115    Asian Multicenter Prospective Study in HER2 Po...\n",
       "3116                     RAPA-201 Therapy of Solid Tumors\n",
       "3117    Study of Sacituzumab Govitecan-hziy Versus Tre...\n",
       "3118    Awareness Scale Related To Physiotherapy After...\n",
       "3119    Safety and Efficacy of Combining APL-101 With ...\n",
       "3120    Pancreas Resection for Colorectal Metastasis: ...\n",
       "3121    Perioperative Disitamab Vedotin Plus Toripalim...\n",
       "3122    Study of Immunotherapy in Combination With Che...\n",
       "3123    BGB-43395 Alone or as Part of Combination Ther...\n",
       "3124    Osimertinib in Treating Patients With Stage II...\n",
       "3125    MOv19-BBz CAR T Cells in aFR Expressing Recurr...\n",
       "3126    Preoperative Irradiation for Stage I Breast Ca...\n",
       "3127    JoLT-Ca Sublobar Resection (SR) Versus Stereot...\n",
       "3128    Stereotactic Body Radiation Therapy for Breast...\n",
       "3129    Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody...\n",
       "3130    A Phase 1 Trial of ZN-A-1041 Enteric Capsules ...\n",
       "3131    Dose-Escalation Study of Cabozantinib in Combi...\n",
       "3132    Almonertinib Combined With Anlotinib as First-...\n",
       "3133    IMP4297 in Combination With Temozolomide in Pa...\n",
       "3134    Radioembolisation and Chemotherapy in Liver Me...\n",
       "3135    KN046 Plus Regorafenib or Apatinib in MSI-H Di...\n",
       "3136    Restoring Sensitivity To Immunotherapy In Adva...\n",
       "3137    HANSE - Holistic Implementation Study Assessin...\n",
       "3138    Prospective Study of Particle Radiotherapy for...\n",
       "3139    Chemotherapy Monitoring by ctDNA in HER2- Meta...\n",
       "3140    Nature Sounds as a Pain and Anxiety Reducing S...\n",
       "3141    Thoracic Paravertebral Block Anesthesia for Br...\n",
       "3142    Testing the Addition of Radiotherapy to the Us...\n",
       "3143    Pilot Trial to Assess 68Ga Bombesin PET/CT (Ne...\n",
       "3144    The ONE-MIND Study: Evaluating the Efficacy of...\n",
       "3145    A Study of MRG002 in the Treatment of Patients...\n",
       "3146    Hyperthermic Intraperitoneal Chemotherapy for ...\n",
       "3147    A Phase II Stydy of Bevacizumab Plus Erlotinib...\n",
       "3148    A Phase III Study Comparing Total and Partial ...\n",
       "3149    Proglumide and Chemotherapy for Metastatic Pan...\n",
       "3150    A Study of HC-5404-FU to Establish the Maximum...\n",
       "3151    Pectoralis Nerve Block and Quality of Recovery...\n",
       "3152    Measuring Oncological Value of Exercise and St...\n",
       "3153    The Study of Vidicizumab Combined With Tireliz...\n",
       "3154    Triplex Checkpoint Inhibitors Therapy for Adva...\n",
       "3155    Effect of the Laparoscopic Approach in Reducin...\n",
       "3156    Secondary BRain Metastases Prevention After Is...\n",
       "3157    Niraparib in Combination With Osimertinib in E...\n",
       "3158     FUSCC Refractory TNBC Platform Study (FUTURE2.0)\n",
       "3159    Chemotherapy and Pelvic Hypofractionated Radia...\n",
       "3160    Almonertinib as First-line Treatment in Patien...\n",
       "3161    TINzaparin Prophylaxis in Patients With Metast...\n",
       "3162    AI for Head Neck Cancer Treated With Adaptive ...\n",
       "3163    A Study of NKT2152, a HIF2α Inhibitor, in Pati...\n",
       "3164    A Phase I Dose Escalation Study of Single Frac...\n",
       "3165    Regorafenib Combined With Fulvestrant in Recur...\n",
       "3166    Engineered TILs/CAR-TILs to Treat Advanced Sol...\n",
       "3167          All-in-One Prostate Cancer Staging With MRI\n",
       "3168    Ablative Radiotherapy to Restrain Every Metast...\n",
       "3169    Optimizing Postoperative Recovery After Breast...\n",
       "3170    Trial Evaluating Role of Post Mastectomy Radio...\n",
       "3171    Onco-primary Care Networking to Support TEAM-b...\n",
       "3172    Neoadjuvant FOLFIRINOX in the Treatment of Loc...\n",
       "3173    X-ray Psoralen Activated Cancer Therapy in Hea...\n",
       "3174    Breast Cancer: Axillary Conservation After Neo...\n",
       "3175       SCION: SABR and Checkpoint Inhibition Of NSCLC\n",
       "3176    Study of NEO-201 in Solid Tumors Expansion Coh...\n",
       "3177    Cryoablation Combined With Sintilimab Plus Len...\n",
       "3178    Role of PRoactivE Coaching on PAtient REported...\n",
       "3179    Evaluation and Modeling of the Effect of G-CSF...\n",
       "3180    Sotorasib in Previously Treated Locally Advanc...\n",
       "3181    OFS in Premenopausal Node+ Breast Cancer With ...\n",
       "3182            Pembrolizumab in Early Stage Colon Cancer\n",
       "3183    Hypofractionated Radiation Therapy for Patient...\n",
       "3184    The Benefits of Continued Use of Ovarian Funct...\n",
       "3185    KN026 in Combination With Chemotherapy in HER2...\n",
       "3186    Study to Evaluate the Safety, PK, and Efficacy...\n",
       "3187    Understanding the Post-Surgical Non-Small Cell...\n",
       "3188    The LYMPH Trial - Surgical Versus Conservative...\n",
       "3189       Exercise Preconditioning With Cancer Surgeries\n",
       "3190    Topical Afimoxifene in Treating Patients With ...\n",
       "3191    A Study of BDTX-4933 in Patients With KRAS, BR...\n",
       "3192    Study to Assess Adverse Events and Change in D...\n",
       "3193    Establishment and Clinical Application of Prec...\n",
       "3194    Biomarkers to Detect Endocrine Therapy Resistance\n",
       "3195    Assessment of Early Radiation Oncology Involve...\n",
       "3196    A Randomised Trial of Chemotherapy Plus Surger...\n",
       "3197           Ladarixin With Sotorasib in Advanced NSCLC\n",
       "3198    Sentinel Lymph Node After Neoadjuvant Chemothe...\n",
       "3199    A Study of Atezolizumab in High PD-L1 Expressi...\n",
       "3200    Ramucirumab and Pembrolizumab vs Pembrolizumab...\n",
       "3201    Axillary Lymph Node Treatment Guided by Naocar...\n",
       "3202    Study of a Shortened Radiation Therapy Schedul...\n",
       "3203    Evaluation of PET Probe [64]Cu-Macrin in Cardi...\n",
       "3204    Exploring a Breast Cancer Early Screening Mode...\n",
       "3205                      Ruxolitinib for Cancer Cachexia\n",
       "3206            Saltikva for Metastatic Pancreatic Cancer\n",
       "3207    Evaluating an Endocrine Therapy Dose-frequency...\n",
       "3208    Cognitive Training for Cancer Related Cognitiv...\n",
       "3209    ROCKIF Trial: Re-sensitization of Carboplatin-...\n",
       "3210    Selinexor & Talazoparib in Advanced Refractory...\n",
       "3211    Perioperative Chemotherapy Plus Trastuzumab Pl...\n",
       "3212    Radiotherapy Dose Adaptation Based on Tumor Bi...\n",
       "3213    PENN-Surveillance Markers of Utility for Recur...\n",
       "3214    A Study to Evaluate the Efficacy of Osimertini...\n",
       "3215    Identification and Treatment Of Micrometastati...\n",
       "3216    Evaluation of the Efficacy of a Physical Thera...\n",
       "3217    Neoadjuvant KRAS G12C Directed Therapy With Ad...\n",
       "3218    Talazoparib and Radiation Therapy in Treating ...\n",
       "3219    Comparing 5 and 15 Fractions for Whole Breast ...\n",
       "3220    Risk-stratification Based Bladder-sparing Moda...\n",
       "3221    Assessement of the Concordance of Genomic Alte...\n",
       "3222    Breast CANcer Risk Assessment in Younger Women...\n",
       "3223    Axillary Staging in Node Positive Breast Cance...\n",
       "3224    Early Screening of Colorectal Cancer Based on ...\n",
       "3225    Precision Performance Status Assessment in Bre...\n",
       "3226    Evaluation of Preoperative Acceptance of Proac...\n",
       "3227    FUnctional Selection of Advanced Breast Cancer...\n",
       "3228    Study of CG0070 After Transurethral Resection ...\n",
       "3229    Effectiveness of Modified Integrated Colorecta...\n",
       "3230    Preoperative FOLFOX Versus Postoperative Risk-...\n",
       "3231                     BfedBwell Proof-of-Concept Pilot\n",
       "3232    Effects of Chemotherapy on Perceived Daily Per...\n",
       "3233    of Androgen Receptor Expression in Breast Canc...\n",
       "3234    Efficacy and Safety of Inetetamab Combined Wit...\n",
       "3235    The Effect of Arm Exercises on Arm Oedema Afte...\n",
       "3236    Partial Breast Re-irradiation Using Ultra Hypo...\n",
       "3237    Thermal Ablation of Cervical Metastases From T...\n",
       "3238    Predictive Biomarkers of Response to Checkpoin...\n",
       "3239    Study of Stereotactic Radiosurgery With Olapar...\n",
       "3240    Ivermectin and Balstilimab for the Treatment o...\n",
       "3241    Evaluation of the Fluorescent Green of Indocya...\n",
       "3242    Ultrasound Imaging, Spectroscopy and Ultrasoun...\n",
       "3243    Chiauranib Plus Weekly Paclitaxel in Patients ...\n",
       "3244    Health Literacy in Understanding Radiation The...\n",
       "3245    Chidamide in Combination With Abemaciclib and ...\n",
       "3246    A Clinical Study on Oncolytic Virus Injection ...\n",
       "3247    Laparoscopic Versus Open Lower Mediastinal Lym...\n",
       "3248    Assessing an Oral EGFR Inhibitor, DZD9008 in P...\n",
       "3249    A Study to Evaluate KIN-2787 in Participants W...\n",
       "3250    Supermicrosurgery for Breast Cancer Survivors ...\n",
       "3251    Study to Investigate Outcome of Individualized...\n",
       "3252    Prone Positioning CT Scan and Ultrasound Asses...\n",
       "3253    A Study of VS-6766 and Cetuximab in Patients W...\n",
       "3254    Elacestrant With/Without Triptorelin in Premen...\n",
       "3255    Understanding and Addressing Disparities in Ca...\n",
       "3256    Study Comparing the Standard Administration of...\n",
       "3257    Standard Chemotherapy Plus Moxifloxacin as Fir...\n",
       "3258    Liver Directed RT + Chemo-immunotherapy for ES...\n",
       "3259    REVIVE: Replens Versus Intra-Vaginal Estrogen ...\n",
       "3260    Immunobridging Study of 9-valent Human Papillo...\n",
       "3261    Trial of ZN-A-1041 Enteric Capsules in Patient...\n",
       "3262    Capecitabine, Tucatinib, and Intrathecal Trast...\n",
       "3263    Chemotherapy and Immunotherapy in Extensive-St...\n",
       "3264    Testing Home-based Exercise Strategies in Unde...\n",
       "3265    Women Informed to Screen Depending on Measures...\n",
       "3266    Oncologic Outcomes and Toxicities of Salvage T...\n",
       "3267    A Study of Samuraciclib in Combination With Fu...\n",
       "3268    Retreatment With Intratumoral Diffusing Alpha ...\n",
       "3269    The SNAP Tool for Head and Neck Cancer Survivo...\n",
       "3270    Long-Term Follow-Up in Women With Early Breast...\n",
       "3271    Abemaciclib and Endocrine Therapy in Older Pat...\n",
       "3272    A Study of TQB2930 for Injection Monotherapy o...\n",
       "3273    Positron Emission Tomography (PET) Imaging of ...\n",
       "3274    Circulating Tumor Cells and Treatment De-escal...\n",
       "3275       Study to Evaluate the Safety of Nanoxel M Inj.\n",
       "3276    Simultaneous Integrated Boost in Carbon Ion Ra...\n",
       "3277    Phase 3 Clinical Study of Chiauranib Capsule i...\n",
       "3278    Safety, Tolerability, and Preliminary Efficacy...\n",
       "3279    COLON-IM : Microbiota and Immune Infiltrate in...\n",
       "3280    A Clinical Study on Oncolytic Virus Injection ...\n",
       "3281    Pembrolizumab and Lenvatinib in Advanced/Metas...\n",
       "3282    Her2-BATS and Pembrolizumab in Metastatic Brea...\n",
       "3283    Durvalumab and Consolidation SBRT Following Ch...\n",
       "3284    Multimodal Program for Cancer Related Cachexia...\n",
       "3285                  Family History Study on Cancer Risk\n",
       "3286    A Study of SDX-7320 in Combination With Eribul...\n",
       "3287    Selenoproteins as Prognostic Markers and Thera...\n",
       "3288    Intratumoral CAN1012(Selective TLR7 Agonist) i...\n",
       "3289    Shared Decision Making on Radiation Dose for L...\n",
       "3290    Combining CEM and Magnetic Seed Localization o...\n",
       "3291    Study of ZKAB001 Combined With Carboplatin and...\n",
       "3292    Personalized Peptide Vaccine in Treating Patie...\n",
       "3293    A Phase III Study of Dato-DXd With or Without ...\n",
       "3294     Algology in Oncology Osteopathic Support (ALGOS)\n",
       "3295    Preoperative Boost Associated With Neoadjuvant...\n",
       "3296    Radiomics-based Malnutrition for Cervical Cancer.\n",
       "3297    Myeloid-Derived Suppressor Cell Function in Br...\n",
       "3298    Armatinib Alone or in Combination With SRT for...\n",
       "3299    TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Ant...\n",
       "3300    Exercise Treatment With Standard Therapy for M...\n",
       "3301    A Retrospective Observational Study of Patient...\n",
       "3302    A Study of U3-1402 (Patritumab Deruxtecan) in ...\n",
       "3303    Intra-operative PET-CT: a Novel Approach to De...\n",
       "3304    A Single-arm Phase II Trial of SAcituzumab Gov...\n",
       "3305    Pre-operative Trial for Breast Cancer With Niv...\n",
       "3306    Toripalimab Plus Lenvatinib as Second-line Tre...\n",
       "3307    Ketogenic Diet for Patients Receiving First Li...\n",
       "3308    A Nutritional Supplement to Support People Wit...\n",
       "3309    Chemopreventive Effects of Epigallocatechin Ga...\n",
       "3310    Combination of Abemaciclib and Endocrine Thera...\n",
       "3311    Study on Savolitinib Combined With Osimertinib...\n",
       "3312    Physical Rehabilitation Evaluation and Optimal...\n",
       "3313    Feasibility Study of Intraoperative Detection ...\n",
       "3314    Evaluation of the Acceptability, Appropriatene...\n",
       "3315    Hyperthermic Intraperitoneal Chemotherapy With...\n",
       "3316    MEchanisms of Resistance in EGFR Mutated Nonpr...\n",
       "3317    A Master Protocol Empowering Mechanobiology Tr...\n",
       "3318    GastrOesophageal Tumor, Immune Microenvionnmen...\n",
       "3319    Thiopurine Enhanced Mutations for PD-1/Ligand-...\n",
       "3320    vGRID SBRT: A Phase I Clinical Trial in Unrese...\n",
       "3321    A Pilot Study of Neoadjuvant Chemotherapy With...\n",
       "3322    AMT-151 in Patients With Selected Advanced Sol...\n",
       "3323    Study of CRS-207, Pembrolizumab, Ipilimumab, a...\n",
       "3324    Evaluation of Safety and Performance of Intrao...\n",
       "3325    Study of SAR444881 Administered Alone and in C...\n",
       "3326    Phase II Trial of Sacituzumab Govitecan in Rec...\n",
       "3327    The Immune System's Response to Young Women's ...\n",
       "3328    Using Imaging Data and Genomic Data to Predict...\n",
       "3329    NBTXR3 Activated by Radiation Therapy for the ...\n",
       "3330    A Study Evaluating the Efficacy and Safety of ...\n",
       "3331      Investigator-initiated Clinical Trial of MIKE-1\n",
       "3332    Chidamide in Combination With Vincristine Metr...\n",
       "3333    Circulating Immunes Cells, Cytokines and Brain...\n",
       "3334    Artificial Intelligence for Automated Diagnosi...\n",
       "3335    Neoadjuvant and Adjuvant Ribociclib and ET for...\n",
       "3336    Effect of Aromatase Inhibitors on Ultrasonogra...\n",
       "3337    Cardiovascular Injury and Cardiac Fitness in L...\n",
       "3338    Effects of the Anchor System in the Postural S...\n",
       "3339    Adjuvant Therapy With Abemaciclib + SOC ET vs....\n",
       "3340    Improving the Quality of Life of Cancer Patien...\n",
       "3341    MEM-288 Oncolytic Virus Alone and in Combinati...\n",
       "3342    Evaluating Harms and Benefits of Endocrine The...\n",
       "3343    Efficacy and Biomarker Explanation of IBI-322 ...\n",
       "3344    Comparison of the Cosmetic Results, Quality of...\n",
       "3345    A Phase Ib Study to Evaluate the Safety and Pr...\n",
       "3346    Adoptive Transfer of Tumor Infiltrating Lympho...\n",
       "3347    Durvalumab With Consolidative Radiochemotherap...\n",
       "3348      Rehabilitation on Equal Terms - The ReMig Study\n",
       "3349    An Escape Room Intervention to Help Improve Br...\n",
       "3350    Gedatolisib Plus Fulvestrant With or Without P...\n",
       "3351    Two Combination Treatment Regimens of Nivoluma...\n",
       "3352    (Z)-Endoxifen for the Treatment of Premenopaus...\n",
       "3353    Multicohort Phase II Trial of sEphB4-HSA+Pembr...\n",
       "3354    ARX788 in HER2-positive Breast Cancer Patients...\n",
       "3355    ASTEROID: A Trial of ASTX660 in Combination Wi...\n",
       "3356       Improving Genetic Counseling for BRCA+ Mothers\n",
       "3357    Adoptive Transfer of Tumor Infiltrating Lympho...\n",
       "3358    Study of the Bria-IMT Regimen and CPI vs Physi...\n",
       "3359    The Effect of Hand Exercises on Upper Limb Vol...\n",
       "3360    Testing the Addition of an Anti-cancer Drug, A...\n",
       "3361                                 Scalp Cooling in MBC\n",
       "3362    TPIV100 and Sargramostim for the Treatment of ...\n",
       "3363    Tablet-based Mobile Health Ultrasound for Poin...\n",
       "3364    ctDNA Based MRD Testing for NAC Monitoring in ...\n",
       "3365    Induction Chemotherapy for MRF-negative, Moder...\n",
       "3366    A Study of Olaparib and Pembrolizumab in Peopl...\n",
       "3367    Study of HS-10241 in Combination With Almonert...\n",
       "3368    Integrated Actionable Aging Assessment for Can...\n",
       "3369    Pilot Study of Cabazitaxel and Paclitaxel in H...\n",
       "3370    DETERMINE Trial Treatment Arm 01: Alectinib in...\n",
       "3371    Core Biopsies for Establishing a Breast Tumor ...\n",
       "3372    Implementation of Online Adaptive Radiotherapy...\n",
       "3373    Mini-invasive Detection of Residual Disease in...\n",
       "3374    Study of the Monoclonal Antibody IMT-009 in Pa...\n",
       "3375    Prognostic and Diagnostic Added Value of Medic...\n",
       "3376    Evaluation of Sleep Quality in Prostate Cancer...\n",
       "3377    Olaparib in Combination With Either Durvalumab...\n",
       "3378    A Video Intervention to Improve Patient Unders...\n",
       "3379    Efficacy and Safety of Non Invasive Vagal Stim...\n",
       "3380             PSMA/CD70 Bi-specific CAR-T Cell Therapy\n",
       "3381    The Efficacy and Safety of Utidelone Plus Tire...\n",
       "3382    PBI for Breast In Situ Carcinoma of Intermedia...\n",
       "3383    KPMNG Study of MOlecular Profiling Guided Ther...\n",
       "3384    Liver Transplantation for Non-resectable Color...\n",
       "3385    Classification of Breast Masses Based on Visco...\n",
       "3386    Phase II Trial of Lurbinectedin Combined With ...\n",
       "3387    De-Escalation of Breast Radiation Trial for Ho...\n",
       "3388    Dynamic and Test-retest Whole Body [18F]FES PE...\n",
       "3389                       Autologous TLPO Vaccine Basket\n",
       "3390    Lesion Composition and Quantitative Imaging An...\n",
       "3391    Study of PF-07248144 in Advanced or Metastatic...\n",
       "3392    A Study of Pembrolizumab With Trastuzumab and ...\n",
       "3393    Phase II Trial of Vemurafenib and Sorafenib in...\n",
       "3394    Nivolumab Plus Chemoradiotherapy in Patients W...\n",
       "3395    Targeted Therapy to Increase RAI Uptake in Met...\n",
       "3396    Increasing Cervical Cancer Screening Uptake Am...\n",
       "3397    An Evaluation of Maintenance Therapy Combinati...\n",
       "3398    Culturally Based Brief Expressive Writing Inte...\n",
       "3399    Tucidinostat and Metronomic Capecitabine for M...\n",
       "3400    Extracellular Vesicles in Breast Cancer Patien...\n",
       "3401    Hyperpolarized 13C Pyruvate MRI for Early Immu...\n",
       "3402    Leucoselect Phytosome for Neoadjuvant Treatmen...\n",
       "3403    Study of Tislelizumab for Locally Advanced Non...\n",
       "3404    Preoperative Immunotherapy in Patients With Sq...\n",
       "3405    Robotic vs. Open NSM for Early Stage Breast Ca...\n",
       "3406    A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastu...\n",
       "3407    A Multicenter Clinical Trial on DH001 Tablets ...\n",
       "3408    Study of BO-112 With Radiotherapy and Nivoluma...\n",
       "3409    First in Human Study of TORL-2-307-ADC in Part...\n",
       "3410    PurIST Classification-Guided Adaptive Neoadjuv...\n",
       "3411    Neuroinflammation and Age-associated Brain Pat...\n",
       "3412    A Phase I Open-Label Dose Escalation Study of ...\n",
       "3413    Ovarian Suppression Evaluating Subcutaneous Le...\n",
       "3414    SILibinin in NSCLC and BC Patients With Single...\n",
       "3415    Impact of Immuno-Oncologic Agent on Neoadjuvan...\n",
       "3416    Breast Fractionation Study - Standard Versus I...\n",
       "3417    Organoid-based Functional Precision Therapy fo...\n",
       "3418    MEthods for LOcalization of Different Types of...\n",
       "3419    A Study Evaluating Safety and Therapeutic Acti...\n",
       "3420    Study of Tucatinib and Doxil in Participants W...\n",
       "3421    Lung Cancer Screening Implementation Among Emp...\n",
       "3422    A Feasibility Trial of a Web Based App Interve...\n",
       "3423    Monitoring Early Response to Targeted Therapy ...\n",
       "3424    Respiratory Training and Relaxation Techniques...\n",
       "3425    Effects of Extracorporeal Shock Wave Therapy A...\n",
       "3426      AZD6738 Plus Durvalumab in Biliary Tract Cancer\n",
       "3427    A Study Evaluating the Efficacy and Safety of ...\n",
       "3428    Neoadjuvant Camrelizumab and Fluzoparib and Na...\n",
       "3429    Outcome of Tucidinostat-Based Therapy in HR+ M...\n",
       "3430    DURvalumab in Combination With S-488210/S-4882...\n",
       "3431    Chidamide Combined With Cisplatin for Relapsed...\n",
       "3432    M9241 in Combination With Hepatic Artery Infus...\n",
       "3433    A First-in-Human, Phase 1 Study of JAB-3312 in...\n",
       "3434    Surgical Tissue Flap to Bypass the Blood Brain...\n",
       "3435    Organ Preservation in Early Rectal Cancer Pati...\n",
       "3436    OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain\n",
       "3437    KORE-Innovation: a Prospective, Multi-site Cli...\n",
       "3438    A Study to Evaluate the Combination of ATX-101...\n",
       "3439    Assessing the Benefit of Art & Music Therapy o...\n",
       "3440    European Treatment Patterns and Outcomes Assoc...\n",
       "3441    Effects of Digital Therapeutic in Whole Proces...\n",
       "3442    Testing the Safety of Adding Either Monalizuma...\n",
       "3443    TQB3616 Capsules Plus Fulvestrant Compared to ...\n",
       "3444                                Together After Cancer\n",
       "3445    A Study to Investigate the Efficacy and Safety...\n",
       "3446    A Prospective Feasibility Study Evaluating Ext...\n",
       "3447    A Study to Examine the Clinical Value of Compr...\n",
       "3448    Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF...\n",
       "3449    A Study of ERAS-007 in Patients With Advanced ...\n",
       "3450    Targeting the Tumor Microenvironment in R/M SCCHN\n",
       "3451    Study of Stem Cell Transplant vs. Non-Transpla...\n",
       "3452    Study of Camrelizumab (SHR-1210) and Apatinb B...\n",
       "3453    L-TIL Plus Tislelizumab for PD1 Antibody Resis...\n",
       "3454    Glutamine Plus L. Reuteri Prevents TKI Therapy...\n",
       "3455    The MASTER Study (MAmmary Cancer STatin ER Pos...\n",
       "3456    An Exploratory Study of Surufatinib Combined W...\n",
       "3457    Pharmacodynamic Biomarkers of Standard Anti-mi...\n",
       "3458    Short-course Radiotherapy Followed by Tisleliz...\n",
       "3459    NEO-adjuvant Chemo-immunotherapy in Pancreatic...\n",
       "3460    Atezolizumab in Patients With MSI-h/MMR-D Stag...\n",
       "3461    Olaparib and Durvalumab With Carboplatin, Etop...\n",
       "3462    Pilot Study Assessing the Effect of Cyclin-dep...\n",
       "3463    High-dose Furmonertinib for First-line Treatme...\n",
       "3464    EXERT-BCN: An Exercise and Nutrition Regimen t...\n",
       "3465    A Study Evaluating Maintenance Therapy After F...\n",
       "3466    Monitoring Neoadjuvant Chemotherapy of Breast ...\n",
       "3467    Study Evaluating DNA Double-strand Breaks (DSB...\n",
       "3468    Motor-cognitive Training Effects on Cognition ...\n",
       "3469    Chidamide Combined With Zimberelimab in the Tr...\n",
       "3470    PFMT Educational Intervention for Patients Wit...\n",
       "3471    Efficiency and Safety of Microwave Ablation Pl...\n",
       "3472    Therapy Adapted for High Risk and Low Risk HIV...\n",
       "3473    Collecting Blood Samples From Patients With an...\n",
       "3474    A Prospective Study Comparing Three Injection ...\n",
       "3475    Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadju...\n",
       "3476    A Pilot Trial of Atorvastatin in Tumor Protein...\n",
       "3477    Fluorescence-guided Surgery Using cRGD-ZW800-1...\n",
       "3478    Study of Screening Brain MRIs in Stage IV Brea...\n",
       "3479    Clinical Study on the Treatment of Advanced Re...\n",
       "3480    De-convoluting Interactions Between Genes, the...\n",
       "3481    RC48 Combined With Toripalimab and Radiotherap...\n",
       "3482    Pharmacodynamic Study Goserelin 3.6mg Injectio...\n",
       "3483    Prospective Study of the Prosigna Assay on Neo...\n",
       "3484    A Study of SI-B003 or BL-B01D1+SI-B003 in Pati...\n",
       "3485    Adding Certolizumab to Chemotherapy + Nivoluma...\n",
       "3486    Clinical Study of High-intensity Focused Ultra...\n",
       "3487    RC48 Combined With Tislelizumab for Bladder Sp...\n",
       "3488    Efficacy & Safety of Olvi-Vec and Platinum-dou...\n",
       "3489    Personalized Precision Diagnosis and Treatment...\n",
       "3490    Study on Pembrolizumab in Recurrent, Platinum ...\n",
       "3491    Online Dietary and Resistance Training to Impr...\n",
       "3492     Video Education With Result Dependent dIsclosure\n",
       "3493    Pre-analytical Factors Affecting ctDNA Analysi...\n",
       "3494    A Mind-Body Intervention for Hot Flash Management\n",
       "3495    Different Localization Techniques for Non-palp...\n",
       "3496    Early On-treatment Transcriptional Profiling a...\n",
       "3497    Phase 1 Study of FS-1502 in Patients With HER2...\n",
       "3498    Study of AZD5305 as Monotherapy and in Combina...\n",
       "3499    A Trial of Injectable SHR-A1811 in Combination...\n",
       "3500    Pilot Clinical Evaluation of a Microwave Imagi...\n",
       "3501                            Step by Step After Cancer\n",
       "3502    Prevention of Persistent Pain With LidocAine i...\n",
       "3503    Neoadjuvant Immunotherapy and Chemotherapy Fol...\n",
       "3504    Novel Double Target Therapy Combined With Chem...\n",
       "3505    RC48 Plus Tislelizumab, Low-dose Capecitabine ...\n",
       "3506    Hypofractionated Preoperative Radiation for He...\n",
       "3507    Artificial Intelligence Analysis of Fluorescen...\n",
       "3508    177Lu-PP-F11N for Receptor Targeted Therapy an...\n",
       "3509    Study Comparing Tarlatamab With Standard of Ca...\n",
       "3510    Evaluating the Addition of Adjuvant Chemothera...\n",
       "3511    Proton Radiation for Unresectable, Borderline ...\n",
       "3512    Improving Patient-Centered Communication in Br...\n",
       "3513    With Love, Grandma (\"Con Cariño, Abuelita\") Pi...\n",
       "3514    Icotinib for Completed Resected IB NSCLC With ...\n",
       "3515    Trial of Radiotherapy in Combination With TTI-...\n",
       "3516    Investigation of the Efficiency of Pain Neuros...\n",
       "3517    Phase II Trial of Carboplatin +/- Tocilizumab ...\n",
       "3518    A Prospective Study Comparing Two Radiotherapy...\n",
       "3519    LymphoVenous Anastomosis to Prevent Breast Can...\n",
       "3520    A Study of Mitomycin-c/ Capecitabine ChemoRadi...\n",
       "3521    The Effect of Intensive Dietary Education on N...\n",
       "3522    Staggered, Chemo-Immunotherapy With Durvalumab...\n",
       "3523    Neoadjuvant Upper Tract Invasive Cancer Trial ...\n",
       "3524    Comparison of CE-DBT and MRI in Patients With ...\n",
       "3525    Non-contrast Magnetic Resonance Angiography in...\n",
       "3526    Niraparib in Combination With Trastuzumab in M...\n",
       "3527    Immunotherapy Platform Study in Platinum Resis...\n",
       "3528    Prediction of Neoadjuvant Chemotherapy Efficac...\n",
       "3529    A Digital Art Activity to Enhance Self-Disclos...\n",
       "3530    Exploring Cultural Acceptability of Community ...\n",
       "3531    Breast Cancer Patient Engagement With Patient ...\n",
       "3532    Effect of Salovum™ and SPC-Flakes™ on Abemacic...\n",
       "3533    Minimal Invasive Breast Cancer Excision Using ...\n",
       "3534    Focused Radiation Versus Systemic Therapy for ...\n",
       "3535    Abemaciclib Dose Escalation to Maintain Intens...\n",
       "3536    Cisplatin + Radiation in SCCHN and Correlation...\n",
       "3537    Case Control Study to Identify Modifiable Risk...\n",
       "3538    Intermittent Fasting for the Improvement of Ou...\n",
       "3539    Promoting Informed Choice for Breast Cancer Sc...\n",
       "3540    Pilot Trial of Colchicine in Urothelial Cancer...\n",
       "3541    Imaging Study of 18F-FAC PET Scans to Assess S...\n",
       "3542    Geriatric Care Survivorship Intervention for I...\n",
       "3543    Using a Blood Test to Monitor Metastatic Breas...\n",
       "3544    Neoantigen Dendritic Cell Vaccine and Nivoluma...\n",
       "3545    Chemotherapy Combined With Immunotherapy in HE...\n",
       "3546    Cognitive Stimulation and Chemobrain. An Innov...\n",
       "3547    Evaluation of Lasofoxifene Combined With Abema...\n",
       "3548    Metronomic PLD in Patients With Primary Endocr...\n",
       "3549    A Study of TBio-4101 (TIL) and Pembrolizumab i...\n",
       "3550    Alternate Day Fasting After Surgery for Patien...\n",
       "3551    Comparison of the Pathological Effect Between ...\n",
       "3552    PG2 Injection for the Treatment of moderate-to...\n",
       "3553    EvaLuating negAtive pressUre Wound theRapy in ...\n",
       "3554    Phase 2 Study of Neoadjuvant Chemotherapy With...\n",
       "3555    Domvanalimab and Zimberelimab in Advanced Live...\n",
       "3556        Health Education for Women With Breast Cancer\n",
       "3557    The PIONEER Initiative: Precision Insights On ...\n",
       "3558    Exercise Rehabilitation Via a Mobile Applicati...\n",
       "3559         Researching the Effect of Exercise on Cancer\n",
       "3560    PARP Inhibitor With CDK4/6 Inhibitor and Endoc...\n",
       "3561    A Prospective, Randomized Multicenter, Open-la...\n",
       "3562    Trial of Neratinib Plus Capecitabine in Subjec...\n",
       "3563    Evaluation of the NOVATECH ® LUCIOLA TM EB Fid...\n",
       "3564    Evaluation of PSMA in HER2- AR+ Metastatic Bre...\n",
       "3565    Feasibility Study of Lidocaine Infusion During...\n",
       "3566    What is Optimal Post-operative Prophylactic Th...\n",
       "3567    Phase II Trial of Disulfiram With Copper in Me...\n",
       "3568    Moderate Hypofractionated Radiotherapy for Lun...\n",
       "3569    ARX788 in HER2-positive, Metastatic Breast Can...\n",
       "3570    A Phase 1 in Patients With HLA-A*0201+ and WT1...\n",
       "3571    ELACESTRANT in Women and Men With CDK4/6 Inhib...\n",
       "3572    Efficacy and Safety of Remimazolam Tosylate fo...\n",
       "3573    To Evaluate OBI-833/OBI-821 in Combination Wit...\n",
       "3574    START: Safety and Anti-Tumor Activity of Pepti...\n",
       "3575    Streamlined Localization Using SCOUT® at Biops...\n",
       "3576    Locally ablatiVe therApy in oLigO-pRogressive ...\n",
       "3577    Gene Expression Profiling to Help Define the N...\n",
       "3578    Prospective Biobanking Study in Ovarian, Breas...\n",
       "3579    Anastrazole, Fulvestrant & Abemaciclib for HR+...\n",
       "3580    Evaluation of a Plasma Protein Profile as a Pr...\n",
       "3581    Intravesical Photodynamic Therapy (\"PDT\") in B...\n",
       "3582    Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cell...\n",
       "3583    A Study of JZP815 Oral Capsules in Adult Parti...\n",
       "3584    Everolimus With Investigator's Choice of Chemo...\n",
       "3585    Hypofractionation With Simultaneous Integrated...\n",
       "3586         Exercise in Metastatic Breast Cancer: EMBody\n",
       "3587    S1703 Serum Tumor Marker Directed Disease Moni...\n",
       "3588        The Incidence of Gallstones After Gastrectomy\n",
       "3589    Neo-adjuvant Immunochemotheray Versus Neo-adju...\n",
       "3590    The Safety and Efficacy of Redsenol-1 Plus on ...\n",
       "3591    Intraoperative Electron Radiotherapy for Low-r...\n",
       "3592    Nab-paclitaxel Combined With Oxaliplatin and S...\n",
       "3593    Stereotactic Radiotherapy (SBRT) of Lung Metas...\n",
       "3594    Hypofractionated Radiation Therapy vs Standard...\n",
       "3595    Ifinatamab Deruxtecan (I-DXd) in Subjects With...\n",
       "3596                  PET-MRI Esophagus Feasibility Study\n",
       "3597    4FMFES-PET Imaging of Endometrial and Ovarian ...\n",
       "3598    A Study to Measure the Expression of the HER2-...\n",
       "3599    Clinical Study of Chidamide Combined With Chem...\n",
       "3600    Adapting the Tumor Board Model for Mental Illn...\n",
       "3601    Metarrestin (ML-246) in Subjects With Metastat...\n",
       "3602    Osimertinib and Tegavivint as First-Line Thera...\n",
       "3603    Ribociclib, Tucatinib, and Trastuzumab for the...\n",
       "3604    The MOMENTUM Study: The Multiple Outcome Evalu...\n",
       "3605    Radiotherapy Omission in Low Risk Ductal in Si...\n",
       "3606    Evaluating Safety and Biomarkers Using DK210 (...\n",
       "3607    A Study of RP-3500 in Combination With Standar...\n",
       "3608    Phase 1/2 Study of HS-10376 in Patients With N...\n",
       "3609                       Testosterone & Tamoxifen Trial\n",
       "3610                   Intra-Operative Radiation Registry\n",
       "3611      Development of Clinical and Biological Database\n",
       "3612    A Phase II Study of Lonsurf (TAS-102) in Metas...\n",
       "3613              GD2/CD70 Bi-specific CAR-T Cell Therapy\n",
       "3614    Fulvestrant Versus Capecitabine as Maintenance...\n",
       "3615    Phase I Study to Evaluate SIM0270 Alone or in ...\n",
       "3616    Handheld Ultrasound Device to Triage Women Wit...\n",
       "3617    STEMVAC in Patients With Early Stage Triple Ne...\n",
       "3618    Phase II Study on Sequential AG and FOLFIRINOX...\n",
       "3619    A Neoadjuvant Study of Tislelizumab and SX-682...\n",
       "3620    Study of Pembrolizumab Combination With Chemot...\n",
       "3621    ctDNA in CRC Patients Undergoing Curative-inte...\n",
       "3622    Early Detection of CMP in Patients With Breast...\n",
       "3623             Circulating EV Long RNA Profiles in SCLC\n",
       "3624    A Study of LOXO-783 in Patients With Breast Ca...\n",
       "3625    Enhancing Radioiodine Incorporation Into Radio...\n",
       "3626    Survival Outcome of EGFR-TKI in Uncommon EGFR ...\n",
       "3627    Artificial Intelligence in Breast Cancer Scree...\n",
       "3628    A Phase II Study of Chiauranib in Combine With...\n",
       "3629    The Value of Palliative Primary Tumor Resectio...\n",
       "3630    Estimation of Tumor Response With Linac MRI-gu...\n",
       "3631    68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic C...\n",
       "3632    Study of Quality of Life and Hormone Levels in...\n",
       "3633    Mobile Health for Adherence in Breast Cancer P...\n",
       "3634    Study of XB002 in Subjects With Solid Tumors (...\n",
       "3635    Quaratusugene Ozeplasmid (Reqorsa) in Combinat...\n",
       "3636    STUDY02001740;22SCH740: Estradiol For ER+ Adva...\n",
       "3637    A Quality of Life Intervention (Y-AMBIENT) for...\n",
       "3638    Disitamab Vedotin (RC48) in Hormone Receptor P...\n",
       "3639    TSR-042 in Addition to Standard of Care Defini...\n",
       "3640    Study of Fully Human B7H3 CAR-T in Treating Re...\n",
       "3641    DETERMINE Trial Treatment Arm 05: Vemurafenib ...\n",
       "3642    Cardiac Outcomes With Near-Complete Estrogen D...\n",
       "3643    Achieving Equity in Genomic Testing for Breast...\n",
       "3644    Good Choice of pALliative Chemotherapy to Pati...\n",
       "3645    ATL001 in Patients With Advanced Unresectable ...\n",
       "3646    Observational Study of Effectiveness and Safet...\n",
       "3647    Evaluation of Mirvetuximab Soravtansine (IMGN8...\n",
       "3648    A Study to Investigate the Family History of C...\n",
       "3649    Study on TIL for the Treatment of Advanced Bre...\n",
       "3650    Magnetic Resonance Imaging in Radiotherapy for...\n",
       "3651       Comprehensive Outcomes for After Cancer Health\n",
       "3652    Trial of the Efficacy and Safety of Short and ...\n",
       "3653    Olaparib Maintenance Therapy in Metastatic Bre...\n",
       "3654    A Safety, Pharmacokinetic and Clinical Activit...\n",
       "3655    Cognitive Training and Brain Stimulation in Wo...\n",
       "3656    Study of Ribociclib Administered Concurrently ...\n",
       "3657    Pembrolizumab And Stereotactic Radiosurgery (S...\n",
       "3658    Study of Dato-Dxd as Monotherapy and in Combin...\n",
       "3659    Construction and Clinical Translation of ACE T...\n",
       "3660       PRO1107 in Patients With Advanced Solid Tumors\n",
       "3661    Mechanisms, Predictors, and Social Determinant...\n",
       "3662    Study of SHR-A1811 in HER2-expression Advanced...\n",
       "3663    K-SAB Trial - Sotorasib Followed by SBRT to 1-...\n",
       "3664    Real World Study of First Line Crizotinib for ...\n",
       "3665    Liquid-biopsy Informed Platform Trial to Evalu...\n",
       "3666    Inguinal Node Sparing Radiotherapy For Patient...\n",
       "3667    Study of MCLA-129, a Human Bispecific EGFR and...\n",
       "3668    Phase IIB Trial of Bazedoxifene Plus Conjugate...\n",
       "3669    The Unmet Needs and the Workplace Reintegratio...\n",
       "3670    A Study of an Alternative Treatment Approach (...\n",
       "3671    The T-REX Trial: Tailored Regional External Be...\n",
       "3672    Anlotinib Plus Penpulimab (AK105) for Chemo-re...\n",
       "3673    Famitinib Plus Anti-PD1 Therapy for Advanced U...\n",
       "3674    Atezolizumab and Bevacizumab Pre-Liver Transpl...\n",
       "3675    Testing Olaparib in Patients With Advanced or ...\n",
       "3676    A Study to Test the Safety of Immunotherapy Wi...\n",
       "3677    Neoadjuvant Study of Camrelizumab Plus Chemoth...\n",
       "3678    A Study of Zanidatamab (ZW25) With Evorpacept ...\n",
       "3679    Salud en Mis Manos - Breast and Cervical Cance...\n",
       "3680    TCF-001 TRACK (Target Rare Cancer Knowledge) S...\n",
       "3681    Quantitative MRI Assessment of Breast Cancer T...\n",
       "3682    Reinvigorating TNBC Response to Immunotherapy ...\n",
       "3683    Pembrolizumab With or Without Axitinib for Tre...\n",
       "3684    A Study of the Use of Acellular Dermal Matrix ...\n",
       "3685    DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER...\n",
       "3686    Recombinant Interleukin-15 in Combination With...\n",
       "3687    I-SPY TRIAL: Neoadjuvant and Personalized Adap...\n",
       "3688                    Breast Cancer Liquid Biopsy Trial\n",
       "3689    Improving Adolescent and Young Adult Self-Repo...\n",
       "3690       Exercise, Cancer and Cognition: The ECCO-Study\n",
       "3691    Detection of Cancer in Breath Samples by Train...\n",
       "3692    Study of Intratumoral IVX037 in Patients With ...\n",
       "3693    This is a Multicenter, Randomized, Double-blin...\n",
       "3694    First-in-Human Study of STX-478 as Monotherapy...\n",
       "3695    (CLONEVO): Cell cycLe inhbitiON to Target the ...\n",
       "3696    NeoVax With Nivolumab in Patients With Ovarian...\n",
       "3697    Perioperative Pembrolizumab (MK-3475) Plus Cys...\n",
       "3698    TIL Relation to pCR After Neoadjuvant Therapy ...\n",
       "3699    A Study to Explore Biomarkers in Samples of Bl...\n",
       "3700    A Study of GNC-035, a Tetra-specific Antibody,...\n",
       "3701    Safety of Omitting Axillary Surgery in Breast ...\n",
       "3702    Clinical Data Collection in Breast Tomosynthes...\n",
       "3703    Novel Neoadjuvant and Adjuvant Strategy for Ge...\n",
       "3704    Outcomes Mandate National Integration With Can...\n",
       "3705    The Real World Study of Neoadjuvant Immunother...\n",
       "3706    A Study of PD-1 Inhibitors Combined With Fruqu...\n",
       "3707                Aortic Laryngeal Rehabilitation Graft\n",
       "3708    Concurrent WOKVAC Vaccination, Chemotherapy, a...\n",
       "3709    Omega-3 and Vitamin D Supplementation in Breas...\n",
       "3710    Neoadjuvant Chemotherapy Followed by Radiother...\n",
       "3711    Cabozantinib In Advanced Radioactive-Iodine Re...\n",
       "3712    Development of Clinical and Biological Databas...\n",
       "3713    A Study of Oral MBQ-167 in Participants With A...\n",
       "3714    T Cell Receptor Gene Therapy Targeting KK-LC-1...\n",
       "3715    To Evaluate a Phase Ia/Ib Clinical Study of EG...\n",
       "3716    A Pilot Study to Assess the Clinical Utility o...\n",
       "3717    Study of CRX100 as Monotherapy and in Combinat...\n",
       "3718    Surufatinib Combine With Immunotherapy and Che...\n",
       "3719    TAS-102 With Concurrent Radiation for the Trea...\n",
       "3720                    PRO1184 for Advanced Solid Tumors\n",
       "3721    A Clinical Study on Oncolytic Virus Injection ...\n",
       "3722    Efficacy and Biomarker Explanation of IBI-323 ...\n",
       "3723    A Study of APG-1252 Plus Osimertinib(AZD9291) ...\n",
       "3724    Dedicated Breast CT for Diagnosis of Breast Ca...\n",
       "3725    Preoperative Treatment of HR+/HER2+Breast Canc...\n",
       "3726    A Phase II Clinical Study of Treatment With Di...\n",
       "3727    Imaging With a PET Agent for Detection of Canc...\n",
       "3728    Evaluation of SNDX-5613 in Participants With C...\n",
       "3729    Study of the CHK1 Inhibitor BBI-355, an ecDNA-...\n",
       "3730          Avera/Sema4 Oncology and Analytics Protocol\n",
       "3731    Benefits of Morphine Gel for Pain Reduction in...\n",
       "3732    Phase II Study on Neoadjuvant Therapy of AK104...\n",
       "3733    Osimertinib Then Chemotherapy in EGFR-mutated ...\n",
       "3734    Fluzoparib in Combination With Chidamide or Ca...\n",
       "3735    Pembrolizumab in Treating Participants With Me...\n",
       "3736    A Multiple Antigen Vaccine (STEMVAC) for the T...\n",
       "3737    Oncolytic Virotherapy Combined With Tislelizum...\n",
       "3738    89Zr-DFO*-Trastuzumab PET in Patients With Gas...\n",
       "3739    Molecular Imaging of Gastrin Releasing Peptide...\n",
       "3740    Cardiovascular Prevention Strategies in Elderl...\n",
       "3741    Adjuvant Chemotherapy in Clinical Local Advanc...\n",
       "3742    Cascade Genetic Testing for Hereditary Breast/...\n",
       "3743    Phase III Study of 5tx vs 15tx of RT (X-rays o...\n",
       "3744    Paclitaxel Polymeric Micelles for Injection Ve...\n",
       "3745    Testing Immunotherapy (Atezolizumab) With or W...\n",
       "3746    Catumaxomab in Patients With Non-Muscle-Invasi...\n",
       "3747    A Study of Avutometinib for People With Solid ...\n",
       "3748    Food: A Three-Arm Study Examining Food Insecur...\n",
       "3749    Tucatinib With Brain and/or Spinal XRT in Pati...\n",
       "3750    Application of Preoperative Axillary Lymph Nod...\n",
       "3751    Fecal Microbiota Transplantation in Patients W...\n",
       "3752    A Phase III Study to Assess the Effects of Alm...\n",
       "3753    A Clinical Study to Investigate the Efficacy o...\n",
       "3754    OP-1250 (Palazestrant) vs. Standard of Care fo...\n",
       "3755    Comparison Between ROLL Versus Magnetic Seed f...\n",
       "3756    HIPEC + FLOT vs. FLOT Alone in Patients With G...\n",
       "3757    Tucatinib, Trastuzumab, and Capecitabine With ...\n",
       "3758    Treatment Patterns & Clinical Outcomes of Palb...\n",
       "3759    Th-1 Dendritic Cell Immunotherapy Plus Standar...\n",
       "3760    Immune Therapy in HR-positive/HER2-negative Me...\n",
       "3761    Pembrolizumab and EV With Radiation Therapy fo...\n",
       "3762    Study of Adagloxad Simolenin (OBI-822)/OBI-821...\n",
       "3763    Ipatasertib + Pertuzumab +Trastuzumab in Advan...\n",
       "3764    Testing the Effectiveness of Two Immunotherapy...\n",
       "3765    A Study of ARX788 Combined With Pyrotinib Male...\n",
       "3766    Neoantigen Vaccines in Pancreatic Cancer in th...\n",
       "3767    Fulvestrant+Abemaciclib With or Without Run-In...\n",
       "3768    FES Imaging to Optimize Tamoxifen for Metastat...\n",
       "3769    A Study of AK117/AK112 in Metastatic Triple-Ne...\n",
       "3770    Efficacy of HIPEC in Patients With Colorectal ...\n",
       "3771    Quantitative Fluorescence Endoscopy Using Durv...\n",
       "3772                Contrast-Enhanced Stereotactic Biopsy\n",
       "3773    CALM: Managing Distress in Malignant Brain Cancer\n",
       "3774    Endocrine Treatment Alone for Elderly Patients...\n",
       "3775    Comparative Performance of Molecular Breast Im...\n",
       "3776         PBMT for the Management of CIA ( HAIRLASER )\n",
       "3777    Oxygen Partial Pressure After Breast Cancer Su...\n",
       "3778    Breast Screening - Risk Adaptive Imaging for D...\n",
       "3779    Study of Nab-Paclitaxel and Gemcitabine With o...\n",
       "3780    Pyrotinib Combined With Trastuzumab, Dalpicicl...\n",
       "3781            Prehabilitation for Breast Cancer Surgery\n",
       "3782       BRaziLian outcomE for metAStatic breasT Cancer\n",
       "3783    Clinical Outcomes of Indocyanine Green Tracer ...\n",
       "3784    Induction Tislelizumab Combined With Chemother...\n",
       "3785                 Developing Breast (Cancer) Organoids\n",
       "3786    MRI Radiomics Assessing Neoadjuvant Chemothera...\n",
       "3787    Phase I Study of Autologous CAR T-Cells Target...\n",
       "3788    Metastases-directed Radiotherapy in Addition t...\n",
       "3789    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase I...\n",
       "3790               APG-115 in Salivary Gland Cancer Trial\n",
       "3791    Healthy Lifestyles After Cancer for Adolescent...\n",
       "3792    PLD-cyclophosphamide-Nab-P Continuously Combin...\n",
       "3793    Radiation During Osimertinib Treatment: a Safe...\n",
       "3794    A Clinical-biological Prospective Cohort of Pa...\n",
       "3795    Gemcitabine+ Capecitabine Vs Capecitabine in C...\n",
       "3796    Functional Precision Oncology for Metastatic B...\n",
       "3797    Evaluating the Efficacy and Safety of Bevacizu...\n",
       "3798    Lenvatinib and Pembrolizumab in People With Ad...\n",
       "3799    Study of RP2 Monotherapy and RP2 in Combinatio...\n",
       "3800    HGWD Improve the Paclitaxel-related Neurotoxic...\n",
       "3801    Study of Magrolimab Combination Therapy in Pat...\n",
       "3802               Study of Trilaciclib and Lurbinectidin\n",
       "3803    Methods for Increasing Genetic Testing Uptake ...\n",
       "3804    Testing the Combination of Two Anti-cancer Dru...\n",
       "3805    Trained Immunity in Thyroid Carcinoma and Colo...\n",
       "3806    Immunologic Effects of CDX-301 and CDX-1140 in...\n",
       "3807    Screening for and Responding to Food Insecurit...\n",
       "3808    Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Wit...\n",
       "3809    Study to Evaluate the Bioavailability of Tisle...\n",
       "3810    A Phase 2 Study of ABSK021 in Patients With Ad...\n",
       "3811    EF-36/Keynote B36: A Pilot, Randomized, Open-l...\n",
       "3812    A Study to Evaluate the Combination of Nivolum...\n",
       "3813    Positioning of Molecular Markers in Clinical R...\n",
       "3814    Combination of Nivolumab Plus Relatlimab in Pa...\n",
       "3815    A Study of DB-1303/BNT323 vs Investigator's Ch...\n",
       "3816    Perioperative Exercise and Nutritional Optimis...\n",
       "3817    A First-in-Human Study of SON-DP in Participan...\n",
       "3818    Investigation of Tumour Spectrum of Germline M...\n",
       "3819    Using an End-of-life Conversation Game to Enga...\n",
       "3820    Topical Dermaprazole for Radiation Dermatitis ...\n",
       "3821    Study of 3-Day Partial Breast Radiation Therap...\n",
       "3822    Colonoscopy Screening: Setting Epic Follow-up ...\n",
       "3823    T-Cell Clonality After Stereotactic Body Radia...\n",
       "3824    Development of a Personalised Therapeutic Appr...\n",
       "3825    Predictive Toxicity Test Linked to Radiotherap...\n",
       "3826    CIMAvax Vaccine, Nivolumab, and Pembrolizumab ...\n",
       "3827             Male breAsT cAncer preDisposition Factor\n",
       "3828    IN10018 in Combination With Pegylated Liposoma...\n",
       "3829    Neoadjuvant Regorafenib in Combination With Ni...\n",
       "3830    Multiparametric Magnetic Resonance Imaging (MR...\n",
       "3831    Pancreatic Cancer Screening for At-risk Indivi...\n",
       "3832    Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...\n",
       "3833    DWIBS-MRI: An Adjunct to the Traditional Diagn...\n",
       "3834    HER2(Human Epidermal Growth Factor Receptor 2)...\n",
       "3835    Protective Effects of the Nutritional Suppleme...\n",
       "Name: STUDY_TITLE, dtype: object"
      ]
     },
     "execution_count": 106,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "merged_df['STUDY_TITLE']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "output = {\"age_min\" : \"age\",\n",
    "          \"age_max\" : \"age\" }\n",
    "system_prompt = f\"\"\"You are helpful assistant to max age and min age from given senetence and give output in json format as {output} \"\"\"        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "age_input = df[\"AGE\"][6]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "response = openai.chat.completions.create(\n",
    "            model='gpt-4-0125-preview', \n",
    "            temperature=0,\n",
    "            messages=[\n",
    "                {\"role\":\"system\", \"content\":system_prompt},\n",
    "                {\"role\":\"user\", \"content\":f\"\"\" Extract the max age and min age from given input 18 Years|75 Years|Adult|Older Adult and give output in {output} format. \"\"\"},\n",
    "                {\"role\":\"assistant\", \"content\":\"\"\"{\"age_min\" : \"18\",\n",
    "          \"age_max\" : \"75\" }\"\"\" },\n",
    "          {\"role\":\"user\", \"content\":f\"\"\" Extract the max age and min age from given input {age_input} and give output in {output} format. \"\"\"},\n",
    "            ],\n",
    "            max_tokens = 1024,\n",
    "            response_format={ \"type\": \"json_object\" }\n",
    "            \n",
    "        )\n",
    "      "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'{\"age_min\": \"18\", \"age_max\": \"75\"}'"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response.choices[0].message.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
